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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 EPIDEMIOLOGY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA 
Although cancer is not a common disease in children, mortality data demonstrate 
that after accidents cancer is the second cause of death in children (1,2). Each year 
approximately 380 children less than 15 years of age are diagnosed with cancer in the 
Netherlands, with an incidence rate of 13.9 per 100,000 children per year, in boys 
slightly higher (-14.8) than in girls (-13) (3-5). In general, these incidence rates are 
comparable within Europe and the rest of the world, but the lowest incidence rates are 
found in developing countries (2,6-12). The latter can most probably be explained by 
misdiagnosis, underreporting, or pre-emptive death from infectious diseases (2,7,8). The 
difference in incidence rates between white and black children is clearly shown in the 
USA where the annual incidence of cancer is 12.9 per 100,000 white children per year 
and 9.7 per 100,000 black children per year (6,7,11-13). 
Pediatric cancers appear to be a distinct group of diseases (14). They are mainly 
embryonal in type and evolve from malignant transformation of developing tissues (14), 
in which genetic influences are probably greater than environmental factors (14). In 
concordance with this is the fact, that young children « 5 years) are more frequently 
stricken by malignant tumors than older children (>5 years) (Table 1) (3,4). 
Leukemia is the most common cause of cancer in children, accounting in the 
Netherlands for 28% of all cases (Figure 1) (3,4). Central nervous system (CNS) tumors 
are second most common, followed by lymphomas, soft-tissue sarcomas, renal tumors, 
and tumors of the sympathetic nervous system (SNS) (predominantly neuroblastomas) 
(Figure 1) (3,4). Each year 100-110 children with leukemia are diagnosed (3-5,16-19). 
Incidence rates are 3.8 per 100,000 children per year for boys and 3.6 per 100,000 
children per year for girls (3,4). These childhood leukemia rates in the Netherlands 
appear to be more or less similar to those in other countries of similar socio-economic 
status (7-9,20-23). As in other malignant tumors, leukemia occurs more often in males 
than in females, a pattern that is consistent across racial and geographic boundaries 
(20-22,24). 
TABLE 1. Incidence rates per 100,000 person-years for invasive tumors among children according to sex 
and age in 1989/1990 in the Netherlands3 • 
Age {years} Male Female Total 
<1 17.6 18.3 18.0 
1-4 18.6 17.8 18.2 
5-9 12.6 9.3 11.0 
10-14 13.4 11.8 12.6 
a. According to Netherlands Cancer Registry/coordinating Council of Comprohensive Canc~r Centres (soe references 3 and 4). 
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Figure 1. The relative frequency of various malignant tumors among children (age < 15 years) in the 
Netherlands (1989 M 1990) according to the Netherlands Cancer Registry (3,4). The classification is 
according to Birch and Marsden (15). Abbreviations used: eNS, central nervous system; SNS, 
sympathetic nervous system. 
About three quarter of all leukemias in children are acute lymphoblastic leukemias 
(ALL) (Figure 2)' with a peak incidence between the ages of two and five years 
(Figure 3) (19). This peak was first found in Great Britain during the 1920s and 1930s 
and occurred later on in other industrialized countries (19-22); in the USA in the 1940s 
and in Japan in the 19605 (20-22). This peak appeared to be an exclusive characteristic 
of precursor B·ALL (19·22). This has prompted speculation that this peak may reflect 
environmental exposures associated with modernization and better socio-economic 
status, all the more since in Africa and many developing countries this peak does not 
occur (19·22,25). 
Childhood ALL subtypes have been identified by immunological marker analysis 
(Figure 2) (see also section 1.3: Diagnosis of childhood ALL). The geographical 
distribution and proportional representation of these ALL subtypes was very similar in 
various developed countries, while precursor 8-ALL appeared to occur in a relative lower 
frequency in developing countries and T-ALL correspondingly in a relative higher 
frequency (19·22). Although it has been hypothesized that this results from 
underdiagnosis of precursor 8-ALL in developing countries, it has also been suggested 
that children in industrialized countries are exposed to leukemogens that specifically 
cause precursor B·ALL (19-22,25). 
Over the years, there has been considerable interest in the reported occurrence of 
so-called leukemic clusters, i.e. the observation of a greater than expected number of 
leukemic cases within a geographic area or time period (26-28). The documentation of 
these leukemic clusters would have profound epidemiological implications, potentially 
permitting identification of common infectious or environmental exposures (26-28). 
However, in the majority of possible clusters, relations of leukemia with certain risk 
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Figure 2. The relative frequency of 
leukemia and immunological subtypes of 
ALL in children (age < 1 5 years) in the 
Netherlands (1987~1992). With permission 
from the Dutch Childhood Leukemia Study 
Group (DCLSG) (3,4,19). 
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leukemia ALL 
factors were difficult to prove (26-28). Recently, new indications were suggested for a 
transmissible/infectious agent (e.g. virus) as etiologic factor for ALL based on cluster 
analyses (29). 
Survival rates of childhood cancers dramatically improved throughout the last 20 
years; this occurred particularly in leukemias, brain tumors, soft tissue sarcomas, and 
renal tumors (6,9,10,12,30-32). Especially, in ALL the survival rates improved signifi-
cantly (6,9,10,12,30-33). In the Netherlands, the overall survival rate improved from 
Figure 3. Number of ALL 
patients and age at diagnosis 
in the Netherlands (1986~ 
1991). Adapted from Dr. 
J.W.W. Coebergh et al. (19) 
with permission. 
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Figure 4. Survival rates of children with ALL in the Netherlands between 1972 and 1991 (33). With 
permission from the DCLSG (33). 
-30% in 1975 till -70% in 1991 as indicated in Figure 4(33). 
1.2 ETIOLOGY OF CHILDHOOD ALL 
Both inherited and environmental factors are assumed to be responsible for the 
induction of leukemia by various mechanisms (14,20,34,35). The various genetic and 
environmental factors associated with the etiology of ALL are summarized in Table 2. 
The relation between genetic abnormalities and leukemia is clearly indicated by the 
relatively high incidence rates for acute leukemias in Down's syndrome or Klinefelter's 
syndrome (34~38). In other genetic diseases, characterized by abnormalities of DNA 
repair processes, also higher incidence rates for ALL are found (Table 2) (34,35,37,39-
43). Evidence that inherited factors playa role in the induction of leukemia are weak, 
although occasional familial clustering has been reported (37,44). However, strong 
support for an inherited predisposition gives the high concordance rate (up to 25%) of 
infant ALL in identical twins. This concordance rate appeared to diminish with age 
(14,37,45). The association between immunodeficiencies and lymphoid malignancies is 
evident (46,47). The majority of lymphoid malignancies in immunodeficiencies is, 
however, of mature B-cell type (e.g. B-cell non-Hodgkin lymphomas (NHL)). probably 
except for T-ALL in ataxia telangiectasia (41,42,46,47). 
The relation between environmental factors and ALL was proven by studies on 
young survivors of the atomic bomb in Japan and possibly a marginally increased rate of 
ALL in children subjected to diagnostic irradiation in utero (37,48-50). The risk of acute 
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TABLE 2. Possible factors associated with etiology in childhood ALLIiI. 
Genetic factors 
Down's syndrome 
Klinefelter's syndrome 
Bloom syndrome 
Fanconi's anemia 
Ataxia telangiectasia 
Immunodeficiency 
Wiskott-Aldrich syndrome 
Congenital hypogammaglobulinemia 
Ataxia telangiectasia 
a. References 14,29,34.-.68. 
Environmental factors 
Radiation - atomic bomb explosions 
- fallout from nuclear testing or accidents 
- therapeutic irradiation 
- diagnostic radiation in utero 
Low frequency electromagnetic fields 
Chemicals - benzene 
- herbicides and pesticides 
Drugs - alkylating agents 
- Topoisomerase II inhibitors 
Viral infections 
17 
leukemia (acute myeloid leukemia (AML) more than ALL) after therapeutic irradiation 
was proven in several studies, analyzing data of patients treated with radiotherapy for 
primary cancers or ankylosing spondilitis (51,52). Several studies, suggesting a relation 
between ALL and radiation from nuclear plants (53)' accidents with nuclear plants (54), 
or fallout from nuclear testing (55,56), could not be confirmed upon re-examining the 
data (57,58). The role of background or 'natural' radiation as an etiologic factor in the 
induction of ALL remains unclear so far because it is difficult to investigate (59-61). 
Exposure to chemicals, such as benzene, pesticides, and herbicides, is associated 
with an increased risk of leukemia (62,63). In case of exposure to benzene, the 
association with the development of AML in adults is clear (62). However, direct 
evidence linking such exposure to the development of childhood ALL does not exist. A 
possible association between herbicides and pesticides and leukemia was found in a 
leukemic cluster in the Netherlands, where a four times higher incidence of 
hematological neoplasms was found (63). 
There is substantial evidence that chemotherapy, particularly alkylating agents has 
leukemogenic potential (64). Most of these leukemias are AML (64). Other factors 
studied for possible association with ALL include exposure to electromagnetic fields, 
maternal use of alcohol, contraceptives, or cigarettes (14,65). Definitive links between 
these factors and the risk of childhood ALL have not been confirmed. 
The role of viral infections in the induction of ALL is, in spite of its clear relation 
with Burkitt lymphoma (Epstein Barr virus) and adult T-cell leukemia and lymphoma 
(human T-cell leukemia virus), not proven (66,67). Moreover, the lack of evidence of 
clustering childhood leukemia argues against a viral factor to the etiology of ALL, 
despite Greaves' hypothesis (68-71). This hypothesis emphasizes the role of either a 
non-specific antigenic challenge or infection by a specific agent (e.g. virus) in modula-
ting the late-stage malignant events leading to ALL (68-71). Recently, by re-analyzing 
several clusters of ALL, new indications were found for a transmissible agent important 
as an etiologic factor of ALL (29). 
Even though in a minority of ALL cases the correlation with one of the above 
mentioned risk factors is likely, the cause of childhood ALL remains unknown (72). The 
solution to the 'mystery' of childhood ALL may lie within the developmental biology of 
the cell type from which this disease arises (73-75). The immature B- and T-cells are, 
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due to its intrinsic developmental program, at higher risk of '(spontaneous) mutation' 
than other somatic cells, particularly at early stages of its development (76-80). This 
mutagenic activity is partly based on rearrangement processes, dependent on several 
recombination enzymes (e.g. recombination activating genes (RAG1 and RAG2)) (81). 
Therefore, children are probably more prone to develop ALL than adults, because their 
immune system goes through a rapid developmental stage and moreover, encounters a 
tremendous amount of 'new' antigens from their environment (e.g. infectious agents) 
(76-80). 
It seems logical that several risk factors, which are mentioned above (e.g. genetic 
diseases, radiation, or viral infections) (Table 2), can influence directly .or indirectly the 
occurrence of mutations (72). Still, leukemias will only develop through mutatianal 
events when these mutations affect certain genes (73,82,83). Many .of these crucial 
genes are so-called preto-encogenes, genes designed te regulate .or premete n.ormal 
grewth (84-94). When these genes are made hyperactive by mutatiens, such as peint 
mutatiens, translecatiens, .or amplificatien, they can cause inappropriate gr.owth (84-94). 
Cenversely, tumer suppresser genes normally restrain growth, but inactivatien by point 
mutations, deletions, and chromesemalless, contributes to once genic change (86-95). 
The findings .of non-random chromosomal abnermalities associated with ALL has 
focussed on the role .of specific genes, which reside nearby chramosomal breakpoints 
(93,94,96-104). Moreover, the role .of proteins encoded by these genes or fusion 
proteins (also called chimeric oncoproteins) encoded by genes on both sides .of the 
chramosomal breakpoint, increasingly have been the subject .of research the last decade 
(105,106). Many of these proteins are encoded by kn.own proto-oncogenes, some by 
known tumor suppressor genes (95,99,104). They can be classified by their lecatiens 
.outside the cell, en "the cell surface, or in the cytoplasm .or nucleus (Figure 5) (91,99,-
104,107). Furtherm.ore, in most cases their function can be linked te parts .of the signal 
transduction pathway involving growth and proliferation of the cell (Figure 5) (91,99,-
104). It is therefare lagical that deregulatian of several of the main steps in this Signal 
transduction pathway were faund t.o be asseciated with human malignancy, in particular 
ALL (Figure 5) (91,99,104). However, it should be kept in mind that malignant transfor-
mation of a cell is a complex phenomenon and generally a multiple-step process. It is 
likely that the activation of a preto-oncogene, as described here, provides only one of 
these steps and must be preceded or followed by other genetic or epigenetiC alterations 
to accomplish neoplastic grawth in vivo (91,94,99,104). Not all chromosomal 
abnormalities are assumed to be causal factors in the etiolagy of childhOOd ALL. 
Especially numerical chromosomal abnormalities, frequently found in childhood ALL, are 
probably secondary to the malignant transformation and maturati.on arrest .of an 
immature Iympheid cell. 
ALL, like other lymphoid malignancies, is believed to devel.op as a consequence .of 
malignant transformation of a single abnormal progenitor cell, which has the capability 
to expand by unrestrained growth and self-renewal (87,104). The ability to differentiate 
is decreased or blocked. Therefore, heterageneity within the ALL cell population is 
seldomly found. This is in contrast with AML, in which heterogeneity is an important 
feature. Some AML appeared to have the ability to differentiate (87,104,108). 
Evidence for the clonal origin .of ALL are derived from studies of glucose-6-
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Signal transduction 
Factor Defeot Malignancy 
T --GF IL-3 1(5:14) common ALL ¥ GFR ........... CSF1R mutation MDS,AML 
membran~ ~ GD·········· ABL 1(9:22) CML, ALL, AML 
cytoplasm 1 
0~ BCR 1(9:22) CML, ALL, AML RAS mutation many 
1 
nucleuSr~ MLL 1(4:11) null ALL HLF 1(17:19) common ALL 
transcription PBX1 1(1:19) pre~B~ALL 
factors I regulators c~MYC 1(8:14) B-ALL 
TAU 1(1:14) / TAU del T-ALL 
RBTN1/2 1(11 :14) T-ALL 
ABL 1(9:22) CML, ALL, AML 
suppressors i RB mutation, de! many ~ p53 mutation, del many 
Bio[ogical response 
Figure 5. Schematic representation of a signal transduction pathway involving growth factors (GF), 
growth factors receptors (GFRL tyrosine kinases (TK), G~proteins (G), GTPase activating proteins (GAP)' 
and nuclear transcription factors, transcription regulators, and suppressor genes. Examples of altered 
signal transduction genes and their relation with malignancy are also shown (Abbreviation used: del, 
deletion of chromosome or chromosomal region). Adapted from Yunis and Tanzer (99). 
phosphate dehydrogenase isoenzyme types (109)' immuno[ogioa[ marker analysis 
(110,111), deteotion of identioa[ immunog[obulin (Ig) idiotypes (112,113), ohromosome 
studies (114-116), and mo[eou[ar biology studies of leukemic [ymphob[asts, suoh as 
analysis of [g and T-oell receptor (TcR) gene rearrangements (117-120), analysis of 
restriction fragment length polymorph isms (121), determination of X-chromosome 
inactivation, and determination of X-linked DNA polymorph isms (122-125). Several of 
these techniques will be discussed in section 1.3: Diagnosis of childhood ALL. 
1.3 DIAGNOSIS OF CHILDHOOD ALL 
Introduction 
ALL is a disorder characterized by the uncontrolled growth and proliferation of immature 
lymphoid oells, which then represent 25% or more of all bone marrow (BM) cells 
(14,126). The presenting features of ohi[dhood ALL reflect the suppression of normal 
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hematopoiesis causing anemia, neutropenia, and thrombocytopenia, which can lead to 
infection and hemorrhage, and/or involvement of lymphatic tissue, causing obstruction 
of vital organs (e.g. vena cava superior syndrome) (14,127). Symptoms of ALL may be 
subtle and misdiagnosed for other more common disorders. The majority (85%) of 
children with ALL develop symptoms more insidiously over weeks or a few months. 
Common symptoms include pallor I fever, recurrent infections, malaise, abnormal 
bruising, and bone or joint pain (14,127). Due to these varied presentations, childhood 
leukemia must be considered in the diagnosis of any unusual illness especially if 
accompanied by hepatosplenomegaly, lymphadenopathy or bone tenderness (14,127). 
The diagnosis of ALL, traditionally based on the cytology of smears of BM and 
peripheral blood (PB) I has become more accurate, since advances in immunophenoty-
ping, cytogenetics, molecular immunology, and other molecular and cellular techniques 
have improved the specificity of diagnosis and have given the possibility to further 
subcategorize the disease (126,128,129). 
In the Netherlands, ALL in children is diagnosed in the local hospitals and 
confirmed by the laboratory of the Dutch Childhood Leukemia Study Group (DCLSG). 
Immunophenotyping and DNA-ploidy measurements are also centrally performed in the 
DCLSG laboratory. Additional tests, if necessary, are coordinated. Extensive 
immunophenotyping and immunogenotyping of children with ALL, diagnosed in the 
Sophia Children's Hospital, Rotterdam, are performed at the Department of Immunology, 
University Hospital Dijkzigt (immunophenotyping and immunogenotyping). Cytogenetic 
studies of childhood ALL are performed in several major centers in the Netherlands. In 
Rotterdam, cytogenetic studies are performed at the Department of Cell Biology and 
Genetics, Erasmus University, Rotterdam. 
Morphological analysis 
An useful classification system should be reproducible, should have a high degree of 
observer concordance, and should provide relevant information for clustering various 
diseases which share common features of etiology, pathogenesis, biology, clinical 
presentation and response to therapy. In 1976, the French-American-British (FAB) 
collaborative group proposed criteria for classifying ALL into three subtypes based on 
blast cytology, as seen in Romanowsky's or May Grunwald Giemsa stained BM smears 
(130). Assignment to one of these groups (L 1, L2, or L3) is depending on the criteria 
shown in Table 3 (130). Due to difficulties in distinguishing the L 1 and L2 cell types, a 
modification of this proposal was published in 1981 (131). In the revised form, a scoring 
system for identifying L 1 and L2 was suggested, based on four cytologic features: (1) 
nuclear cytoplasmic ratio, (2) presence, prominence and frequency of nucleoli, (3) 
regularity of nuclear membrane outline, and (4) cell size. By this method an overall 
concordance of 84% between observers was reported (131,132). The occurrence and 
prognosis of the FAB classification in ALL are shown in Table 3 (128,131-139). 
To discriminate between AML and ALL cytochemical characteristics are used (126, 
128,140). Cytochemical reactions such as myeloperoxidase (MPO), Sudan black B, and 
a-naphthyl acetate esterase are positive in the majority of AML cases and negative in 
the majority of ALL cases (126,128,139-142), while periodic acid-Schiff (PAS) is 
positive in approximately 90% of ALL cases and negative, or only weakly positive, in 
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TABLE 3. Morphological FAB classification of ALL and its occurrence and prognosis in childrenD • 
L1 L2 L3 
Cytological features 
Cell size small cells predominate large, heterogeneous in large, homogeneous 
1<15"1 size (>15,u.) 
Nuclear chromatin homogeneous in any variable in anyone case finely stippled, homo~ 
one case geneous 
Nuclear shape regular, occasional clef~ irregular, clefting and regular, oval to round 
ting or indentation indentation common 
Nucleoli not visible or very small one or more present, prominent, one or 
often large more 
Cytoplasm 
~ amount scanty variable, often mode~ moderately abundant 
rately abundant 
~ basophilia slight or moderate, variable, deep in some very deep 
rarely intense 
~ vacuolation variable variable often prominent 
Occurrence -85% -14% -1% 
Prognosis good moderate~good moderate 
a. FAB classification according to- Bennen JM at al. (130). 
approximately 90% of AML cases (126,128,139). The presence of a strong, localized 
positivity for acid phosphatase is common in T-ALL, but rare in precursor B-ALL and can 
be used to discriminate between these two types of ALL (126,128). 
Immunological marker analysis 
Immunophenotyping of leucocytes began in the mid-1970s with the development of the 
hybridoma technology by Kohler and Milstein (143). This technology made it possible to 
produce large amounts of specific monoclonal antibodies (McAb) that recognize distinct 
epitopes of cellular antigens. During the last two decades many McAb against cellular 
antigens of leucocytes have become available, in which several McAb recognize 
identical antigens. To create order within these large panels of McAb an international 
nomenclature has been designed. Five Leucocyte Typing Conferences (Paris, 1982; 
Boston, 1984; Oxford, 1986; Vienna, 1989; Boston, 1993) have been organized and 
during these conferences a large part of the McAb against leucocyte antigens have been 
grouped into antibody clusters based on their reactivity with identical antigens (144-
148). Each cluster has its own code, the so-called CD ('cluster of differentiation' or 
'designation') code. So far a total of 130 CD codes have been assigned (144-148). 
Clusters, important fOT immunophenotyping of lymphoid cells, are summarized in Table 
4. In this table, the function and gene location of the recognized antigen, and the 
reactivity pattern of the clustered antibodies are shown. 
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TABLE 4. Immunological markers which are used for classifying ALL * •. 
CD no,-
Precursor marker 
CD34 precursor antigen 
TdT/function in 19 and 
T cR gene rearrangement 
(insertion of nucleotides 
at junction sites) 
B-coll markers 
CD19 
CD20 
C021 
CD22 
CD37 
C072 
CD79a 
CD79b 
pan B~cell antigenl 
function in B-cell acti-
vation: associates with 
C021 antigen (CR2l 
B-cell antigen/function in 
B-cell activation 
B-cell antigen/CR2 (C3d 
receptor): EBV receptor 
B-cell antigen/function in 
8-cell adhesion and B-cell 
activation 
B-cell antigen 
s.-cell antigen/ligand for 
CD5 antigen 
mb--1; [ga (disulfide linked 
to CD79b and associated 
with Smlg)/signal trans-
duction from Sml.9 to 
cytoplasm 
829; 19,6 (disulfide linked 
to CD79a and associated 
with Smlg)/signal trans-
duction from Smlg to 
cytoplasr:n 
weak Cylgf.' (weak cyto-
plasmic expression of rg,u 
chain) 
Smlg (surface membrane 
immunoglobulin); IgM 
IgD, [gA, IgE 
Cylg (cytoplasmic im-
munoglobulin) 
Gano toeetlon 
lq32 
(1 ql 2-qter) 
10q23-q24 
? 
11 q12-ql 3.1 
lq32 
? 
9p 
(>6 kb) 
17q23 
(30 kb) 
14q32.3 
IgH: 14q32 
IglC: 2p12 
Igk 22qll 
IgH: 14q32 
IgK: 2p12 
Ig>..: 22ql1 
14q32 
Rellctlvlty with hlmlGtopo!etie eolb 
precursors of lymphoid 
cells, precursors of myeloid 
cells 
immature lymphoid cells, 
small part of precursors of 
myeloid cells, virtually all 
ALL and some AML 
McAb (mouse botypejb 
conventional antiserad 
precursor B-cells and B-cells Leu-12(-yl)d, B4(-yl)e 
subpopuJation of precursor 
B-cells, all S-cells, follicular 
dendritic reticulum cells 
subpopulations of B-cells 
(e.g. follicular mantle cells), 
follicular dendritic reticulum 
cells, subset of thymocytes 
Bl ('Y2a)" 
precursor B--cells and mature Leu-14('Y2b)C:: 
B-cells 
S-cells; weak expression on 
T-cells, monocytes and gra-
nulocytes 
precursor B-cells and mature: 
B-cells 
precursor S-cells (cytoplas-
mic expression; CyCD79al 
and mature Smlg+ B-cells 
(membrane expression; 
SmCD79a); plasma cells (?) 
precursor B-cells (cytoplas-
mic expression; CyCD79b) 
and mature Smlg + B-cells 
(membrane expression; 
SmCD77b) 
pre-B-cells; only f.' heavy 
chains are weakly expres-
zed in the Cytoplasm (no Ig 
light-chains) 
Smlg positive cells; each B-
cell clone expresses only 
one type of Ig light-chain (K 
or A), but may express mul-
tiple Ig heavy-chains 
Smlg positive cells; each B-
cell clone expresses only 
one type of Ig light-chain (K 
or A), but may express mUl-
tiple Ig heavy-chains 
Cylg positive cells (immuno-
blasts, immunocytes and 
plasma cells) 
Y29/55(-y2a)f 
HM47h'1)h, HM57(-y)h 
detect intracellular epi-
topes of CD79a 
(CD79a-Cy antibodies) 
B29/123h detects intra-
cellular epitope of 
CD79b (CD79b-Cy anti-
body); SN8(-yl)- detects 
extracellular epitope 
selected anti-,u antisera 
conventional antisera 
and McAb 
conventional antisera 
and McAb 
conventional antisera 
and McAb 
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CD no,a Name{s)/functlon Gene location Reactivity wIth hematopoietic calls MeAb {mouse isotypo)b 
T ...cell markers 
CD' T6 antigen; common lq22-q23 cortical thymocytes 66IlC7!'y2a)i 
thymocyte antigen/MHG- (strong), Langerhans cells, 
like protein; can associate subpopulation of dendritic 
with ~2-microglobulin cells, subpopulation of B-
cells 
CO2 T1 1 antigen; SRBC recep- lp13 all T-cells, most NK cells; Tl1 {-y1)0 
tor ("" E rosette receptor); three different antigenic epi-
lFA-2/receptor for T cell topes are known, of which 
activation; ligand for one is the SRBC binding site 
C05S (lFA-3) 
CD3 T3 antigen (associated l1q23 immature T-cells (cytoplas- leu-4{'Y1)C, 
with TcR)/signal trans- mic expression; CyC03) and UCHT{-y' )g,k,l,m,n,o,p,q 
duction from T cR to cyto- mature functional T -(mem-
plasm brane expression); the CD3 
antigen consists of at least 
five protein chains 
CD4 T4 antigen!involved in 1 2pter-p1 2 subpopulation of cortical Leu-3a{'Y1 )c 
MHC-class-II-restricted thymocytes, helperJinducer 
antigen recognition; HIV T -cells, subpopulation of 
receptor monocytes and macropha-
ges; some AMl 
CDS T1 antigen/function in T- 11q13 thymocytes and mature T- leu-1 !'y2a)C 
cell proliferation; ligand lymphocytes, subpopulation 
for CD72 antigen on B- of B-cells; B-Cll 
lymphocytes 
CDS T12 antigen; pan T-cell 
" 
thymocytes and mature T- OKT17!'y2)r 
antigen lymphocytes, subpopulation 
of B-cells; B-Cll 
CD7 Tp41 antigen/Fe receptor 17q25,Z- almost all T cells, NK cells, leu-9{'YZa)C 
for 19M (Fc/kR)? qZ5.3 subpopulation of immature 
myeloid cells; some AMl 
COB TS antigen; the CDS Zp1Z subpopulation of cortical most CDS antibodies 
molecule consists of two thymocytes, cytotoxic/sup- detect COS-or chain: 
diSulfide linked chains: rx-a pressor T-cells, subpoputati- Leu-Za('Y1 )C 
homodimer or ct·~ hetero- on of NK cells 
dimerJinvolved in MHC-
class-I-restricted antigen 
recognition 
TCR-c$ (classical TcR; TcR-a: 14q1 1 TcR-a,8 is expressed by a WT31{'Y1)b and 
TCRZ) TcR-~: 7q35 majority of mature CD3 + T- BMA031 !'yZW probably 
cells recognize non-poty-
morphic epitopes of 
TcR-c$ 
TcR",,(o (alternative TcR; TCR",,(: 7p15 TcR"'j'o is expressed by a anti-TcR"'j'/o-1 f-y1)C and 
TCR1) TcR-,s: 14ql1 minority of mature CD3 + T- TCR,sl (-y1)t recognize 
cells non-polymorphic epito-
pes of TcR""(o 
NK...cell markers 
CD56 NCAM; PI-linked and l1qZ3 NK cells, some T -cells (neu- leu-19f-y1 )e 
transmembrane forms roectoclermal cells) 
CDS7 human natural killer cell '1 q12-pter subpopulation of NK cells, leu-7/HNK-1 (po)e 
antigen subpopulation of T-cells, 
some B-cells 
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co .... Name(al/functlon Gene Joea.tJon 
cross-lineage myeloid markers 
CD13 pan myeloid antigen; 15q22-q26 
aminopeptidase N; dif-
terential gJycosyJation 
generates different epi-to-
pes, detected by McAb 
CD14 monocytic antigen; PI- 5q22-q32 
linked protein 
CD15 Lewis-X (Lex)~ X hapten; 11 q1 2-qter 
3-FAl (3.fucosyl.N-acetyJ-
lactosamine) 
CD33 pan myeloid antigen 1 q13.3 
CDw65 myelomonocytic antigen 11q12-qter 
{fucoganglioside; cera~ 
midedodecasaccharide 
401 
MPO (myeloperoxidase); 17q2l.3~q23 
MPO consists of two sub-
units 
non..Jineage restricted markers 
CD9 p24 antigen (tetras pan 12p13 
molecule)/induction of 
agregation of platelets 
COlO common ALL antigen 3q2l'q27 
{CALLA)/neutral enda-
peptidase (enkephalinase) 
C023 B-cell antigen/F~RII {low lSp13.3 
affinity Fc receptor for 
IgE); two types of FceRIl 
exist, which differ in their 
cytoplasmic domain 
(F~Rlla and FCeRllb) 
CD24 B-cell-granulocytic anti· 
gen; PI·linked protein on 
granulocytes 
C025 Tac antigen!" chain of the 10p15-p14 
Il·2 receptor (low affinity 
Il·2R); high affinity IL-2R 
when associated with (3 
chain (CD122 antigen) 
andlor -y chain 
Rouctlvity wIth horrnItopoiotic coll$ MeAb (mouS(llaotypo)b 
almost aU myeloid celis, My7(-yl )"', leu-M7(,),1 Ie, 
dendritic cells in the skin CL&-mon-gran/2(-y2a)U 
monocytic celis, macropha- My4(-y2b)O 
ges, follicular dendritic 
reticulum cells, B-(weak); 
absent in patients with PNH 
cells of the granulocytic Vim-OS(u.)V, 
lineage, weak expression by ClB-gran/2(j4)U 
monocytes, Reed Sternberg 
cells 
majority of myeloid and mo· My9(-y2W
'
, Leu-M9(-yl)C 
nocytic cells (except for gra· 
nulocytes) 
majority of myeloid and ma- VIM~2(u)m,3.v 
nocytic cells and a part of 
their precursors 
majority of cells of the mye~ MPO.7(-yl )k 
loid lineage (granulocytic 
and monocytic cells) 
subpopulation of precursor BA-2(-y3)W, 
B-cells, subpopulation of B· ClB-thromb/8(-y2aJl,I 
cells (follicular center cells), 
monocytes, megakaryocy. 
tes, platelets, eosinophils, 
basophils 
subpopulation of precursor OKBcALLa{-y2a)O, 
B-cells, subpopulation of B- J5{-y2a)(j,1 
cells (follicular center cells), 
subpopulation of cortical 
thymocytes, granulocytes 
FceRlla is expressed by a Leu-20{-y1 )c, 
subpopulation of B-cells TGl (-yl )O,I,I,X 
(e.g. follicular mantle cells) 
and B~CLL cells; FceRllb is 
expressed by subpopulation 
of B·cells, monocytes, eo-
sinophils, dendritic cells 
sub population of (precursor) BA~ 1 (,u)W, 
B-cells, granulocytes; ab- CLB""9ran.B-ly/1 (-y1)U 
sent on granulocytes in 
patients with PNH 
activated T-celJs, activated 2A3{-yl)e 
B·cells, activated macropha~ 
ges; HCL 
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CD no! 
CD71 
Nmno(lIllfunction 
T9 antigen (homodi· 
mer)/transferrin receptor 
Gene location 
3q26.2·qter 
HLA-DR, non-polymorphic 6p21.3 
antigen/MHC-class II 
molecule 
nuclear antigen in proli- 10 
ferating cells 
MDR1; P-glycoprotein <p. 7q21.1 
gp)/transmembrane pump 
for cytotoxic pro-ducts, 
including several Cytosta· 
tics, thereby causing mul-
tidrug resistance (MDR) 
a. CD = cluster of differentiation, as described du-
ring the Leucocyte Typing Conferences (Paris, 
1982; Boston, 1984; 
Oxford, 1986; Vienna, 1989; Boston, 19931. 
b. Only McAb are included, which are routinely 
used in the Immunodiagnostic laboratory of the 
Department of Immunology, University Hospital 
Dijkzigt, Rotterdam, The Netherlands. 
c. Becton Dickinson, San Jose, CA. 
d. Supertechs, Bethesda, MD. 
e. Coulter Clone, Hialeah, Fl. 
f. Dr. H.K. Forster, Hoffmann La Roche, Basel, 
Switzerland. 
g. Immunotech S.A., Marseille, France. 
h. Dr. D.Y. Mason, Oxford, UK. 
i. Monosan, Sanbio B.V., Uden, The Netherlands. 
k. DAKOPATTS, Glostrup, Denmark. 
I. Sera Lab, Crawley Down, UK. 
m. Serotec, Oxford, UK . 
Reoctlvlty with hlll'niltopolot!c cens McAb (mouse l$otypo)1> 
proliferating cells (e.g. thy· 661Gl0(-y2a)i 
mocytes), activated cells, 
macrophages 
hematopoietic precursor 
cells, 8-ceHs, activated T· 
cells, monocytic cells and 
macro phages 
proliferating cells during late 
Gl, S, G2 and M phases of 
the cell cycle 
very low expression (gene· 
rally not detectable by use 
of antibodies) in blood and 
bone marrow cells; high 
expression in some leukemi-
as, especially a part of AML 
L243(72a)C 
Ki-67(71 )k 
JSs., (71)1 and 
C219(-y2a)Y detect . 
intracellular epitope of 
MDR1; MRK16(72a)9.l: 
detects extracellular 
epitopes of MDRl 
n. PharMingen. ITK Diagnostics B.V., Uithoorn, The 
Netherlands. 
o. Cymbus Bioscience Ltd, Southhampton, UK. 
p. Sigma Immunochemicals, Brussels, Belgium. 
q. Ansell Corporation, Uiufelfingen, Switzerland 
r. Ortho Diagnostic Systems, Raritan, NJ. 
s. Behring, Marburg, FRG. 
t. T-CELL DIAGNOSTICS, Cambridge, MA. 
u. Central Laboratory of the Blood Transfusion 
Service, Amsterdam, The Netherlands. 
v. Dr. W. Knapp en Dr. O. Majdi6, Vienna, Austria. 
w. Boehringer Mannheim, Mannheim, FRG. 
x. Biotest, Dreieich, FRG. 
y. Centocor Europe, Leiden, The Netherlands. 
z. Hoechst Japan LTD, Kawagoe, Japan. 
Recently clustered antibody (Leukocyte Typing 
Conference V, Boston, 1993), of which the 
availabilitY is not yet known. 
.... Adapted from Van Dongen JJM and Comans-Bitter WM. LeukocytentYpering en de CD nomenclatuur. In: Van 
Dongen JJM, Groeneveld K, Adriaansen HJ, and Hooijkaas H, eds: ImmunofenotYpering in de diagnostiek: 
lndicatiestellingen. uitvoering en interpretatie. Afdeling lmmunologie, EUR Rotterdam, 1994. 
Beside morphological characterization, immunological marker analysis can further 
characterize the cells of the various hematopoietic differentiation stages (110,111,128,-
149-153). Although immunological markers represent differentiation antigens, they 
usually are not specific for one differentiation stage, but are expressed in several stages. 
However, the expression of a specific set of markers can designate a cell to a particular 
differentiation stage (110,111,149-153). The combination of the various markers per 
lymphoid differentiation stage is summarized in Figure 6. 
Several markers are not restricted to one differentiation lineage, but are expressed 
in several lineages (B-, T-, or myeloid lineage) (Figure 6 and Table 4). The enzyme TdT is 
present in the nucleus of immature lymphoid cells, but is absent in more mature stages 
(110,111,152). The precursor antigen CD34 is found on most immature cells of both 
lymphoid and myeloid stages (Figure 6 and Table 4) (110,111,152). The HLA-DR 
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gg~ (pr&(l ~mllll'.cD7tl1 poripheral T-NHL O CyCD79 ~rQo-B Cyrg~ 
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HLADR ~'" -- --~
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thymocyto O~ *"k 
~~~ "''''{q~a porlphoml T-NHL 
d;8& common thymocyto ~ T·ALL T-LGL leukemia I 
C05 ~ 0--0-- @ 
~~3 matum cytotoxic! activated 
CO, thymocyto supprossor cytotoXic! 
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Figure 6. Hypothetical scheme of lymphoid differentiation. The expression of relevant immunological 
markers is indicated for each differentiation stage; markers in parentheses are not always expressed. The 
bars represent the various types of leukemias and NHL and indicate where these malignancies can be 
located according to their maturation arrest: ALL, acute lymphoblastic leukemia; ATLL, adult T~cell 
leukemia lymphoma; AUL, acute undifferentiated leukemia; CS, centroblastic lymphoma; CSMCC, 
centroblastic~centrocytic lymphoma; CC, centrocytic lymphoma; CLL, chronic lymphocytic leukemia; 
CTLL, cutaneous TMcell leukemia lymphoma (mycosis fungoides/Sezary syndrome); HCL, hairy cell 
leukemia; HTLV, human T~cel! leukemia virus; T~LGL, T-cell large granular lymphocytic leukemia; NK cell 
LGL, NK cel! large granular lymphocytic leukemia; NHL, nonMHodgkin lymphoma; PLL, prolymphocytic 
leukemia. Adapted from ref. 111 and reproduced with permission from the authors. 
antigen is expressed by cells in 
by B~cells, monocytic cells, 
examples are shown in Table 4. 
immature hematopoietic differentiation stages, but also 
and activated T-Iymphocytes (110,111,152), More 
The reactivity of the McAb can be visualized by staining methods, in which 
fluorochromes or enzymes are generally used as labels (154,155). These staining 
techniques can be used for the detection of immunological markers on hematopoietic 
cells in suspension as well as on cells in tissue sections (154,155). Not only single 
staining, but double and -even triple stainings can be done by use of different fluorochro-
mes or enzymes (156). The evaluation of immunofluorescence (IF) stained cells can be 
performed with IF-microscopic or flow cytometric techniques (155,157-160), 
The maturation arrest of the ALL is localized in the immature differentiation stages 
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TABLE 5. Immunophenotypes of ALL. 
ALL TdT HLA-OR C019 C010 Cylg~ pre~B Smlg pan T~cell 
and/or Smlg~~ marker 
C022 C079 
null ALL + + + 
common ALL + + + + 
pre~B~ALL + + + + + 
tr~pre~B~ALL + + + + + + 
B~ALL + + -/+ + 
T~ALLa + -/+ -/+ + 
a. Several subtypes of T·ALL can be recognized, based en their positivity for tho various T ·coll markers. 
(110,111,149,150,152,153)_ Chronic lymphocytic leukemias (CLL) are the malignant 
counterparts of cells in more mature differentiation stages (11,0,111,150). Generally, 
NHL have a mature immunophenotype (Figure 6) (110,111,150), Initially, the ALL were 
divided in four distinct subgroups according to Nadler et al. (161). Nowadays, we 
recognize five different types according to their immunophenotype: null All, common 
ALL, pre-B-ALL, B-ALL and T-ALL (110,111,150-153,162)_ The pre-B-ALL is defined by 
the cytoplasmic expression of Ig heavy chain I" (CyI9l") _ Recently a subgroup of the pre-
B-ALL has been defined, which expresses not only Cy19l" but also a pre B-cell complex 
(pre-B Smlgl"-C079) on the surface membrane_ This subgroup of pre-B-ALL is called 
transitional pre-B-ALL (tr-pre-B-ALL) (153,162,163)_ The immunophenotypes of all six 
ALL are summarized in Table 5. T-ALl can be subdivided into several immature and 
more mature subtypes, as indicated in Figure 6 (111,164)_ 
The distribution of specific immunophenotypes of ALL is clearly influenced by age 
(Figure 7) (19)_ In infants, there is a predominance of null ALL, while in children 
between the age of two and five years the CD10+ precursor B-ALL dominate (common 
ALL and pre-B-ALL) (Figure 7)_ T-ALL are relatively more frequently found in older 
children starting with the age of six (Figure 7)_ 
The prognostic significance of subtyping childhood ALL is based on the fact that 
the different subtypes of ALL have different outcomes when compared to each other 
(153,165-167). Common ALL have the best prognosis, while null ALL and T-ALL have 
the worst (153,165,167). Upon looking at single markers or combination of markers as 
individual prognostic features, such as CD10 or CD34 expression or activation status 
(C038 or C071 positivity) of the malignant cells (168-171), the results are uncertain 
because in the majority of studies no adjustments were made for other risk factors, such 
as age, high white blood cell (WBC) count, or therapy (168-171)_ Recently, several 
articles have been published about cross-lineage marker expression in ALL (e.g. myeloid 
marker positive precursor B-ALL) (167,172-178)_ Although large groups of childhood 
precursor B-ALL patients have been analyzed, the conclusions of these results are not 
concurrent. Still a tendency towards a worse prognosis for myeloid marker positive 
precursor B-ALL is observed (153,1 67,173-178) _ The clinical outcome of the various 
subtypes of ALL seems to be also dependent on the presence of specific karyotypic 
abnormalities (153,179)_ The prognosis of these ALL can, therefore, not only be 
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null ALL common ALL 
T-ALL 
1 2 3 4 5 6 7 S 9 10 11 ~ 13 '4 15 0 , 2 3 4 5 6 7 a 9 10 '1 12 m ~ 15 
age at dlagnosls 
Figure 7. Number of ALL patients divided in four subgroups (null ALL, common ALL, pre-B-ALL, and T-
ALL) according to age at diagnosis in the Netherlands (1986-1991l. Adapted from Coebergh JWW et al. 
(19) with permission. 
determined by immunological marker analysis. 
Cytogenetic analysis 
Cytogenetic analysis in ALL is more difficult than in AML. In ALL, despite high cellularity 
and high percentages of leukemic cells in BM and PB, only a low yield of leukemic 
meta phases is obtained, with chromosomes which are very fuzzy and of poor morpholo-
gy (180,181). The success rate of chromosome studies in ALL is dependent on the time 
between harvesting and analyzing the leukemic cells and on the experience of cytogene-
tic laboratories (180,181). In multicenter trials an average of -70% successful 
cytogenetic analyses is reached (182), whereas in several single-center trials, 
cytogenetic analysis is successful in 90-95% (180,181,183). 
)0 In childhood ALL the abnormal karyotypes are distributed in five categories, based 
on changes in ploidy: high hyperdiploid with more than 50 chromosomes, hyperdiploid 
with 47-50 chromosomes, pseudodiploid, normal (diploid), and hypodiploid (116,183-
187). The frequencies of these different groups in childhood ALL are summarized in 
Table 6 (116,181,183-188). The DNA content of leukemic cells can easily be estimated 
by flow cytometry in nearly all ALL cases (189-191). With this method, a DNA index 
(ratio of the DNA content of leukemic GO/G , cells versus that of normal diploid cells) can 
be derived, which serves to distinguish two prognostic categories of patients based on 
the findings: < 1.16 or ;" 1.16 (approximately equal to < 53 or ;" 53 chromosomes) 
(191). These hyperdiploid groups show a specific pattern of gain of chromosomes with 
mainly trisomy of chromosomes X, 4, 6, 10, 14, 17, 18 and often tetrasomy 21 
(116,181,183,187,192). Several studies about large groups of ALL patients have con-
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TABLE 6. Distribution of karyotypes in childhood ALL o• 
Ploidy-group 
Hypodiploid 
near haploid 
hypodiploid (30-40 chromosomes) 
hypodiploid (41-45 chromosomes) 
Pseudodiploid 
Normal (diploid) 
Hyperdiploid 
hyperdiploid (47-50 chromosomes) 
hyperdiploid (> 50 chromosomes) 
near triploid 
near tetraploid 
a. References 116,181,183-188,212. 
Frequency (%) 
5 
<1 
<1 
5 
25-35 
10-20 
40 
10-15 
25-30 
<1 
1 
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sistently indicated that a DNA index '2:: 1.16 equates with a favorable outcome, 
especially in precursor S-ALL (192-202). 
The largest ploidy group in ALL is the pseudodiploidy group, characterized by a 
chromosome number of 46 per cell with structural abnormalities, mainly translocations 
(Table 6) (116,181,183,187). As recently indicated in the literature, it is likely that the 
occurrence of these chromosomal abnormalities is underestimated when analysis is 
performed with standard cytogenetic techniques (203). However, molecular screening 
for such abnormalities by the polymerase chain reaction (peR) or with the fluorescence 
in situ hybridization (FISH) technique will identify more cases that are missed by 
cytogenetic studies, either because of technical difficulties or because these abnormali-
ties were not visible by light microscopy (203-208). Two other advantages of the FISH 
technique is the detection of both numerical and structural aberrations not only in 
metaphase spreads but also in interphase nuclei, and the possibility to combine the FISH 
technique with morphological or immunological analysis (207-211). The incidence of 
ALL cases that lack apparent cytogenetic abnormalities will probably diminish when 
these new techniques are used routinely. 
Hypodiploidy is a relatively uncommon finding in ALL, affecting only 5-7% of 
patients (116,181,187). Most cases (> 80%) have 45 chromosomes with loss of 
chromosome 20 (187). Recently, three subdivisions of the hypodiploid category were 
recognized (Table 6) (212). Prognostic implications can not be determined for each of 
these categories due to the limited number of cases reported (187,212). 
In the majority of ALL cases at least one non-random chromosomal abnormality 
could be detected, often in association with a specific immunophenotype (179;187,-
213,214). Describing ALL by the types of structural abnormalities found in chromoso-
mes of the leukemic cells has led to impressive advances in the understanding of the 
origin and development of leukemia (94,105). Molecular analysis of genes adjacent to 
the breakpoints of these structural abnormalities and studies on the functions of their 
protein products have helped to gain understanding in the complex interactions that 
support leukemogenesis and perpetuate the leukemic cell phenotype {see also section 
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1.2: Etiology of childhood ALL) (94,105). Table 7 summarizes the cytogenetic 
abnormalities associated with childhood ALL, their frequency of occurrence, the genes 
involved, and their association with specific leukemic immunophenotypes. 
Within each ALL subgroup specific structural chromosomal abnormalities are found. 
In null ALL, 11 q23 abnormalities, especially t(4;11 )(q21 ;q23) have the highest incidence 
(187). These 11 q23 abnormalities are associated with a high WBC count, CNS involve-
ment, young age at diagnosis, often absence of hyperdiploidy, and a poor prognosis 
(116,187,215-217,219,220). The Philadelphia chromosome or t(9;22)(q34;q11) is the 
most frequent translocation in adult ALL and is the hallmark of chronic myeloid leukemia 
(315). It is found less frequently in childhood precursor B-ALL and rarely in T-ALL 
(116,251-253,255); it is associated with a FAB-L2 morphology and has a poor progno-
sis (254,255,316). The t(1 ;19)(q23;p13) is clearly correlated with the pre-B-cell 
immunophenotype and is one of the most common translocations in childhood ALL 
(116,187). This translocation occurs in either a balanced, t(1 ;19)(q23;p13) (25%). or an 
unbalanced, -19, +der(19). t(1;19)(q23;p13) (75%) form (261). They are associated 
with several adverse prognostic features: such as high WBC count and the lack of 
hyperdiploidy and they have an intermediate outcome (265,266). Recently, it was found 
that patients with the balanced t(1 ;19) have a significantly worser outcome when 
compared with the unbalanced der(19) form (317). 8-ALL contains one of three specific 
chromosomal translocations: the t(8;14)(q24;q32) (90%), or less commonly, either the 
t(2;8)(p12;q24) (4-5%!. or the t(8;22)(q24;q11) (6-10%). This translocation is associa-
ted with FAB-L3 morphology and extramedullary disease and has an intermediate 
prognosis (271). 
A large part of chromosomal abnormalities in T-ALL involve one of the TcR genes, 
located on either 14q11 (TcR-a/o). 7q35 (TcR-ill, or 7p15 (TcR-'l) (187,287,318). 
Apparently, these chromosomal abnormalities originate from TcR gene rearrangements 
during T-cell differentiation. Alteration of the TAL 1 gene (located on 1 p32) occurs either 
by translocation t(1 ;14)(p32;q11) or by a submicroscopic deletion of -90 kb (298-
300,303). The TAL1 deletion is the most frequent genetic lesion associated with T-ALL 
(10-30%) (299). Also in these cases the recombinase system, used in Ig and TcR gene 
rearrangements, is active via recombination signal sequences found in these gene 
regions (299). 
Lineage independent chromosomal aberrations occur rather frequently in ALL and 
encompass abnormalities of 6q, 9p, and 12p (187). In the majority of cases these 
abnormalities are deletions (187). No correlation with a specific immunophenotype is 
found although most cases with a 12p aberration have a precursor B-ALL immunophe-
notype (248). The critical region involved in 9p deletions is p21-p22, which encloses the 
interferon a and {3 gene clusters (313,314). These deletions possibly lead to loss of 
tumor suppressor genes located in this 9p region (313,314). 
The prognostic value of specific karyotypic abnormalities in ALL is high as indicated 
before. Table 8 summarizes the outcome of the various cytogenetic abnormalities found 
in the different childhood ALL. The group of patients with high hyperdiploidy shows the 
highest response rate and a probability of cure of about 85% with current therapy. 
Favorable response rate and survival time is found for the group of patients with normal 
karyotype and with slight aneuploidy (45-50 chromosomes!. provided that the poor-risk 
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TABLE 7. Cytogenetic abnormalities associated with childhood ALL n. 
Frequency (%) 
Chromosome (within immunophenotypic Immuno- Genes 
abnormality subgroup)b phenotype involvedc References 
precursor B-lineage 
t(l ;11 )(p32;q23) <1 null ALL _d ;MLL 114,215-217 
t(4; 11 Hq21 ;q23) 2 (80) null ALL AF4;MLL 114,21 5-228 
t(9;11 )(p22;q23) <1 null ALL AF9:MLL 114,229-233 
t(ll :14)(q23;qll) <1 null ALL MLL:TcR-a/o 234 
t(ll :17)(q23;q21) <1 null ALL MLL; - 235,236 
t(11:,9)(q23;p13) <1 null ALL MLL:ENL 217,237-242 
t(5:14)(q31 ;q32) <1 common ALL IL3;IGH 243-245 
dic(7;9j(p13:pll ) <1 common ALL 116,246,247 
dic(9; 12)(p11-p12;p12) 1-2 (15) common ALL 248-250 
t(9;22)(q34;qll) 2-5 (20-30) CD10+ precursor B-ALL ABL;BCR 251-255 
t(l 0;11 )(p14-p15;q23) <1 common ALL -; MLL 215,217 
t(12;21 )(pl1-p12;q22) <1 common ALL -;- 256 
t(17;l9)(q22:p13) <1 common ALL HLF;E2A 247,257,258 
t(l ;19)(q23;p13) 5-6 (90) pre-B-ALL PBX1;E2A 114,259-267 
B-lineage 
t{2;8)(pl1 ;q24) <1 (4-5) B-ALL IGK;MYC 268-271 
t{8;14)(q24;q32) 1·2 (90) B·ALL MYC;IGH 268,271-274 
t(8;22)(q24;q11 ) <1 (6-10) B·ALL MYC;IGL 268,271,275,276 
T-lineage 
t(9;22)(q34;ql1 ) <1 T-ALL ABL;BCR 116 
t(l 0,11 )(p13-14;ql4-21 I <1 T-ALl 
- I - 277 
TcR-a/O locus, located on 14q11 
t(8;14)(q24:ql1 ) <1 (2) T-ALL MYC;TcR-cdo 278,279 
t(l 0;14)(q24:qll) 1 (5-10) T·ALL HOX11;TcR-a!o 280-286 
t{11 ;14)(p13;qll) 1-2 (7) T-ALL RBTN2;TcR-rx/o 114,287-294 
t{ll ;14j(p15:ql1) <1 (1) T-ALL RBTN1;TcR-~!o 
287,290,291,293,294 
inv(14)(ql1 ;q32) <1 T·ALL TcR-~!o;IGH 287,295 
TAL 1 locus, located on 1 p32 
tal-1 deletion (1 p321 3 (10-30) T-ALL TAU 296-301 
t(l ;7)(p32;q35) <1 T-ALL TAU;TcR.{J 302 
t(1 ;14)(p32;ql1) <1 (3) T-ALL TAU;TcR·~/o 303 
TcR·{J locus, located on 7q35 
t(l ;7)(p34;q3S) <1 T-ALL LCK;TcR'{J 304,30S 
t(7;9)(q35;q34) <1 T-ALL TcR-{J;TAN1 302,304,306 
t(7;9){q3S;q32) <1 T-ALL TcR-{J;TAL2 302,304,306 
to;,0)(q35;q24) <1 T-ALL TcR-{J;HOX4 187,307 
t(7;11 )(q35;p13) <1 T-ALL TcR-{J;RBTN2 116,187,292 
t(7;19)(q35;p13) <1 T-ALL TcR-{J;LYL1 187,308 
inv(7)(p15;q35) <1 T-ALL TcR,;TcR-{J 187,309 
Non-lineage specific 
del{6q) 4-13 187,188,310 
t/del(9p) 7·13 187,230,311-314 
t/del(12p) -10 187,197,246 
a. Adapted from Pui C-H et al. (116), Crist WM et al. (185), and Raimondi SC (187). 
b. If known, the frequency of the chromosomal abnormality within a specific ALL immunophenotypic subgroup is 
given between brackets. 
c. Genes involved: MLL is also named ALL 1 and HRX; AF4 is also named FEL; AF9 is also named MLL T3; ENL is also 
named MLLT1; TAU is alsO named SCL and TCL5; HOX11 is also named TCL3; RBTN2 is also named TTG2; 
RBTN1 is also named TTG 1 . 
d. -, the involved gene or gene locus is not known. 
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TABLE 8. Immunophenotype and prognostic value of childhood ALL with various karyotypeso. 
Karyotype 
Hyperdiploid (> 50 chromosomes) 
die{9;' 2){p11 ~p12;p12) 
Hyperdiploid (47·50 chromosomes) 
Normal 
Hypodiploid (45 chromosomes) 
Translocations (pseudodip[oid) 
tl1 ;19)(q23;p131 
tI8;14)(q24;p131 
tl11 ;14)(p13;q111 
inv(14)(q11 ;q32) 
tI8;14)(q24;q321 
Hypodiploid 
near haploid 
tI9;22)(q34;q111 
t14;1111q21 ;q231 
tl11 ;191Iq23;p131 
6q-
9p-
12p' 
near tetraploid/triploid 
lmmunophenotype 
common ALL 
common ALL 
no specific 
immunophenotype 
pre-B-ALL 
T-ALL 
T-ALL 
T-ALL 
B-ALL 
common ALL 
common ALL 
null ALL 
null ALL 
no specific 
immunophenotype 
a, Roforonces 116,181,183.185,187,192, 197·202,212,220,241,271,291,316,317. 
Outcome 
Good 
Favorable 
Intermediate 
Poor 
Very poor 
Unclear 
translocations are absent. Poor outcome is found in patients with a near haploid 
karyotype. Translocations, particularly t(9;221, t(4; 11 I and t(11; 191 have been shown to 
identify patients with the shortest survival (Table 81. 
Molecular genetic analysis 
ALL is a clonal disease, in which each cell has quite similar characteristics. Based on 
this fact, recombinant DNA techniques, which enable analysis of genes at the DNA or 
mRNA level, can be used to determine clonality of suspected cell populations (120,3191. 
The techniques used are Southern blotting and PCR (319-3211_ With both techniques 
gene rearrangements, deletions, or mutations can be detected. In the case of Southern 
blotting this is done with specific probes and in the case of the PCR technique by 
amplification of a specific piece of DNA (319-321 I. Nowadays, both techniques have 
earned their place in research of leukemias and lymphomas and both are frequently used 
.in the diagnosis of hematopoietic malignancies, especially in those cases in which other 
techniques are not conclusive (120,323). In the ensuing chapters of this thesis the 
usage of both techniques in the analysis of childhood ALL will be discussed in more 
detail. 
Characterization of ALL with other techniques 
In addition to the above described techniques, characterization of ALL can further be 
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done by ultrastructural morphology and cell culture analysis (323-328). Ultrastructural 
morphology and cytochemistry are not essential for the diagnosis of ALL. However in 
case of undifferentiated or minimally differentiated acute leukemias, electron microscopy 
and cytochemistry (e.g. MPO) provide conclusive information for diagnosis and classifi-
cation of these acute leukemia cases (325-328). 
Cell culture analysis has a low diagnostic value in ALL. Still, for the detection of 
residual ALL cells in cultures of 8M obtained during remission, this technique has shown 
its merit (323,326,329-331). Especially for research purposes, such as specific growth 
patterns or determination of cell death after addition of different growth factors, 
cytokines or cytostatic drugs, the in vitro culture experiments of ALL cells at diagnosis 
appear to be important (330-336). Furthermore, these in vitro findings may have 
prognostic significance for obtaining remISSion or developing relapse and for 
stratification of treatment protocols (330-332,334,336). 
1.4 PROGNOSIS OF CHILDHOOD ALL 
The prognosis of children with ALL has improved remarkably during the last two 
decades (337-339). Presently, 70-80% of newly diagnosed children may be expected to 
survive with current treatment protocols (339). However, still 20-30% of children will 
eventually die as a cause of this disease. The prediction which children with ALL have a 
high probability of treatment failure has become possible through the definition of 
prognostic factors that may be determined at the time of diagnosis (339-341). A variety 
of factors that have been associated with prognosis in ALL is summarized in Table 9. 
The initial leucocyte count is perhaps the most significant prognostic factor 
identified (342). Children with a high WBC count (more than 50,000 cells/mm3) tend to 
have a poorer prognosis (342). There is also a clear relationship between age at 
diagnosis and outcome. Patients who are young when diagnosed « 2 years of age) and 
older patients (> 1 0 years of age) have a relatively poor prognosis in contrast to children 
in the intermediate age group (343,344). Studies analyzing the prognostic importance of 
sex revealed that boys have a poorer prognosis than girls (345,346). Immunophenotype 
and FAB morphology also correlate with prognosis, in which patients with a B-ALLlL3 
phenotype have an intermediate prognosis (153,347). Cytogenetic abnormalities both in 
chromosomal number (ploidy) and structure appeared to have prognostic significance 
(see section 1.3: Cytogenetic analysis) (116,185,348). Except for race, all other factors 
TABLE 9. Factors that have been associated with poor prognosis in ALLa • 
Initial WBC count (> 50.1 0 9 cells!!) 
Age at diagnosiS «2y and >10y) 
Cytogenetics/ploidy 
Sex (M>F) 
Immunological subtype 
FAB morphology 
Mediastinal mass 
a. References 116,153,185,342-350. 
Organomegaly and lymphadenopathy 
Low hemoglobulin level 
Race (black> white children) 
Low platelet count 
Low serum immunoglobulins 
Slow leukemic cytoreduction (>4-6 weeks) 
CNS leukemia at diagnosiS 
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summarized in Table 9 are more or less associated with the tumor burden at diagnosis 
and its effect on normal hematopoiesis (349,350). The prognostic importance of the 
factors shown in Table 9 is dependent on the applied therapy protocol. They may lose 
prognostic significance with more intensive and specific chemotherapy (351-353). So in 
some categories, therapy appeared to be the most important prognostic feature. 
1.5 TREATMENT OF CHILDHOOD ALL 
Introduction 
Nowadays, the majority of children with ALL in developed countries achieve long-term 
survival and cure, caused by improved treatment protocols during the last decades 
(338,339,353-360). The current principles of curative treatment of childhood leukemia 
are based on eradication of the malignant cells with aggressive strategies involving the 
earlier use of intensive therapy, prophylactic treatment for relapse of leukemia in the 
meninges, optimal supportive therapy and reduction of side effects of treatment. The 
combination of these principles in treatment is one of the reasons for this success. 
The therapy of first choice in childhood ALL is chemotherapy. Bone marrow 
transplantation (BMT) (allogeneic, syngeneic, or autologous) will be done after first 
relapse during second remission. 
Chemotherapy 
In the Netherlands, children with ALL are treated according to DCLSG protocols since 
1972. The current protocols (ALL VII 1988-1991 and ALL VIII 1992-not closed) are 
based on treatment principles of the International Berlin-frankfurt-Munster (BFM) Study 
Group. Children with ALL are stratified into three treatment groups according to the BFM 
risk factor (based on WBC count, liver and spleen size), the presence or absence of 
mediastinal mass, CNS leukemia, chromosomal aberrations, and a specific immuno-
phenotype. The stratification of the ALL patients over the three treatment groups is: 
34% in the standard risk group (SRG), 59% in the medium risk group (MRG), and 7% in 
the high risk group (HRG) in case of ALL VII. Each risk group starts with an identical 
induction treatment of five weeks. After this, the treatment is divided into separate 
protocols. ,Each of these protocols consist of an intensive chemotherapy (consolidation 
treatment) until 28 to 32 weeks, starting from diagnosis, after which maintenance 
treatment is applied until two years of therapy. 
The initial aim of All treatment is induction of remission. Complete remission (CR) 
is achieved when BM has a normal cellularity with less than 5% Iymphoblasts and 
absence of leukemic cells in PB, eNS, or elsewhere in the body (129). The induction 
treatment includes a combination of prednisone, vincristine, daunorubicin, and l-
asparaginase. Presently a CR is achieved in - 97% of All cases. During this induction 
phase intrathecal eNS prophylaxis is given containing methotrexate, cytosine 
arabinoside (ARA-C), and prednisolone. After induction treatment intensive consolidation 
chemotherapy is continued with several other cytostatic drug combinations. During 
maintenance treatment all All patients receive 6-mercaptopurine daily and methotrexate 
weekly. 
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Unfortunately, treatment failure because of drug resistance occurs. The resistance 
to cytostatic drugs may represent 'apparent' drug resistance or 'true' drug resistance. 
Apparent drug resistance may be caused by hiding of leukemic cells in locations which 
are less accessible for the cytostatic drugs such as eNS, or by pharmalogical factors 
such as drug scheduling or dosage (361,362). True drug resistance is considered to be a 
resistance at the cellular and/or molecular level, such as an increased production of the 
enzyme which is the target for the drug. An example is the resistance to methotrexate 
due to amplification of the dihydrofolate reductase gene (363,364). Another type of 
drug resistance is the multidrug resistance (MDRL which implies resistance against a 
variety of drugs including anthracyclines, vinca-alkaloids, and actinomycin D (365-367). 
The significance of the latter form of drug resistance appeared to be low in ALL (368-
370). 
Bone marrow transplantation 
BMT involves the administration of intensive cytoreductive therapy (high-dose 
chemotherapy in doses lethal to normal BM), in combination with total body irradiation 
and subsequently intravenous infusion of BM obtained from an appropriate compatible 
donor (371). 
As mentioned above, BMT as therapy for childhood ALL is only applied after first 
relapse, because the results of standard intensive chemotherapy regimens in children are 
sufficiently good (339,372). In some treatment protocols, BMT is performed as part of 
the primary therapy in ALL with very poor prognosis such as in cases with special 
translocations (e.g. t(9;22) and t(4;11)) (339,373,374). 
Allografting in second remission with a HLA-matched sibling (allogeneic BMT) has 
an equal overall survival as with autologous BMT (ABMT). This was shown in a study 
comparing both types of BMT in relapsed childhood ALL (375). A higher rate of subse-
quent relapses was found in ABMT, due to the presence of residual leukemic cells in the 
graft, while a higher rate of deaths was found in the allogeneic BMT group, caused by 
graft versus host disease (375). Survival rates of -30% are obtained after allogeneic 
BMT in relapsed childhood ALL patients, as shown in a recent study which analyzed 
123 patients during 12 years follow-up (376). A second course of chemotherapy for 
childhood All after relapse, instead of BMT, results in lower survival rates (5-30% for 
chemotherapy, and 45% for BMT or ABMT), but long-term follow-up is needed to be 
conclusive (377). 
The role of growth factors (such as GM-CSF, G-CSF, and IL-3) in the treatment of 
ALL has to be investigated. They are able to shorten the duration and severity of 
chemotherapy-induced myelosuppression and can therefore provide a potential means 
for intensifying treatment in the future. Furthermore, they are able to stimulate the 
hematopoietic stem cells after BMT to a more rapid development of sufficient hemato-
poiesiS and thereby reducing the isolation period and prophylactic and supportive 
treatment of ALL patients. 
Late effects of ALL treatment 
The improved survival of children with ALL has focussed attention on the late effects of 
anti-leukemic therapy (339,378-380). Most important are the effects of therapy, 
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especially radiotherapy, on the eNS, resulting in cortical atrophy, mineralizing microan-
giopathy, impaired intellectual and psychomotor function, and neura-endocrine abnor-
malities resulting in growth retardation and, fortunately, rarely in reproductive problems 
(339,378-382). In addition to these adverse sequelae affecting the CNS, other late 
effects may occur, such as organ failure (e.g. cardiomyopathy, hemorrhagic cystitis, or 
hepatotoxicity), occurrence of second malignancies (383-385), sterility, and impaired 
psychosocial status (e.g. behavorial problems) (339,378-380,386). 
To reduce these late effects of ALL treatment optimal supportive care during and 
after therapy must be provided not only for the child but also for his or her environment. 
Application of methods for minimal residual disease (MRD) detection in ALL patients 
during follow-up can be used to monitor the effectiveness of the applied chemotherapy 
and subsequently for adaptation of treatment protocols in patients with or without MRD. 
1.6 RELAPSE OF ALL 
Relapse is defined as a reappearance of morphologically distinct leukemic blasts 
(> 25% in the BM) following a complete remission, or leukemic blasts in PB or elsewhe-
re in the body (129). CNS leukemia (relapse) is defined as the presence of > 5 
cells/mm3 and cytomorphologically proven leukemic blasts in the liquor cerebrospinalis 
(387,388). The most common site of leukemia relapse is the BM. BM relapse is often 
accompanied by the same hematologic features and clinical signs and symptoms present 
at the time of diagnosis. These include anemia, bruising, and bone pain (14,127). 
Extramedullary spread is not an unusual feature in ALL (14,389). Although not 
always detectable without invasive diagnostic procedures, extramedullary relapse is 
significant, because it may cause morbidity at a localized site and because such relapses 
frequently precede a BM relapse, by "seeding" from this extramedullary site (390). The 
CNS and testes are the most common sites of extramedullary relapse in childhood ALL. 
Currently, the incidence of CNS relapse is reduced to 5-10%, due to CNS prophylaxis. 
Leukemia in the CNS and other sanctuaries are believed to develop as a result of 
leukemic metastases (391). Recently, clonal evolution at the Ig gene level of the 
leukemic clone in CNS was found when compared with the BM clone (392), but in the 
majority of CNS diseases the leukemic clone has an identical (immuno)phenotype and 
karyotype. The clinical signs and symptoms of CNS leukemia are among others 
headache, vomiting, lethargy, and papilledema caused by increased intracranial pressure 
(14). 
The testes are a common site of extramedullary relapse in boys (393). At present, 
clinically overt testicular relapse manifested by painless enlargement of one or both 
testes, occurs in less than 5% of boys. A number of factors are associated with an 
increased likelihood of developing testicular relapse, including a high initial WBC, T-ALL, 
prominent lymphadenopathy, splenomegaly, and thrombocytopenia. The time to 
development of overt testicular relapse ranges from 2 months to several years (14,393). 
On rare occasions ALL may recur in other isolated sites. These sites are lymph 
nodes, pleural space (especially T-ALL), the ovary, the anterior chamber of the eye, the 
kidney, the skin, spleen, muscles, bones (femur or rib) and the gastrointestinal tract 
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(394-401). Extramedullary relapses are generally followed by BM relapse. 
Re[ative[y little is known about the nature of relapse, although in most cases 
regrowth of leukemic cells usually represents the emergence of resistance to cytostatic 
drugs applied to the patient (see chapter 1.5). That this is not always the case is shown 
by a prompt leukemic response when identical drugs are used again at relapse. Other 
factors that cause relapse are not associated with characteristics of the leukemic cell 
but with factors causing individual variability among patients that result in decreased 
exposure of the malignant cells to the administered drugs (e.g. poor compliance in 
taking medication, intestinal malabsorption, or variations in the pharmacokinetics of the 
antileukemic drugs) (402). An extramedullary relapse in a pharmacologic sanctuary (e.g. 
the eye) is an example in which the leukemic cells may still be drug sensitive. 
In the majority of relapse cases a relation with the initial leukemia can be proven by 
identical morphology, immunophenotype, or genotype. However in a large percentage of 
cases, changes are found (see Chapter 4). When major shifts occur and no relation is 
found between the initial and relapse leukemia a second malignancy, either or not 
induced by the applied treatment (especially in case of Topoisomerase II inhibitors). is 
diagnosed (383-385,403). It has been suggested that the occurrence of secondary 
leukemia and the 11 q23 translocation are related (404). 
1.7 INTRODUCTION TO THE EXPERIMENTAL WORK 
ALL patients 
According to age, ALL can be divided into three groups: First, adult ALL (age > 15 
years); second, childhood ALL (age 1-15 years); and third, infant ALL (age < 1 year). 
Approximate[y 7% of adult leukemias represent ALL with an incidence of 1-2 per 
100,000 adults (4,5). Adult ALL form a distinct group with several adverse prognostic 
factors (e.g. age, t(9;22), and T-ALL phenotype) (405). Results of treatment have not 
been improved considerably during the last decades. A[though remission rates are high 
(68-91 %). overall survival and disease free survival did not change significantly (25-
41 %), regardless the intensity of the applied chemotherapy (405). Still for some 
subgroups (T-ALL and B-ALL) better outcome is achieved (405). These findings contrast 
sharply with the experiences in childhood ALL as described in the previous sections. 
Although infants with ALL have their own characteristics (e.g. null ALL phenotype 
and t(4;11)) and a poor prognosis (339,406-409). This thesis does not distinguish 
between infant and childhood ALL This was due to the fact that the number of infant 
ALL was too small in the studied series of childhood ALL cases. 
The majority of childhood ALL patients described in this study were treated at the 
Sophia Children's Hospital, Rotterdam. Their diagnosis and relapse cell samples were 
harvested by pediatricians of the Division of Hemato[ogy/Oncology, Department of 
Pediatrics, Sophia's Children Hopita[, Rotterdam and send to the Department of 
Immunology, University Hospital Dijkzigt/Erasmus University, Rotterdam. The other 
childhood ALL patients were treated at different hospitals in the Netherlands and their 
diagnosis and relapse cell samples were collected by the DCLSG, The Hague. [n case of 
a relapse, both diagnosis and relapse cell samples were send to the Department of 
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Immunology, University Hospital DijkzigtJErasmus University, Rotterdam for immuno-
genetic analysis. 
Aim of the study 
The objective of this study was to get more insight into the factors and mechanisms 
which influence the development of a relapse in childhood All. For this purpose, 
extensive analyses have been performed on the leukemic cells at diagnosis and relapse 
in both a nationwide retrospective study (in collaboration with the DCLSG, The Hague) 
and a prospective study (in collaboration with the Sophia Children's Hospital, Rotter-
dam). The retrospective study was expected to provide information about differences 
between the cells at diagnosis and at relapse, whereas the prospective study could 
provide information about differences between ALL which relapse and those which 
remain in remission. 
The analyses of the cell samples aimed at determination of phenotypic characteris-
tics (e.g. morphological and immunological phenotype) as well as genotypic characteris-
tics (e.g. cytogenetic aberrations and configuration of Ig and TcR genes). If necessary, 
the results were correlated with other features of these patients, especially clinical 
characteristics. 
We studied the antigen specific receptor genes (Ig and TcR) and gene 
rearrangements of B- and T-Iymphocytes, (especially the IgH and IgK gene rearrange-
ments) by Southern blot analysis. The latter is important for clonality studies in patients 
with Iymphoproliferative disorders (e.g. ALL) (Chapter 2). 
In addition, the occurrence of 19 and cross-lineage TcR gene rearrangements in 
precursor 8-ALL at diagnosis were analyzed, with accent on the prognostic implications 
of these gene rearrangements as well as the significance for the junctional region 
minimal residual disease (MRD)-PCR technique (Chapter 3). 
Furthermore, we investigated the phenotypic (morphological and immunological) 
and immunogenotypic changes in ALL at relapse. The possibilities of development of 
ALL relapse and the consequence of the changes in phenotype or genotype at relapse 
for the detection of MRD by immunological marker analysis and peR, respectively are 
discussed (Chapter 4). 
The molecular biology (cytogenetics and immunogenotype) of ALL and the 
applications for detection of MRD with the peR technique are summarized. Furthermore, 
we analyzed a new PCR target for the detection of MRD (Chapter 5). 
Finally, the significance of the presented experimental data for the origin of 
precursor B-ALL are discussed. In addition, the relevance of the usage of leukemias as 
experimental model for 8- and T-cell differentiation is addressed. 
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CHAPTER 2.1 
ANTIGEN SPECIFIC RECEPTOR GENES: BASiC ASPECTS 
Introduction 
The daily production of lymphopoiesis results in 106 to 107 mature 8- and T-Iympho-
cytes (1,2). These B- and T-Iymphocytes form the antigen specific part of the immune 
system (2-4). The ability of the immune system to recognize specificalty a large variety 
of antigens is based on the presence of an enormous diversity of antigen receptors, 
which are expressed on the cell membrane of lymphocytes (2-4). Surface membrane 
bound immunoglobulin (Smlg) molecules represent the antigen specific receptors of 8-
lymphocytes, while the T-cell receptor (TcR) is the antigen specific receptor of T-
lymphocytes (5-7). The huge diversity of these receptors is based on rearrangement 
processes in the 19 and TcR genes, which occur early during lymphoid differentiation (5-
8). 
Antigen specific receptors 
Ig molecules are composed of two Ig heavy (lgH) chains and two Ig light (lgL) chains, 
which are held together by disulfide bonds (Figure 1). The IgL chains of each B-Iympho-
cyte are of the same isotype: either IgK or Ig}, (7,8). 
The TcR is composed of two chains, which are generally held together by a 
disulfide bond. Four TcR chains are known: TcR-a, TcR-iJ, TcR-'Y, and TcR-o. The 
majority of T-Iymphocytes expresses a classical TcR composed of a TcR-a: and TcR-,6 
chain, while a minority (2-15%) expresses the alternative TcR composed of a TcR-,), and 
TcR-o chain (Figure 1) (5,6,8). 
Both surface membrane bound antigen specific receptors are closely associated 
with specific transmembrane molecules, which are probably involved after antigen 
recognition in signal transduction of the Ig or TcR molecule to the cytoplasm (9-12). 
These transmembrane molecules are in case of the 19 molecule two protein chains 
(CD79 complex) and in case of the TcR molecule a CD3 complex which contains five 
Figure 1. Schematic diagram of an 
Ig molecule, closely associated 
with CD79 chains, forming the 
Smlg-CD79 complex, on the cell 
membrane of a B-Iymphocyte (left) 
and the TcR-C03 complex on the 
membrane of aT-lymphocyte 
(right). ~H c", c"' u ,o~1I m~mbrnno 
TcR·(> TcR·r' 
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Figure 2. Schematic diagram of human 19 genes. The IgH gene complex consists of many (> 1 00) V gene 
segments, at least 30 D gene segments, six functional J gene segments, and C gene segments for the 
constant domains of the various IgH classes and subclasses. Most C gene segments are preceded by a 
switch gene (s), which plays a role in IgH (sublc[ass switch. The 19"': gene complex consists of >50 V 
gene segments, five J gene segments, and one C gene segment. The Kde (K deleting element) plays a role 
in the deletion of the CK gene in B~cells, which rearrange their Ig}.. genes. The Ig}.. gene complex consists 
of >40 V gene segments and four functional C genes, all of which are preceded by a J gene segment. 
Pseudo genes (f) are indicated with open symbols. 
TcR-a and TcR-a gene complex 
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III III III III III "'---.---If---II--1~' ~ 1111111111 N 1111111. 
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Figure 3. Schematic diagram of human TcR genes. The TcR~a gene complex consists of >50 V gene 
segments, a remarkably long stretch of - 55 functional J gene segments, and one C gene segment. The 
TcR~i3 gene complex consists of >70 V gene segments and two C gene segments, both of which are 
preceded by one D and six or seven J gene segments. The TcR-"(' gene complex consists of a restricted 
number of V gene segments (six functional V gene segments and nine pseudo genes) and two C gene 
segments, each preceded by two or three J gene segments. The major part of the TcR·o gene complex is 
located between the Va and Ja gene segments and consists of six V, three D, and four J gene segments 
and one C gene segment. The oREC and 1/IJa gene segments playa role in TcR~o gene deletions, which 
precede TcR·a gene rearrangements. Pseudo genes (1/1) are indicated with open symbols. Recently, a new 
functional Jo gene segment (J(4) is found and located between the Jo1 and Jo2 gene segments (73,74). 
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protein chains (Figure 1) (9-13). 
Each of the Ig chains and TcR chains consists of a variable and one or more 
constant domains (8). The variable domains are encoded by combinations of gene seg-
ments: a variable (V) gene segment, a diversity (D) gene segment in case of IgH, TcR-i>, 
and TcR-o chains, and a jOining (J) gene segment (Figure 2 and 3) (8,14-36). The 
constant domains of the different Ig and TcR chains are encoded by constant (e) gene 
segments (Figure 2 and 3) (8). The location of the three Ig gene loci (lgH, IgK, and Ig}..) 
is on chromosomes 14q32, 2p 12, and 22q 11, respectively (37-40). The location of the 
four TcR gene loci (TcR-a, TcR-i>, TcR .... , and TcR-o) is on chromosomes 14q11, 7q35, 
7p15, and 14q11, respectively (41-45). 
Antigen specific receptor diversity and gene rearrangement 
As indicated before, the large diversity in specificity of the two types of antigen specific 
receptors of lymphocytes is based on gene rearrangements (8,46-50). Early during B-
and T-cell differentiation these gene rearrangements result in specific combinations of V, 
(D)' and J gene segments, thereby deleting all intervening sequences (Figure 4) (8,46-
50). These gene rearrangements are performed by a recombinase enzyme complex, 
including the protein products of recombining activating genes (RAG1 and RAG2) and 
are precisely regulated via recombination signal sequences (RSS) (49-52). These RSS 
generally consist of heptamer-nonamer sequences, separated by a spacer of 12 or 23 
basepairs, which flank the V, D, and J gene segments (8,50). After this recombination 
process the gene complex can be transcribed into precursor messenger(m)RNA, which 
germ line IgH genes 
VH DH JH s 
D -+ J joining 
rearranged IgH genes V -+ D-J joining 
"-.. 
! transcription 
precursor IgH mRNA ~ ~ .,....... ~~~ 
=:J'j.H '-' ~Wl
! RNA splicing 
mature IgH mRNA ~
VOJ ell 
Figure 4. Schematic diagram of human IgH gene rearrangement. In this example first DH3 is joined to 
JH4, followed by VH4 to DH3~JH4 joining, thereby deleting all intervening sequences. The rearranged 
gene complex can be transcribed into precursor mRNA, which will be transformed into mature mRNA by 
splicing out all non-coding intervening sequences. 
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will be transformed into mature mRNA by splicing out all non-coding intervening 
sequences (Figure 4). Protein chains can now be produced via translation of the mRNA. 
The various combinations of V, (0,) and J gene segments of each 19 or TcR 
molecule and the combination of two different chains (lgH and IgL in case of B-cells and 
either TcR-a and TcR-jl, or TcR--y and TcR-v in case of T-cells) results in a large combina-
torial diversity (Table 1) (8,46-50). This diversity is increased by random deletion and 
insertion of nucleotides at the junctions of the rearranging gene segments, which 
together form the junctional diversity. The insertion of N-region nucleotides is mediated 
by terminal deoxynucleotidyl transferase (TdT) (53-55). TdT is able to add nucleotides, 
DNA template independable, to 3' ends of DNA breakpoints. Insertion of so-called P-
region nucleotides increases the junctional diversity (56). P-region nucleotides represent 
junctional region nucleotides that are derived from an untrimmed rearranging gene 
segment (56). Based on these data, the theoretical repertoire (combinatorial and 
junctional diversity) of Ig and TcR molecules can be estimated (Table 1) (8). The actual 
repertoire is probably lower due to preferential usage of particular V, (D), or J gene 
segments. 
TABLE 1. Estimation of repertoire of human 19 and TcR molecules. 
Number of functional 
gene segments: 
~ V gene segments 
~ D gene segments 
~ J gene segments 
Combinatorial diversity 
Junctional diversity 
ESTIMATION OF TOTAL 
REPERTOIRE 
Ig molecules 
19H 19K '9' 
>100 >50 >40 
30' 
6 5 4 
>5 X 106 
++ ± ± 
>1012 
TcR~o:.8 molecules 
>50 >70 
2' 
55 13 
>5 x 106 
+ ++ 
>1012 
TcRryo molecules 
TcRry TcR-O 
8 6 
3' 
5 3 
>5000 
++ ++++ 
>1015 
In TcR-1) gene rearrangements multiple D geno segmonts might be used; this implies that the number of junctions can vary frem 
one to four. In IgH and TcR·,8 gene rearrangements genorally only one D gone segment is used. 
lymphoid differentiation and gene rearrangement 
Ig and TcR genes are rearranged early during lymphoid differentiation. These 19 and TcR 
gene rearrangements seem to occur in a hierarchical order (57-59). During B-cell 
differentiation IgH gene rearrangements precede IgK gene rearrangements, which in turn 
precede Ig:.\ gene rearrangements. In general, B-cells start to rearrange their \g:.\ genes 
after both IgK alleles are non-functionally rearranged and subsequently deleted via kappa 
deleting element rearrangements (60-63). Eventually, this will result in IgK or Ig,- bearing 
B-Iymphocytes (Figure 5). 
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pre-pre-B-cen pre-s..cell immature B-cell mature B-cell plasma ceJl 
CyCD79 CyCD79 Smlg-CD79 Smlg-CD79 Cylg 
PfO-B-CyI91J.!:--___________ -".-.,.-,_-",., 
rTdT\ _______ Ig1 genes rearranged (In 191+ cells) I 
~ ~ro-B-cell ____ ~-----:,-g<-g-.-n-.-s-r.:-:arran=,..g--.-:d-;(C:::<--:;d.::'.-.t.,-ed='n-m-o-st:-,"'g",·:-c::.:::"s"')! (CyCD79) ~ _______ IgH genes rearranged Z IgH class switch may occur! 
C :~h~~ft ~/ ................... ..... .alt.;n~;ivQmphOC;1e 
{TdT\ TcR..y8-cD3 
~ pro~D~r~ 9 ········0 ~@ @~rethymocyte helper/inducer 
TdT TdT (CyCD3) T-Iymphocyte 
RAG RAG _______ TcA-(:t.!}-CD3 TcA-aJ3-CD3 
immature common --""""""'9 ........ 0 thymocyte thymocyte RA~ .... 
CyCD3 CyCD3 
(TcR-CD3) mature thymocyte suppressor / 
(CyCD3) cytotoxic T-Iymphocyte 
TcA-(:t.!}-CD3 TcR-(:t.j)-CD3 o 
NKcell 
TcR-o genes rearranged TcR..o genes deleted (In most TcR-o:~+ cells) 
________ TcR-y1 ________ TcR-y2 genes rearranged I 
_______ TcR-~ genes rearranged: D-J ... ..y-D-J (also in many TcR-y3"" celiS)! 
TcR-Ct genes rearranged (in TcR-Ct~"" CeliS)! 
Figure 5_ Hypothetical scheme of lymphoid differentiation, summarizing the available data about the 
ordered rearrangement of Ig and TcR genes, as well as the expression of TdT, Ig molecules and TcR 
molecules. The horizontal bars represent the rearrangement of the Ig genes (lgH, 19K, and IgA) and TcR 
genes (TcR-t:Y, TcR-,6, TcR-y, and TcR-o). The different forms of Ig and TcR expression (pre-B 19wCD79, 
Smlg-CD79, Cylg, and TcR-CD3 (TcR-t:Y,6 or TcR--yo) is indicated, as welJ as the CyCD3, CyCD79, and TdT 
expression per differentiation stage. 
During T-cell differentiation probably the TcR-o and TcR-/, genes will rearrange first. 
resulting in TcR-yo bearing T-Iymphocytes when both TcR genes are functionally 
rearranged. It is not yet clear whether the TcR-yo differentiation pathway is separated 
from the TcR-a.B differentiation pathway, in which TcR-.8 genes rearrange first, followed 
by TcR-a genes. Before TcR-a genes can rearrange, the TcR-o gene locus, which is 
located between the Vo: and Jo: gene segments, will be deleted (Figure 3). Therefore, the 
rearrangement and deletion processes in the TcR-alo locus are probably important for 
the separation of the 'Y-O and a(3 differentiation pathways. It is still not known where in T-
cell differentiation this bifurcation occurs (Figure 5) (64). 
The Smlg-CD79 complex is then expressed when a functional rearrangement of 
both the IgH and IgL molecules has occurred (Figure 5) (65). The first signs of functional 
60 CHAPTER 2.1 
19 gene rearrangements can be found in the pre-B-cell stage: weak cytoplasmic expressi-
on of Ig,u chain (pre-B Cylg,u) occurs as a result of a functional 19 H gene rearra~gement 
(Figure 5). [n addition, expression of the so-called pre-B-cell complex (pre-B [g,..-CD79) 
on the celJ membrane can occur. In that case the pre-B-cell complex consists of CD79 
chains, Ig,u chains, and a pseudo IgL chain, encoded by non-rearranging 19A like genes 
(Figure 5) (66). 
Ana[ogous to the Sm[g-CD79 complex, a TcR-CD3 complex will be expressed 
when the involved TcR genes are functionally rearranged. Recently, also a so-called pre-
T-cell complex is found on the surface membrane of thymocytes of the a{3 differentiation 
pathway. This pre-T-cell complex consists of CD3 molecules and a complex of a TcR-1> 
chain and a second unidentified TcR chain (67,68). 
Strikingly, early during B- and T-cell differentiation cytoplasmic expression of CD79 
protein chains (CyCD79) and the CD3 protein chains (CyCD3) is found (65,69). 
Apparently, these signal transduction mOlecules are prepared early and ready to be 
joined with functionally rearranged antigen specific molecules. Finally, TdT is expressed 
in all immature lymphoid cells and it disappears when the antigen specific receptors are 
expressed (53-55). Activation of the RAG genes, shown by RNA expression, is also 
found during these stages (70-72). 
Conclusion 
8- and T -lymphocytes form the cells of the specific immune system and therefore playa 
crucial role in the host defense processes via their antigen specific receptors. The 
structure of the Ig and TcR genes, the rearrangement processes, and the random 
deletion and insertion of nucleotides in the junctional regions form the basis of the 
diversity of these antigen receptors of 8- and T -lymphocytes. 
Lymphoid malignancies consist of clonal cells which are arrested at certain stages 
of differentiation. Since Ig and T cR gene rearrangements are different in each lymphocy-
te or lymphocyte clone, they can be used as markers for clonality. The Southern blot 
technique allows a detailed analysis of clonally-rearranged Ig or TcR genes. For this 
purpose detailed information about the gene configuration, restriction maps, and probes 
should be available as well as information about the occurrence of polymorph isms and 
their frequency in the population. This will be discussed in the next chapters of this 
thesis. 
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CHAPTER 2.2 
DETECTION OF IMMUNOGLOBULIN HEAVY-CHAIN 
GENE REARRANGEMENTS BY SOUTHERN BLOT ANALYSIS: 
RECOMMENDATIONS FOR OPTIMAL RESULTS' 
Auke Beishuizen, Marie-Anne J. Verhoeven, Ellen J. Mol, TImo M. Breit, 
Ingrid LM. Wolvers-Tettero and Jacques J.M. van Dongen 
SUMMARY 
Department of Immunology, University Hospital Dijkzigt/Erasmus University, 
Rotterdam, The Netherlands 
Southern blot analysis of immunoglobulin (Ig) and T-cell receptor (TcR) genes has 
proven to be important for detection of clonal rearrangements in patients with Iymphoproli-
ferative diseases. To improve the detection of clonal 19 heavy chain (lgH) gene rearrange-
ments, we carefully determined the precise restriction map of the joining (J)H and constant 
(C),u region of the IgH locus, and evaluated relevant combinations of restriction enzymes 
with JH and C" probes. 
Our extensive Southern blot analyses revealed that rearrangements in the JH region 
are optimally detectable by use of a JH probe in combination with at least two restriction 
enzyme digests which are not affected by polymorph isms, and which produce small 
germline bands (e.g. 8g/ll and 8amH IIHind II I) , thereby reducing the chance of comigration 
of germline and/or rearranged bands. Application of a JH or a Cp. probe in combination with 
8amHI or EcoRI digests should be avoided, because of the large size of the restriction 
fragments and the occurrence of polymorphisms. Comparison of different types of JH 
probes demonstrated that optimally reproducible signals, independent of the rearranged JH 
gene segment, are only obtained if the JH probe is complementary to the 3 ~ flanking 
sequences of the JH gene region, such as our IGHJ6 probe. 
INTRODUCTION 
B-cell malignancies can be regarded as malignant counterparts of B-cells in the various 
stages of lymphoid differentiation, because malignant B-cells have comparable phenotypic 
and genotypic characteristics, as normal B-Iymphocytes (1-3). Since rearrangements of /g 
variable, (diverSity,) and J gene segments occur early during lymphoid differentiation, 
virtually all B-cell malignancies have rearranged Ig genes (4-8), which can be used as unique 
• Published in: Leukemia 1993;7:2045-2053. 
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clonal markers for diagnostic purposes. Southern blot analysis of 19 genes has proven to 
be important for lal distinguishing monoclonal from polyclonal B-cell proliferations, Ibl 
detection of subclones within a malignancy, (c) determination of the cell lineage when 
analysis is performed in association with immunophenotyping, and (d) aSsessment of 
residual disease and early relapse 18-111. 
Since J gene segments are assumed to be involved in all rearrangements of IgH genes, 
these rearrangements can be detected by use of Southern blotting with appropriate 
restriction enzymes and a JH region probe or a Cp, region probe (12). The choice of 
restriction enzymes is dependent on the precise position of the restriction sites in the IgH 
gene locus, and the size of the resulting restriction fragments (12), as well as on the 
occurrence of polymorph isms, such as polymorphic restriction sites, resulting in restriction 
fragment length polymorphisms IRFLPI or variable numbers of tandem repeats IVNTRI 
resulting in hypervariable polymorphic IHVPI regions 112-151. 
During the last decade Cp. probes and several types of JH probes hybridizing to 
different parts of the JH gene region have been used in rearrangement studies (6,12,16-21). 
The position of the different JH probes varies remarkably from the 5' side, down to the 3' 
side of the JH gene region. Theoretically, JH probes which only recognize sequences at the 
3" side of the JH gene region will result in optimally reproducible signals, independent of 
the rearranged JH gene segment. Therefore, we developed a JH probe, which recognizes 
1.0 kb of the JH gene region 3' of the JH6 gene segment. 
Based on sequence data from the literature and our extensive Southern blot analysis 
of cell samples with germline IgH genes, the precise position of restriction sites, and the 
occurrence of polymorph isms in the JH-CJL region was determined. Furthermore, our JH 
probe (tGHJ6) was compared with CJL probes, and two examples of frequently used JH 
probes ISau3A-JH and H24-JH; Figure 11, in a detailed study of B-ceilleukemias. The latter 
comparison demonstrated the importance of the position of the JH probe in routine 
Southern blot analysis of IgH genes for diagnostic purposes. 
JH 
enh 
.IGHJ6 
Sau3A-JH 
H24-JH 
I IGHJ5 
s 
c 
II IGHMU 
II IGHM2 
2 kb 
M 3' 
Figure 1. Position of the DNA probes in the JH and Cp. gene region of the human IgH genes. The location of 
relevant BamHI (B), 8g/ll (Bg), EcoRl (E), Hindlll (HL Sacl (S), and Xbal (X) restriction sites are indicated. Also 
the location of the HVP region at the 5' side of the JH region as well as the IgH enhancer (enhL the IL switch 
region (SIL) and membrane IL (Mp.l gene segments are depicted (12-17,24-26). The solid bars represent the 
four JH probes and two Cp. probes: the IGHJ6, the Sau3A-JH, the H24-JH, the IGHJ5, the IGHMU, and the 
IGHM2 probe. 
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MATERIALS AND METHODS 
Cell samples 
Peripheral blood (PB) or bone marrow (BM) samples were obtained from 20 precursor B~cell acute 
lymphoblastic leukemia (ALL) patients, and 45 chronic B-cell leukemias. Mononuclear cells (MNC) were 
isolated by FicoJl~Paque centrifugation (density: 1.077 g/cm3; Pharmacia, Uppsala, Sweden). These MNC 
samples were frozen and stored in liquid nitrogen. For polymorphism studies, we used PB-MNC from 75 
patients with germline IgH genes, as well as granulocytes from 75 healthy individuals. The granulocytes were 
obtained from the cell pellet after Ficoll-Paque centrifugation. Granulocytes and non-hematopoietic human cell 
lines were used as the source for germline control DNA. 
Southern blot analysis 
DNA was isolated from frozen MNC, freshly isolated granulocytes, and cell lines as previously described 
(12,22). Fifteen micrograms of DNA were digested with the appropriate restriction enzymes (Pharmacia) as 
previously described (12). The restriction fragments were size-separated in 0.7% agarose gels and transferred 
by vacuum blotting to Nytran-13N nylon membranes (Schleicher and Schuell, Dassel, Germany) (12). The 
membranes were hybridized with the appropriate 32P~random oligonucleotide labeled probes (12). 
Restriction map and polymorphisms 
DNA from granulocytes and non-hematopoietic cell lines was used for digestion with BglIl, BamHI, EcoRI, 
Hindlll, Sacl, Xbal and several combinations of these restriction enzymes (Pharmacia) to locate the precise 
position of the restriction sites in the JH and C", regions. In addition, granulocyte DNA from 75 healthy 
individuals, andlor DNA from PB~MNC of 75 patients with germline IgH genes was used to determine the 
occurrence of RFLPs and to evaluate which germJine restriction fragments are affected by the VNTR-HVP 
region -1.8 kb upstream of the JH gene segments. 
Sau3A..JH probe and H24..JH probe 
The Sau3A-JH probe is a 2.2 kb Sau3A fragment containing the JH2-JH6 region and only 230 bp of the 3' 
flanking sequences. This probe was isolated from the 6.0 kb BamHllHindlll JH clone (pWH), kindly provided 
by Dr. M.H. Siegelman (23). The H24-JH probe is a 2.5 kb EcoRllBglII fragment containing the JH3-JH6 
region, as well as 1.1 kb of the 3' side of the JH gene region, and was isolated from the H24 clone, kindly 
provided by Dr. T. Honjo (16). The precise position of the Sau3A-JH and H24-JH probes is indicated in 
Figure 1. 
Construction of IGHJ5, IGHJ6, IGHMU and IGHM2 DNA probes 
The IGHJ5 probe (462 bpI, IGHJ6 (1 020 bpI, IGHM (1365 bpI probes were obtained by cloning the purified 
polymerase chain reaction (PCR) amplification products of granulocyte DNA from a healthy individual, using 
specific oligonucleotide primer sets and pUC19 as cloning vector (22). The oligonucleotide primers with 
aspecific tails containing £coRI or Hlndlll restriction sites for cloning are indicated in Table 1. All 
oligonucleotide primers were synthesized according to published sequences of the JH and CIL gene region 
(17,24-26) on a 392 DNA synthesizer (Applied Biosystems, Forster City, CA, USA) with the solid-phase 
phosphotriester method and used without further purification. 
PCR was essentially performed as previously described (22,27). A 1 .0 ",g sample of granulocyte DNA. 
12.5 pmo! of the upstream and downstream oligonucleotide primers and one unit of AmpliTaq DNA 
polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA) were used in each peR of 100 ILl. The PCR products 
were sized fractioned by 0.7% agarose gel electrophoresis. After electrophoretical recovery from the agarose 
gel using a separation chamber (Biotrap; Schleicher and Schue!!), the PCR products were digested with EcoRI 
and/or Hlndlll and cloned, using pUC19 as cloning vector (22). All probes were partly sequenced (at least 150 
bpI at both sides to confirm their position in the IgH gene region. 
The IGHJ5 probe recognizes sequences between the JH5 and JH6 gene segment (Figure 1). The IGHJ6 
probe recognizes -1.0 kb of the 3' flanking sequences of the JH locus (Figure 1). The IGHM probe can be 
divided into the IGHMU probe (552 bpI and IGHM2 probe (813 bpI by use of the restriction enzyme EcoRI 
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TABLE 1. Oligonucleotide primers used in construction of IgH gene DNA probes. 
Probe Cloning Relative 
name Size sites Code position3 Sequenceb Referencec 
5 ' 3' 
IGHJ5 462 bp EcoRI-Hindlli JHS-pS' +21 bp t~gaanCACTTAGGGAGACTCAGC 17 
JHS-p3 • +471 bp cgaaagCTTCTGTCTCCGGGCGTC 17 
IGHJ6 1020 bp EcoRI-Hkldll! JHS-pS' -lbp GGTAA~CCACTCTAGGGCCTT 17 
JH6-p3 • +1002bp acacaaGCTTCCT AAAAT AGACTCTCGCGGTG 26 
IGHMd 1365 bp Hindill-Hindill SwpS' -516 bp TGGCTCCAaGCTTCACATTCAGGTA 26 
CwP3' -100 bp ~caa9CTTGGCCGCTCTGGGAAGCCA 25 
a. Tho position of tho oligonucleotide primors is indicated upstronm I-lor downstream (+) relative to an oxon splice site. The positions 
of the DNA probes arc indicated in Figure 1. 
b. Tho-sequences in lowor case characters represent the ilspecific nucleotides, which generato restriction sitos (undorlined). 
c. Sequence information used to dosign the oligonucleotido primors was derived from the indicated literature referonces. 
d. The IGHM probo can be dividod into tho tGHMU probe {552 bpi and IGHM2 (813 bpI probe by digestion with EeaRI. 
(Table 1 and Figure 1). The IGHMU probe recognizes 509 bp of the 5' flanking sequences of the Cp. locus 
and 43 bp of the Cp. exon 1. The IGHM2 probe recognizes sequences of the Cp. exon 1 (296 bp), the complete 
Cp. exon 2 and a part of the intron sequences (Figure 1). 
Comparison of three JH probes 
Each Southern blot filter with 8g/ll or 8amHI/Hindlii digested MNC~ONA from the 65 leukemia patients was 
successively hybridized with the 32P~labeled Sau3A·JH, H24~JH, and IGHJ6 probes. Rearrangements to the 
JH6 gene segment were proven, by demonstrating deletion of the JH5 gene segment, via hybridization with 
the 32P.labeled IGHJ5 probe. After each hybridization the membranes were washed according to the following 
protocol: one washing in buffer I (40 mmo1/1 NaHP04, pH 7.2; 2% SOS; 1 mmol/l EOTA; 0.5% BSA) for 5 
min at 65°C; four washes in buffer II (40 mmol/l NaHP04, pH 7.2; 1 % 50S; 1 mmol/l EOTA) for 3·5 min at 
65°C; and four washes in buffer III (10 mmol/l NaHP04, pH 7.2; 1 % 50S) for 3·5 min at 65°C. Finally, the 
membranes were rinsed with 100 mmol/I NaHP04 (pH 7.2) and autoradiographed. Before rehybridization, 
filters were stripped with 50% formamide and 6x SSC for 30 min at 65°C (12). 
Southern blot dilution experiment 
The detection limit of the Southern blot technique with the Sau3A-JH probe and the IGHJ6 probe was 
determined by diluting B-chronic lymphocytic leukemia (Cll) cells with two rearranged IgH genes in PB·MNC 
from a healthy individual, resulting in mixtures with the following leukemic cell content: 100%, 85%, 70%, 
60%,50%,40%,30%,20%,15%,10%,7.5%,5%,3%,2%,1%, and 0% of 8-Cll cells. DNA was 
isolated from all mixtures, digested with 8gll1 or BamHI/Hindlll and subjected to Southern blotting and 
successive hybridization with the 32P·labeled Sau3A-JH probe and 32P·labeled IGHJ6 probe. 
RESULTS 
Restriction map of the JH-CJ.t region 
Sequence data from the literature (17,24-26)' and extensive Southern blot analysis of DNA 
from granulocytes of healthy individuals and cell lines with germline IgH genes, were used 
to determine the precise position of the restriction sites. The obtained detailed restriction 
map of the germline JH and ell- region is presented in Figure 1, whereas the sizes of the 
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TABLE 2. DNA probes and restriction enzymes for detection of IgH gene rearrangements. 
Size of insert Restriction enzymes Size of germline 
in bp (restriction used for digestion restriction fragments Allelic frequency 
DNA probea enzymes) of genomic DNA in kbb of polymorphismsc 
IGHJ6 1020 8gnt 3.8 0.3% (1/300) 
(EcoRI~Hindlll) SamHI/Hindll1 6.0 0% (0/300) 
Xbal 6.2 0% (0/150) 
SamHI/Sacl 7.8 0% (01150) 
Hlndlll 9.9 VNTR 
Sac! 11.6 VNTR 
BamHI 16.0 0% (01150) 
EcoRI 16.2 VNTR 
IGHMU 552 8gnt 16.7 0% (0/150) 
(£coRI-Hindlll) SamHIIHind1l1 10.0 0% (0/150) 
Xbal 6.6 0% (01150) 
Hindlll 10.2 0% (0/150) 
Sacl 4.2 0% (0/150) 
BamHI 16.0 0% (0/150) 
EcoRI 16.2 VNTR 
IGHM2d 813 EcoRI 1.2 0% (0/150) 
(EcoRl~Hindlll) 
a. The precise position of the probes is presented in Figure 1. 
b. The sizes of the germline restriction fragments, based on published sequence data, are presented in bold (17,24-26). The sizes of 
ali othor germline fragments were dotormined by extensive Southern blot analysis of granulocyte DNA from 75 hoalthy individuals 
(all restriction enzymes) as well as DNA from 75 patients with germlino IgH genes (in caso of 8g111 and &mHIIHindlll). 
c. Tho Hindlll, &cl, and EcoRI germlinc restriction fragments of tho JH region vary in size due to the presonce of the VNTR-HVP region 
at tho 5' side ofthe JH region (12-15). 
d. The germline restriction fragmonts obtained with the IGHM2 probe are similar to those obtained with tho IGHMU probe except for 
the EcoRI restriction fragment (Figure 1). 
germline restriction fragments are summarized in Table 2. 
Optimal choice of restriction enzymes and probes 
Based on our extensive Southern blot analyses and published sequence data, we conclude 
that rearrangements in the JH region are optimally detectable by use of Bgnl, BamHIIHindlll, 
Xbal, and BamHI/Sacl digests (resulting in small germline bands of 3.8 kb, 6.0 kb, 6.2 kb, 
and 7.8 kb, respectively) in combination with a JH probe (Figures 1, 2 and Table 2). 
However, digestion with BamHl and EcoRI (resulting in large germline bands of 16.0 kb and 
16.2 kb, respectively) in combination with a CM probe or a JH probe frequently leads to 
comigration of germline bands and/or rearranged bands (Figures 1, 2 and Table 2). 
Polymorph isms 
The main polymorphism in the JH-CM region is a HVP caused by the presence of a VNTR, 
located -1.8 kb upstream of the JH region (Figure 1) (12-151. In 80% of individuals this 
HVP causes differences between the restriction fragments of the two 19H alleles, which can 
vary up to 2.2 kb (13). This implies that interpretation of JH region Southern blot analysis 
with the restriction enzymes EcoRI, Hind 11 I and Sacl might be difficult, because their 
germline restriction fragments include the VNTR region (Figure 1). 
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Figura 2. Southern blot analysis of IgH genes in four representative precursor 8-AlL at diagnosis. Control DNA and DNA from precursor a·ALL samples were digested 
with (A) Bg/ll, IS) BamHI/Hindlll, and (e) EcoRI. The 8U/ll and BamHllHlndlll filters were hybridized with the IGHJ6 probe and the EcnRr filter with the IGHMU probe. In 
the EcoRI filter the rearranged IgH gene bands varied from 9.1 to 16.2 kb, while in the 89/11 filter the rearranged bands varied from 1.4 to a,9 kb. Comigration of IgH 
gene bands occurred in several lanes of the EcoAr filter, but optimal separation of most rearranged bands was obtained in the BglIl and BamHlfHlndl1l filte(s. 
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Our additional studies on polymorphic restriction sites in the JH and Cp. region revealed 
only one polymorphic Bgnl site (11300 IgH alleles; 0.3%), i.e. the Bgnl site upstream of the 
JH gene region (Figures 1 and 3). The other relevant restriction sites downstream of the 
VNTR region did not show any polymorphism (Table 2). 
Comparison of JH probes 
In a large series of 20 precursor 8-ALL and 45 chronic 8-cell leukemias, IgH gene 
rearrangement patterns were determined by successive hybridization of Southern blotfilters 
with the Sau3A-JH, H24-JH, and IGHJ6 probes (6,16,17). The Sau3A-JH probe and H24-JH 
probe recognize JH gene segments, including - 0.2 kb and -1.1 kb of the 3" flanking 
sequences, respectively, whereas the IGHJ6 probe only recognizes -1.0 kb of the 3' 
flanking sequences (Figure 1). The IGHJ6 probe resulted in distinct rearranged IgH gene 
bands of comparable density in all chronic 8-cell leukemias, and in a large part of the 
precursor 8-ALL. In 32% (14/44) of rearranged IgH alleles in precursor 8-ALL and in 30% 
(26/87) of rearranged IgH alleles in chronic B-cell leukemias the rearranged bands were 
weaker upon hybridization with the H24-JH probe, and faint or absent upon hybridization 
with the Sau3A-JH probe (Figure 4). These weak, or faint rearranged bands, represented 
rearrangements to the JH6 gene segment, as proven by hybridization with the IGHJ5 probe, 
which shows deletion of the JH5 gene segment if rearrangement to the JH6 gene segment 
has occurred (Figures 1 and 4). 
Detectability of subclones 
In many precursor B-ALL more than two rearranged IgH gene bands, generally differing in 
density, were found by use of the IGHJ6 probe, proving subclone formation (biclonality or 
oligoclonality) within the leukemias. In ten cases (eight biclonal and two oligoclonal), only 
a part of the multiple rearranged bands were detected by use of the Sau3A-JH probe 
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Figure 4. Comparison of JH probes for Southern blot analysis of IgH genes in three precursor a·ALL patients at diagnosis. The Bgfll filter was successively hybridized 
with the Sau3A-JH probe, the H24-JH probe, the IGHJ6 probe, and the IGHJ6 probe. In all three precursor 8-ALL hybridization with the IGHJ6 probe resulted in rearranged 
bands of comparable density, whereas in two patients one band (3.2 kb in patient EY and 1.7 kb in patient GAl was weaker upon hybridization with the H24-JH probe 
or faint upon hybridization with the Sau3A-JH probe. Upon hybridization with the IGHJ5 probe the weak or faint bands were absent (arrows), thereby proving that they 
represented rearrangements to the JH6 gene segment. Densitometry of the rearranged bands in these two patients disclosed that the hybridization signals of the JH6 
rearrangements were only - 5% with the Sau3A-JH probe and -60% with the H24-JH probe as compared to the hybridizetion signal with the IGHJ6 (data not shown). 
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Figure 5. Comparison of JH probes 
for Southern blot analysis of IgH 
genes in one patient at diagnosis and 
relapse. The 8g/lt filter was successi-
vely hybridized with the Sau3A-JH 
probe and the IGHJ6 probe. Upon 
hybridization with the IGHJ6 probe 
three distinct and one weak rear-
ranged band were seen at diagnosis, 
whereas only one distinct and one 
weak rearranged band were detected 
at relapse. The weak band at diagno-
sis was identical to the weak band at 
relapse, indicating a clonal relation-
ship between the diagnosis and 
relapse cell sample. Upon hybridizati-
on with the Sau3A-JH probe this 
clonal relationship was not detecta-
ble. Sau3A-JH probe IGHJ6 probe 
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(Figure 5). Also by use of the H24-JH probe several of the weak rearranged bands were 
missed. 
Several precursor B-ALL, with subclone formation, were analyzed at diagnosis' and 
subsequent relapse. Although we have found major differences in IgH gene rearrangement 
patterns by use of the IGHJ6 probe, a clonal relationship could be proven between the 
leukemic cells at diagnosis and relapse, in the majority of patients. However this was not 
always possible when the Sau3A-JH probe was used, as is illustrated by Figure 5. 
Detection limit of the Southern blot technique 
In a dilution experiment, in which cells from a mature B-celileukemia with two rearranged 
IgH alieles (including one involving the JH6 gene segment) were diluted in PB-MNC from a 
healthy individual, the Southern blot detection limit of the Sau3A-JH probe appeared to be 
40-50% in case of a JH6 rearrangement and 10% if the rearrangement involved a further 
upstream JH gene segment. However, the detection limit of the IGHJ6 probe was 5%, 
independent of the rearranged JH gene segment (Figure 6). 
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Figure 6. Dilution experiment in which B~CLL cells with two rearranged IgH alleles were diluted in PBwMNC 
from a healthy individual. The 8gfll filter was successively hybridized with the Sau3A-JH probe (upper pannell 
and lGHJ6 probe (tower pannel). In this dilution experiment the two IgH gene rearrangements of the S-ell 
were still detectable in the 5% dilution mixture upon hybridization with the IGHJ6 probe. Upon hybridization 
with the Sau3A-JH probe one rearranged IgH gene band was visible down to the 10% dilution mixture, but 
the other rearranged band (representing a JH6 gene rearrangement) was only visible down to the 40·50% 
dilution mixture. 
DISCUSSION 
To improve further the detection of clonal IgH gene rearrangements by routinely 
performed Southern blot analysis for diagnostic purposes, we carefully determined the 
precise restriction map of the JH and Cp, region of the IgH locus (Figure 1) and evaluated 
relevant combinations of restriction enzymes with JH and Cp, probes. 
According to our longstanding experience with Southern blot analysis of rearrange-
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ments in Ig and TcR genes, restriction enzymes which result in small germline restriction 
fragments give better results than enzymes which result in large germline restriction 
fragments (12). This is mainly due to the fact that limited separation or co migration of 
germline restriction fragments and rearranged restriction fragments, is not frequently seen 
when they are small «10 kb). However the chance of insufficient separation and 
comigration increases progressively with the size of the restriction fragments, especially 
when they are> 15 kb (121. Our data indicate that rearrangements in the JH region are 
optimally detectable by use of Bgm, BamHIIHindlll, Xbal, or BamHl/Sacl digests in 
combination with a JH probe, whereas usage of BamHI or EcoRI digests in combination with 
a elL or a JH probe should be avoided. 
Polymorph isms of the restriction sites of the four optimal restriction enzyme digests 
are rare, if they occur at all (Table 2). Furthermore, the obtained restriction fragments do 
not contain the VNTR region, which is located -1.8 kb upstream of the JH region (Figure 
1). Nevertheless, we feel that appropriate Southern blot analysis should always include two 
different restriction enzyme digests per probe and that a third restriction enzyme digest 
should be used in case of doubt, e.g. suspicion of a polymorphism. The latter problem can 
be prevented by using granulocyte or fibroblast !;:INA from the patient as a control (12). 
Although elL probes are not optimal for detection of IgH gene rearrangements, they 
might be useful for studying IgH class switching in mature B-cell malignancies by 
demonstrating deletion of the elL region or by hybridization of the elL probe to the same 
restriction fragment as the JH probe. For the latter purpose the IGt:MU probe presented 
here can be used in combination with both BamHI and EcoRI digests, whereas the 
traditional C" probes (e.g. IGHM21 are only informative in BamHI digests (Figure 1 I. 
In a large series of B-ceilleukemias IgH gene rearrangement patterns were determined 
by successive hybridization of Southern blot filters with the Sau3A-JH, H24-JH, and IGHJ6 
probes (6,16,171. The IGHJ6 probe resulted in distinct rearranged IgH gene bands of 
comparable density in all chronic B-cellieukemias and in a large part of the precursor 8-ALL. 
In 32% (14/44) of rearranged IgH alleles in precursor B-ALL, and in 30% (26/87) of 
rearranged IgH alleles in chronic B-ceilleukemias, the rearranged bands were weaker upon 
hybridization with the H24-JH probe, and faint or absent upon hybridization with the 
Sau3A-JH probe. We assumed that these weak or faint rearranged bands represented 
rearrangements to the JH6 gene segment, because a large part of the H24-JH probe and 
the main part of the Sau3A-JH probe recognize JH gene sequences, which are deleted upon 
rearrangement to the JH6 gene segment. This implies that the hybridization signal is 
restricted to the remaining 3' part of the probe, which is 1.1 kb in case of the H24-JH 
probe, and only 230 bp in case of the Sau3A-JH probe. In all patients our assumption was 
proven to be correct by use of the IGHJ5 probe, which shows deletion of the JH5 gene 
segment if rearrangement to the JH6 gene segment has occurred., The frequent usage of 
the JH6 gene segment is in agreement with data published in the literature (28,29). 
Densitometry of the rearranged bands in Figure 4 revealed that the hybridization 
signals of the JH6 rearrangements were only - 5% with the Sau3A-JH probe and - 60% 
with the H24-JH probe as compared to the hybridization signal with the IGHJ6 (data not 
shown). This relative decrease in density of JH6 rearranged bands is in line with the 
restriction of the hybridization to the 3' part of the Sau3A-JH and H24-JH probes 
(Figure 1). 
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The frequency of biclonality or oligoclonality as determined by Southern blot analysis 
of IgH genes in precursor B-ALL is reported to be 15-30% (11,21,30-32). whereas we 
detected subclone formation in 38% of 60 non-random (consecutive) precursor &-ALL (33). 
It is obvious from the data presented here, that this discrepancy is probably due to the use 
of different probes and different restriction enzymes, resulting in larger (comigrating) 
restriction fragments. In several precursor B-ALL with subclone formation analyzed at 
diagnosis, and subsequent relapse, we found major differences in IgH gene rearrangement 
patterns by use of the IGHJ6 probe. However, in the majority of patients a clonal 
relationship could be proven between the leukemic cells at diagnosis and relapse (34), while 
this was not always possible when the Sau3A-JH probe was used. 
These data indicate that due to its position, the Sau3A-JH probe is not suitable for 
optimal detection of each IgH gene rearrangement and that the H24-JH probe will result in 
bands of different density, depending on the rearranged JH gene segment. The latter might 
result in low density bands of JH6 rearrangements being erroneously interpreted as 
sub clone formation (Figure 4). Therefore, application of these probes will lead to: (a) 
underestimation of the frequency of IgH gene rearrangements in 8-cel1 malignancies, (b) 
underestimation and misinterpretation of subclone formation in precursor B-All, and (c) 
misinterpretation of clonal relationship and clonal evolution between diagnosis and relapse 
in precursor 8-AlL. The above mentioned false-negative results of Southern blot analyses 
with the Sau3A-JH probe are probably caused by the low sensitivity of this probe. This was 
proven by use of a dilution experiment in which 8-ell cells with two rearranged IgH alleles 
(including one involving the JH6 gene segment) were diluted in PB-MNC from a healthy 
individual. The Southern blot detection limit olthe Sau3A-JH probe appeared to be 40-50% 
in case of a JH6 rearrangement, and 10% if the rearrangement involved a further upstream 
JH gene segment (Figure 6). However, the detection limit of the IGHJ6 probe was 5%, 
independent of the rearranged JH gene segment (Figure 6). These data indicate that the 
detectability of clonal IgH gene rearrangements in lymphoproliferative diseases by use of 
the Sau3A-JH probe is highly dependent on the involved JH gene segment, as well as the 
relative frequency of the tumor cells. 
We conclude that IgH gene rearrangements are optimally detectable in routinely 
performed Southern blotting by use of JH probes, which are complementary to the 3' 
flanking sequences of the JH gene region (such as our IGHJ6 probe), in combination with 
at least two appropriate restriction enzyme digests (e.g. BglII and BamHlfHind II I) , which 
produce small germline bands and which are not affected by polymorph isms. It can be 
anticipated that these rules most probably also apply for optimal detection of rearrange-
ments of other Ig and TcR genes. 
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DETECTION OF IMMUNOGLOBULIN KAPPA LIGHT-CHAIN GENE 
REARRANGEMENT PATTERNS BY SOUTHERN BLOT ANALYSIS' 
ABSTRACT 
Auke Beishuizen, Marie-Anne J. Verhoeven, Ellen J. Mol, 
and Jacques J.M. van Congen 
Department of Immunology, University Hospital Dijkzigt/Erasmus University, 
Rotterdam, The Netherlands 
Immunoglobulin (lg) light-chain (lgL) gene rearrangements occur in a sequential order 
during normal B-cell differentiation with 19K gene rearrangements prior to 19)... gene 
rearrangements. Therefore, 19K producing B-cells usually retain IgA genes in germline 
configuration, whereas the 19K genes are generally deleted on one or both alleles in most 
IgA producing B-cells. The deletion processes in the 19K locus are mediated via rearrange-
ment of the kappa deleting element (Kde), which is located ...... 24 kb downstream of the 
constant {elK gene segment. Kde rearrangements can delete the CK region (including the 
IgK enhancer) or the complete joining (J)K-CK region via rearrangements to a heptamer 
recombination signal sequence in the JK-CK intron (intron RSS) or via rearrangement to a 
variable (V)K gene segment, respectively. 
To improve the Southern blot detection of clonal IgK gene rearrangements and 
deletions in a-lineage malignancies, we developed a new set of optimal JK, CK, and Kde 
probes, and made a detailed restriction map of the JK, CK, and Kde region. Extensive 
Southern blot studies revealed that rearrangements in the JK gene region are optimally 
detectable by use of a JK probe in combination with at least two appropriate restriction 
enzymes i.e. BamHI, 8g/ll, EcoRI, Hindlll, and/or Sac!. JK gene rearrangements are also 
detectable with the CK probe in 8gm and 8amHI digests, if no deletion of the CK region has 
occurred. The two different types of Kde-mediated JK and/or CK gene deletions are easily 
detectable with the Kde probe in 8g/ll, Hind II I andlor £coRI digests. This is in contrast to 
the inaccurate information obtained with the JK and CK probes, because these probes can 
detect deletions only in the form of decreased densities of JK and/or CK germline bands in 
the absence of rearranged bands. 
Our detailed analysis of 217 B-lineage leukemias revealed that 62% (69/111) of 
precursor B-cell acute lymphoblastic leukemias (ALL) had rearranged and/or deleted IgK 
genes. All 53 Ig:A + chronic 8-cell leukemias contained IgK gene deletions; in 75% this 
concerned biallelic JK and/or CK gene deletions. Virtually all IgK gene deletions appeared to 
* Leukemia, in press. 
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be mediated via Kde rearrangements, while only 1.5% of the \9K gene deletions were 
mediated via an alternative deletion mechanism which involved the JK region. 
INTRODUCTION 
During 8-cell differentiation Ig heavy-chain IIgH) gene rearrangements precede IgK gene 
rearrangements, which in turn precede Ig/.. gene rearrangements (1-3). However, IgA gene 
rearrangements in the presence of germline 19K genes have been found in several human 
cell lines and leukemia patients (4-7), suggesting that rearrangement of 19K genes on one 
or both alleles is not obligatory for 19A gene rearrangements in human cells (8,9). 
Nevertheless, 19K producing B-cells usually retain IgA genes in germline configuration, 
whereas the 19K genes are generally deleted on one or both alleles in most IgA producing 
B-cells (10,11). It is assumed that the IgK gene deletions are needed to exclude transcripti-
on and protein expression of (aberrant) pre-existing V K-JK gene rearrangements in order to 
prevent potential double IgL expression. 
The deletion processes in the IgK locus are mediated via a site-specific rearrangement 
of the so-called Kde, which is located - 24 kb downstream of the CK gene segment (12-
15). Two types of Kde-mediated IgK gene deletions can occur; i.e. rearrangement of Kde 
via heptamer-nonamer RSS at the 5 " side of Kde either to the intron RSS, thereby deleting 
the CK region (including the IgK enhancer), or to heptamer-nonamer RSS at the 3" side of 
a VK gene segment, thereby deleting the JK and CK regions (Figure lA) (12-15). An 
alternative recombination mechanism resulting in deletion of only JK gene segments has 
also been described (Figure 1 B) (16-19). Feddersen et al. postulated a two-step deletion of 
the JK region: first, rearrangement of a JK gene segment to the intron RSS, thereby only 
retaining the joined RSS (the so-called signal joint)' and second, rearrangement of a V K gene 
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Figure 1. Schematic diagrams of 
IgK gene deletions mediated by 
Kde rearrangements (A) and by an 
alternative deletion mechanism (B). 
(A) Two types of Kde-mediated IgK 
gene deletions can occur: Kde 
rearrangement either to the intron 
RSS (upper diagram) or to the RSS 
of a V K gene segment (lower 
diagram). (B) The alternative 
deletion mechanism results in 
deletion of JK gene segments. 
First, rearrangement of a JK gene 
segment to the intron RSS occurs, 
retaining the signal joint and se-
cond, a VK gene segment rearran-
ges to the still present RSS of the 
JK gene segment. 
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segment to the still present RSS of the rearranged JK gene segment (Figure 1 B) (19). 
Southern blot analysis represents a powerful tool for detection of clonal rearrange~ 
ments of Ig genes (20). Since a-cell malignancies are clonal proliferations of immature and 
mature B-cells, Ig gene analysis has been widely used for diagnostic purposes (21-24). In 
addition to IgH gene rearrangement studies, Southern blot analysis of IgK genes has been 
used to provide additional information concerning differentiation lineage or clonality of cell 
populations (24-34). Usage of JK and CK probes, generally allows the detection of clonal 
IgK gene rearrangements. However, detection of IgK gene deletions appears to be difficult, 
especially in cell samples with small clonal a-cell populations, because IgK gene deletions 
are only detected by the absence of a hybridization signal when JK or CK probes are used. 
Since the majority of 19K gene deletions is mediated via Kde rearrangements, usage of an 
optimal Kde probe will allow the detection of small clonal a-cell populations with IgK gene 
deletions (20). 
To improve the detection of clonal IgK gene rearrangements and/or deletions by 
routinely performed Southern blot analysis, we developed new JK, CK, and Kde probes. 
Based on sequence data from the literature and our extensive Southern blot analysis of cell 
samples with germline IgK genes, we also made a detailed restriction map and determined 
the occurrence of restriction fragment length polymorphisms (RFLP's) in the JK, CK and Kde 
regions. Finally, we studied the IgK gene rearrangement patterns and the occurrence of the 
different types of IgK gene deletions in a large series of 217 B-Iineage leukemias. 
MATERIALS AND METHODS 
Cell samples 
Peripheral blood (PS) or bone marrow (BM) samples were obtained from 111 precursor S-ALL patients and 
106 chronic B-cellieukemias (chronic lymphocytic leukemias (Cll), hairy cell leukemias, and prolymphocytic 
leukemias). The series of 106 chronic B-cellieukemias consisted of 53 IgK+ leukemias and 53 IgA + leukemias. 
Mononuclear cells (MNC) were isolated by Ficoll-Paque centrifugation (density: 1.077 g/cm 3; Pharmacia, 
Uppsala, Sweden). The percentage of leukemic cells in all samples was at least 80%, as determined by 
immunophenotyping of the MNC (35). The MNC samples were frozen and stored in liquid nitrogen. Control 
DNA was obtained from the non-hematopoietic cell line Hela and granulocytes from healthy volunteers. The 
granulocytes were obtained from cell-pellets after Ficoll-Paque centrifugation. 
Southern blot analysiS 
DNA was isolated as previously described (20,36), Fifteen ,ug of DNA were digested with the appropriate 
restriction enzymes (Pharmacia). The restriction fragments were size-separated in 0.7% agarose gels and 
transferred by vacuum blotting to Nytran-13N nylon membranes (Schleicher and Schuell, Dassel, Germany). 
The membranes were hybridized with 32P-random oligonucleotide labeled probes (20). 
Restriction map and polymorphisms 
DNA from granulocytes and the Hela cell line was used for digestion with the restriction enzymes BamHI, 
BglII, EcoRI, Hindlll, Sacl, Xbal and combinations of them (PharmaciaJ, to determine the precise position of 
the restriction sites in the JK, CJ<. and Kde regions. In addition, granulocyte DNA from 75 healthy volunteers 
and/or DNA from PB-MNC of 88 patients with germ line IgJ<. genes were used to determine the occurrence of 
RFLP's. 
Construction of IGKJ, IGKC, and IGKDE DNA probes 
The IGKJ (JJ<.)' IGKC (CK) and IGKDE (Kde) probes were obtained by cloning the purified polymerase chain 
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TABLE 1. Oligonucleotide primers used in construction of 191C DNA probes. 
Probe Relative 
name Code positiona Sequenceb Referencec 
5 • 3' 
IGKJd J",·pS' + 64 ctataagCTTCTGAAA TTTGGGTCTGATG G C 3. 
J..:-p3' + 974 actggaatTCAGGAAAGCTGGCTACGGCAG X67858 
IGKC CK-p5 • + 10 tgttgaaTTCTTTCCTCAGGAACTGTGGCTG 37 
CK"p3' + 497 ACCACAGGTGCAAAGcTTCACTTTAT 37 
IGKDE Kdo-p5 • + 42 GGGCGACTCCTCATGAGTCTGC 13 
Kdo-p3 • + 533 TCGAGAGCTCTCAGCCCATGATGGCG 13 
a. Tho position of tho 3' ond of the oligonuclootide primers is indicated downstroam (+) of tho closest joining 
site ('" start of RSS).ln case of tho IGKJ probe, tho RSS of tho J.<S gone sogmont. and in case of tho IGKOE 
probe, the RSS of Kdo. In case of the IGKC probe tho position of the 3' end of tho oligonucleotide primers is 
indicated downstream (+) of the 5' exon splice sito of the Co: oxon. 
b. The sequences in lower case characters represent the aspecific nuclootidos, which generato rostriction sites 
(underlined). 
c. Sequence information used to design the oligonucleotide primers was derived from tho indicated literature 
references and EMBL databank accession number. 
d. The lGKJ5 probo is a 540 bp HindlllfSacl subclono of tho lGKJ probo. 
reaction (PCR) amplification products of granulocyte DNA from a healthy volunteer. The oligonucleotide 
primers with aspecific tails containing EcoRI, Hlndlll, Pstl, or Sacl restriction sites for cloning are given in 
Table 1. All oligonucleotide primers were synthesized according to published sequences of the JJ(, CJ(, and 
Kde regions (13,37,38, Whitehurst et ai., EM8L databank accession no. X67858) on a 392 DNA synthesizer 
(Applied 8iosystems, Forster City, CA, USA) with the solid-phase phosphotriester method and used without 
further purification. 
PCR was essentially performed as previously described (36,39). An 1.0,ug sample of granulocyte DNA, 
12.5 pmol of the upstream and downstream oligonucleotide primers and one unit of AmpllTaq DNA 
polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA) were used in each PCR of 100,u1. The PCR products 
were digested with the appropriate restriction enzymes and size-separated by 1.0% agarose gel 
electrophoresis. After recovery from the agarose gel using Mi11ipore Ultrafree-MCiilters (Millipore Corporation, 
Bedford, MA. USA) the PCR products were cloned, using pUC19 as cloning vector (36). Al1 three probes were 
partly sequenced from both sides (at least 100 bp) to confirm their position in the JIC, CIC, and Kde regions 
(Figure 2). All sequence reactions were performed with the T7-sequencing kit (Pharmacia) following the 
manufacturer's instructions using 35S-radiolabeling, and run in denaturing 8% polyacrylamide sequence gels. 
The IGKJ5 probe was obtained from the IGKJ probe by use of Hind II I and SacJ digestion and subsequent 
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Figure 2. Restriction map of the human IgK gene, i.e. the JIC and CIC region and Kde region, located -24 kb 
downstream of the CIC region. The location of relevant BamHI (8), Bg/ll (8g). EcoRI (E), Hlndlll (H), Sacl (S}' 
and Xbal (X) restriction sites are indicated. Also the location of the intron RSS as well as the IgK enhancer 
(enh) are depicted (13,36,37,39, Whitehurst et ai, EMBL databank accession no. X67858). The solid bars 
represent the three 19K DNA probes: the IGKJ5, IGKC, and IGKDE probes. The asteriks indicates two 
polymorphic restriction sites (Xbal and Sac!). 
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cloning in the pUC19 vector (Tab[e 1) (36). The lGKJ5 probe recognizes 540 bp of the 3' flanking sequences 
of the JK region. The [GKC probe recognizes 527 bp of the CK region. The [GKDE probe recognizes 507 bp 
of the 5' part of Kde sequences (Figure 2 and Tab[e 1). The latter probe does not cross-hybridize with 
sequences on the long arm of chromosome 2 (locus 2q1.1) as described for other Kde probes (12, 15). 
Southern blot dilution experiment 
Cells from a Ig).., + CLL with biallelic C" gene deletions were diluted in P8-MNC from a healthy volunteer, 
resulting in mixtures with the following leukemic cell content: 100%, 80%, 60%, 40%, 20%, 10%, 5% and 
0% of 8-CLL cells. DNA was isolated from all mixtures, digested with Bglll and subjected to Southern blotting 
followed by successive hybridization with the 32P_Iabeled IGKC and IGKDE probes. 
RESULTS 
Restriction map of the J", CIC, and Kde region 
Sequence data from the literature (13,37,38,40, Whitehurst et al., EMBL databank 
accession no. X67858) and extensive Southern blot analysis of control DNA were used to 
determine the precise position of the relevant restriction sites. The obtained detailed 
restriction map of the germline JK, CK, and Kde regions is presented in Figure 2, whereas 
the sizes of the relevant germline restriction fragments are summarized in Table 2. 
TABLE 2. Genomic probes and restriction enzymes for detection of Ig..: gene rearrangements and deletions. 
Size of insert Restriction enzymes Size of germ line 
in bp used for digestion restriction fragments Allelic frequencies 
DNA probea (cloning sites) of genomic DNA in kbb of RFLP's 
IGKJ5 540 Sacl 1.9 0% 10/150) 
(HindJJJlSacl) Hindlll 5.1 0% 10/298) 
EcoRI 9.3 0% 10/102) 
Xbal 9.9 112.5) 7% 18/112) 
8gm 10.8 0% 10/300) 
8amHI 11.8 0% 10/118) 
IGKC 527 Sacl 0.5 & 5.1'13.7) 11 % 1171148) 
(EcoRIIHJi7dlll) Hindlll 5.9 0% 10/142) 
EcoRI 2.7 0% 10/114) 
Xbal 9.9 112.5) 7% 18/112) 
8gm 10.8 0% 10/300) 
8amH[ 11.8 0% 10/120) 
IGKDE 507 Sacl 11.4 0% 10/114) 
(Pstl-Sacl) Hindlll 2.7 0% 10/148) 
EcoRI 10.7 19.4) 0.7% 111144) 
XbaJ 3.9 0% 10/110) 
8glll 7.6 0% 10/140) 
8amHI 17.3 0% 10/104) 
a. The precise positions of tho probes are presented in Figure 2. 
b. The sizes of the Sacl germline restriction fragments, based on published sequence d<lt<l, arc presented in bold numbers (36,37, and 
Whitehurst et aI., EMBL databank accession no. X678S8). Tho numbers in parentheses ropresont the sizes of the polymorphic 
germline restriction fragmonts. 
c. Two gormline restriction fragments (O.S kb and 5.1 kb) are obtained with the IGKC probe in Sacl digests (Figure 2). 
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Figure 3. Southern blot analysis of four patients, who were selected for their 191( gene rearrangement and/or 
deletion patterns. Control DNA and DNA from three chronic B~cell leukemias samples (lane two, three, and 
four) and one precursor 8-ALL (lane five) were digested with 8gll!. The ONA filter was successively hybridized 
with the 32P_1abeled IGKJ5, IGKC, and lGKDE probes. The sizes (in kb) of the germline bands (G) and several 
mOlecular mass markers are indicated. The configuration of the 19K genes of the four patients was: patient 
A, VI<. to JI<. on both alleles; patient B, VI<. to J" and Kde to the intron RSS: patient C, Kde to the intron RSS 
and Kde to VK; patient D, alternative JK gene deletion on one allele and the other allele in germline 
configuration. 
Probes and restriction enzymes 
We developed new IgK DNA probes (IGKJ5, IGKC, and IGKDE) for optimal detection of IgK 
gene rearrangements and 19K gene deletions, according to the same criteria as previously 
described (Figure 2 and Table 2) (20,41,42). The IGKJ5 (JK) probe optimally detects IgK 
gene rearrangements in Sacl, Hindl1l, EcoRI, Xbal, Bg/ll or BamHI digests, which result in 
germline bands of 1.9-11.8 kb (Figures 2, 3 and Tables 2, 3). The IGKC (CK) probe can only 
detect 19K gene rearrangements in 8amHI or 8g/11 digests, which contain the complete JK-CK 
region. The IGKDE (Kde) probe easily detects alllgK gene deletions, which are mediated via 
rearrangement of Kde either to the intron RSS, or to the RSS of a VK gene segment. When 
rearrangement of the Kde to the intron RSS occurs, the IGKDE probe and IGKJ5 probe 
recognize an identical restriction fragment in 8amHI, 8g/ll, EcoRI, H,ndlll or Xbal digests 
(Table 3). Rearrangement of Kde to the intron RSS can also be proven with the IGKDE 
probe in Sacl digests, which results in an invariable 0.95 kb restriction fragment indepen-
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TABLE 3. Hybridization patterns of IgK gene rearrangements found with Ig..: DNA probes. 
Type of IgK. gene IgK. DNA probes 
rearrangement Restriction 
or deletion enzymea IGKJ5 IGKC IGKDE 
VIC to JIC BamHI, BglIl, and Xbal R Rid G 
EcoRI, and HIi'1dlll R G G 
Sacl R G G 
Kde to intron RSS BamHI, 8g/ll, and Xbal R D Rid 
(CK. gene deletion) EcoRl, and Hindlll R D Rid 
Sacl R D R (0.95 kblb 
Kde to VIC 8amHI, BglIl, and Xbal D D R 
(JIC""CK. gene deletion) EcoRI, and Hli1dlll D D R 
Sacl D D R 
VK./JIC to intron RSSc BamHl, 8g/ll, and Xbal D R G 
(JIC gene deletion) EcoRI, and Hindlll D G G 
Sacl D G G 
Symbols used: R, roarranged band; Rid' rearranged band, which is identical to tho rearranged band detectod with the IGKJ5 probe; G, 
germline band; 0, deletion of the involved gono segment. 
a. The restriction enzymes 8amHI, 8g/l!, and XbaJ and the restriction enzymes EcoRI, and HlndUI are combined because they give 
comparable hybridiUltion patterns. 
b. In caso of a recombination botween Kde and the intron RSS, the hybridizntion panern of the IGKDE probe shows an invariable 0.95 
kb rearranged band in Sect digc-sts. 
c. In this 19K gene doletion mechanism only JK gono sogments are deleted (see Figure 1 B) (19). 
dent of the preexisting VK-JK gene rearrangement. Hybridization patterns of the three IgK 
DNA probes in several restriction enzyme digests were determined for the various types of 
IgK gene rearrangements and deletions, as summarized in Table 3. 
Polymorphisms 
Our studies on polymorphisms in the JK, CK, and Kde region revealed a polymorphic Xbal 
restriction site located 4.3 kb upstream of the JK gene region. This RFLP showed a 
polymorphic germline band of 12.5 kb instead of 9.9 kb, with an allelic frequency of 7% 
(Table 2 and Figures 2, 4). Therefore, Xbal is not recommended to use in Southern blot 
analysis of IgK gene rearrangements and or deletions. Another RFLP, not important for IgK 
gene rearrangement studies and previously reported in the literature (43,44), was found in 
the Sacl restriction site located 3.5 kb downstream of the CK region. This RFLP showed a 
polymorphic germline band of 3.7 kb instead of 5.1 kb, with an allelic frequency of 11 %, 
comparable with the allelic frequencies (9-12%) found in the literature (Table 2 and Figures 
2, 4) (43,44). In the Kde region a rare EcoRI RFLP (polymorphic germline band of 9.4 kb 
instead of 10.7 kb) was found with an allelic frequency of 0.7% (Table 2). 
IgK gene rearrangement patterns in B-lineage leukemias 
DNA samples from a group of 217 B-lineage leukemias were examined for the presence of 
rearranged and/or deleted IgK genes. The results are summarized in Table 4. Rearrange-
ments and/or deletions of the 19K genes were found in 62% of precursor B-ALL cases and 
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Figure 4. Southern blot analysis of two RFLP's in the J/C'-C/C region. (A) DNA from five healthy volunteers 
(control I-V) was digested with Xbal. The DNA filter was hybridized with the 32P-labeled IGKJ5 probe. 
Controls 111 and V contained a RFLP on one and both alleles, respectively, which was caused by a poly-
morphic Xbal restriction site, located 4.3 kb upstream of the JIC region. (6) DNA from two healthy volunteers 
(control VI and VII) was digested with Sacl (S), a combination of Sacl and Hindlll (S/H), and a combination 
of Sac! and EcoRI (S/E). The DNA filter was hybridized with the 32P_labeled IGKC probe. Control VII contained 
a RFLP, caused by a polymorphic Sacl restriction site, located 3.5 kb downstream of the CK region. 
in 100% of mature B-cell leukemia cases. Rearrangement of Kde occurred in 50% of 
precursor B-ALL cases on one or both alleles, in 32% of IgK+ chronic B-cell leukemias on 
one allele, and in 100% of Igl\ + chronic B-cell leukemias on one allele (13 cases) or both 
alleles (40 cases), 
The allelic distribution of the different types of IgK gene rearrangements and deletions 
is summarized in Table 5. In precursor B-ALL patients, more than half of the IgK alleles 
(54%) was found to be in germline configuration. Deletions of IgK gene segments occurred 
in 38% (85/222) of alleles. The majority of deletions, 95% (81/85), was due to rearrange-
ment of Kde: in 31 % (25/81) to the intron RSS and in 69% (56/81) to the RSS of a VK 
gene segment. In two precursor B-ALL patients, an alternative deletion of the JK region was 
found on one allele, while the CK region was still present (Figures 1 Band 3), In IgK+ 
chronic B-cell leukemias, only 24% of the IgK alleles remained in germline configuration. 
More than half of the IgK alleles (60%) contained VK-JK gene rearrangements. In 16% of 
the IgK alleles, a Kde-mediated deletion was found, more or less equally divided over both 
types of Kde-mediated IgK gene deletions. In Igl\ + chronic B-ceilleukemias, the majority of 
IgK alleles (88%;93/106) contained IgK gene deletions, In 98% (91/93) of these alleles the 
deletions were due to recombination of Kde: in 55% (50/91) to the intron RSS and in 45% 
(41/91) to the RSS of a VK gene segment, In only 1 % (one allele) an alternative deletion 
was found as described above. 
Our data indicate that IgK gene deletions in precursor B-ALL are more frequently me-
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TABLE 4. Ig.oc: gene rearrangement patterns in B-lineage leukemias. 
JK~C"':'Kde region JK~CK region Kde region 
germline Rearrangement Deletion rearrangement 
B-lineage 
leukemia all IgK probes IGKJ5 probe IGKJ5 probe IGKC probe iGKDE probe 
type (GIG) (RIG, R/R or D/R) (D/G or DID) (D/G or DID) (RIG or RJR) 
precursor B~ALL 38% 30% 32% 50% 50% 
(42/1'1) (33/111) (36/111) (56/111 ) (56/111) 
Ig"'+ chronic 0% 100% 0% 32% 32% 
J3..cell leukemia (0/53) (53/53) (0153) (17/53) (17/53) 
Ig).. + chronic 0% 83% 17% 100% 100% 
B~cell leukemia (0/53) (44/53) (S/53) (53/53) (53/53) 
Symbols used: A, rearranged allele; G, germline allele; D, deletion of the involved gene segment. 
diated via rearrangement of Kde to a V K gene segment than via rearrangement of Kde to 
the intron RSS (69% vs 31 %). On the other hand in chronic B-ceilleukemias we found a 
nearly equal distribution in IgK+ chronic B-cellieukemias and a slight reversed preference 
in 19A + chronic B-cell leukemias (45% vs 55%). 
In two precursor 8-ALL and one IgA + chronic B-cellieukemia no hybridization signals 
were detected on one allele with all three IgK DNA probes, indicating deletion of the 
complete JK-CK-Kde region e.g. by loss of chromosome 2. Unfortunately, no cytogenetic 
data were available in these cases. 
Detectability of small malignant B-cell populations by use of Ig< DNA probes 
The value of an optimal Kde probe for detection of IgK gene deletions of small malignant 
8-cell populations, was evaluated in a dilution experiment (Figure 5). Hybridization of the 
DNA filter with the IGKC probe revealed a decreased density of the CK germline bands, 
TABLE 5. Allelic frequencies of different types of Ig", gene rearrangements and deletions in B-lineage leukemias. 
Ig", gene deletion 
B-lineage IgK gene 
leukemia in germline V", to J", Kde to Kde to VK/J", to J...:·C",·Kde 
type configuration rearrangement intron ASS V, intron ASS deietiona 
precursor B-ALL 54% 8% 11% 25% 1% 1% 
(11S/222) (181222) (25/222) (56/222) (2/222) (2/222) 
19"'+ chronic 24% 60% 8% 8% 0% 0% 
B-cell leukemia (25/106) (64/106) (81106) (S/106) (0/106) (0/106) 
Ig).. + chronic 5% 8% 47% 39% 1% 1% 
B-cell leukemia (5/106) (8/106) (50/106) (41/106) (11106) (1/106) 
a. No hybridization signals were detected with all three Ig", probes, indicating deletion of the complete JK-C...:-Kde region, 
e.g. by loss of chromosome 2. 
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Figure 5. Dilution experiment in which 
8-ell cells with two Kde-mediated 19K 
gene deletions were diluted in PB-MNC 
from a healthy individual. The 8gll1 
filter was successively hybridized with 
the lGKC probe (upper pane!), and 
IGKDE probe (lower panel). In this 
dilution experiment the Kde rearrange-
ments were still detectable in the 5% 
dilution mixture (unfortunately, one of 
the Kde rearrangements comigrated 
with the germ line band (7.6 kbl of the 
Kde probe). Upon hybridization with 
the IGKC probe a decreased density of 
the ex germline bands was found down 
to the 40-50% dilution mixture. 
which could not be interpreted reliably when less than 40-50% of tumor cells were present. 
Upon hybridization with the IGKDE probe two rearranged bands were observed, which 
remained detectable down to the 5% dilution step (Figure 5). 
DISCUSSION 
To further improve the detection of clonal IgK gene rearrangements and deletions by 
routinely performed Southern blot analysis for diagnostic purposes, we developed three 
new IgK DNA probes (IGKJ5, IGKC, and IGKDE). determined the precise restriction map of 
the J", C", and Kde regions of the 19" locus (Figure 2), and evaluated relevant combinations 
of restriction enzymes with the IGKJ5, IGKC, and IGKDE probes. 
According to our experience with Southern blot analysis of rearranged Ig and TcR 
genes, optimal detection of clonal rearrangements can generally be obtained with J probes, 
which are located just 3 ' of the J gene segments, in combination with restriction enzymes 
which result in small non-polymorphic germline restri,ction fragments (20,41 A2). The small 
size of the restriction fragments reduces the chance of co-migration of germline bands and 
rearranged bands (20,42). 
Our data indicate that rearrangements in the JK region are easily detectable by use of 
Sacl, Hindlll, EcoRI, 8glll, or 8amHI digests in combination with the IGKJ5 probe (Figures 
2, 3 and Table 3). If no C" gene deletion has occurred, these rearrangements are also 
detectable by use of the IGKC probe in 8amHI or 8gm digests, because their germline 
restriction fragments contain the complete J"-C,, region (Figures 2, 3 and Table 3). Kde-
mediated IgK gene deletions are easily detectable with the IGKDE probe in 8glll, Hindlll, or 
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EcoRI digests. 
Discrimination between the two types of Kde-mediated deletions is possible by 
successive hybridization with the IGKDE and IGKJ5 probes. In case of C" gene deletion 
(rearrangement of Kde to the intron RSS) the IGKJ5 and IGKDE probes will recognize the 
same rearranged restriction fragment, whereas in case of J"-C,, gene deletion (rearrange-
ment of Kde to a VK gene segment) the IGKDE probe will recognize a rearranged band, not 
detectable with the IGKJ5 probe (Figure 3 and Table 3). The third type of IgK gene deletion, 
(i.e. deletion of JK gene segments without deletion of the C" gene segment) is rare and can 
be detected by successive hybridization with the IGKJ5 and IGKe probes in 8gm or 8amHI 
digests, resulting in a rearranged band with the IGKe probe which is not detectable with 
the IGKJ5 probe (Figures 1 B, 2, and 3 and Table 3). RFlP's ofthe relevant restriction sites 
(8amHI, 8g/ll, EcoRI, Hind II I, and Sac!) are extremely rare in the JK, eK, and Kde region 
(Table 2) (43,44). 
The v~lue of an optimal Kde probe for detection of Ig" gene deletions by Southern blot 
analysis was demonstrated in a dilution experiment (Figure 5). Since Kde-mediated deletions 
are recognized as Kde rearrangements by hybridization with the IGKDE probe, a detection 
limit of -5% could be reached (Figure 5). This is in contrast to hybridization with the 
IGKJ5 or IGKC probes, which result in germline bands with decreased density in case of 
IgK gene deletions. It appeared that identification of Ig" gene deletions with J" or C" probes 
is only possible, if the cell samples contain a high tumor load (>40-50%) (Figure 5). 
Therefore, we wish to emphasize that an optimal Kde probe (e.g. the IGKDE probe) should 
be used for reliable detection of 19" gene deletions. Application of this probe also allows 
additional clonality studies in IgA + B-cell malignancies, because they generally have 
monoallelic or biallelic Kde gene rearrangements. 
Ig" gene rearrangement patterns were studied in a series of 217 a-lineage leukemias 
by use of our three IgK DNA probes (Tables 4 and 5). Rearrangements and/or deletions of 
the IgK genes were found in 62% of 111 precursor B-All and in 100% of 106 chronic B-
cell leukemias. The frequencies of IgK gene rearrangements and deletions in precursor B-
All are essentially higher than previously reported (6,24,26,29,32,33,45). This is most 
probably due to the optimal choice of restriction enzymes and probes, especially the use 
of the IGKDE probe (20,42). In the total group of B-lineage leukemias, the far majority of 
Ig" gene deletions occurred via Kde rearrangements, but in 1.5% of alleles with [g" gene 
deletions (in two precursor B-ALL and one IgA + chronic B-cell leukemia) only the J" gene 
segments were deleted. This alternative deletional mechanism has previously been 
described by Feddersen et aI., who found this type of deletion in three out of 65 B-lineage 
leukemias and lymphomas (18,19). 
A striking difference in frequency of the two types of Kde mediated Ig" gene deletions 
was found between our groups of precursor B-ALL and chronic B-cell leukemias. Kde 
rearrangements to V"gene segments were found in 69% (56/81) of Kde-mediated deletions 
in the precursor B-All group, while these were found in only 46% (50/108) of Kde-
mediated deletions in the chronic B-ceilleukemia group. The latter was comparable with the 
40% found by Feddersen et al. in their group of mature 8-cell leukemias and lymphomas 
(38 multiple myelomas and eight ell) (18). Preference for VK-Kde rearrangements can be 
explained by the fact that rearrangements via complete heptamer-nonamer RSS (in case of 
V K-Kde rearrangement) occur more easily than via an incomplete heptamer RSS, as present 
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in the JK-CK intron (46). Therefore, the lower frequency of VK-Kde rearrangements in 
mature B-cells as compared to immature B-cells might be caused by a smaller number of 
available germline VIC gene segments due to (continuing) VK-JK rearrangements (47), and/or 
the lower accessibility of V K gene segments to rearrangements in mature B-cells. 
Our analysis of the large group of chronic B-ceilleukemias provided evidence for the 
hierarchical model of ordered IgL gene rearrangements (10,11), because in alllg)." + chronic 
B-cell leukemias one or two 19K gene rearrangements and/or deletions were detected, and 
only a minority (- 6%) of 19K+ chronic B-ceilleukemias contained rearranged 19)." genes 
(unpublished results). Some reports describe the occurrence of IgA gene rearrangements in 
the presence of germline IgK genes in a few cases of B-lineage ALL (4-6). This would be 
in favour of the stochastic rearrangement model (8,9), but it should be noted that this 
phenomenon has only been found in immature B-cells and not in mature 8-cells. Probably 
these ALL originated from a small pool of "unusual" precursor 8-cells, which rearranged 
their 'lgA genes prior to IgK genes or this phenomenon is related to the malignant 
transformation of the immature 8-cell. 
The regulatory signals which are responsible for the model of ordered IgL gene 
rearrangements in 8-cells are not known. It has been suggested that deletion of IgK genes, 
particularly the 19K enhancer sequences, may allow progression from 19K to IgA gene 
rearrangement, either by elimination of inhibitory sequences or by encoding a transacting 
factor that can induce IgA gene rearrangement (12-15) . However, severallgK gene targeting 
studies in mouse (by deleting CK and/or IgK enhancer sequences) demonstrate that 
rearrangements in the IgA locus can occur in the absence of IgK gene rearrangements or 
Kde-mediated IgK gene deletions (48-50). These data suggest that IgK gene deletion is not 
a prerequisite for the progression of IgKto IgA gene rearrangements. It is more plausible that 
\gK gene deletions playa role in deleting non-functionallgK genes or in deleting functionally 
rearranged IgK genes, which code for auto-reactive Ig molecules (51,52). Moreover, IgK 
gene deletions will avoid double IgL expression on the cell surface of 8-cells (7,53). 
We conclude that all types of IgK gene rearrangements and deletions are optimally 
detectable in routinely performed Southern blotting with the three presented IgK DNA 
probes (lGKJ5, IGKC, and IGDKE probes) in combination with at least two appropriate 
restriction enzymes (i.e. HIi1dlll, 8gm, EcoRI, Sacl, andlor BamHI). Hybridization ofthe three 
probes to Hind II I filters results in the same germline bands as in BamH1!Hind II I filters. 
Nevertheless, we recommend to use the three probes in combination with BglII digests and 
8amHIIHindili double digests (instead of Hind II I single digests), because these two digests 
also allow optimal analysis of IgH gene rearrangements with the IGHJ6 probe (42). Our 
extensive analyses in a series of 217 8-lineage leukemias show that IgK gene rearrange-
ments and deletions occur in higher frequencies than reported previously (especially in case 
of precursor 8-ALL), and that IgK gene deletions are virtually always mediated via Kde 
rearrangements. 
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CHAPTER 3.1 
ANTIGEN SPECIFIC RECEPTOR GENES: CLINICAL APPLICATIONS 
Introduction 
In general, acute lymphoblastic leukemias (ALL) consist of clonal cells, which are regarded 
as malignant counterparts of normal immature 8- and T-cells (1-5). Immunoglobulin (lg) and 
T-cell receptor (TcR) gene rearrangements occur early during lymphoid differentiation (see 
Chapter 2.1) (6-8). Therefore, cells of immature lymphoid malignancies will have identically 
rearranged 19 or TcR genes (2,7,9). Based on this concept, the various precursor B-ALL and 
T-ALL have been used to study the Ig and TcR gene rearrangements during lymphoid 
differentiation (2,9-16). On the other hand, analysis of Ig and TcR genes with the Southern 
blot technique and polymerase chain reaction (peR) technique can be used for diagnostic 
studies (2,9,12,16,17-25). 
Secondary gene rearrangements 
In order to obtain antigen specific receptors on their cell membrane, 8- and T-cells try to 
assemble functional 19 and TcR molecules by recombination of their 19 and TcR genes, 
respectively (6-8). These rearrangements occur in a hierarchical order (7,26-28). Because 
these rearrangement processes are highly complex, non-functional and aberrant Ig or TcR 
genes rearrangements occur frequently (6,8,29). To partly overcome these problems, each 
8- and T-cell has two Ig or TcR alleles on which the Ig and TcR genes are located, 
respectively (7). 
As confirmed in ALL studies most B- and T-cells have biallelic Ig or TcR rearrange-
ments (2,9,16,17). In addition to the biallelic rearrangements, secondary gene rearrange-
ments can occur in order to rescue precursor B- and T-cells, with two non-functionally 
rearranged Ig or TcR genes (30-40). The various secondary rearrangements and their 
occurence in the different antigen receptor gene rearrangements are summarized in Table 
1 and shown in Figure 1. D-JH replacements in B-cells replace preexisting out-of-frame DJH 
TABLE 1. Secondary rearrangements (replacements). 
19 genes TcR genes 
IgH IgK IgA TcR-a TcR-~ TcR""Y TcR-o 
D-J replacements!! +' 1+1 1+1 
V-J replacements + 1+1 + 1+1 + 
V replacements + + 1+1 
a. Abbreviations used: V, variable gene segment; 0, diversity gene segment; J, joining gene segment. 
b. Symbols usod: +, secondary rearrangement reported to occur; (+), secondary rearrangement C<ln occur, but is not reported so far; 
-, this form of secondary rearrangement is impossible in the involved Ig or TcR gono locus. 
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Figure 1. Schematic diagram of 
secondary rearrangements. Upper 
panel: An example of a O-JH repla-
cement. A DH1-JH5 rearrangement 
replaces a preexisting aut-af-frame 
DJH complex. Middle panel: An 
example of a V-JK replacement. A 
VK3-JK4 rearrangement replaces a 
preexisting out-af-frame or self-
reactive V-JK rearrangement. Lower 
panel: An example of a VH to V-D-
JH rearrangement. The VH4 gene 
segment is replaced by the VH3 
gene segment via a rearrangement 
process in which heptamer (indica-
ted as 7) joining sequences are 
involved (31). 
complexes by joining an upstream DH to a downstream JH (Figure 1). In case of V-J 
replacement, a comparable process will take place (Figure 1). These replacements may 
occur repeatedly in the same Ig or TcR locus as long as it carries unrearranged V, 0, or J 
gene segments. V replacements represent a third type of secondary rearrangements, in 
which a rearranged V gene segment is replaced by a new upstream V gene segment. This 
rearrangement is mediated by a heptamer recombination signal sequence (RSS) found in the 
3' region of VH, V{3, and V-y genes (Figure 1) (31). So far no V-y replacements have been 
reported (31). The internal heptamer RSS are not present in the V gene segments of IgLand 
TcR-cdllloci (31). 
Diagnostic applications of Ig and TcR gene analysis. 
Traditionally, Southern blot analysis of 19 and TcR genes is used for determination of 
c!onality in a part of the Iymphoproliferative disorders. Since the discovery of the peR 
technique in 1985, its value has been proven in the diagnosis of clonallymphoproliferative 
disorders, especially in combination with denaturing gradient-gel electroforeses (DGGE) or 
single-strand confirmation polymorphism (SSCP) analysis (19-25,41,42). The main 
advantages of the peR based technique compared to the Southern blot technique in the 
assessment of clonality are: it is much less time-consuming; there is no requirement for 
radioactive isotopes; it requires less starting material, and it offers improved sensitivity for 
detection of clonality (0.2-1 %) if combined with DGGE or SSCP analysis (25,41,42). 
The peR technique is highly sensitive during follow-up when patient-specific probes 
are used for detection of low numbers of tumor cells. Therefore, all possible precautionary 
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TABLE 2. Comparison of two techniques used in Ig and TcR gene rearrangement studies at diagnosis or 
during follow-up. 
amount of DNA per test 
time consumptiona 
sensitivity 
radioactivity 
false-positive (contamination) 
false-negative 
Southern blotting 
10-15,ag 
1 week 
-5% 
yes 
no 
peR analysis 
0.1-' I-'g 
6 hours 
0.2-1 % {at diagnosis)b 
0.01-0.0001 % (during follow-up)c 
not essential 
yesd 
15-30% 
a. The time consumption mentioned is independent of the time nocessary for ONA extraction, rehybridization of DNA filters, or oxtra 
peR analysis in case of negative results. 
b. The detection limit of the peR technique is 0.2-1 % if comb'lnod w'rth OGGE or ssep analysis. 
c. The detection limit of tho peR technique is 0.01 -0.0001 % during follow-up when patient-specific prebes are used for dotection of 
low numbers of tumor colis. 
d. Folse positive results due to contamination of smallllmounts of DNA (peR products) from other pationts hnve important implications 
for the detection of MRD by peR analysis during follow-up. 
measures should be taken to prevent cross-contamination of peR products between patient 
samples in PeR-mediated minimal residual disease (MRD) studies, causing false-positive 
results (43,44)_ False-negative results obtained with the peR technique in 15-30% of 
monoclonal cases can be explained by either technical problems (e_g. Taq polymerase 
inhibition and bad primer annealing)' substrate problems (e.g_ germline configuration, 
deletion of the involved gene segments, point mutations in the primer template sequences), 
incomplete rearrangements (O-J instead of V-O-J rearrangements)' or rare V gene usage 
(23,45)_ The latter cause can be overcome by developing more primers which will recognize 
these V gene segments_ The comparison between the two techniques is shown in Table 2_ 
The various clinical applications of Ig and TcR gene analysis by the Southern blot and 
peR technique are summarized in Table 3. They can be divided in three phases of disease 
stages. First, analysis of cell samples at diagnosis; second, analysis of cell samples during 
and after tr~atment; and third, analysis of cell samples at relapse. The most often used 
diagnostic application is the discrimination between polyclonal and monoclonallymphoproli-
ferative diseases at presentation_ It should be noted that monoclonality not necessarily 
implies a malignancy (Table 3) (9,46-51). In addition, using the presence of cross-lineage 
Ig or TcR gene rearrangements in acute non-lymphoblastic leukemia clonality can be proven 
(9,52). Other clinical applications at diagnosis are: the detection of two or more subcJones 
and proof or exclusion of the common clonal origin of two malignant lymphoid cell 
populations (9,53-58). During and after treatment the detection of MRD is possible with a 
detection limit of - 5% in case of the Southern blot technique and a detection limit of 0.0'1-
0.0001 % in case of the peR technique, thereby using leukemia-specific junctional region 
probes (59-63)_ Diagnostic applications at relapse are determination of identicallg and/or 
TcR gene rearrangements (clonal relation), determination of differences in Ig and/or TcR 
gene rearrangements (clonal evolution), or diagnosis of secondary malignancies at relapse 
(64-69). 
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TABLE 3. Diagnostic applications of 19 and TcR gene rearrangement analysisu• 
At diagnosis 
1. Discrimination between polyclonal and monoclonal lymphoid cell populations 
Caution; Monoclonality does not necessarily imply malignancy (e.g. large granular lymphocytic 
leukemia and monoclonal or oligoclonal lymphoproliferations in primary and secondary 
immunodeficiencies) . 
2. Assignment or exclusion of the differentiation lineage of a malignancy. 
Caution: cross~lineage 19 and TcR gene rearrangements can occur. 
3. Detection of two or more sublones within one malignancy. 
4. Proof of exclusion of the common clonal origin of two malignant lymphoid cell populations. 
Caution: One should try to discriminate between two independent lymphoid malignancies and 
subclone formation within a malignancy. 
During and after treatment 
5. Detection of low numbers of malignant cells. 
Caution: The detection limit of the Southern blot technique is -5% and of the peR technique 0.01-
0.0001 %. 
At relapse 
6. Analysis of lymphoid malignancies at diagnosis and subsequent relapses. 
- Determination of identical rearranged Ig and TcR genes (clonal relation). 
- Determination of differences in Ig and TcR gene rearrangements (clonal evolution). 
- Diagnosis of secondary leukemia. 
a. Adapted from referonce 9. 
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SUMMARY 
Sixty precursor B-cell acute lymphoblastic leukemia (ALL) patients were analyzed for 
the configuration of their immunoglobulin (lg) genes. Rearrangements and/or deletions of 
the Ig heavy-chain (lgH), Ig kappa-chain (lgK), and Ig lambda-chain (lg>-) genes were 
detected in 98, 48, and 23% of cases, respectively. Although these percentages suggest 
the presence of a hierarchical order in IgH and Ig light-chain (lgL) gene rearrangements 
during 8-cell differentiation, no correlation was found between the immunophenotype of the 
precursor B-ALL, and the arrangement patterns of their IgH and IgL genes. 
Multiple rearranged IgH gene bands, generally differing in density, were found in 27 
(45%) of the precursor B-ALL in various restriction enzyme digests. Cytogenetic data were 
used to determine whether the presence of more than two rearranged IgH gene bands was 
caused by hyperdiploidy of chromosome 14 or other chromosome 14 aberrations. The 
combined cytogenetic and IgH gene data allowed the precursor 8-ALL to be divided into 
three groups: a monoclonal group (n=36; 60%), a biclonal group (n=16; 27%), and an 
oligoclonal group (n = 8; 13%). In five biclonal ALL, biclonality at the IgK gene level was 
also found. Such subclone formation was not detected at the Ig", gene level. As the 
detection limit of the Southern blot technique is 2-5%, it might well be that small subclones 
remained undetected, implying that the frequency of subclone formation at the IgH gene 
level in precursor B-ALL is probably higher than 40%. 
It has been suggested that precursor B-ALL with multiple IgH gene rearrangements 
have a higher tendency to relapse. Although higher relapse rates were found in the 
oligoclonal group (53%) and in the combined bi-Ioligoclonal group (33%) compared with 
• Published in: Leukemia 1991;5:657-667. 
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the monoclonal group (20%)' the log rank trend test showed no significancy. 
The occurrence of multiple subclones in precursor 8-ALL as found by IgH gene 
analyses will severely hamper the detection of minimal residual disease (MRD) using the 
polymerase chain reaction (peR) mediated amplification of "tumor-specific" IgH gene 
junctional regions, because it cannot be predicted which detectable (or undetectable) 
subclone will cause MRD and/or relapse. Therefore it can be expected that the peR 
technique will frequently produce false-negative results during the follow-up of precursor 
8-ALl. 
INTRODUCTION 
Leukemias and malignant lymphomas are generally thought to represent clonal 
expansions from a single transformed cell. This concept is supported by cytogenetic studies 
(1,2), glucose-6-phosphate dehydrogenase enzyme analyses (3), restriction fragment length 
polymorphism studies (4). and the detection of identical Ig idiotypes (5,6). Analyses of 
rearrangements in Ig and T-cell receptor (TcR) genes have also been used for identification 
of clonal expansions of malignant (precursor) B- and T-ce~ls (7-11). Rearrangement of 
variable (V). (diversity (D),) and joining (J) gene segments of Ig and TcR genes generates 
unique DNA sequences at the junctional region of these gene segments. This junctional 
region is different in each lymphocyte or lymphocyte clone and is known as complementari-
ty determining region III for Ig genes (12). Therefore, junctional regions of rearranged Ig and 
TcR genes in leukemias and malignant lymphomas can be regarded as "tumor-specific" 
markers (13-17). Based on this assumption, several workers have suggested that the peR 
can be used for the amplification of "tumor-specific" junctional regions of rearranged IgH 
genes to detect MRD in precursor 8-ALL (14,16,17). 
Rearrangements of IgH genes occur in about 98% of precursor B-ALL, whereas 
rearrangements and/or deletions of IgL genes (lgK or IgA) are reported to occur in 5-40% 
of precursor B-ALL (18-22). Although the IgL gene rearrangements seem to occur in a 
hierarchical order during normal B-cell differentiation with 19K gene rearrangements prior to 
IgA gene rearrangements {22-24J. this is not supported by precursor B-ALL studies, since 
19L gene rearrangements are detectable in different subtypes of precursor B-ALL at variable 
frequencies (22,25). 
Several studies indicate that multiple rearranged IgH genes may occur in precursor B-
ALL, as detected by the use of a JH probe in various restriction enzyme digests (26-32). 
The reported frequencies of these multiple IgH gene rearrangements varyfrom,15-30% (26-
32). Kitchingman et al. (27) suggested that the presence of multiple rearranged bands is 
due to the presence of subclones (bi-Ioligoclonality) and may be related to a poor prognosis 
in childhood ALL. The latter was not confirmed by Katz et al. (32), but the median follow-
up in their study was only 14 months. 
This paper reports a detailed study ofthe configuration of the IgH and IgL genes in 60 
consecutive, well-characterized cases of precursor B-ALL, in which the frequency of 
multiple rearranged Ig gene bands was carefully determined and the prognostic significance 
of biclonality and oligoclonality associated with IgH gene rearrangement was evaluated. 
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MATERIALS AND METHODS 
Cell samples 
Lymphoblasts were obtained at initial diagnosis from 60 of 87 consecutive children with precursor B~ALL, who 
presented at the Sophia Children's Hospital, Rotterdam, The Netherlands. The availability of sufficient cells 
for DNA extraction was the only selection criterion, which appeared not to be related to age or other 
established poor prognostic factors except of white blood cell (WBC) count. The median WBC count of the 
27 non~selected precursor B~ALL was 4.8 x 10911 (range 1.0-36.8 x 109/1), but 20 x 10911 (range 2.8~268 
x 109/1) for the 60 selected precursor B~ALL, indicating that the WBC count at least partly influenced the 
availability of sufficient cells for this study. The 60 patients were treated according to seven different therapy 
protocols. All cell samples were obtained after informed consent according to the guidelines of the Medica[ 
Ethics Committee of the University HospitallErasmus University, Rotterdam. For three samples the cell bank 
of the Dutch Childhood Leukemia Study Group (DCLSG)' The Hague, was relied upon. 
Mononuclear cells (MNC) were isolated by Ficoll~Paque centrifugation (density 1.077 g/cm3; Pharmacia, 
Uppsala, Sweden) from peripheral blood and bone marrow samples. In one case the malignant cells were 
derived from a lymphnode biopsy. These MNC samples were subjected to a detailed immunological marker 
analysiS (see later) and the remaining MNC were stored in liquid nitrogen. 
Immunological marker analysis 
The MNC of the precursor B~ALL patients were analyzed for the following: nuclear expression of terminal 
deoxynuc[eotidyl transferase (TdT) (Supertechs, Bethesda, MD, l:lSA); cell membrane expression of the B~cell 
markers C09 (BA~2; Hybritech, San ~iego, CA, USA), CD1 0 (VIL·A1; Or. W. Knapp, Vienna, Austria), ·CD19 
(B4; Coulter Clone, Hialeah, FL, USA), CD20 (81; Coulter Clone), CD22 (Leu~14; Becton Dickinson, San Jose, 
CA, USA), and CD37 (Y29/55; Dr. H. K. Forster, Hoffman~La Roche, Basel, Switzerland); cytoplasmic 
expression of the Ig heavy~chain p. (weak Cylg,u) (Kallestad Laboratories, Austin, TX, USA); membrane 
expression of the T~cell markers CD2 (T11; Coulter Clone), CD3 (Leu-4; Becton Dickinson), CDS (Leu-1; 
Becton Dickinson) and CD7 (3A 1; American Type Culture Collection, Rockville, MD, USA); membrane 
expression of the myeloid cell markers CD13 (My7; Coulter Clone), CD14 (My4; Coulter Clone), CD15 (VIM-
05; Dr. W. Knapp), and CD33 (My9; Coulter Clone); HLA-DR antigen (L243; Becton Dickinson) and the 
precursor marker CD34 (BI-3C5; SeraLab, Crawley Down, UK). The immunofluorescence stainings for TdT, 
Cylg,u and the cell membrane markers were performed as described previously (33) and evaluated with Zeiss 
fluorescence microscopes (Carl Zeiss, Oberkochen, Germany) andlor FACScan (Becton Dickinson). A leukemia 
was considered to be a precursor B-ALL if the malignant cells were positive for TdT, CD19, and HLA-DR (null 
ALL), or for TdT, CD10, CD19, and HLA~DR (common ALL), or for TdT, CD10, CD19, HLA-DR, and Cylg,u 
(pre~B~ALL). 
Southern blot analysis 
DNA was isolated from frozen MNC as described previously (34,35). Control DNA was obtained from 
granulocytes or other cell samples with germ line Ig genes. DNA (20 ,ug) was digested with the appropriate 
restriction enzymes (Pharmacia). The restriction fragments were size-separated in 0.7% agarose gels and 
blotted onto Nytran-13N nylon membranes (Schleicher and Schuell, Dassel, Germany) as described previously 
(35). 
IgH gene rearrangements were detected with a 32P_random oligonUCleotide labeled JH probe (35). The 
JH probe was a 0.95-kb estEll fragment which recognizes sequences just 3' of the JH gene segments (35). 
The configuration of the IgK genes was analyzed with a JK and a constant (C)K probe. The JK probe was a 
0.55-kb Haell! fragment which recognizes sequences just 3 ' of the JK gene segments (35). The CK probe was 
a 2.5-kb EcoRI fragment (35). All 60 DNA samples were analyzed by use of the JH, JK and CK probes in Bglll 
digests, as weI! as in BamH IIHind II I and BamHI/Sacl double digests. [f necessary for confirmation, EcoRI 
andlor Pstl digests were also used. Deletions of the C,u gene segment were detected using the 1.2~kb EcoRI 
C,u fragment in Bg/ll and BamHIIHind1l1 digests (35). The configuration of the Ig}.. genes was analyzed with 
the C}..3 probe (a 0.8-kb BglIl/EcoRI fragment) (35). Fifty-seven DNA samples were analyzed with this probe 
in EcoRI/Hindll1 double digests and three DNA samples in an EcoRI digest (35). 
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Recombinant plasmids were handled under PZEK1 containments according to the National1nstitutes 
of Health guidelines for research involving recombinant DNA molecules. 
Cytogenetic analysis 
Cytogenetic studies of the cell samples were performed according to standard procedures, including in some 
cases the methotrexate treatment of cultures (36). In each case multiple metaphase spreads were studied for 
the number of chromosomes and for the presence of structural chromosome abnormalities. The karyotypes 
were established according to the ISeN (1985) (37). 
Statistical data 
The Kruskal-Wallis test was performed to determine the statistical significance of the WBe count in the 60 
precursor B-ALL (38). The Kaplan~Meier plot was used to analyze the relationship between the number of 
subclones and the disease~free survival in the 60 precursor B~ALL (39). Statistical significance of these data 
was determined with the log rank trend test (38). 
RESULTS 
Immunological marker analysis 
Immunological marker analysis of the 60 precursor B-ALL revealed that two were null ALL, 
40 were common ALL, and 18 were pre·B·ALL. The results of the analyses are summarized 
in Table 1. Most of the precursor B-ALL were negative for the T-cell and myeloid markers 
tested, but some expressed the T-cell marker CD7 or the myeloid markers CD13 or CD33. 
TABLE 1. Immunophenotypo of the 60 precursor B-ALL patients. 
Immunological markersll 
precursor 
B-ALL typo TdT HLA-OR C034 CD' C010 C019 C020 C022 C037 Cyl9l'b Smlg 
null ALL + + + + + ± 
(n=2) (112) 
common ALL + + ± ± + + ± ± ± 
(n=40) (15/19) (29/37) (16/38) (23/32) (2/37) 
pre-B-ALL ± + ± + ± + ± ± ± + 
(n=18)b (17/18) (3/8) (16/18) (7/18) (5/10) (2/13) 
a. Symbols used: (+) expression (> 50% of MNC) in all leukomias; (±) a part of the leukemias was positive (the number of positive 
loukemias/tested leukemias is indicated in parontheses); {-I no expression « 15% of MNC) in all leukemias. Percentage positivity 
between 15-50% was not found. 
b. A leukemia was considered to be a pre·B-ALL if moro than 15% of the leukemic cells exprossod Cy191" 
Southern blot analysis of immunoglobulin gene rearrangements 
DNA samples from the 60 precursor B-ALL were examined for the presence of rearranged 
IgH and IgL genes. Rearrangements andlor deletions of the IgH genes, IgK genes, and IgA 
genes were found in 98% (59 cases), 48% (29 cases), and 23% (14 cases) of the 
precursor B-ALL, respectively (Figures 1-3 and Table 2). No clear correlation was found 
between the immunophenotype of the precursor B-ALL and the rearrangement patterns of 
the IgH and IgL genes (Table 2). In one common ALL, IgH gene analYSis only revealed a 
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TABL.E 2. Summary of Ig gene fea:rrangemenU in the 60 precursor B·AL.L patients." 
IgH genes 19IC genes Ig}.. genes 
Rearrangament Delation Rearrangement Deletion Roarrangement 
Precursor B·ALL JH probeb JH llnd CIL probe JIC prebed JIC probe c.: prebo C).. probe 
",po (R/G, R/R, or R/Dle (DID) (R/G, R/R. or RID) (DID or DIG) (DID or DIG) (RIG or R/R) 
null ALL (n ... 2) 100% (2/2) 0% (O/2) 0% (012) 0% (O/2) 0% (012) 50% (1/2)° 
common ALL (n ... 40) 90% (36/40) 8% (3/40) 38% (15/40) 18% (7!40) 43% (17/40) 28% (11/40)<1 
pre-B-ALL. (n .. 18) 100% (18J18) 0% (0/18) 28% (5/18) 11% (2/18) 28% (5/18) 11% (2/18) 
Total 93% (56i60) 5% (3/S0) 33% (20/60) 15% (9/S0) 37% (22/60)1 23% (14/60) 
98% {59/60} 48% (29/60) 
a. In case of subclone formation. the Ig gene rearrangement patterns of the major ciano have been used in this table. 
b. Twenty-seven patients had three or more rearranged IgH genes, generally differing in density. In 24 patients this was due to subclone 
formation and in the other three patients hyperdiploidy of chromosome 14 caused one or twO additional rearranged IgH gene bands. 
c. Symbols used: (R) rearranged allele; (G) germline allele; (D) deletion of the studied gene segment. 
d. Two patients had three rearranged IglC gene bands of different density, two patients had twO rearranged IglC gene bands of obvious 
different density, and one patient had two weak rearranged IglC genes and a strOng germline band. which was not due to non-leukemic 
cells. All five belonged to the group of biclonal ALL, as detormined by IgH gone analysis and cytogenetics. 
e. Rearranged Ig).. gonos but gorm!ine IglC genes were found in one null ALL and two common ALL. 
f. All pntionts had at least one rearranged and/or doleted JIC gene. 
germline band, which was not due to contaminating non-leukemic cells, as the leukemic cell 
load was 93% in this patient. This common ALL also had germline IgL genes. In three 
common ALL, the JH and GIL gene segments were deleted on both alleles. In one of these 
cases this was partly caused by the loss of one chromosome 14. In the other two cases 
several C gene segments of the IgH gene locus were still present (data not shown) and no 
translocation or other karyotypic changes involving chromosome 14 were detectable, which 
suggests that the JH and GIL gene segments had been selectively deleted. 
Rearrangements in the JK gene region occured in 20 cases (33%) of precursor 6-ALL 
on one or both alleles, whereas in nine cases (15%) deletion of the JK gene region on one 
allele (with the other allele in germline configuration), or both alleles was found. In 22 cases 
(37%1 deletion of the GK gene segments on one allele (10 casesl or both alleles (12 casesl 
was found. In these cases deletion of the JK gene segment was found in 50% of the IgK 
gene alleles with a deleted CK gene segment. However, in one ALL the JK gene segments 
were deleted on both alJeles, while the CK gene segment was still present on one allele. In 
most cases with rearranged IgA genes, the IgK genes were deleted and/or rearranged, but 
rearranged IgA genes with germline configuration of both the IgK gene loci were found in 
three precursor 8-ALL patients (one null ALL and two common ALLI. This implies that IgL 
gene rearrangements were found in 53% of cases. Further details concerning the 
rearrangement patterns of the IgH and IgL genes are summarized in Table 2. 
Multiple rearranged IgH gene bands, generally differing in density, were found in 27 
precursor B-ALL. In 18 patients (30%) three or four rearranged IgH gene bands were found, 
and in nine patients (15%) more than four rearranged IgH gene bands were detected. The 
presence of genetic polymorphisms, such as are due to the hypervariable polymorphic 
region at the 5' side of the JH gene locus (40-42), were excluded by using different 
combinations of restriction enzymes (8gm, 8amH IIHind II I and 8amHI/Sacli. Detailed analysiS 
of the IgK genes revealed that in five ALL with multiple IgH gene bands, two or more 
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Figure 1. Southern blot analysis of the IgH genes in several precursor 8-ALL. Control DNA and DNA from precursor B-AlL were 
digested with BgIII {AI and a combination of BamHI and HindUI (B), size-separated and blotted onto nylon membrane filters which 
were hybridized with the 32P-labeled JH probe. The sizes (in kb) of the germline bands (G) and several molecular weight markers 
are indicated. The leukemic cell load is given in percentages below the patient's initials. In 13 of the presented precursor 8-All 
cases more than two rearranged IgH gene bands were detected, which differed in density in most instances. In two patients (Sl 
and EW) trisomy 14 (+ 14) was the cause of one of the extra bands. Based on the combined IgH gene and cytogenetic data it was 
possible to conclude whether the precursor 8-All were monoclonal (mono), biclonal (bi), or oligo clonal (oligo). Detailed information 
concerning the biclonal and oligoclonalleukemias is given in Tables 3 and 4. 
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rearranged IgK gene bands of different density were present, as determined in at least two 
restriction enzyme digests (Figure 2 and Table 3). No such multiple rearranged bands were 
found upon Ig" gene analysis (Figure 3). The assumption that multiple rearranged IgH or IgK 
gene bands are caused by the occurrence of two or more subclones with differently rearran-
ged Ig genes, is only feasible if the presence of extra copies of chromosome 14 (which 
contains the IgH gene locus in band 14q32) and chromosome 2 (which contains the IgK 
gene locus in band 2p12) has been excluded by cytogenetic analysis. 
Cytogenetic analysis 
Karyotypic analysis at diagnosis was performed in 57 of the 60 patients. Five patients had 
a hypodiploid karyotype « 46 chromosomes), 1 6 patients had a hyperdiploid karyotype 
(>46 chromosomes), and eight patients had a translocation (e.g. t(l; 19)' t(4; 11), and 
t(9;22)). In the other 28 patients no clonal aberrations were found. One patient with a 
hypodiploid karyotype had lost one copy of chromosome 14, whereas IgH gene analysis 
demonstrated a complete deletion of the JH and CIL gene loci on both alleles. Another 
patient with a hypodiploid karyotype had lost one copy of chromosome 14 in a part of the 
leukemic cells, which correlated with the finding that IgH gene analysis showed one clear 
rearranged IgH gene band and one weak rearranged IgH gene band. Five patients with a 
hyperdiploid karyotype had one extra copy of chromosome 14 and one patient had two 
extra copies of this chromosome. In four of these six precursor 8-ALL patients, the 
presence of more than two rearranged IgH gene bands could be correlated with extra copies 
of chromosome 14. This allowed the conclusion that three patients had a monoclonal ALL 
instead of a biclonal ALL (e.g. patient S.L. in Figure 1) and that one patient (patient E.W.) 
had a biclonal ALL instead of an oligoclonal ALL (Figure 1). The other two patients with a 
hyperdiploidy of chromosome 14 had no additional rearranged IgH gene bands. In the ALL 
with more than two rearranged IgK genes (see earlier), no additional copies of chromosome 
2 were detected. 
On the basis of the combined cytogenetic and IgH gene data, the precursor B-ALL 
(n=60) were divided in three groups: a monoclonal group (n=36; 60%), a biclonal group 
(n = 16; 27%), and an oligoclonal group (n =8; 13%) (Tables 3 and 4). 
Clinical and biological characteristics of patients in the monoclonal~ biclonal, and oligo clonal 
groups 
The median age in the monoclonal group was 4.8 years (range 1.3-15.0), in the biclonal 
group 3.7 years (range 1.6-12.2), and in the oligoclonal group 5.3 years (range 0.2-12.4). 
The median WBC count at diagnosis was 14.6 x 109/1 (range 2.8-198.7 x 10911), 18.4 x 
109/1 (range 8-88.2 x 10911), and 74.1 x 109/1 (range 17.5-268 x 10911) for the monoclonal, 
biclonal and oligoclonal groups, respectively. A significant p-value of 0.03 in the WBC 
count data was found with the Kruskal-Wallis test, demonstrating a relationship between 
bi-/oligoclonality and high WBC count. Additional clinical and laboratory characteristics at 
diagnosis of the 16 biclonal and eight oligoclonal precursor 8-ALL patients are given in 
Tables 3 and 4. 
Of the 36 monoclonal ALL patients one was diagnosed as null ALL, 27 as common 
ALL, and eight as pre-B-ALL. Of the 16 biclonal ALL, 11 patients were diagnosed as 
common ALL and five patients as pre-B-ALL. Of the eight oligoclonal ALL one patient was 
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Figure 2. Southern blot analysis of the 19K genes in several precursor a-ALL. Control DNA and DNA from precursor 8-ALL patients 
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patients (FG, MD, RBo and OW) had rearrangements of the Jx gene locus. In patient MO three rearranged bands of different 
density and one germline band due to non-leUkemic cells (-23%) are visible. Patient RBo had one rearranged 19K gene allele 
(Table 4), which appeared as a 9.1 kb band in the EcoRI digest; this band almost co-migrated with the germllne band. In patient 
OW two rearranged and one germline band are present, the latter being caused by the presence of non-leukemic cells (-27%). 
In patient RB the Jx gene segments were deleted on both alleles. For more detailed description see Tables 3 and 4. 
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TABLE 3. Clinical charact~lIistics and Southern blot analysis of 16 blclonal precursor B·All patients.a 
Patients 
Clinical characteristics 
Age {yearslfsexb 
GA 
2.BfM 
wac (x 10911) 8.3 
Duration of remission 66 + 
(months) 
Samplac 8M 
leukemic cells (%Id 92 
AA 
1.61F 
12.9 
8D' 
8M 
9' 
M8 
3.8/M 
25.9 
23' 
8M 
90 
R8h 
4.81M 
10 
", 
8M 
96 
SD 
2.3fM 
88.2 
17 
P8 
91 
MD 
7.91M 
9.7 
61' 
P8 
77 
EE 
41F 
24.0 
58' 
8M 
98 
NK 
5.9fF 
9.6 
'D' 
P8 
84 
MP 
2.4fM 
76 
6" 
8M 
9D 
CR ET AV va 
3.71M 2.2/M 1.91F 12.2fM 
62 
65' 
8M 
97 
16.7 18.4 
5 28+ 
BM BM 
98 94 
16.5 
32' 
'M 
99 
EW 
21' 
" 54' 
P8 
6D 
DW 
1.81M 
24.1 
39 
P8 
73 
EY 
4.7/M 
8 
31' 
LN 
98 
Southern blot analysis 
IgH genes {JH probe)e 
BgM GW,3R 2A,2Rw OW,3R 
GW,3R.Rw 
GW,3R,Rw 
2R,RW 
2R,Rw 
NT{I,h 
GW ,3R G,A,2AW 2R,2Rw GW,3R G,2R,Rwf 2R.Rw 3R G,2R,Rw 2R,2Rw G,3R,2Rw G,2R,2Rw 2R,Rw 
BamHlfHindl1i 
BamHlfSacJ 
Igl; genes (J( probel 
BgM 
BamHIfHindll1 
BamHIfSacl 
Ig.l; genes (Co; probe) 
B9J1l 
BamHlfHindlU 
19). genes (e)" probel 
EcaAIfHindlll 
GW ,3R 
GW ,3R 
G 
G 
G 
G 
G 
G 
2R,2RW 
2R,2Rw 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
A,RW 
R,Rw 
R,Aw 
R,D 
G,D 
G 
GW,2R OW,R,2Rw 2R,2Rw GW,3R GW,3R,Rw 2R,Rw 3R 
GW,3R NTh NTh GW,3R G,2Rf 2R,2Rw 3R 
GW,R,RW G,R,2Rw G,R,2Rw G,R GW,R,D G,2Rw 0,0 
GW,A,Rw G,R,2Rw G,R,2Rw O,R OW,R,D O,2Rw G,D 
NTh NTh NTh G,R GW,R,D G,2Rw G,D 
GW,D,RW 
G,D 
G 
G,D 
G,D 
G,RI 
G,D,2RW G,R 
G,D G 
G,R G 
GW,R,D 
G,D 
G' 
G,D 
G,D 
G 
G,D 
G,D 
G 
G.2R 
G.2R 
G 
G 
G 
G 
G 
G,R 
2R,2RW G,3R,2Rw G,2R,IRw 
2A,RW G.3R,2Rw 
G G,A 
G G,A 
G G,R 
G 
G 
G,R 
G 
G 
G,R 
NT 
G,R,R 
G,A,R 
NT 
G,R,D 
G,D 
G 
2R,AW 
2R,Rw 
G 
G 
G 
G 
G 
G 
a. Biclonality was defined as the presence of two subc!ones, as deduced from the detection of three or four rearranged bands and/or a strong germline band, which could not be attributed to the 
presence of non-leukemic cells (leukemIc cells >90%). The rearranged bands often differed in density and were not attributable to hyperdiploidy of chromosome 14 or other chromosome 14 
aberrations, except of patient EW (sea text). 
b. 1M) male; IF) female. 
c. (BM) bone marrow; (PSI peripheral blood; (IN) lymph node. 
d. The leukemIc cell load was determined by the percentage of TdT, COW, and C019. 
e. In most cases the rearrangement patterns were confirmed with fcaRi digests and In a few cases with Pst! digests. 
Symbols used: (0) allele in germline configuration; (Gw ) weak germline band; IRJ rearranged allele; IR"') weak rearranged band; tDJ deletion of the involved gene (segment). 
f. The G·band in B9111 and BamHIISacl digests of patient MP probably represents a rearrangement, because in the BamHIfHindlll and in an £CoRI digest an extra rearranged band and a weak germfine 
band were detected. 
g. (Nn not tested. 
h. The reanangement pattern could be confirmed In an fcoRI digest. 
I. In this patient the Ig). genes were analyzed with the C).. probe in an fcoRI digest. 
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TABLE 4. Clinicnl characteristics and Southern blot nnalysis of eight origoclonnl precursor B-ALL patients". 
Patients RBo PB HD RH IN NO SR JV 
Clinicnl characteristics 
Age (yoars)/sext' S, 'l/F 9.3/M 5.3/M 0.2/M 3,2/M 0.9/F 12.41M 1.S/F 
WBe (x 10911) 155 26B 37 202.2 20.9 74.1 17.5 20.2 
Duration of remission 14 9 ... 6 75· 56 54· ". (months) 
Samprec PB BM BM P' BM PB BM pB 
Leukemic cells (%)d 93 96 9B 95 B4 B4 93 93 
Southem blot annlysis 
IgH genes (JH probe)O 
8glll GW ,3R,Rw GW ,2RARw G,2RARw G,R,4Rw GW ,2RARw GW ,R,5Rw 4R,2Rw G,R,5Rw 
BomHr/Hindlll GW,3R,Rw GW,2RARw G,2R,4Rw G,R,2Rw GW,2RARw GW,R,5Rw 4R,2Rw G,R,SRw 
BomHI/Sacl GW ,3R,Rw GW ,2RARw G,2RARw NT' GW ,2R,3Rw GW,R,SRw NT G,5Rw 
Ig.: genes (J.: probe) 
89111 G,R G G,D G G G G G 
BomHI/Hlndlll G,R G G,D G G G G G 
8amHI/Sacl G,R G G,D NT G G NT G 
IglC genes (Ct: probe) 
89111 G,D G 0,0 G G G G G 
8DmHIIHindili G,D G 0,0 G G G G G 
19)" genes (C)" probe) 
EcoRI/HindUI G G G,R G G G G G 
a. O!igoclonality was defined as the presence of more than twO subclones as deduced from the dotection of five or more rearranged 
bands andlor a strong germJine band which could not be attributed to the presence of non· leukemic cells (leukemic cells> 90%), or 
four reorranged bands which could not be paired due te differences in density (e.g. patient RBo). 
b. (M) male; (F) female. 
c, (BM) bone marrow; (PB) peripheral bleod, 
d. The leukemk cell load was determined by the percentage of TdT, CD' 0 and CD19. 
e. In most cases the rearrangement panerns were confirmed with EcoRI digests and in a few cases with Pstl digests. 
Symbols used: G, allele in gorrnline configuration; (GWj weak germlino b;:md; (R) rearranged allole; (R~ weak rearranged band: (D) 
deletien of the involved gene (segment). 
f. (NTI not tested. 
diagnosed as null ALL, two patients as common ALL, and five patients as pre-B-ALL. The 
frequencies of pre-B-ALL in the monoclonal. biclonal, and oligoclonal groups are 23% 
(8/36)' 33% (5/16)' and 63% (5/8), respectively, suggesting a correlation between 
oligoclonality and pre-B-ALL. 
Disease-free survival in the monoclonal .. biclonal, and oligo clonal groups 
In the monoclonal group seven patients developed a relapse; only one was diagnosed as 
a high risk patient because of high WBe count (> 50 x 10911). Six other high risk patients 
did not relapse. In the biclonal group three relapses occurred. One of these three patients 
was diagnosed as a high risk patient. In the oligoclonal group four relapses occurred. All 
four were diagnosed as high risk patients. Figure 4 shows the relationship between the 
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Figure 4. Kaplan-Meier plots concer-
ning the relationship between the 
number of clones in precursor B-ALL 
and disease-free survival. Median 
follow-up: 41 months (range 5-971, 
A. The monoclonal group (n = 36; 
80%, SE = 8.9) is indicated with 
the thick line, the biclonal group (n 
= 16; 78%, SE = 16.8) with the 
dotted ljne, and the oligoctonal 
group (n = 8; 47%, SE = 17.5) 
with the broken line. B. The mono~ 
clonal group (n = 36; 80%, SE = 
8.9) is indicated with the thick line 
and the combined bi~/oligoclonal 
group (n = 24; 67%, SE = 12.4) 
with the broken line. Although the 
oligoclonal group tends to have a 
higher relapse rate, no significant 
differences were found between the 
groups in the log rank trend test. 
number of clones in precursor B-ALL and disease-free survival in two Kaplan-Meier plots. 
The median follow-up time is 41 months (range 5-97). The disease-free survival rate of the 
three different groups is 80% (S.E. 8.9) for the monoclonal group, 78% (S.E. 16.8) for the 
biclonal group, and 47% (S.E. 17.5) for the oligoclonal group (Figure 4A). The log rank 
trend test shows a p-value of 0.19. When the biclonal and oligoclonal groups are combined 
the disease-free survival rate is 67% (S.E. 12.4) with a p-value of 0.5 (Figure 46). 
DISCUSSION 
Immunoglobulin gene rearrangements 
Sixty precursor 8-ALL were analyzed for the configuration of their Ig genes. Rearrange-
ments and/or deletions of the IgH, IgK, and Ig'/\ genes were found in 98%, 48%, and 23% 
of the precursor B-ALL, respectively. The percentages of IgL gene rearrangements are 
higher than reported elsewhere (18-22), probably due to our choice of restriction enzymes 
and probes (35). Although the frequency of IgH and IgL gene rearrangements suggests the 
presence of a hierarchical order in Ig gene rearrangements during 8-cell differentiation (22-
24), no correlation could be found between the immunophenotype and Ig gene rearrange-
ment pattern of the precursor 8-ALL. In addition, it is assumed that IgK genes rearrange 
prior to IgA genes (23,43), but in this series of precursor 6-ALL three ALL had rearranged 
19'/\ genes with germline IgK genes. This implies that IgL gene rearrangements were found 
in 53% of cases. In four common ALL no rearranged tgH gene bands were detected. The 
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IgH genes were germline in one patient, whereas in the other three a complete deletion of 
the JH and Cp. gene locus was found on both alleles. An unusual deletion of the IgK genes 
was found in one precursor B-ALL in which JK gene segments were deleted on both alleles, 
while the CK gene segment was still present on one allele. These aberrant rearrangements 
and deletions are not found in normal mature B-Iymphocytes (23,43,44). Nevertheless, it 
might well be that these rearrangement and deletion processes also occur in normal 
precursor B-cells, thereby leading to cell abortion, which would be in line with the fact that 
only a small part of precursor B-cells reach the mature B-cell stage (45,46). 
Multiple rearranged 19 gene bands 
Several studies indicate that multiple rearranged IgH gene bands occur in 15-30% of all 
precursor B-ALL, as detected by a JH probe in multiple restriction enzyme digests (26-32). 
In 45% (27 cases) of this series of precursor B-ALL, more than two rearranged IgH gene 
bands were found, which generally differed in density. 
Cytogenetic data were used to determine whether the presence of more than two 
rearranged IgH gene bands was caused by hyperdiploidy of chromosome 14 or translocati-
ons with a chromosomal breakpoint situated in or near the JH gene locus (1,2,47,48). In 
five precursor B-ALL patients trisomy 14, and in one patient tetrasomy 14 was found. In 
two precursor B-ALL with trisomy 14, only two rearranged IgH gene bands were detected, 
which indicates that no additional rearrangements had occurred in the IgH gene on the extra 
chromosome 14, or that a deletion of the IgH gene locus had occurred on one chromosome 
14. In the other four precursor B-ALL with hyperdiploidy of chromosome 14, more than two 
rearranged IgH gene bands were found, which could be attributed to the presence of 
additional copies of chromosome 14. These data suggest that cytogenetic events (e.g. 
duplications of chromosomes) can occur prior to or after rearrangement processes. The 
combined cytogenetic and IgH gene data allowed the division of the precursor B-ALL into 
three groups: a monoclonal group (n = 36; 60%)' a biclonal group (n = 16; 27%) (Table 3), 
and an oligoclonal group (n = 8; 13%) (Table 4). This heterogeneity at the DNA level 
(biclonality and oJigoclonality) was not clearly associated with immunophenotypic 
heterogeneity (data not shown). As the detection limit olthe Southern blot technique is 2-
5% (35)' it might well be that small subclones remained undetected, implying that the 
frequency of subclone formation at the IgH gene level in precursor B-ALL is probably higher 
than 40%. 
In five biclonal ALL, two or more rearranged IgK gene bands of different density were 
found (Figure 2 and Table 3). The absence of additional copies of chromosome 2 in these 
five biclonal ALL allowed the conclusion that both clones had differently rearranged IgK 
genes. Such subclone formation was not detected at the IgA gene level. To our knowledge, 
this is the first report on the finding that subclone formation at the IgH gene level can be 
accompanied by subclone formation at the IgK gene level in precursor B-ALL. 
Biclonality and oligoclonality at the Ig gene level can be attributed to somatic 
mutations or to continuing rearrangement processes in the original clone (30,49,50), such 
as D to JH rearrangements and VH to D-JH rearrangements, or secondary rearrangements 
such as D-JH replacements and VH replacements (30,51-53). It is improbable that somatic 
mutations playa role in the subclone formation in precursor B-ALL, as most multiple 
rearranged bands were detectable in all restriction enzyme digests, whereas somatic 
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mutations will be unlikely to affect all restriction sites (49,50). 8ird et al. (30) analyzed a 
biclonal ALL and an oligoclonal ALL by molecular cloning and sequencing of the junctional 
regions. Their results indicate that continuing rearrangements and/or secondary rearrange-
ments most probably cause subclone formation. It is predictable that these processes of 
continuing rearrangements and/or secondary rearrangements probably represent 
physiological mechanisms, which also occur during normal 8-cell differentiation. 
Biclonality and oligoclonality might be associated with a higher relapse rate 
Kitchingman et al. (27) suggested that precursor B-ALL with multiple IgH gene rearrange-
ments have a higher tendency to develop a relapse, probably because these All may be 
more resistant to cytostatic therapy. This was not confirmed by other workers (31,32). 
According to the Kaplan-Meier plots, a 33% higher relapse rate was found here in the 
oligoclonal group compared to the monoclonal group (median follow-up: 41 months) (Figure 
4A). The combined biclonal and oligoclonal group had a 13% higher relapse rate than the 
monoclonal group (Figure 4B). Although the oligoclonal precursor B-ALL seems to have a 
higher tendency to develop a relapse, the log rank trend test did not reveal significant 
differences. 
Katz et al. (32) suggested that multiple rearranged bands in precursor B-ALL have a 
poorer ol!tcome together with other risk factors. In this study a clear relationship was found 
between biclonality and oligoclonality on one hand, and high WBC count on the other. A 
correlation between oligoclonality and the pre-B immunophenotype (CyI9.u +) was also 
found. The latter finding may be due to a higher chance for a functionally rearranged IgH 
gene in ALL with multiple IgH gene rearrangements. 
The 60 precursor B-ALL patients were treated according to seven different therapy 
protocols. Therefore an additional study needs to be performed on a larger series of patients 
receiving identical treatment to determine whether the occurrence of multiple IgH gene 
rearrangements (biclonality and oligoclonality) represents an independent risk factor for 
relapse or a risk factor coherent with other high risk factors. 
Minimal residual disease 
Recent reports indicate that the PCR technique may be useful for the detection of MRD in 
lymphoid malignancies via the amplification of the junctional regions of rearranged Ig and 
TcR genes (13-17). Several workers claim that MRD in precursor B-ALL is detectable using 
PCR mediated amplification of "tumor-specific" IgH gene junctional regions (14,16,17). 
However, this application of the PCR technique in precursor B-ALL will be severely 
hampered by the high frequency of subclone formation at the IgH gene level, because most 
subclones will have their own specific junctional region (30), and because it is unpredictable 
which detectable (or undetectable) subclone will cause MRD and/or relapse. Therefore, it 
can be anticipated that the PCR technique will frequently cause false-negative results during 
the follow-up of precursor B-ALL (22,54). 
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CONCLUSION 
The results of this study indicate that biclonality and oligoclonality at the IgH gene 
level occur at a high frequency (at least 40%) in precursor B~ALL at diagnosis and that this 
can be accompanied by subclone formation at the IgL gene level. The follow~up data 
suggest that patients with an oligoclonal ALL may have a higher tendency to relapse than 
patients with a monoclonal ALL, although no significancy was found. The occurrence of 
multiple IgH gene rearrangements in precursor B~ALL has important implications for the 
detection of MRD using the peR mediated amplification of "tumor-specific" IgH gene 
junctional regions, because it can be foreseen that the subclone formation at the IgH gene 
level will frequently lead to false~negative results. 
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CHAPTER 3.3 
DIFFERENCES IN IMMUNOGLOBULIN HEAVY-CHAIN GENE 
REARRANGEMENT PATTERNS BETWEEN BONE MARROW AND 
BLOOD SAMPLES IN CHILDHOOD PRECURSOR B-ACUTE 
LYMPHOBLASTIC LEUKEMIA AT DIAGNOSIS· 
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Elisabeth R. van Wering3 and Jacques J.M. van Dongen 1 
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SUMMARY 
2. Department of Pediatrics, subdivision of Hematology-Oncology, 
Sophia Children's Hospital/Erasmus University Rotterdam; 
3. Dutch Childhood Leukemia Study Group, The Hague, The Netherlands. 
Bone marrow (BM) and corresponding peripheral blood (PB) samples from 30 patients 
with precursor B-acute lymphoblastic leukemias (precursor B-ALL) were analyzed for the 
configuration oftheir immunoglobulin (Ig) heavy-chain (lgH) and Ig kappa-chain (lgK) genes. 
Rearrangements and/or deletions of the IgH and IgK genes were detected in 100% and 
47% of patients in this series of precursor B-ALL, respectively. Multiple rearranged IgH 
gene bands, generally differing in density, were found in 10 precursor B-ALL samples. This 
multi-band pattern is most probably caused by subclone formation due to continuing 
rearrangement processes. In five of the 10 bi-/oligoclonal cases (50%) differences in IgH 
gene rearrangement patterns between BM and PB samples were observed, which could be 
interpreted as the presence of an extra subclone in two cases and differences in the size 
of the subclones in three cases. In the 20 monoclonal precursor B-ALL, no dissimilarities 
in IgH gene rearrangement patterns between BM and the corresponding PB samples were 
found. Differences in 19K gene rearrangement patterns between BM and PB were not 
observed in this series of precursor B-ALL, which is in line with the finding that no multiple 
IgK gene rearrangements were detectable. 
In all five cases, the extra subclones or the relatively larger sized subclones were 
found in the BM samples, suggesting that subclone formation in precursor B-ALL occurs in 
the tissue compartment from which the precursor 8-ALL cells are thought to originate. This 
phenomenon will lead to underestimation of subclone formation, if only IgH gene analysis 
of PB samples is performed. In addition, it will hamper the detection of minimal residual 
disease (MRD) by the polymerase chain reaction (peR)-mediated amplification of ··Ieukemia-
• Published in: Leukemia 1992;6:60·63. Erratum 1993;7:928. 
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specific" IgH gene junctional regions, because it is unpredictable which subclone will cause 
MRD andlor relapse. 
INTRODUCTION 
The different types of ALL are generally regarded as malignant counterparts of 
precursor B- and T-cells (1-5). Comparable to normal precursor B-cells, precursor B-ALL are 
thought to originate from 8M, while most T-ALL probably arise from cortical thymocytes 
(1-4). Therefore, analysis of ALL such as the rearrangement pattern of Ig and T-cell receptor 
genes has provided important insights into early human lymphoid differentiation (5-11). 
Rearrangements of IgH genes occur in about 98% of precursor B-ALL (5,6,11-14), 
whereas rearrangements andlor deletions of the IgK and Ig lambda-chain (lgA) genes are 
found in - 45 and - 20% of precursor B-ALL, respectively (13,14). Several studies have 
indicated that multiple rearranged IgH genes may occur in precursor B-ALL, as detected by 
use of a joining (J)H probe in various restriction enzyme digests (14-21). This multi-band 
pattern of rearranged IgH genes occurs at high frequency (at least 40%) in precursor 8-ALL 
at diagnosis (14,22). Such multiple rearrangements have also been found at the 19K gene 
level (6% of precursor B-ALL), but not at the IgA gene level (14). Most probably these 
multiple Ig gene rearrangements are caused by subclone formation (biclonality and 
oligoclonality) due to continuing rearrangement processes (14, 19)_ It might be speculated 
that these precursor B-ALL subclones differ in biological behaviour, such as their 
dissemination pattern from 8M to PB or to other extramedullary sites_ This led us to 
determine whether differences in IgH and IgK gene rearrangement patterns occur between 
BM and PB from the same precursor B-ALL patient. For this purpose we have analysed both 
BM and PB samples from 30 patients at diagnosis. 
MATERIALS AND METHODS 
Cell samples 
Lymphoblasts from BM and P8 were obtained at initial diagnosis from 30 children with precursor B-ALL, who 
presented at the Sophia Children's Hospital, Rotterdam. Mononuclear cells (MNC) were isolated by Ficoll-
Paque centrifugation (density 1.077 g/cm 3 ; Pharmacia, Uppsala, Sweden) from 8M and PB samples in each 
case. These MNC samples were subjected to a detailed immunological marker analysis according to standard 
protocols (for detailed description, see Chapter 3.2 and reference 23). The remaining MNC were stored in 
liquid nitrogen. A leukemia was considered to be a precursor 8-ALL if the malignant cells were positive for 
terminal deoxynucleotidyl transferase (TdT), CD19 and HLA-DR (null ALL), or for TdT, CD1 0, CD19 and HLA-
DR (common ALL), or for TdT, COlO, CD19, HLA-DR, and cytoplasmic 19 heavy-chain p. (pre-S-ALL) (3,24). 
Southern blot analysis 
DNA was isolated from frozen MNC as described previously (25,26). Control DNA was obtained from 
granulocytes or other cell samples with germline Ig genes. Fifteen p.g of DNA were digested with the 
appropriate restriction enzymes (Pharmacia). Completeness of digestion was checked with}.. DNA and plasmid 
DNA in parallel digests as described previously (26). The restriction fragments were size-separated in 0.7% 
agarose gels and transferred to Nytran-13N nylon membranes (Schleicher and Schuell, Dassel, Germany) as 
described (26). 
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To take care that the BM and PB lanes of each patient contained comparable amounts of DNA, the DNA 
content of the digested samples was checked before loading into the agarose gel (26), This was funher 
verified by staining of the agarose gel with ethidium bromide. 
IgH gene rearrangements were detected with a 32P_random oligonucleotide labeled JH probe (26). The 
JH probe was a 0.95-kb BstEIl fragment which recognizes sequences just 3' of the JH gene segments (26). 
The configuration of the 19K genes was analyzed with a JK probe. The JK probe was a 0.55-kb Haell! 
fragment which recognizes sequences just 3' of the JK gene segments (26). All 30 DNA samples were 
analyzed by use of the JH and JK probes in 8glll digests, as well as in a combination of BamHI and Hindlll 
digests. 
RESULTS AND DISCUSSION 
Immunological marker analysis of the 30 precursor B-ALL revealed that two were null 
ALL 1 6 were common ALL and 12 were pre-B-ALL. Except for differences in blast cell 
counts, no discrepancies were found in morphology or immunological marker expression 
between BM and corresponding PB samples of the precursor B-ALL patients. 
DNA from BM and PB samples of the 30 precursor B-ALL was examined for the 
presence of rearranged IgH and IgK genes. Rearrangements andlor deletions of the IgH and 
IgK genes were found in 100% (all 30 cases) and 47% (14 cases) of the precursor B-ALL, 
respectively. Multiple rearranged IgH gene bands, generally differing in density, were found 
in 10 precursor B-ALL. Six were biclonal ALL and four were oligoclonal ALL (for detailed 
description, see Chapter 3.2). Subclone formation at the 19K gene level was not found in 
the present series of precursor B-ALL. 
In the 20 monoclonal precursor B-ALL no differences in IgH and IgK gene rearrange-
ment patterns between 8M and corresponding PB samples were found. However, in five 
out of the 10 bi-/oligoclonal cases (50%) differences in IgH gene rearrangement patterns 
between BM and PB samples were observed. Two patients (one biclonal and one 
oligo clonal) showed weak additional bands in their BM sample (Figure 1 A) and in three 
other patients (one biclonal and two oligoclonal) obvious differences in density of the 
rearranged bands were found (Figure 1 B), indicating that the number or size of the 
subclones in BM and PB differed in these five patients. Differences in blast cell counts 
between BM and PB could only partly explain these detected differences in rearrangement 
patterns. The five cases with differences in rearrangement patterns were pre-B-ALL, 
corresponding with the fact that this phenotype is associated with a high frequency of 
subclone formation (14). In the 10 bi-/oligoclonal ALL no differences in IgK gene 
rearrangement patterns between BM and PB were detectable, which is in line with the 
absence of multiple IgK gene rearrangements in this series of precursor B-ALL. 
Interestingly, in all five cases with differences in rearrangement patterns between BM 
and PB the extra subclones or the larger sized subclones were found in the BM samples, 
suggesting that subclone formation in precursor B-ALL (due to continuing Ig gene rearrange-
ments) occurs in the tissue compartment from which precursor B-ALL cells originate. This 
would imply that dissemination of the different subclones occurs independently and may 
be related to the phase of subclone formation, i.e. the phase of the continuing rearrange-
ment process. Therefore, the differences described here in IgH gene rearrangement patterns 
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Figure 1. Southern blot analysis of 
IgH gene rearrangements in bone 
marrow (BM) and peripheral blood 
(PS) samples from two precursor 
8~ALL patients at diagnosis. Con-
trol DNA and DNA from the leuke-
mic cell samples were digested 
with 8g/l1 (Al or a combination of 
BamHI and Hindl1l (BL size sepa-
rated and blotted onto nylon mem-
brane filters which were hybridized 
with the 32P_Iabeled JH probe. The 
sizes (in kb) of the germline bands 
(Gl and rearranged bands are 
indicated. A: In both 8M and PB 
lanes four clearly rearranged bands 
are visible, while two faint additio-
nal bands are visible in the BM 
lane (arrows). B: In both BM and 
PB lanes four rearranged bands are 
visible. Two rearranged bands 
(16.0 and 2.2 kb) have similar 
densities in the BM lane and to the 
PB lane, whereas two other rear~ 
ranged bands 0.2 and 2.0 kb) 
have an obvious higher density in 
the 8M lane than in the the PB 
lane (arrows). 
between BM and PB in precursor B-ALL at diagnosis will lead to an underestimation of 
subclone formation if only PB samples are analyzed. 
Moreover, variability in the occurrence of subclones with differently rearranged IgH 
genes will hamper the detection of MRD by USe of the PeR-mediated amplification of 
"leukemia-specific" IgH gene junctional regions (27-29), as it is unpredictable which 
subclone will cause MRD andlor relapse (30). 
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CHAPTER 3.4 
CROSS-LINEAGE T-CELL RECEPTOR GENE REARRANGEMENTS 
IN CHILDHOOD PRECURSOR B-ACUTE LYMPHOBLASTIC LEUKEMIA' 
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ABSTRACT 
A large series of 116 precursor B-cell acute lymphoblastic leukemia (ALL) patients was 
analyzed for cross-lineage rearrangements and/or deletions in the T-eell receptor (TcR)-.8, 
TeR-')', and TcR-o genes. In 108 cases all three TcR genes were analyzed. In 94% 
(101/10S) of the precursor 8-ALL patients one or more genes were rearranged. TcR-i1 gene 
rearrangements were found in 36% (40/11 0), TcR-,), gene rearrangements in 57% (62/1 OS). 
TcR-o gene rearrangements in 50% (5S/116), and deletions in 41 % (47/116) of the cases. 
TcR-,6 gene rearrangements were monoallelic complete V(D)J,B gene rearrangements 
in 54% of cases or incomplete 0,6-J{32 gene rearrangements in 37% of cases. TcR,.. genes 
most frequently (78%) contained monoallelic rearrangements to J')'1 gene segments and 
at least SO% of TcR-o gene rearrangements represented incomplete V02-003 or 002-053 
gene rearrangements. 
Identification of T cR gene rearrangements is needed for subsequent polymerase chain 
reaction (peR) analysis of TcR gene junctional regions for detection of minimal residual 
disease (MRD) during follow-up of ALL patients. In precursor 8-ALL this especially concerns 
TcR-;- and TcR-a gene rearrangements. In at least 78% of precursor B-ALL the junctional 
region of these TcR gene rearrangements can be identified and used as target for PCR-
mediated MRD detection. 
INTRODUCTION 
The enormous diversity of immunoglobulin (lg) and TcR molecules is generated during 
B- and T-cell differentiation by a series of ordered rearrangements of variable (V), diversity 
(0)' and joining (J) gene segments (1,2). The germline configuration of the various TcR 
• Submitted for publication. 
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genes (TcR-", TcR-Il, TcR-y, and TcR-o) is shown in Figure 1. Ig and TcR gene 
rearrangements are different in each lymphoid cell, but identical in each clone of lymphoid 
cells. Analysis of 19 and TcR genes has become an important tool for determining clonality 
in lymphoid malignancies. In addition, immunophenotyping and immunogenotyping studies 
have provided evidence for the idea that leukemias and malignant lymphomas represent 
clonal expansions of hematopoietic (precursor) cells, arrested at distinct stages of 
maturation (3-8). Initially, 19 and TcR gene rearrangements were regarded as B-lineage and 
T-lineage specific markers, respectively (4-6). However, the finding of cross-lineage 
expression of "lineage-specific" immunological markers and cross-lineage 19 and TcR gene 
rearrangements has disputed this view (9-11). 
Cross-lineage rearrangements of Ig heavy-chain (lgH) genes have been observed in 10-
15% of T-ALL and in - 5% of mature T-celileukemias and lymphomas (12-14), but cross-
lineage rearrangements of Ig light-chain (lgL) genes in malignant T-cell proliferations are 
extremely rare « 1 %) (14,15). On the other hand TcR-Il, TcR-y, and TcR-o gene 
rearrangements and/or deletions have been found in -30%, -50%, and -80% of 
precursor 8-ALL, respectively (13,14,16-46). Cross-lineage TcR gene rearrangements in 
chronic B-cell leukemias and B-cell lymphomas are found less frequently « 5%) 
(14,20,25,31,36,38,47-54). Most TcR gene rearrangements in precursor 8-ALL are 
monoalielic and incomplete (14,17,22,23,30,31,38,40,41,54-59). Furthermore, 
transcription of rearranged TcR-.8 or TcR-,), genes in precursor B-ALL is rare (1-5%) 
(18,23,25,34,35,60). In the far majority of precursor 8-ALL TcR-1l gene rearrangements 
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Figure 1. Schematic diagram of human TcR genes. The TcR-o: gene complex consists of >50 V gene 
segments, a remarkably long stretch of -55 functional J gene segments, and one C gene segment. The TcR-,6 
gene complex consists of > 70 V gene segments and two C gene segments, both of which are preceded by 
one D and six or seven J gene segments. The TcR.." gene complex consists of a restricted number of V gene 
segments (six functional V gene ,segments and nine pseudo genes) and two C gene segments, each preceded 
by two or three J gene segments. The major part of the TcR-o gene complex is located between the Vo: and 
Jo: gene segments and consists of six V, three 0, and four J gene segments and one C gene segment. The 
5REC and ,pJo: gene segments playa role in TcR-5 gene deletions, which precede TcR-a: gene rearrangements. 
Pseudo genes (,p) are indicated with open symbols. Recently, a new functional J5 gene segment (J54) is found 
and located between the Jo1 and J52 gene segments (81,82). 
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occur in the TcR-J.82 locus and TcR"'"')' gene rearrangements occur in the TcR-J)'1 locus 
(14,17,22,23,31,40,55,57), whereas in T-ALL the TcR-i31 and TcR-i32 loci are used in 
comparable frequencies and the TcR-y2 locus is used in the majority of TcR"'"')' gene 
rearrangements (14,23,31,40). In precursor B-ALL the far majority of TcR-o gene 
rearrangements are incomplete V02-002 and 002-D03 rearrangements, whereas in T-ALL 
complete Vo1-Jo1 and Vo2-Jo1 rearrangements dominate (41,42,54,56,58,59,61,62). 
Moreover, cross-lineage TcR gene rearrangements in precursor B-ALL seem to occur in the 
same hierarchical order as found during normal T-cell differentiation (first, TcR-o gene 
rearrangements, followed by TcR-y gene rearrangements, and subsequently TcR-.B gene 
rearrangements). IgL gene rearrangements and (VO-) Do-Jo rearrangements seem to be more 
lineage-specific, because they are rarely found in T-Iineage or B-lineage cells, respectively. 
Apparently, the final steps in Ig and TcR gene rearrangements are more tightly controlled 
in a lineage-specific way. The occurrence of cross-lineage rearrangements has been 
explained by the finding that B- and T -cells use a common recombinase system for gene 
rearrangement (63), but this does not explain the difference in frequency of cross-lineage 
rearrangements between immature and mature leukemias and the occurrence of Ig and TcR 
gene rearrangements in acute myeloid leukemias (14,64). 
Junctional regions of rearranged Ig and TcR genes in leukemias and lymphomas can 
be regarded as 'tumor-specific' markers, because they are formed by joining of different V, 
(D), and J gene segments as well as by deletion and random insertion of nucleotides at the 
junctions of the gene segments (1,2,65-67). Therefore, each junctional region of rearranged 
Ig and TcR genes is different in each leukemia and lymphoma. Currently, it has been proven 
that in precursor B-ALL the PCR can be used for amplification of 'tumor-specific' junctional 
regions of cross-lineage rearranged TcR-/, and TcR-o genes to detect MRD (66-75). 
The aim of our study was to determine the precise frequency of cross-lineage TcR 
gene rearrangements in childhood precursor B-ALL, to evaluate the occurrence of 
preferential TcR gene rearrangements, and to estimate the number of precursor B-ALL 
patients with identifiable cross-lineage rearrangements, which are therefore suitable targets 
for PeR-mediated MRD detection. In 116 well-characterized cases of precursor B-ALL the 
configuration of the TcR-.8, TcR-'Y, and/or TcR-o genes was analyzed and compared with 
almost all previously published childhood precursor B-ALL cases. The detection of 
rearrangements in the TcR-a locus by Southern blotting is difficult due to the long stretch 
of Ja gene segments (about 85 kb) (Figure 1). The occurrence of TcR-a gene 
rearrangements in precursor B-ALL can therefore only be assumed based on TcR-o gene 
deletions In this manuscript, when TcR-o gene rearrangements are described, 
rearrangements in the TcR-O/a locus are ment. 
MATERIALS AND METHODS 
Cell samples 
Peripheral blood (PB) or bone marrow (BM) samples from children with precursor 8-ALL (116 cases) were 
obtained at initial diagnosis. Most cases (n = 99) were diagnosed at the Sophia Children's Hosphal, Rotterdam. 
Their cell samples were collected by the Department of Immunology, Erasmus University Rotterdam. The other 
17 children were treated in different Dutch hospitals and their cell samples were collected by the Dutch 
Childhood Leukemia Study Group (DCLSG), The Hague. The age distdbution of the 116 precursor B-ALL was 
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from 2 months till 16 years and 6 months (median 4 years and 7 months). Seventeen children were younger 
than 2 years and six of them were infants (age <1 year). 
The diagnosis of precursor B-ALL was made according to the FA8 classification (76), based on 
cytomorphology of 8M smears stained with May~GrOnwa!d Giemsa and cytochemistry (periodic acid~schiff). 
Each diagnosis was confirmed by the laboratory of the DCLSG. 
Mononuclear cells (MNC) were isolated from PB or 8M samples by Ficoll~Paque centrifugation (density 
1.077 g/cm3; Pharmacia, Uppsala, Sweden). The freshly obtained MNC samples were subjected to a detailed 
immunological marker analysis according to standard protocols (for detailed -description, see references 
7,8,77). Remaining MNC were stored in liquid nitrogen. A leukemia was considered to be a precursor B-ALL, 
if the malignant cells were positive for terminal deoxynucleotidyl transferase (TdT), CD19 and HLA-DR (null 
ALL), for TdT, CD1 0, CD19 and HLA-DR (common ALL), or for TdT, COlO, CD19, HLA-DR and cytoplasmic 
Ig heavy chain /k (Cylg/k) (pre-B-ALL) (8,78). Immunological marker analysis of the 116 precursor B-ALL 
revealed that five were null ALL, 80 were common ALL, and 31 were pre-B-ALL. 
Southern blot analysis 
DNA was isolated from frozen MNC as described previously (79,80). ContrOl DNA was obtained from 
granulocytes or a non-hematopoietic cell line with germline TcR genes. Fifteen /kg of DNA were digested with 
the appropriate restriction enzymes (Pharmacia). The restriction fragments were size-separated in 0.7% 
agarose gels and transferred onto Nytran-13N nylon membranes (Schleicher and Schuell, Dassel, Germany) 
180). 
TcR-/3 gene rearrangements were analyzed with the 32P_random oligonucleotide labeled TCRSD1 U (D/31 
upstream), TCRSD1 (0/31 downstreamLJ.B1, TCRBD2U (0.B2upstream), TCRS02 (0.B2downstream), TCRSJ2 
(J,62) and TCRSC (constant (Cl,6) probes in EcoRI and/or Hindlll digests and for confirmation in 8gnl digests 
(80 and Breit et a1. unpublished results). The configuration of the TcR--y genes was analyzed by use of the 
J-y1 .3 and J-y2.1 probes in EcoRI digests and for confirmation in Kpnl and/or 8gJlI digests, and by use of the 
J'Y1.2 probe in a 8gnl digest (80). The configuration of the TcR-o genes was analyzed by use of TCRDV1 
IVol), TCRDV2 IV02), TCRDV3 IV03), TCRDRE 10REC), TCRDDl IDol), TCRDD3 ID03), TCRDJl IJol), 
TCRDJ2 (Jo2), TCRDC4 (Co), and TCRAPJ (fJa) probes in EcoRI, Hind111 and 8gnl digests (59). 
The used combinations of probes and restriction enzymes allow identification of the various types of 
incomplete (0-0,6, D-J,6, V-D/3) and complete (V(-Dl-J,6) TcR-,6 gene rearrangements in the TcR-J,61 and TcR-
J/32 locus (80). In addition, they allow the precise identification of rearrangements of the various V'Y gene 
segments to the J'Y1 (J'Y1.1, J'Y1.2, and J'Y1.3) or J-y2 (J'Y2.1 and J'Y2.3) gene segments (80). Finally, they 
allow the detection of the various (preferential) types of TcR-O gene rearrangements and deletions (59,80). 
RESULTS 
TcRM,6 gene rearrangements 
DNA samples from 110 precursor B-ALL at diagnosis were examined for the presence of 
rearranged TcR-i> genes. In the total group of precursor B-ALL we found in 36% (40/110) 
of cases a rearranged TcR-i> gene on one or both alleles (Table 1). In all five null ALL no 
TcR-,6 gene rearrangements were detected. In common ALL and pre-B-ALL, TcR-,6 gene 
rearrangements were detected in 42% (31/74) and 29% (9/31), respectively (Table 1). The 
allelic frequencies of TcR-,6 gene rearrangements are summarized in Table 2. Germline 
configuration was found in 74% (163/220) of TcR-,6 alleles. The upstream and downstream 
Di> probes allowed the detection of the incomplete V-Di>, D-Di>, and D-Ji> gene 
rearrangements (Figure 2A). No rearrangements were detected with the TCRBD1 and Ji>1 
probes; only rearrangements in the TcR-,62 locus were detected. The majority concerned 
complete V(D)Ji>2 rearrangements (54%) or incomplete Di>-Ji>2 rearrangements (37%) 
(Table 2). 
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TABLE 1. Frequencies in precursor B~AlL of cross-lineage TcR gene rearrangements!!. 
TcR gene rearrangements and/or deletions 
TcR-o 
TcR TeR-,B TeRry 
precursor a-ALL (GIG) (RIG or R/R) (RIG or R/R) (RIG, RIR or D/R) (DIG or DID) 
null ALL 20% 0% 20% 40% 20% 
(115) (0/5) (liS) (2/5) (1/5) 
common ALL 3% 42% 61% 53% 41% 
(2/72) (31/74) (44nZ) (42/aO) (33/aO) 
pre-B-ALL 13% 29% 55% 45% 42% 
(4/31) (9/31) (17/31) (14/31) (13/31) 
total group of 6% 36% 57% 50% 41% 
precursor 8-ALL (7/108) (40/110) (6Z/108) (58/116) (47/116) 
Symbols used: R. rearranged allele: G. allele in germline configuration; 0, deletion of tho C) gone segment. 
a. Numbor of patients with germlino or rearranged cross-lineage TeR ganes per total group of precursor B-ALL patients in parentheses. 
TABLE 2. Allelic frequencies of TcR-.8 gene rearrangements in precursor B-ALL 
total group of 
TcR-.6 gene null ALL common ALL pre-B-ALL precursor B-ALL 
configuration (n =10) (n=148) (n=62) (n=220) 
Germline 100% 70% 81% 74% 
configuration (10) (103) (50) (163) 
Rearrangement 0% 30% 19% 26% 
(0) (45) (12) (57) 
---------------------------------~~--------------~------------~ 
Rearrangements!! 
Dp1-Jp1 } 0% 0% 0% 0% VP-DP1 (0) (0/45) (0/12) (O/57) VP(-Dpj-JP1 
DP1-DP2 0% 4% 0% 4% 
(0) (2/45) (O/12) (2/57) 
Dp1-Jp2 0% 9% 8% 9% 
10, (4/45) (1/12) (5/57) 
Dp2-Jp2 0% 31% 17% 28% 
(0) (14/45) (2f12) (16/57) 
VP-OP2 0% 2% 17% 5% 
(0) (1/45) (2/12) (3/57) 
VP_(DP)_Jp2b 0% 53% 58% 54% 
(0) (24/45) (7112) (31/57) 
a. In our group of precursor B-ALL no TcR·,81 gene roarrangement were detectod. 
b. Southern blot analysis does not allow identification of the 0,8 gene sogment{s) in complete V,8(-0fJ)-J,82 gene roarrangements. 
TcR-y gene rearrangements 
DNA samples from 108 precursor 8-ALL at diagnosis were examined for the presence of 
rearranged TcR-')' genes. In the total group of precursor 8-ALL we found TcR--y gene 
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rearrangements on one or both alJeles in 57% (62/108) of cases (Table 1). The distribution 
of the TcR-,\, gene rearrangements in the three precursor 8-ALL subgroups was: 20% (1/5) 
in nulJ ALL, 61% (44/72) in common ALL, and 55% (17/31) in pre-8-ALL (Table 1). The 
allelic frequencies of TcR-y gene rearrangements are summarized in Table 3. TcR-')' genes 
in germline configuration were found in 50% of alleles. The majority (79%; 84/107) of TcR-
'Y gene rearrangements occurred to J')'1 gene segments (Figure 28). In 60% of these J')'1 
gene rearrangements a V gene segment of the V-yl family was used. Strikingly, the J')'1 
gene rearrangements in pre-B-ALL occurred to the V'¥II (V')'9) gene segment in 57% of 
cases, whereas in common ALL Vy9-J')'1 gene rearrangements were found in only 22% of 
cases. The only TcR-,), gene rearrangements in null ALL concerned biallelic V'YIV-J')'1 gene 
rearrangements. The majority of J')'2 gene rearrangements (91 %) involved V gene segments 
of the V'll family (Table 3 and Figure 28). 
TcR-o gene rearrangements 
DNA samples from 116 precursor 8-ALL were analyzed for the presence of TcR-o gene 
rearrangements and/or deletions. In the total group of precursor B-ALL patients TcR-o gene 
rearrangements were found in 50% (58/116) and TcR-1i gene deletions in 41 % (47/116). 
equally distributed over the three different precursor 8-ALL subgroups (Table 1). The allelic 
A g ". 
'" '" 
B e 
"' 
c g 
'" '" '" "' c 
'" 
". 
'" 
E 
" ;0 c " ;0 '" " 0 
" " '" 
0 
'" 
0 
"' '" M 0 
'" 
". ". 0 ". ". 0 
'" 
". 
'" 
kb kb kb 
3.3 _ 
-ce = G (J-y2.3) 3.1 I/N-y7 11.0-5.8 -
- -
- V02-Do3 
8.6 - v. - vo2·Jc< 7.9 - lUI Wilii. -G 2.2 - ,~ 1l%M& - V,,5 
6.1 
-
-
- VE2·JO' 
1.8 -
""'" 
- G (J,,1.3) 
2.5 -
-
,~~, -G 
2.0 -
-
0.9 -
- V-y2f4 
" 
"' 
EcoRI, TCRBD2U probe EcoRI, Jy1 .3 probe 8glll, TCRDV2 probe 
Figure 2. Southern blot analysis of TcR genes in several precursor B-ALL patients. Control DNA and DNA from 
precursor B-ALL patients were digested with the appropriate restriction enzymes, size-separated, and blotted 
onto nylon membrane filters, which were hybridized with 32P-Iabeled probes. (A) TcR-.6 gene analyses using 
EcoRI with the TCRBD2U probe. (B) TcR",), gene analyses using EcoRI with the Jy1.3 probe. (C) TcR-o gene 
analyses using 8gfJI with the TCRDV2 probe. The germ line bands (G) and severa! TcR gene rearrangements 
in the TcR-O/o: locus are indicated. 
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TABLE 3. Allelic freQuencies of TcR"')' gene rearrangements in precursor B-ALL. 
total group of 
TcR"')' gene null ALL common ALL pre-B-ALL precursor 8-ALL 
configurationa (n=10) (n= 144) (n=62) (n=216) 
Germline 80% 46% 56% 50% 
configuration (8) (66) (35) (109) 
J'Y' gene 20% 41% 37% 39% 
rearrangements (2) (59) (23) (84) 
J'Y2 gene 0% 13% 6% '1% 
rearrangements (0) (19) (4) (23) 
------------------------------------------------------------------------
J'Y1 gene rearrangements 
V,[ 0% 71% 35% 60% 
(0110) (42/59) (S/23) (50/S4) 
V'YII 0% 22% 57% 31% 
(0110) (13f59) (l3f23) (26fS4) 
V'YIII 0% 0% 4% 1% 
(OflO) (Of 59) (1f23) (1f84) 
V'YIV 20% 7% 4% 6% 
(2fl0) (4f59) (1f23) (5fS4) 
J')'2 gene rearrangements 
V,[ 0% 95% 75% 91% 
(0) (18f19) (3/4) (21f23) 
V'YII 0% 0% 0% 0% 
[0) (Of19) (Of4) (0123) 
V'YIII 0% 0% 0% 0% 
[0) (Of19) (Of4) (Of23) 
V'YIV 0% 5% 25% 9% 
(O( (1f19) (1/4) (2/23) 
a. Tho -h'1 locus consists of J')'1.1, J')'1.2, and J')'1.3 gone sogments and tho J')'2 of J')'2. 1 and J')'2.3 gono sogments. Tho V')'I family 
consists of V')'1, V')'2, V')'3, V-y4, V')'5, '/tV')'5, V')'6, '/tV')'7, and V')'8 gene sogmonts; tho V')'li, V')'!!I, and V,),IVfamilies contain tho V')'9, 
yN,),10, and '/tV')',1 gone sogments, respoctivoly. The V')'A, V')'B and V')'12 (Vg1) gene segments are psoudogenes and no 
rearrMgoment of these three V')' gone segments was found in our sories of TcR..,.. gone roarrangements. 
frequencies of TcR-o gene rearrangements and deletions are summarized in Table 4. TcR-o 
genes in germline configuration were found in 22% (51/232) of alleles. In 72% of 
rearranged alleles a V02-003 rearrangement and in 9% a D02-D03 rearrangement was 
found (Figure 2C). The remaining TcR-o gene rearrangements (in which the Co gene 
segment was still present) were all detected by use of the J01 probe, but could not be 
identified precisely. They are probably caused either by rearrangements of a Va: gene 
segment to the 003-J01 region or by translocations or other chromosomal aberrations in 
the TcR-o locus (59). Indications of TcR-o gene rearrangements to the recently discovered 
J04 gene segment, located between the J01 and Jo2 gene segments were not found 
(Figure 1) (81,82). Based on rearrangements of VO and Do gene segments in the absence 
of the Cli gene region, we concluded that in 36% (36/102) of the TcR-1i gene deletions a 
Vli2 or Dli2 gene segment was probably rearranged to a J", gene segment (Figure 2C). 
Based on our extensive TcR-o Southern blot analyses, we assumed that in the majority of 
TcR-o gene deletions a Va:-Ja: gene rearrangement had occurred, because upon hybridization 
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TABLE 4. Allelic frequencies of TcR-o gene rearrangements or deletions in precursor BMALL. 
total group of 
TeR-a gene null ALL common ALL pre-B-ALL precursor 8-ALL 
configuration (n~10) (n~160) (n~62) (n~232) 
Germline 60% 19% 23% 22% 
configuration 161 131} (14) (51) 
TeR-a gene 20% 36% 31% 34% 
rearrangements 12) (58) (19) (79) 
TcR..o genea 20% 44% 47% 44% 
deletions 121 (71) (29) (102) 
--------------
TcR..o gene rearrangements 
V52-053 100% 71% 74% 72% 
(2f2) (41/58) (14f19) (57nS) 
002-003 0% 10% 5% 9% 
(0/2) (6/58) {1/19} (7(79) 
otherb 0% 19% 21% 19% 
(0/2) (11/58) (4/19) (1SnS) 
a. Based on roarrangements of V02 or 002 gono sogments in the absence of tho Co) gone region, we assumed that in these TeR-o geno 
deletions (35%; 36/102) a Vo2 or 052 gene segment was rearranged to a Joe gene segment. A VO/"Ja rearrangement was assumed 
in 60% (61/102) based on the fact that no hybridization signal was obtained when all TcR-S and "J!Jf;i. probes were used for 
hybridization, excopt for germline hybridization signals with VO or oREC probes in some cases. Translocations or other chromosomal 
aberrations occuring in the TcR· .. 5/a locus could not be ecxluded. 
b. Rearrangod TcR..o bands (in which the Co locus is present) probably caused either by rearrangements of Va gene segments to the 
Do3-Jo1 locus or by translocations or other chromosomal aberrations in the TcR-o locus. 
with all TcR-/) and ';'Ja probes no hybridization Signal due to deletion of the invoved TcR-/) 
and -.f;Ja gene segments was observed, except for germline hybridization signals with VO 
or OREC probes in some cases. Still, translocations or other chromosomal aberrations 
occurring in the TcR-ooo locus cannot be excluded. In four precursor B-ALL patients (five 
alleles) an unique hybridization pattern was found in which VO, OREC, and 001 probes 
resulted in germline hybridization signals, whereas all other TcR-o probes and the 1jtJex probe 
showed no hybridation signal due to the deletion of these DNA gene segments. In these 
precursor B-ALL cases, it cannot be excluded that potential targets for rearrangements are 
present in the 002-003 region or that chromosome aberrations in the TeR-o/a locus are 
present. 
Combinations of cross-lineage TcR gene rearrangements 
The different combinations of cross-lineage TcR gene rearrangements in our total group of 
precursor a-ALL are summarized in Table 5. In the five null ALL no combinations of cross-
lineage TcR gene rearrangements were found, whereas in common ALL 35% of cases had 
all three TcR genes rearranged or deleted_ Twenty-nine percent of precursor B-ALL cases 
showed TeR-o rearrangements and/or deletions, with germline TcR-,B and TcR-')' genes. In 
contrast, TcR-,6 and/or TcR-,), gene rearrangements without TcR-l/ gene rearrangements 
and/or deletions were observed in only 3% of cases. Similarly, 28% of precursor B-ALL 
cases had a rearranged TcR-,), gene with a germline TcR-,B gene, while only 8% showed 
TcR-,B gene rearrangements without TcR-,), gene rearrangements. These data indicate that 
TcR-o gene rearrangements and/or deletions oecur most frequently and that virtually all 
TeR-,6 and TcR-,), rearrangements coincide with TeR-ogene rearrangements and/or deletions. 
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TABLE 5. Combination of TcR gene rearrangements in childhood precursor B-ALL from our data and data 
reviewed from the literature. 
Cross-lineage TeR gene rearrangements and/or deletions 
References G ~ ~ 0 ~+~ ~+o ~+o #+-y+o 
Hara,1988 (30) 10% 0% 0% 34% 0% 3% 24% 28% 
(n~29) 13) 10) 10) (10) 10) )1) (7) 18) 
Oyer,1989 (13) 0% 0% 0% 25% 0% 8% 17% 50% 
(n~12) 101 10) 10) 13) 10) 11) 12) I.) 
Felix,1990 (39) 15% 4% 0% 25% 0% 6% 29% 21% 
(n~52) 18) 12) 10) (13) 10) 13) (15) (11) 
Fey,1990 (40) 0% 0% 0% 43% 0% 14% 29% 14% 
(n~7) (0) 10) 10) 13) 10) (1) 12) 11) 
This study 6% 2% 1% 29% 0% 6% 27% 30% 
(n~108) 17) 12) 11) (31) 10) I.) (29) (32) 
total group of 9% 2% <1% 29% 0% 6% 26% 28% 
precursor B-ALL 
(n~208) (18) 14) 11) (60) 10) (12) (55) (58) 
Symbo!s used: G. gormline configuration; P. TcR-P gene rearrangement; "y. TcRry gone rearrangoment: O. TcR-e gene rearrangement 
llnd/or deletion. 
DISCUSSION 
A large group of 116 precursor B-ALL patients was analyzed for the configuration of 
their cross-lineage TcR gene rearrangements. Rearrangements and/or deletions ofthe TcR-,B, 
TcR-')', and TcR-o genes were found in 36%, 57%, and 91 %, respectively. Since the first 
reports on cross-lineage TcR gene rearrangements in precursor B-ALL (16-20), the 
configuration of TcR-iJ, TcR-y, and TcR-o genes of a large group of precursor 8-ALL patients 
has been published (13,14,21-46). To determine the frequency of rearrangements and 
deletions of the various cross-lineage TcR genes in childhood precursor B-ALL we reviewed 
the reports, which indicated that childhood cases were analyzed, or the reports which were 
performed in collaboration with a children's hospital (13,17,19,21,24,28,30,32-35,38-44). 
It was found that TcR-,B gene rearrangements occur in 33% of precursor S-ALL, TcR-')' gene 
rearrangements in 440/0, and TcR-o gene rearrangements and deletions in 57% and 26%, 
respectively (Table 6). These percentages of TcR gene rearrangements and/or deletions are 
lower than in our series of childhood precursor 8-ALL (Table 1). This discrepancy is 
probably due to our larger panels of TcR DNA probes (especially for the TcR-iJ and TcR-o 
genes) and restriction enzymes in comparison with the published studies. Ig and TcR gene 
rearrangements are easily missed when only one DNA probe is used in combination with 
a restriction enzyme which results in large germline restriction fragments (59,80,83,84). 
The combination of our TcR gene rearrangements in childhood precursor B-ALL and 
those reviewed from the literature are summarized in Table 5. Only four research groups 
analyzed and compared all three cross-lineage TcR genes in a total number of 100 cases 
(13,30,39,40). Theirs and our combined data show that TcR-o gene rearrangements andlor 
deletions occurred in the majority of cases (- 90%) and that 29% (60/208) of childhood 
138 CHAPTER 3.4 
TABLE 6. Summary of TcR gene rearrangements in childhood precursor B-All reviewed from the literatureD• 
TcR gene rearrangements and/or deletions 
TcR-o 
TcR·~ TcR·"! 
precursor B-ALL IRIG or RIR} IRIG or RIR} IRIG, RIR or D/RI IDIG or DID} references 
null ALL 19% 25% 36% 36% 13,21,24-26, 
Ill/52) (16/64) (9/25) (9/25) 33,35,38,41 
common ALL 39% 51% 36% 64% 13,21,24,26, 
(49/125) (72{140) (5{14) (9/14) 32,35.40 
pre-B-ALL 26% 38% 100% 0% 13,21,24,35,40 
('1/42) (15/40) (4/4) (0/4) 
CD10+ 34% 48% 56% 32% , 3,21 ,24-26,32, 
precursor B-ALL b (94/273) (142f294) (53{94) (30/94) 33,35,38.40,41 
total group of 33% 44% 57% 26% 13,19,21,24-26,28,30, 
precursor B-ALL C (151/462) (Z07/470) (143/253) (661253) 32,33,35,3841,43,44 
Symbols used: R, rearrangod allclc; G, allelo in germline configuration; 0, deletion of the CO gene segment. 
o. The data about TcR gene rO<lrrangements in childhood precursor B-ALL are derived from reports, which indicated that only childhood 
cases were studied'or which were performed in collllborlltion with a children's hespital (13,17,19,21,24-28,30,32-35,38-44). Several 
research groups have published data on TcR gene rearrangements in precursor B-ALL moro than once. To avoid double counting, wo 
have selected tho most informative roports from each research group: the data from refs 24 and 30 woro used, while data from ref. 
34 were excluded; the data from refs. 17 and 21 were combined; data from rots. 28 and 39 were used, while data from ref. 27 were 
excluded. 
b. This pationt group contains all published childhood CD1 0+ precursor a-ALL cases, including the above mentioned common ALL and 
pre-B-ALL cases. 
c. This patient group contains all published childhood precursor 8-ALL cases, including the obovo mentioned precursor a-ALL cases. 
precursor B-ALL had TcR-o gene rearrangements and/or deletions with germline TcR--y and 
TcR-1> genes (Table 5). In contrast, TcR-'Y andlor TcR-1> gene rearrangements without TcR-o 
gene rearrangements and/or deletions were found in only 2% (5/208) of cases (Table 5). 
Similarly, 27% (56/208) of precursor B-ALL cases had rearranged TcR-'Y genes with 
germline TcR-1> genes, while only 8% (16/208) showed TcR-1> gene rearrangements without 
TcR-,), gene rearrangements (Table 5). Apparently in precursor B-ALL, rearrangements in the 
TcR-o/a locus occur first, followed by TcR--y gene rearrangements, and subsequently by 
TcR-.8 gene rearrangements. 
The frequencies of cross-lineage TcR gene rearrangements seem to be related to the 
maturation stages of B-cells. The frequency of TcR gene rearrangements is lower in 
immature precursor B-ALL (null ALL) as compared to the CD1 0+ precursor B-ALL (common 
ALL and pre-B-ALL) (see Table 1 and 6) and no combinations of cross-lineage TcR gene 
rearrangements were found in null ALL. Unfortunately, conclusions are difficult to draw 
because only five null ALL were analyzed. When comparing our common ALL and pre-B-ALL 
subgroups, it is striking that in the "mature" (Cylg,u. +) pre-B-ALL group a higher frequency 
of patients have all TcR genes in germline configuration (13% in pre-B-ALL versus 3% in 
common ALL). Cross-lineage TcR gene rearrangements are rare « 5%) in mature B-cell 
malignancies, such as chronic leukemias and lymphomas (14,20,25,31,36,38,47-54). 
These combined data suggest that the occurrence of cross-lineage TcR gene 
rearrangements is dependent on the activity of the V(D)J recombinase in the malignant 
cells. Apparently, in immature B-cells (null ALL) and more mature B-cells (pre-B-ALL, chronic 
B-cellieukemias, and B-celllymphomas) V(D)J recombinase is less active, or the mature 8-
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cell malignancies have already passed the lineage commitment point so that TcR gene 
rearrangements are no longer possible. 
The occurrence of cross-lineage TcR gene rearrangements in precursor B-ALL has been 
explained by the assumption that B- and T -cells use a common recombinase complex for 
gene rearrangements (63). It has been suggested that the cross-lineage TcR gene 
rearrangements in precursor 8-ALL are related to a high activity of the recombinase 
enzymes in B-cell precursors (85,86). However, expression of the recombination activating 
genes (RAG1 and RAG2) is not higher in precursor B-ALL with cross-lineage TcR gene 
rearrangements as compared to precursor 8-ALL without cross-lineage TcR gene 
rearrangements (87). A second explanation could be that TcR gene rearrangements only 
occur in early precursor cells and that the occurrence of TcR gene rearrangements in 
precursor B-cells stops the differentiation and maturation of these cells, because in normal 
precursor B-cells no cross-lineage TcR gene rearrangements were found (88), and they are 
rare in mature 8-cell malignancies « 5%) (14). One could speculate that in case of 
precursor B-cells in the BM, as in case of cortical thymocytes in the thymus, a large fraction 
of proliferating, immature cells with cross-lineage gene rearrangements survive only when 
they become neoplastic (11). However, this would implicate that oncogenic transformation 
preferentially affects precursor B-cells with cross-lineage TcR gene rearrangements. A third 
explanation could be that crOSS-lineage TcR gene rearrangements in precursor B-ALL 
represent a genetic deregulation due to the continuing activity of the recombinase system 
after malignant transformation and the maturation arrest (9,10). We prefer the latter 
explanation, because this would explain the virtual absence of cross-lineage TcR gene 
rearrangements in normal precursor B-cells and in mature 8-cell malignancies. 
Several laboratories have published details about the different types of TcR gene 
rearrangements in precursor B-ALU14, 17,22,23,30,31 ,38,40-42,54-59). It appears that 
in precursor B-ALL most TcR-iJ gene rearrangements are monoallelic complete V(D)JiJ2 
rearrangements, TcR-'Y genes most frequently (78%) contain monoallelic rearrangements 
to the J')'1 gene segments, and at least 80% of TcR-o gene rearrangements represent 
incomplete V02-D03 or D02-D03 rearrangements (14,17,22,23,30,31,38,40-42,54-59). In 
general, our data confirm these findings, but we found a significantly higher frequency of 
incomplete TcR-,6 gene rearrangements (46% of all TcR-,6 gene rearrangements) (Table 2). 
This is probably due to our usage of four different 0,6 probes, which allow identification of 
incomplete V-DiJ, D-DiJ, and D-JiJ gene rearrangements. 
Due to their enormous diverSity, junctional regions of rearranged Ig and TcR genes 
represent ideal peR targets for the detection of MRD (65-67). In precursor B-ALL this 
especially concerns junctional regions of IgH, TcR-,), and TcR-o genes. For this purpose the 
precise configuration of the gene rearrangements (i.e. the V,(D), and J gene segments) has 
to be identified at diagnosis. We determined the frequency of precursor 8-ALL, which has 
an identifiable type of TcR--y (57%) andlor TcR-o (43%) gene rearrangement and found that 
in at least 78% (831108) of precursor B-ALL one or more rearranged TcR-"\, andlor TcR-o 
genes can be used as targets for PeR-mediated MRD detection. The stability of these 
leukemia-specific TcR gene junctional regions was reasonably high as found by our study 
on 40 childhood ALL patients at diagnosis and relapse, which showed that in at least 75% 
of rearranged TcR-,), and/or TcR-o alleles the rearrangement remained stable (89). 
Our study indicates that cross-lineage TcR gene rearrangements and/or deletions in 
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childhood precursor 8-ALL occur in high frequency, in a hierarchical order I and are 
incomplete in a large part of cases (TcR-iS and TcR-o genes). The occurrence of these cross-
lineage TcR gene rearrangements in precursor 8-ALL might be explained by a genetic 
deregulation due to the continuing activity of the recombinase system after malignant 
transformation. In at least 78% of precursor 8-ALL these TcR gene rearrangements can be 
identified and used as targets for PeR-mediated MRD detection. 
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CHAPTER 4.1 
CHARACTERIZATION OF ACUTE 
LYMPHOBLASTIC LEUKEMIA AT DIAGNOSIS AND RELAPSE 
Chemotherapy is highly effective in childhood acute lymphoblastic leukemia (ALL) (1). 
Nevertheless, 20-30% of children with ALL eventually develop a bone marrow (BM) andlor 
extramedullary relapse (1,2). As indicated in the General Introduction (section 1.6), there 
is still no adequate explanation of the biological basis for the failure of treatment in these 
patients. Apparently I a minority of leukemic cells are able to escape destruction in the 
present treatment protocols. This may be due to selection of sub clones which have a 
different biological behaviour or due to development of resistance to the applied cytostatic 
drugs (see also Chapter 3). During the last two decades various studies, analysing data at 
diagnosis and relapse, have been performed to obtain insight into the mechanisms that 
influence the occurrence of relapse in ALL. These studies concern: comparative glucose-6-
phosphate dehydrogenase and glucocorticoid receptor analyses (3,4), detection of 
morphological (5-7), immunophenotypic (8-10), and karyotypic shifts at relapse (11-19), 
comparative studies on immunoglobulin (lg) idiotype (20), DNA-fingerprints (21), oncogene 
amplification or mutation (22,23), and analysis of Ig and T-cell receptor (TcR) genes at 
diagnosis and relapse (24-36). 
The results of these comparative studies (especially analysis of immunophenotypic, 
karyotypic, and immunogenotypic shifts) have direct consequences for the detection of 
minimal residual disease (MRD) during and after therapy. Detection of MRD by several 
methods (e.g. immunological marker analysis and polymerase chain reaction (peR) analysis) 
is not only important for analysing the cytoreduction of ALL cells caused by the applied 
therapy protocol, but also for early detection of relapse. 
Comparative karyotypic analysis at diagnosis and relapse in 246 childhood ALL 
patients published in the literature showed in at least 33% (81/246) karyotypic shifts at 
relapse (Table 1; A~A + and A~B) (11,12,14,15,17,18). In 95% (77/81) of these shifts 
additional structural changes were found proving the clonal relation between the clones at 
diagnosis and relapse (Table 1). In a minority (5%; 4/81) of all studied childhood ALL cases, 
no clonal relation was found between karyotypes at diagnosis and relapse (Table 1). 
Karyotypic shifts from normal to abnormal or from abnormal to normal were not included 
in these calculations, because, as indicated in the General Introduction (section 1.3), finding 
of a normal karyotype at diagnosiS or relapse does not always exclude chromosomal 
abnormalities. First, technical failures or bad leukemic metaphases may interfere with 
identification of the abnormal clone and second, a low percentage (25-50%) of Iympho-
blasts present in the BM of patients in relapse might influence the rate of identification of 
the leukemic clone. 
Two studies reported only data of a complete change in karyotype at relapse (13,19). 
Cytogenetic evidence for a complete change in karyotype at relapse in 166 childhood ALL 
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TABLE 1. Cytogenetic findings of 246 childhood ALL at diagnosis and relapse as published in the literature. 
Cytogenetic findings 
number no changes changes 
of ALL 
patients N-N A-A N-A A-N A-A + A-B references 
51 3 8 6 4 28 2 11 
12 4 8 12 
21 5 5 1 2 8 14 
21 2 3 3 13 15 
25 2 6 2 2 12 17 
116 43 35 17 12 8 18 
246 55 57 33 20 77 4 
{%l (22) (23) (13) (8) (31) (2) 
Abbreviations used: N, normal karyotype; A, abnormal karyotype; A +, additional chromosomal abnormalities at relapse; B, complete now 
abnormal karyotype at relapse. 
was found in 10% (16/166) of cases and could be confirmed with changes in immunophe-
notype in 15 cases (13,19). The occurrence of karyotypic shifts without clonal relation 
could have important implications for the PeR-mediated MRD detection of leukemia-specific 
fusion regions offrequently occurring translocations (t( 1; 19). t(9;22), and t(4; 11)) in ALL. 
In only one case « 1 %) of all published childhood ALL cases (n = 412), a t( 1; 19) was lost 
at relapse (13), confirming the stability of karyotype in ALL and its value for PCR-mediated 
MRD detection. 
In Chapter 4.2, morphological and immunophenotypic analysis of a large group of 40 
ALL patients (32 precursor B-ALL and 8 T-ALL) has been performed at diagnosis and 
relapse. The occurrence of morphological and immunophenotypic shifts will be discussed 
as well as their consequences for MRO detection with immunological marker analysis. In 
Chapter 4.3, comparative Ig and TcR gene analysis on DNA samples of 40 ALL patients (30 
precursor B-ALL and 10 T-ALL) at diagnosis and relapse are described. Eighteen precursor 
B-ALL and six T-ALL of this group of patients are also described in Chapter 4.2. The 
occurrence and possible cause of immunogenotypic changes (clonal evolution) will be 
discussed, as well as the consequences for the PCR-MRD detection on patient-specific 
junctional regions of Ig andlor TcR genes. 
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ABSTRACT 
To get more insight into the phenotypic changes of childhood acute lymphoblastic 
leukemia (ALL) at presentation and at relapse, a detailed morphological and immunophe-
notypic study in 40 childhood ALL cases (32 precursor 8-ALL and S T-ALL) was perfor-
med. 
Monoclonal antibody (McAb) panels for non-lineage specific markers (terminal 
deoxynucleotidyl transferase (TdT). CD34, and HLA-DR), B-lineage markers (CD1O, 
CD19, CD20, and CD22). T-lineage markers (CD1, CD2, CD3, CD4, CD5, CD7, and 
CDS). and cross-lineage myeloid markers (CD14, CD15, and CD33) were compared at 
diagnosis and at relapse. In cases of low blast counts (,,;70%) at relapse, double 
labeling for membrane markers and TdT were used in order to define the precise 
immunophenotype of the TdT+ leukemic cells. An immunological marker-shift was 
defined as either a conversion from positive to negative and vice versa or a difference in 
positivity of =::50%. 
Morphological differences between diagnosis and relapse were detected in 34% of 
precursor B-ALL and 12% of T-ALL. Differences in immunological marker expression 
were found in 69% of precursor 8-ALL and in 63% of T-ALL. The morphological shifts 
and marker-shifts were not correlated. 
Marker-shifts were found in all markers tested in precursor B-ALL, except for HLA-
DR. A shift in CD10 expression was observed only in relapses occurring 30 months or 
more after diagnosis. In four precursor B-ALL an intra-lineage shift was found at relapse 
(one common ALL to null ALL and three pre-B-ALL to common ALL or null ALL) and two 
precursor 8-ALL cases were diagnosed as acute non-lymphocytic leukemia (ANLL) at 
relapse based on morphology and immunophenotype. In T-ALL, neither intra-lineage nor 
• Submitted for publication. 
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inter-lineage shifts were detected, although shifts were observed in all T-cell markers 
tested, except for the lineage specific C03 and T-cell receptor (TcR) markers. 
In conclusion, marker-shifts at relapse are frequently found in precursor B-ALL and 
T-ALL, in a small percentage leading to an intra-lineage shift (10%) or inter-lineage shift 
(5%). Therefore monitoring for minimal residual disease (MRD) by immunological marker 
analysis should include the usage of multiple marker combinations, preferentially in 
combination with polymerase chain reaction (peR) analysis of rearranged immunoglobu-
lin (lg) and/or TcR genes. 
INTRODUCTION 
Although the prognosis of childhood ALL has improved during the last years (1-4), 
20-30% of the patients relapse. To obtain insight into the mechanisms which influence 
the development of a relapse in childhood leukemia and for determining the therapy 
thereafter, we need to know the phenotypic and genotypic characteristics of the 
leukemic cells at diagnosis and at relapse. 
Several comparative studies on childhood ALL at diagnosis and relapse report 
morphological changes (5-8) and immunophenotypic changes at relapse (8-12). Major 
immunophenotypic changes generally accompany a conversion of hematopoietic cell 
lineage: lymphoid to myeloid or vice versa, a so-called inter-lineage shift (6,13). This 
inter-lineage shift is either due to multi-lineage properties of the leukemic clone at 
diagnosis, or due to irradication of the original malignant clone and induction of a 
second independent neoplasm (14). However, most changes reported in the literature 
are minor immunophenotypic shifts with loss or acquisition of one or few antigens. In 
some cases this might lead to a change in immunophenotypic classification, a so-called 
intra-lineage shift, such as from pre-B-ALL to common ALL. 
In precursor B-ALL marker-shifts generally concern loss or acquisition of CD 10 
antigen (common ALL antigen) (8,9,11,15-17), HLA-OR (8,9,11), TdT (11), or C020 
antigen (16)' and sometimes loss of cytoplasmic immunoglobulin heavy-chain p. (Cylgp.) 
(12). In T-ALL only few shifts have been reported, which generally concerned C02 
antigen (E rosette receptor) (10) or TdT (12,16). However most reports did not study 
the expression of all relevant B-cell, T-cell, and myeloid markers at diagnosis and at 
relapse. Also the comparability of these studies is limited, because of major differences 
in McAb panels, application of different techniques, and differences in definition of 
immunophenotypic shifts. 
The aim of this study was to get more insight into the phenotypic changes 
(morphological and immunological) of childhood ALL at presentation and at relapse, 
because such changes might influence their classification for treatment and might limit 
the immunophenotypic detection of MRO (12,18,19). Therefore we performed a detailed 
morphological and immunophenotypic study in 40 childhood ALL cases, i.e. 32 precur-
sor B-ALL and eight T-ALL. 
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MATERIALS AND METHODS 
Patients 
In the Netherlands, bone marrow (BM) and peripheral blood (PB) samples of children suspected of having 
leukemia are send to the laboratory of het Dutch Childhood Leukemia Study Group (DCLSG) for 
confirmation and classification of diagnosis and relapse. Between 1989 and 1993, 40 relapses were 
registered including six second or third relapses (33 precursor B-ALL and 7 T-ALL), with adequate BM or 
PB samples for blast cell immunophenotyping at both diagnosis and relapse by comparable methods. This 
was 45% of all hematological relapses in childhood ALL in the Netherlands in this period. We added cell 
samples of 6 additional relapses (3 precursor B-ALL and 3 T-ALL), who relapsed before september 1989 
and of whom sufficient mononuclear cells (MNC) from diagnosis and relapse cell samples were stored in 
liquid nitrogen. 
Morphology and Cytochemistry 
BM and PB smears at diagnosis and at relapse were stained by standard techniques including periodic 
acid-Schiff reagens, Sudan Slack B, myeloperoxidase (MPO), a combined naphthol AS-D chloroacetate 
esterase and a-naphthyl acetate esterase. Classification followed French-American-British (FAB) criteria at 
diagnosis and at relapse. 
Immunophenotyping 
MNC were isolated from 8M, PS, or pleural exudate by Ficoll-Paque centrifugation (density 1.077 g/cm3 ; 
Pharmacia, Uppsala, Sweden) for 15 min. (room temperature (RT), 1250 g). The MNC were analysed on 
cytocentrifuge preparations (Shandon Cytospin II; Life Sciences International Limited, Runcorn, England) 
for nuclear expression of TdT as well as for intracellulair expression of Cylg,u, CD22 (Leu-14), MPO, and 
CD3 (Leu-4). Cell membrane immunophenotype was analysed for HLA-OR antigen and CD34 (BI-3C5); the 
B-cell markers CD9 (BA2), CD10 (VIL-A1), CD19 (84), CD20 (B1), CD22 (Leu-14), CD24 (BA1); the T-cell 
markers CD1 (Leu-6), C02 (T11), CD3 (Leu-4), CD4 (Leu-3a), COS (Leu-1), CD7 (3A1), CDS (Leu-2a), 
TcR-a,B (BMA031) and TcR"/,o (11F2); and the myeloid markers CD14 (My4L CD15 (VIM-D5), CD33 
(My9), CDw65 (VIM-2). The rabbit anti-TdT antiserum was purchased from Supertechs (Bethesda, Mo, 
USA); the McAb of the Leu series, anti-HLA-OR, and 11 F2 were obtained from Becton Dickinson (San 
Jose, CA, USA); 3A1 hybridoma was obtained from American Type Culture Collection (Rockville, MD, 
USA): BMA031 was kindly provided by Dr R. Kurrle (Behring, Marburg, Germany); B4, B1, and the My 
series were obtained from Coulter Clone (Hialeah, FL, USA); VIL-A1, VIM-2, and VIM-D5 were kindly 
provided by Dr W. Knapp (Vienna, Austria); SAl was obtained from Hybritech (San Diego, CA, USA); 
BA2 and BI-3C5 from Seralab (Crawley Down, England); T11 and anti-MPO from the Central Laboratory of 
the Blood Transfusion Service (Amsterdam, the Netherlands). 
Washing of cells was performed with phosphate buffered saline (PSS; pH 7.8) supplemented with 
1 % bovine serum albumine (SSA). Cytocentrifuge preparations were made with a cell concentration of 
106/ml. For labeling of cells in suspension the cell concentration was adjusted to 107/ml. 
In 20 cases at diagnosis, immunophenotyping was performed by immunoperoxidase stainings on 
cytocentrifuge preparations, except for detection of TdT and Cylg,u, for which immunofluorescence 
stainings were used. For all other analyses at diagnosis and relapse we used immunofluorescence stai-
nings of cells in suspension (membrane antigens) or cytocentrifuge preparations (intracellular antigens). 
The immunofluorescence stainings were analyzed by fluorescence microscopy (Zeiss, Oberkochen, 
Germany) andlor a FACScan flow Cytometer and Lysis-II software (Secton Dickinson). 
Some antigens were difficult to detect by use of immunoperoxidase stainings; this especially 
concerned the CD24, CD33 and CD34 antigens. Therefore, in all cases where an immunophenotypic shift 
was found which could be due to differences in applied techniques, immunophenotyping was repeated by 
immunofluorescence stainings. See tables for specification of technique per cell sample. 
Immunoperoxidase 
Cytocentrifuge preparations were fixed in buffered formaldehyde acetone (pH 7.4; 4°C; 30 sec) rinsed in 
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water, ,washed with PBS (pH 7.4), incubated with 50}.'1 of the relevant McAb (RT; 60 min), washed and 
incubated with 50,tt1 peroxidase-conjugated rabbit anti-mouse antiserum with 2% pooled AS human serum 
added. After washing, staining with diaminobenzidine 0.5 mg/m[ and 0.05 M tmidazole was performed in 
0.05 M Tris-He! buffer (pH 7.6) and 0.02% H20 2 (RT; 10 min), followed by counterstaining with hema-
toxylin. At least 200 MNC were counted. 
Immunofluorescence 
50 JLI of a cell suspension was incubated (4°C, 30 min) with 50 ,al of the relevant McAb, washed, and 
subsequently incubated with 50 1'1 fluorescein isothiocyanate (FITC) conjugated goat anti-mouse-Ig 
antiserum (4°C, 30 min) and washed again. The labelled cell suspension was either mounted in glycerol 
with 1 mg p-pheny[eendiamine per ml and analyzed on a fluorescence microscope, or measured and ana[y-
zed by use of a FACScan flow cytometer. 
TdT detection 
Cytocentrifuge preparations were fixed in methanol (4°C, 30 min), washed, incubated with 15 1'1 rabbit 
anti-TdT antiserum in a moist chamber (RT; 30 min) washed, subsequently incubated with 15 JL[ FITC-
conjugated goat anti-rabbiHg antiserum and washed again. The preparations were mounted in glycerol 
with 1 mg p-phenyleendiamine per ml. 
Double marker analyses 
For double marker analysis of TdT and membrane markers, MNC in suspension were labeled with the 
relevant McAb and a tetramethylrhodamine isothiocyanate (TRITC) conjugated goat anti-mouse [g 
antiserum. The labeled cells were spun onto slides, fixed, and subjected to TdT staining. At least 200 TdT 
positive cells were analyzed for expression of the tested membrane marker (20). Double marker immuno-
phenotyping was done in all relapse cases with less then 70% blasts. 
Definitions 
A relapse was defined by the treatment protocol as having ~ 20% blasts. Immunological markers were 
judged to be positive if expressed in ;::: 20% of the malignant cells. A leukemia was classified as a 
precursor B-ALL, if the malignant cells were positive for TdT, C019, and HLA-OR (null ALL), or for TdT, 
COlO, C019 and HLA-OR (common ALL), or for TdT, COlO, C019, HLA-OR and CylgJ.' (pre-8-ALL) (20). 
A T-ALL was defined by positivity for TdT, cytoplasmic C03 (CyC03)' surface membrane C03 (SmC03), 
and CD7 (20). 
An immunophenotypic shift was defined as a conversion from positive to negative and vice versa. 
Restriction to this rule would exclude major shifts in marker positivity (e.g. from 85% to 25%), because 
the cut-off point of marker positivity was defined at 20%. Therefore we also defined loss or acquisition of 
a marker, if the percentage positivity differed ~50% between diagnosis and relapse. If the blast count at 
relapse was ~70%, double marker analysis was used for defining positivity and for defining a shift. An 
intra-lineage shift was defined as a change in sub-classification within the precursor B-ALL or T-ALL 
groups (for instance from pre-B-ALL to common ALL). An inter-lineage shift was defined as a change from 
ALL to ANLL. 
RESULTS 
Morphological classification 
In 11 of 32 precursor B-ALL and in 1 of 8 T-ALL a cytomorphological shift was obser-
ved. In 2 of these 12 cases, ALL at diagnosis shifted to ANLL at relapse (Figure 1), 
whereas the other changes represented shifts from L 1 at diagnosis to L2 at relapse 
(n=5), or vice versa (n=5) (see Tables 1-3). 
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Figure 1. Cytomorphology of 8M smears in two precursor s..ALL patients at diagnosis and relapse. A: 
According to the FAB classification precursor 8-ALL patient 3797 had a L 1 morphology at diagnosis (A 1), 
which changed to M5 at relapse (A2). B: Precursor B-ALL patient 4522 had a L 1 morphology at diagnosis 
(B1) and relapsed as a M4 (82). 
Immunological marker analysis of precursor B-ALL at diagnosis and relapse 
The 32 precursor B-ALL at diagnosis were classified as null ALL (n = 1). common ALL 
(n=21), and pre-B-ALL (n=10). 
In 22 of the 32 precursor B-ALL (69%) marker-shifts were found at relapse: the 
null ALL, 11 of 21 common ALL, and all 10 pre-B-ALL (Table 1). The remaining ten 
common ALL retained their original immunophenotype (Table 2). Shifts occured in nearly 
all tested markers except for HLA-OR. In approximately half of the patients with a 
marker-shift, this concerned only one marker, but up to five marker-shifts were found in 
patient 4522 and seven marker-shifts in patient 3797; both patients relapsed as ANLL 
(Table 1 and Figure 1). 
The marker-shifts were found in the pan B-cell markers CD19 (3/32) and CD22 
(6/32) as well as in other 8-cell markers like CD9 (6/32), CD1 0 (5/32). and CD20 (5/32) 
(Table 4). Changes in Cyl91' expression were observed in five cases (5/32) (Table 4). 
Also non-lineage-restricted markers like TdT and C034 as well as cross-lineage markers 
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L2 76 51 
L2 75 68 
L1 95b 93 
11 92b 87 
11 86 90 
11 22 30 
11 77 76 
62 
11 92b 86 
11 71 91 
l2 93 83 
11 90 98 
11 72 80 
11 83b 76 
11 65 
11 92 
68 
86 
DR 34 
96 
99 
94 
88 
82 
87 
76 
69 
93 
94 
96 
94 
29 
85 
94 
93 
94 
97 
87 
93 
79 
98 
2 
5 
6 
o 
~-P i$j ~o 
16 
1 
59 
80 
10 
2 
o 
64 
83 
~l:r 
;Hi 
M i~! 
~1 
a-lineage T -lineage 
CD CD CD CD CD CD CD Cylgp. Smlgp. CD CD 
10 t9 22 22 20 9 24 3 7 
95 
99 
58 
86 
97 
94 
93 
1 
3 
91 
71 
94 
25 
99 
79 
93 
94 
94 
98 
83 
90 
61 
83 
95 
97 
94 
89 
97 
94 
90 
74 
94 
94 
94 
96 
25 
93 
86 
94 
93 
94 
98 
86 
95 
59 
89 
Cy Sm Sm 
93 
44 
92 
}~ 
79 
36 
90 
91 
88 
88 
97 
92 
88 
56 
92 
89 
96 
28 
74 
62 
93 
77 
93 
97 
87 
93 
45 
72 
92 
48 
67 
80 
98 
92 
92 
o 
1 
90 
82 
77 
23 
33 
3 
2 
! 
~_1 
54 
77 
~. M 
95 
86 
93 
70 
73 
59 
32 
r~ 
94 
23 
99 
75 
95 
92 
94 
97 
67 
91 
~. 
97 
99 
95 
86 
96 
93 
94 
9 
90 
90 
51 
28 
77 
65 
94 
34 
41 
97 
88 
99 
74 
52 
o 
o 
~,~ 
iJM 
99 
96 
96 
o 
o 
o 
o 
62 
tV 
o 
o 
67 
60 
o 
1 
o 
10 
o 
o 
o 
2 
o 
o 
1 
3 
o 
o 
o 
7 
o 
o 
o 
27 
3 
o 
2 
o 
5 
o 
3 
o 
3 3 
1 2 
3 6 
o 0 
o 2 
5 5 
2 2 
4 5 
45c 38° 
10 14 
4 6 
o 
2 
3 
3 
o 
15 
13 
o 
3 
3 
3 
1 
21 
12 
Ll 81 69 81 42 73 81 
89 
53 
85 
8 
5 
65 
34 
81 
90 
3 
2 
8 12 
5 
15 
6 L1 93 90 92 80 91 81 
Myeloid 
CD CD 
14 15 
2 
o 
o 
o 
o 
2 
3 
o 
1 
o 
o 
3 
4 
o 
o 
r~ 
o 
1 
o 
3 
1 
o 
1 
8 
o 
3 
3 
36 
5 
1 
25 
3 
14 
o 
o 
6 
4 
3 
6 
1 
7 
3 
CO 
33 
2 
o 
o 
3 
o 
o 
3 
3 
2 
o 
o 
o 
2 
4 
5 
;~i I~ 
Immuno-
phenotype 
common All 
common ALL 
pre-B·ALL 
common All 
pre-B-All 
pre-B-ALl 
pre-B-All 
null All 
null All 
common All 
common All 
pre-B-ALL 
common ALL 
common ALL 
common ALL 
pre-B-All 
pre-B-AlL 
common ALL 
common ALL 
common ALL 
common ALL 
common ALL 
!!~ common ALL 
@~ common ALL 
Symbols used: pat nr, DClSG patient number; f, female; m, male; y, years; mo, months; 0, diagnosis; R, relapse; R·l, first relapse; R-2, second relapse; R-3, third relapse; 
Rl, relapse or secondary leukemia; FC, flow cytometer: IF, immunofluorescence mlCfoscoPY; JP, immunoperoxidase; -, no lmmunophenotypic date were 
available with this McAb In thIs cell sample. 
a. The expression of the used McAb is given in percentage positivity. 
b. Percentage of blasts before Rcoll centrifugation; thIs implies that after cell separation the percentage of blast cells would be higher, due to enrichment. 
c. Interpreted as normal T-Iymphocytes. 
d. Flrst relapse in the bone marrow. 
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TABLE 2, Immunophenotype of precursor a·All without immunophenotypic shifts8 • 
p" 
"' (sex, 
age) 
3968 
(m,14y) 
3997 
{m,2y} 
4511 
(mAy) 
4638 
(f,2y) 
4675 
{m,6yl 
4777 
(m,9yl 
4778 
(m,ly) 
4896 
(m,13y) 
4980 
(m,2y) 
Non·lineage 
D/R method! FAB Bl 
% 
TdT HLA CD 
(time from cell 
diagnosis sample 
In months) 
D 
R·l(40) 
D 
R·1(451 
o 
R·1(391 
D 
R·t(361 
o 
R·t(20) 
o 
R·1{24} 
D 
R·2(29)d 
o 
R·1(22) 
o 
R·t(t8) 
IP/BM 
IF/8M 
per TdT 
L2 95 
It 67 
IP/BM Lt 89 
IF/BM II 44 
per TdT 
98 
64 
95 
48 
IF/8M Lt 95b 94 
FC/BM II 
per TdT 
35 47 
IP/BM 
FC/8M 
L1 77 77 
IF/BM 
FC/BM 
IP/8M 
FCIBM 
IP/BM 
FCIPS 
IPleM 
FC/8M 
l2 79 86 
11 84 89 
l2 82b 72 
L1 
L1 
l2 
L1 
L1 
L1 
62 
73 
66 
87 
86 
91 
77 
90 
72 
94 
91 
95 
IP/BM L1 86 82 
70 Fe/BM L1 52 
per TdT 
DR 34 
93 
80 
96 
61 
88 
62 
77 
55 
90 
78 
86 
89 
62 
82 
93 
91 
92 
75 
4 
2 
o 
o 
1 
72 
23 
61 
44 
81 
70 
31 
78 
6 
o 
71 
90 
60 
62 
70 
B·lineage T·lineage 
CD CD CD CD CD CD Co Cyl9fl Smlgf' CD CD 
10 19 22 22 20 9 24 3 7 
74 
48 
67 
88 
40 
98 
92 
60 
97 
68 
47 
81 
67 
83 
85 
66 
89 
50 
88 
84 
69 
99 
83 
62 
80 
79 
58 
82 
94 
61 
83 
43 
56 
89 
76 
80 
85 
64 
86 
64 
84 
68 
77 
90 
Cy Sm Sm 
81 
60 
81 
20 
63 
79 
81 
64 
65 
54 
67 
86 
50 
67 
39 
69 
56 
76 
68 
82 
86 
88 
38 
58 
65 
11 
9 
10 
o 
12 
o 
2 
10 
o 
10 
8 
10 
3 
13 
o 
63 
82 
o 
o 
o 
2 
47 
62 
73 
10 
23 
1 
5 
19 
6 
77 
42 
87 
74 
73 
84 
72 
78 
84 
96 
79 
69 
99 
67 
96 
86 
10 
97 
51 
84 
72 
88 
90 
91 
78 
99 
o 
2 
o 
o 
o 
4 
o 
4 
9 
o 
2 
o 
o 
o 
7 
2 
o 
2 
o 
2 
3 
6 
o 
4 
o 
3 
8 
o 
13 
5 
14 
7 
8 
8 
12 
3 
18 
6 
9 
23t 24c 
25t n c 
6 6 
7 11 
2 
16' 
o 
8 
o 
2 
6 
9 
3 
21' 
o 
13 
o 
8 
7 
Myeloid 
CD CD 
14 15 
6 
3 
6 
3 
3 
o 
3 
4 
2 
o 
10 
2 
4 
5 
11 
22 
6 
7 
5 
12 
6 
7 
10 
CD 
33 
22 
11 
o 
19 
21 
24 
o 
o 
5 
6 
o 
2 
o 
6 
18 
o 
2 
Symbols used: pat nr, DCLSG patient number; f, female; m, mala; y, years; 0, diagnosis; R, relapse; R·1, first relapse; R·2, second relapse; FC, flow cytometer; 
IF, immunofluorescence microscopy; IP, immunoperoxidase; - no immunophenotypic data were available with this McAb In this eel! sample. 
a. The expression of the used McAb is given In percentage positivity. 
b. Percentage of blasts before FicoH centrifugation; this implies that after cell separation the percentage of blast celis would be higher, due to enrichment. 
c. Interpreted as normal T·lymphocytes. 
d. First relapse in the bona marrow. 
Immuno· 
phenotype 
common ALL 
common All 
common All 
common ALL 
common All 
common ALL 
common ALL 
common ALL 
common ALL 
common ALL 
common ALL 
common ALL 
common ALL 
common ALL 
common ALL 
common ALL 
common All 
common ALL 
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TABLE 3.lmmunophenotype of T·ALL at diagnosis and relapse8 • 
P,( 
"' (sex, 
agel 
3729 
(f,tty) 
3810 
(m,6y) 
3987 
(m,8y) 
4529 
(m,t3y) 
4564 
(m,3y) 
4623 
(m,9y) 
4727 
(m,7y) 
5t58 
(mAy) 
O/R method/ 
(time from cell 
diagnosis sample 
in months) 
o 
R-l(33) 
o 
R- t(17) 
R-2(25) 
o 
R-3(18) 
o 
R-2(45) 
o 
R-t{t5) 
o 
R-t02) 
R-2(2t) 
o 
R-1(12) 
o 
R-1 (11) 
IF/8M 
IF/8M 
IF/8M 
FC/8M 
FC/BM 
FC/BM 
FC/BM 
FCIP8 
FC/PL 
FC/8M 
FC/PB 
FC/BM 
IF/8M 
IF/8M 
FC/PB 
FC/BM 
FC/8M 
FC/BM 
Non-lineage 
FAB BL 
% 
TdT HLA CO 
L2 84b 78 
11 63b 72 
11 63 
11 80 
11 8t 
11 97 
11 95 
11 80 
NO 95 
11 59 
11 87 
11 9t 
11 79 
L1 78 
L2 90 
L2 88 
L2 95 
L2 74 
6( 
76 
3. 
85 
7t 
6 
o 
6. 
64 
Qi 
1J3 
!!.3 
., 
70 
96 
54 
OR 34 
1. 
10 
o 
1 
2 
o 1. 
o 
4 
6 
o 
2 
3 
,il 
:~fl 
o 
2 
",: i~ 
1 
4 
2 
o 
I.~: ll~ ;,~f 
90 
62 
27 
7t 
T-lineage 
co 
1 
o 
1 
I:l4 I~. 
1 
o 
14 
o 
o 
o 
o 
4 
2 
CO 
2 
96 
96 
~, 
I:~! 
98 
91 
1·:1 
@ 
72 
93 
110 
j::;! 
~.:g 
!QI 
33 
47 
CO 
3 
Cy 
88 
92 
85 
92 
96 
97 
99 
85 
73 
60 
73 
92 
68 
75 
92 
60 
99 
85 
CO 
3 
Sm 
84 
92 
15 
o 
2 
89 
89 
2 
o 
20 
23 
o 
6 
1 
o 
o 
91 
79 
TcR TeR CO 
n{J ')1> 4 
o 
4 
o 
2 
69 
84 
3 
12 
8 
9 
2 
4 
o 
o 
4 
49 
76 
o 
1 
6 
4 
o 
3 
1 
o 
o 
o 
+ 
65 
1 
o 
~ 
I:*J 
57 
78 
88 
99 
2. 
S. 
B~ 
.H~. 
7. 
48 
30 
80 
68 
co 
, 
88 
77 
90 
86 
98 
94 
it 
63 
90 
90 
78 
79 
65 
20 
98 
74 
CO 
7 
96 
97 
86 
89 
98 
98 
84 
91 
99 
65 
92 
II~.:. 1$ M 
89 
92 
97 
85 
a-lineage 
CO 
• 
o 
o 
r] 
~:~::; 
57 
94 
69 
61 
53 
85 
2 
3 
2 
4 
4 
CO 
(0 
o 
o 
38 
25 
60 
1 
4 
43 
64 
21 
35 
o 
9 
3 
42 
89 
76 94 
47 60 
CO 
20 
1 
2 
2 
o 
4 
" 7 
o 
1 
1 
2 
1 
o 
6 
Myeloid 
CO 
(4 
o 
3 
o 
o 
2 
2 
5 
" 
3 
4 
o 
o 
o 
2 
CO 
15 
2 
4 
o 
o 
2 
o 
3 
7 
6 
o 
o 
1 
8 
CO Immuno-
33 phenotype 
3 
o 
o 
o 
9 
o 
6 
~t 
TcR·~ T-ALL 
TcR,1> T-ALL 
C03' T-ALL 
COY T-All 
C03- T-ALL 
TcR-,,{J T-ALl 
TcR-"P T-ALL 
C03' T-ALl 
C03- T,ALL 
C03' T-ALL 
C03' T-AlL 
C03' T-ALl 
C03- T-ALL 
C03' T-ALL 
C03' T,ALL 
C03' T-ALl 
o TcR,/) T-ALL 
6 TcR--')~ T-ALL 
Symbols used: pat nr, DCLSG patient number; f, female; m, male; y, years; D, diagnosis; R, relapse; R,t, fjrst relapse; R-2, second relapse; R-3, third relapse; FC, flow cytometer; 
IF, immunofluorescence microscopy; PL, pleural exudate; NO, not determined; +, positive expression of MeAb; -, no immunophenotyplc data were available with 
this MeAb in this cell sample. 
a. The express!on of the used McAb is given in percentage positivity. 
b, Percentage of blasts before Ficoll centrifugation; this implies that after cell separation the percentage of blast cells would be hIgher, due to enrichment. 
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160 CHAPT£R4.2 
CD14, CD15, and CD33 were found to change in expression. Examples of marker-shifts 
in CD10 and CD34 are given in Figure 2. 
In four precursor B~ALL cases (13%)' the shifts in marker expression lead to an 
intra-lineage shift: one common ALL at diagnosis changed to null ALL at relapse (patient 
27171 and three pre-B-ALL at diagnosis changed to common ALL (patients 4714 and 
4803) or to null ALL (patient 3963). Two precursor B-ALL cases (one common ALL and 
one pre-B-ALL) were diagnosed as ANLL at relapse (6%). both by morphology as well as 
by immunological marker analysis (Table 1). 
TABLE 4. Total of immunophenotypic shifts per McAb in precursor B_ALLl'. 
null ALL common ALL pre-B-ALL Total 
(n=1) In=21) In=10) In=32) 
FAB 0% (0/1) 33% (7Ill) 40% (4/10) 34% (11/32) 
non-lineage markers 
TdT 0% (0{1) 10% (2121) 20% (2/10) 13% (4/32) 
HLA-OR 0% (Of1) 0% (Olll) 0% (0/10) 0% (0132) 
C034 0% (Of1) 20% (4/20) 33% (3/9) 23% (7/30) 
S-lineage markers 
CD10 0% (0/1) 14% (3/21) 20% (2/10) 16% (5/32) 
CD19 0% (0/1) 10% (2/2,) 10% (1/10) 9% (3/32) 
CD22 100% (1(1) 19% (4{21) 10% (1/10) 19% (6/32) 
CD20 0% (OIl) 14% (3/21) 20% (2/10) 16% (5/32) 
CD9 0% (Om 24% (5/21) 10% (1/10) 19% (6/32) 
CD24 7% (1/15) 11 % (1/9) 8% (2124) 
Cyl91k 0% (011) 0% (0/2l) 50% (SIlO) 16% (5/32) 
Smlgp. 0% (0/1) 0% (0/12) 0% (0/9) 0% (0/22) 
T ~Iineage markers 
SmCD3 0% (011) 0% (0/19) 0% (0/9) 0% (O/29) 
CD7 0% (011) 0% (0/21) 0% (019) 0% (0/31) 
Cross-lineage myeloid markers 
CD14 0% (OIl) 7% OIlS) 0% (0/9) 4% (1/25) 
CD15 100% (1/1) 13% (2/16) 0% (019) 12% (3/26) 
CD33 20% (3/15) 0% (019) 13% (3/24) 
Symbols used: -, no immunophonotypic data woro available with this McAb. 
a. Percentago of immunophonotypic changos within the tostod precursor S-ALL cases. 
Immunological marker analysis of T -ALL at diagnosis and relapse 
Based on expression of SmCD3, the eight T-ALL were classified as SmCD3- T-ALL 
(n =5) and SmCD3+ T-ALL (one TcR-a!>+ and two TcR--yo+) (Table 3). In five of the 
eight T-ALL cases marker-shifts were found. Shifts were observed in all tested T-cell 
markers, except for the lineage specific C03 and TcR markers, i.e. CyC03, SmC03, 
TcR-a!> and TcR-')'o expression remained stable (Tables 3 and 5). Examples for marker-
shifts in C02 and CD5 expression are given in Figure 3. Like in precursor 8-ALL no clear 
shift in HLA-DR antigen expression was found at relapse. Only one case (patient 5158) 
Figure 2. Histogram analysis 
of two precursor B-ALL 
patients at diagnosis and 
relapse. left part: CD19 (V[L~ 
A 1 FITC) IF staining of BM 
cells at diagnosis (top) and at 
relapse (bottom) of patient 
3869. Right part: CD34 (81-
3C5 FITC) IF staining of BM 
cells at diagnosis (top) and at 
relapse (bottom) of patient 
4870. Symbols used: 1, IgG1 
control; 2, McAb. Detailed 
information concerning the 
percentage positivity of 
expression of the immunolo~ 
gical markers in both patients 
is shown in Table 1. 
t, 4529 diagnosis 
4529 
relapse 
Immunophenotypic shifts in ALL at relapse 
W 1-' 
-, 
3869 
diagnosis 
3'69 
relapse 
4529 
diagnosis 
452' 
relapse 
4870 
diagnosis 
161 
4870 
relapse 
4727 
diagnosis 
4727 
relapse 
Figure 3. Histogram analysis of two T-ALL patients at diagnosis and relapse. left part: CD2 (T1l FITC) IF 
staining and middle part: CD5 (Leu~1 FITC) IF staining of PB cells at diagnosis (top) and pleural exudate 
cells at relapse (bottom) of patient 4529. Right part: C02 (T11 FITC) IF staining of PB cells at diagnosis 
(top) and BM cells at relapse (bottom) of patient 4727. Symbols used: 1, IgG1 control; 2, MoAb. Detailed 
information concerning the percentage positivity of expression of the various immunological markers in 
both patients is shown in Table 3. 
showed a small change from negative to positive HLA-DR expression, possibly due to 
contaminating non-malignant cells (Table 3). Despite the frequent marker-shifts (fre-
162 CHAPTER 4.2 
TABLE 5. Total of immunophenotypic shifts per McAb in T_ALL8. 
CD3' T-ALL T cR-ail" T -ALL TcR-')'o T-ALL Total 
(n=5) (n=1) (n=2) (n=8) 
FAB 0% (0/3) 0% (0/1) 50% (1/2) 14% (1m 
Non-lineage markers 
TdT 20% (1/5) 0% (Oil) 0% (0/2) 13% (1/8) 
HLA-DR 0% (0/5) 0% (Ofl) 0% (O/2) 0% (O/S) 
CD34 50% (2/4) 0% (Ofl) 0% (0/2) 29% (2m 
T -lineage markers 
CD1 20% (1/5) 100% (l/l) 0% (O/2) 25% (lIS) 
CD2 80% (4f5) 0% (011) 0% (0/2) 50% (4/8) 
CyCD3 0% (0/5) 0% (Oil) 0% (0/2) 0% (0/8) 
SmCD3 0% (0/5) 0% (Ofl) 0% (O/2) 0% (O/3) 
TcR-a.6 0% (O/3) 0% (0/1) 0% (0/2) 0% (0/6) 
TcR--yo 0% (013) 0% (OIl) 0% (OIl) 0% (O(5) 
CD4 60% (S/5) 0% (0/1) 0% (0/2) 38% (3/8) 
CDS 20% (lIS) 0% (Oil) 0% (0/2) 13% (1'S) 
CD7 20% (1/5) 0% (Ofl) 0% (0/2) 13% (1/8) 
CD8 20% (1/5) 0% (OIl) 0% (0/2) 13% (1/8) 
B-lineage markers 
CD10 0% (015) 0% (011) 0% (0/2) 0% (0/8) 
CD20 0% (0/3) 0% (0/1) 0% (0/2) 0% (0/6) 
Cross~lineage myeloid markers 
CD14 0% (0/3) 0% {O/2} 0% (CIS) 
CD15 0% (013) 0% (O/2) 0% (O/S) 
CD33 50% (1/2) 0% (0/1) 33% (1/3) 
Symbols usod: -, no immunophenotypic data were availablo with this McAb. 
a. Percontage of immunOPhenotypic changes within tho tested T ·ALL cases. 
quently multiple marker-shifts per leukemia), no intra-lineage nor inter-lineage shifts were 
found in the 8 T-ALL cases. 
Time of relapse and changes in marker expression 
There seems to be neither a hierarchical order nor a relation with time for changes in 
marker expression between diagnosis and relapse except perhaps for CD 1 O. Shifts in 
CD 10 expression were only observed in relapses occuring 30 months or more after 
diagnosis. The two inter-lineage shifts, from ALL to ANLL were also found late, i.e. 
occuring 49 months (patient 3797) and 53 months (patient 4522) after diagnosis and 
off-therapy. 
DISCUSSION 
Comparative immunophenotyping studies of leukemias at diagnosis and relapse 
might be hampered by several problems such as: 1. the lack of adequate cell samples at 
both diagnosis and relapse; 2. changes in the applied immunophenotyping method 
during the time interval between diagnosis and relapse; 3. limited McAb panels at 
/mmunophenotypic shifts in ALL at relapse 163 
diagnosis or relapse and changes in McAb panels with time; 4. interpretation difficulties 
due to low blast cell counts in the studied cell samples at relapse; and 5. unclear criteria 
for defining an immunophenotypic shift. In our study, most of these problems were 
neutralized. Originally cell samples at diagnosis were tested with immunoperoxidase 
stainings, but we repeated the analyses by immunofluorescence microscopy or flow 
cytometry in case a shift was found in order to be sure that the shift was not due to 
differences in the applied methods. Furthermore, nearly identical McAb panels were 
used at diagnosis and at relapse: expression of non-lineage specific markers (TdT, 
CD34, and HLA-DRI, B-lineage markers (CD1O, CD19, CD20, and CD221, T-lineage 
markers (CD1, CD2, CD3, CD4, CD5, CD7, and CD8), and cross-lineage myeloid 
markers (CD14, CD15, and CD33) were compared in all relevant cases (see Tables 1-3). 
The problem of low blast cell counts at relapse was met by use of double labeling for 
membrane markers and TdT in order to define the precise immunophenotype of the 
TdT+ leukemic cells. Finally, the definition for marker-shifts was very strict, i.e. a 
change from positivity to negativity or vice versa (with a cutt-off point at 20% positivi-
ty) or a shift in positivity of ~50%. 
In our study, 40 ALL patients were analyzed at diagnosis and at relapse for cyto-
morphological and immunophenotypic shifts. Differences in cytomorphology between 
diagnosis and relapse were detected in 34% (11/32) of precursor B-ALL and 14% (1/7) 
of T-ALL (Tables 4 and 5). Differences in immunological marker analysis between 
diagnosis and relapse were found in 69% (22 cases) of precursor B-ALL and in 63% (5 
cases) of T-ALL. Curiously, the morphological and immunophenotypic shifts were not 
correlated, which underlines the poor relationship between morphology (FAB type L 1 
and L2) and immunophenotype in ALL. 
In precursor B-ALL, the phenotypic changes included four intra-lineage shifts and 
two inter-lineage shifts to ANLL. All four intra-lineage shifts concerned shifts to a more 
immature immunophenotypic classification. In T-ALL, no such shifts were observed, due 
to the stability in expression of the lineage specific markers CyCD3, SmCD3, and TcR. 
In precursor B-ALL, loss or acquisition of lineage specific markers like C022 and/or 
Cyl9tt were found in ten patients and therefore precursor B-ALL seem to have a less 
stable phenotype. It should be noted that this is especially true for pre-B-ALL, because 
all ten pre-B-ALL showed at least one marker-shift at relapse. 
Changes in immunophenotype between diagnosis and relapse have been described 
in some other reports (8-17). Early studies used very small panels of polyclonal antibo-
dies (9,10,15) and found phenotypic shifts in common ALL antigen, HLA-DR, TdT or E-
rosettes in 17-25% of cases. Later on, Pui et a!. used a larger panel of McAb and 
reported changes in the expression of cell markers in -25% of cases (11). This 
relatively low frequency of immunophenotypic shifts is probably due to the fact that 
only CD10 and HLA-DR were tested in all 68 relapses. Abshire et al. also reported shifts 
in expression of CD10 (14%), and HLA-DR (27%) (8). They found intra-lineage shifts in 
15% of the 175 relapsed cases. This is comparable with the -13% intra-lineage shifts 
in our series of precursor B-ALL. In contrast to other studies, we did not find a clear 
shift in HLA-OR expression except for a minor shift in percentage positivity in aT-ALL 
case (patient 5158). 
Shifts in CD10 expression were found, but this appeared to occur only in late 
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relapses. The earliest COlO shift in our study was found in a relapse occuring 31 
months after diagnosis. This relationship between remission duration and marker~shift 
was not found for other markers, although there seems to be a greater chance for inter-
lineage shifts in late "relapses" in our study. Pui et al. found a median time of 3 years in 
13 cases with inter-lineage shifts (14). It should be emphasized that detection of an 
inter-lineage shift does not automatically imply the development of a secondary 
leukemia, since in patient 3991, shown in a previous study (21).. with an inter-lineage 
shift from ALL to ANLL, seven rearranged Ig and TcR alieles were identical at relapse, 
excluding the development of a secondary leukemia (21). Apparently, in this case the 
leukemic clone at diagnosis had multi-lineage properties. 
Reliable information about stability of marker expression and the occurrence of 
immunophenotypic shifts is essential when immunological marker analysis is used for 
detection of MRD. Combinations of T-cell markers and TdT are used for MRD detection 
in T-ALL (12,18,19,22,23). Campana et al. also proposed double marker analysis for 
myeloid markers (CD13 and/or CD33) and TdT, or Cylgl' and TdT for MRD detection in 
precursor B-ALL (12). They stated that myeloid marker expression in B-lineage ALL 
remains stable and found loss of Cylg,u expression in only one out of four pre-B-ALL in a 
total series of 10 precursor B-ALl. However it is clear from our data, that shifts can 
occur in any marker tested in precursor B-ALL, also myeloid markers and Cylgl" Even 
CD34 expression might change at relapse in 20-25% of precursor B-ALL, although other 
scientists proposed to use CD34 as a marker in MRD studies (Table 4) (23). Although 
CD3 and TcR expression patterns appeared to be stable in our T-ALL series, shifts were 
frequently seen for other T-cell markers. Even loss of TdT expression was found in one 
T-ALL Conversion to TdT negativity was also observed in three precursor B-ALL cases. 
This loss of TdT expression in ...... 12% of ALL cases at relapse is in line with other stu-
dies (12,16,18). 
In 24 of the 40 patients here described, analysis of Ig and TcR receptor genes at 
diagnosis and subsequent relapse was performed (21). The presence of two or more 
subclones at diagnosis was found in the null ALL and three of seven pre-B-ALL studied, 
and was always accompanied by changes in marker expression at relapse. In ten 
common ALL and six T -ALL examined no subclones were found at diagnosis. No clear 
correlation was found between the immunophenotypic changes and the immunogenoty-
pic changes at relapse: in contrast to the data of Bunin et aI., new \g and TcR gene rear-
rangement patterns at relapse were also found in patients without immunophenotypic 
shifts and vice versa (17,21). 
In conclusion, marker-shifts in leukemia at relapse are frequently found in precursor 
8-ALL and T-ALL. In a smail fraction this will lead to an intra-lineage shift (10%) or inter-
lineage shift (5%). Therefore, monitoring for MRD by immunological marker analysis 
should not be restricted to one or two markers or marker combinations. If possible, 
several marker combinations should be used for MRD detection, preferentially in 
combination with PCR analysis of rearranged 19 and/or TcR genes or chromosome 
aberrations (21,22). 
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CHAPTER 4.3 
ANALYSIS OF IMMUNOGLOBULIN AND T-CELL RECEPTOR 
GENES IN 40 CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIAS 
AT DIAGNOSIS AND SUBSEQUENT RELAPSE: 
Implications for the detection of minimal residual disease 
by polymerase chain reaction analysis' 
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Karel Hahlen2,3, Herbert Hooijkaas', and Jacques J.M. van Dongen' 
1. Department of Immunology, University Hospital Dijkzigt/Erasmus University, Rotterdam; 
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Erasmus University, Rotterdam, The Netherlands. 
ABSTRACT 
The rearrangement patterns of immunoglobulin (19) and T-cell receptor (TcR) genes 
were studied by Southern blot analysis in 30 precursor B acute lymphoblastic leukemias 
(ALL) and 10 T-ALL at diagnosis and subsequent relapse. Eight precursor S-ALL appeared 
to contain bi-/oligoclonallg heavy-chain (lgH) gene rearrangements atdiagnosis. Differences 
in rearrangement patterns between diagnosis and relapse were found in 67% (20 cases) 
of precursor S-ALL (including all eight bi-/oligoclonal cases) and 50% (five cases) of T-ALL. 
In precursor B-ALL, especially changes in IgH and/or TcR-o gene rearrangements were 
found (17 cases), but also changes in TcR-i>, TcR--y, IgK and/or Ig/- genes (11 cases) 
occurred. The changes in T-ALL concerned the TcR-i>, TcR-'Y, TcR-o and/or IgH genes. Two 
precursor a-ALL showed completely different Ig and TcR gene rearrangement patterns at 
relapse, suggesting the absence of a clonal relation between the leukemic cells at diagnosis 
and relapse and the development of a secondary leukemia. The clonal evolution in the other 
23 ALL patients was based on continuing rearrangement processes and selection of 
subclones. The development of changes in Ig and TcR gene rearrangement patterns was 
related to remission duration, suggesting an increasing chance of continuing rearrangement 
processes with time. These immunogenotypic changes at relapse occurred in a hierarchical 
order with changes in IgH and TcR-o genes occurring after only 6 months of remission 
duration, whereas changes in other Ig and TcR genes were generally detectable after 1 to 
2 years of remission duration. 
The heterogeneity reported here in Ig and/or TcR gene rearrangement patterns at 
diagnosis and relapse might hamper polymerase chain reaction (PeR)-mediated detection 
• Published in: Blood 1994;83:2238~2247. 
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of minimal residual disease (MRD) using junctional regions of rearranged 19 or TcR genes 
as peR targets. However ,our data also indicate that in 75-90% of ALL, at least one major 
rearranged IgH, TcR-'Yt or TcR-a band (allele) remained stable at relapse. We conclude that 
two or more junctional regions of different genes (lgH, TcR--y, and lor TcR-o) should be 
monitored during follow-up of ALL patients for MRD detection by use of peR techniques. 
Especially in bi-Ioligoclonal precursor B-ALL cases, the monitoring should not be restricted 
to rearranged IgH genes, but TcR-y andlor TcR-o genes should be monitored as well, 
because of the extensive changes in IgH gene rearrangement patterns in this ALL subgroup. 
INTRODUCTION 
Despite major improvements in the treatment of ALL patients during the last two 
decades, 20-30% of children with ALL still relapse (1-3). The pathogenesis of leukemia 
relapse is still poorly understood (4). To obtain insight into the mechanisms that determine 
development of relapse in ALL, several studies have been performed: detection of 
morphological and immunophenotypic shifts at relapse (5-10), detection of shifts in 
leukemic cell karyotype at relapse (9,11), comparative glucose-6-phosphate dehydrogenase 
studies (12) and analysis of Ig and TcR genes at diagnosis and relapse (13-18). 
Ig and TcR gene rearrangement patterns in leukemias and malignant lymphomas have 
been used as markers for clonality, which are unique for each malignancy (19). This 
especially concerns the junctional regions of rearranged Ig and TcR genes, because they 
are regarded as "tumor-specific" markers (20-22). Based on this assumption, several 
investigators have used the PCR for amplification of the "tumor-specific" junctional regions 
of rearranged IgH, TcR-y and TcR-o genes to detect MRD during follow-up of ALL patients 
(23-27). However, it should be noted that multiple rearranged IgH genes occur in 30-40% 
of precursor 8-ALL (16,28-30). When excluding hyperdiploidy of chromosome 14, the 
multiple IgH gene rearrangements are most probably due to subclone formation (16,28-30)' 
which is suggested to be related to poor prognosis in childhood ALL (28,30). This subclone 
formation can be explained by continuing rearrangement processes such as VH to O-JH 
joining or VH replacements (29-36). 
Detailed analysis of the leukemic cells at diagnosis and relapse by use of 19 and TcR 
gene rearrangement patterns may give insight into the heterogeneity at diagnosiS (process 
of subclone formation) and at relapse (selection of subclones, possibly related to 
development of therapy resistance), and into the implications of this heterogeneity for MRD 
detection by PCR-mediated amplification of junctional regions. So far, only a few studies 
on limited numbers of patients have been published (13-18). These studies were restricted 
primarily to IgH, 19K and/or TcR-.8 genes and demonstrated changes in rearrangement 
patterns in 15-40% of ALL (13-18). Therefore, we performed detailed comparative 
Southern blot analyses of IgH, IgK, IgA, TcR-Il, TcR-y and TcR-/i gene rearrangement 
patterns in 30 precursor B-ALL and 10 T-ALL at diagnosis and subsequent relapse. 
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MATERIALS AND METHODS 
Cell samples 
Peripheral blood (PB) andlor bone marrow (BM) samples from children with ALL (30 precursor B~ALL and 10 
T~ALL) were obtained at initial diagnosis and at first relapse in 32 cases and at first and at second relapse in 
eight additional cases (six precursor B~ALL and two T~ALL). In one T-ALL, we received bilateral testis biopsies 
at relapse as well. Twenty-one children were treated at the Sophia Children's Hospital, Rotterdam. Their 
diagnosis and relapse cell samples were collected by the Department of Immunology, Erasmus University, 
Rotterdam. The other 19 children were treated at different hospitals in The Netherlands and their diagnosis 
and relapse cell samples were collected by the Dutch Childhood Leukemia Study Group (DCLSG), The Hague. 
The diagnosis of acute leukemia was made according tothe French-American-British (FAB) classification 
(37), based on cytomorphology of BM smears stained with May-Grunwald Giemsa and cytochemistry (periodic 
acid-Schiff, acid phosphatase, Sudan black B, myeloperoxidase and a-naphtylesterase). Each diagnosis and 
relapse was independently confirmed by the laboratory of the DCLSG. 
Mononuclear cells (MNC) were isolated from PB andlor BM samples by Ficoll-Pague centrifugation 
(density 1.077 g/cm3; Pharmacia, Uppsala, Sweden). The freshly obtained MNC samples were subjected to 
a detailed immunological marker analysis according to standard protocols (30,38). Remaining MNC were 
stored in liquid nitrogen. A leukemia was considered to be a precursor B-ALL if the malignant cells were 
positive for terminal deoxynucleotidyl transferase (TdT), C019 and HLA-OR (null ALL), or for TdT, C010, 
CD19 and HLA-OR (common ALL), or for TdT, CD1 0, CD19, HLA-DR, and cytoplasmic Ig heavy-chain p. (pre-
B-ALL) (39,40). A leukemia was considered to be a CD3- T-ALL if the malignant cells were positive for TdT 
and cytoplasmic CD3, as well as for C02, CDS andlor CD7. A C03+ T-ALL was diagnosed, if the malignant 
cells were positive for TdT and membrane TcR-C03 complex expression as well as for C02, C05, C07 and 
CD4 or CDS (39,40). A leukemia was considered to be an acute myeloid leukemia (AML) if the malignant cells 
were positive for CD13, CD33, COw65 and/or myeloperoxidase (MPQ), as well as for HLA-DR, CD34, CD14, 
CD1S and/or CD36 (39). 
Southern blot analysis 
DNA was isolated from frozen MNC as described previously (41,42). Control DNA was obtained from 
granulocytes or other cell samples with germline Ig and TcR genes. Fifteen micrograms of DNA was digested 
with the appropriate restriction enzymes (Pharmacia). Completeness of digestion was checked with )..-phage 
DNA and plasmid DNA in parallel digests as described previously (42). The restriction fragments were size-
separated in 0.7% agarose gels and transferred onto Nytran-13N nylon membranes (Schleicher and Schuell, 
Dassel, Germany) as described previously (42). To take care that the diagnosis and relapse lanes of each 
patient during the gel electrophoresis contained comparable amounts of DNA, the DNA contents of the 
digested samples were checked (and adapted, if necessary) before loading into the agarose gel. This was 
further verified by staining of the agarose gel with ethidium bromide (42). 
IgH gene rearrangements were detected with a 32P~random oligonucleotide labeled joining (J)H probe. 
The JH probe (IGHJ6) was a 1.0-kb probe, which recognizes sequences just 3 • of the JH gene segments (43). 
The configuration of the 19K genes was analyzed with a 32P-labeled JK probe, a 32P_labeled constant (C)K 
probe, and a 32P-Iabeled K deleting element (Kde) probe. The JK probe was a 0.55-kb Hael[[ fragment, which 
recognizes sequences just 3' of the JK gene segments (42), the CK probe was a 2.5-kb EcoRI fragment (42), 
and the Kde probe (lGKDE) was a O.S-kb probe (see chapter 2.3). All diagnosis and relapse DNA samples 
were analyzed by use of the JH, JK, and CK probes in 8gll1 digests and BamHI-Hindrrl double digests and by 
use of Kde probe in 8g/1l and HJi1dlll digests. If necessary for confirmation, EcoRI and/or HJi7dll1 digests were 
also used. The configurat'lon of the Ig).. genes was analyzed with the 32P-labeled C)..3 probe (a 0.8-kb 8g/ll-
EcoRI fragment) in EcoRI~Hindlll double digests and/or in EcoRI digests (42). 
TcR~.B gene rearrangements were detected with 32P-Iabeled J.B1, J.B2, and C.B probes in EcoRI, and 
Hindlll digests, and for confirmation in 8g/l1 digests (42). The configuration of the TcR..,.. genes was analyzed 
by use of the 32P-labeled J-y1.2, J'Y1 .3 and J'Y2.1 probes in EcoRI digests, and for confirmation in Kpnl and/or 
8g/ll digests (42). The configuration of the TcR..o genes was analyzed by use of 32P_labeled Jo1, Jo2, and 
Co probes in EcoRI, Hlndlll, and BglII digests (42). In 24 cases, the TcR-a gene rearrangements were further 
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analyzed with 32P-Iabeled variable (V)01, V02, V03, liREC, diversity (D)01; and 1/;Jct probes in EcoRI, HJi7dlll, 
and 8g111 digests (44J. 
RESULTS 
Immunological marker analysis 
Immunological marker analysis of the 30 precursor B-ALL revealed that two were null ALL, 
17 were common ALL, and 11 were pre-B-ALL. Changes in immunophenotypic classificati-
on occurred in seven precursor g...ALL. In two of them, an inter-lineage shift occurred to 
AML (Tables 1 and 2). 
The 10 T-ALL could be divided in six CD3-' T-ALL and four CD3+ T-ALL (three TcR-
cx/3+ T-ALL and one TcR-,),o+ T-ALL). No changes in immunophenotypic classification were 
found in the T-ALL (Table 3). 
Southern blot analysis of 30 precursor B-AlL at diagnosis 
DNA samples from 30 precursor 8-ALL at diagnosis were examined for the presence of 
rearranged 19 and TcR genes. At diagnosis, rearrangements and/or deletions of the IgH, IgK, 
and Ig>- genes were found in 100% (all 30 cases), 57% (17 cases), and 17% (five cases) 
of precursor B-ALL, respectively (Tables 1,2 and Figure 1). In 10 cases, multiple rearranged 
IgH gene bands, generally differing in density, were found at diagnosis (30). In eight 
patients we could exclude hyperdiploidy of chromosome 14 as a cause of these multiple 
rearranged bands. In the other two patients (2665 and 4553), no cytogenetic data were 
available, but the density of the three rearranged IgH gene bands were comparable, 
suggesting trisomy 14. In patient 2665, this was further supported by the presence of one 
germline and two rearranged TcR-o gene bands of comparable density (Table 2). Therefore, 
we have concluded that in eight precursor B-ALL the presence of multiple rearranged bands 
was due to the presence of two or more subclones (bi-/oligoclonality) with differently 
rearranged IgH genes (Tables 1, 2 and Figure 1) (30). 
Rearrangements and/or deletions of the TcR-,8, TcR-'Y, and TcR-o genes at diagnosis 
were found in 33% (10 cases), 53% (16 cases), and 83% (25 cases) of precursor B-ALL, 
respectively (Tables 1, 2 and Figure 2). 
Southern blot analysis of 10 T-ALL at diagnosis 
DNA samples from 10 T-ALL at diagnosis were examined for the presence of rearranged 
Ig and TcR genes. Rearrangements of the IgH genes at diagnosis were found in 40% (four 
cases) of T-ALL (Table 3). No rearrangements andlor deletions of the Ig light-chain (lgL) 
genes were found (Table 3). Rearrangements andlor deletions ofthe TcR-iJ, TcR--y, and TcR-
Ii genes were found in all 10 T-ALL at diagnosis (Table 3 and Figure 2). In one T-ALL 
(patient 3288), three rearranged TcR-iJ2 gene bands with different density were found at 
diagnosis, suggesting subclone formation at the TcR-,8 gene level (cytogenetic analysis 
showed diploidy of chromosome 7), 
Changes in Ig and TcR gene rearrangement patterns in precursor 8-ALL at relapse 
Comparative analysis of Ig and TcR gene rearrangement patterns at diagnosis and relapse 
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TABLE'. Southarn blot analysis of 10 praCUl'Sor B-ALL patiants without differences in immunogenotype betwoen diagnosis and 
subsequent relapse(s). 
Ig genese TcR genese 
disease 
DCLSG stage immuno- I,H I" I" TcR-iS TcR--y TcR·1i 
number (time from phenotypic leukemic 
(sex/age) diagnosis}S classification sample cells (%}b Jp1 J/J2 
0128 
° 
common ALL BM 77 R,R G G G G R,G R,G 
(M/2y) Rt (tt) common ALL BM 41 R,R,g G G G G R,G R,G 
R2 {45)d common ALL BM B9 R,R G G G G R,G R,G 
3697 
° 
pre-B-ALL BM 93 R,R G G G G G G 
(M/9 y) R (15) pre_B_ALL BM 7. R,R G G G G G G 
3B37 
° 
pro-B-ALL BM 9B R,R G G G R,G R,R 0,0 
(M/By) R1 (35) pro-B-ALL BM 97 R,R G G G R,G R,R 0,0 
R2 (50) pre-B-ALL BM 98 R,R G G G R,G R,R 0,0 
3995 
° 
common ALL BM 90 D,R G G 0,0 R,R R,R 0,0 
(MIS y) R1 (43) common ALL BM 94 D,R G G 0,0 R,R R,R 0,0 
R2(57) common ALL BM 93 D,R G G 0,0 R,R R,R 0,0 
4535 
° 
pro-B-ALL BM B5 R,R G G G G R,R D,R 
(M/12 y) R (7) pre-B-ALL BM 81 R,R G G G G R,R D,R 
4553 
° 
common ALL PB 85 R,R,R G G G G G R,R 
(M/5 y) R (32) common ALL BM 88 R,R,R G G G G G R,R 
4711 
° 
common ALL BM 95 R,R D,R R,R G R,R G G 
(F/15 y) R (7) common ALL BM 99 R,R D,R R,R G R,R G G 
4714 
° 
pre-B-ALL BM 90 R,R G G G G G R,G 
(F/12 y) R (14) common ALL 8M 40 R,R.g G G G G G R,G 
4745 
° 
pre-B-ALl 8M 95 R,R 0,0 G G R,G R,R 0,0 
(F/6 y) R1 (6) pro-B-ALl 8M 93 R,R 0,0 G G R,G R,R 0,0 
R2 (11) pro-B-ALl BM 9. R,R 0,0 G G R,G R,R 0,0 
4882 
° 
common ALL BM 98 R,Rw D,G G G G R,R 0,0 
(F/1t y) R (22) common ALL BM 88 R,Rw D,G G G G R,R 0,0 
Abbreviations: M, male; F, fomakt; y, years; D, diagnosis; R, rolapse; 8M, bone marrow; PB, peripheral blood. 
a. The timo from diagnosis (in months) is time between diagnosis and {first or second} relapso. 
b. The leukemic eeilioad was determined by the percentages of TdT+, CD10+, andlor CD19+ cells. 
e. Configuration of Ig and TeR ge:l1Os: (G) allele in germline configuration; (g) germline band due to the presence of non-leukemic calls 
(:2: 25%); {R} rearranged band; (RW) wonk rearranged band; (D) deletion of the involved gene {segment}. 
d. Second rolapse aftar bono marrow transplantation. 
were performed in all 30 precursor 8-ALL (Tables 1 and 21, Differences in IgH, IgK, and Ig" 
gene rearrangement patterns between diagnosis and relapse were found in 40%, 28%, and 
43% of precursor B-ALL (with rearrangements or deletions of these genes), respectively 
(Table 4). The precursor B-ALL with these immunogenotypic shifts included all precursor 
B-ALL with bi-/oligoclonallgH gene rearrangements, Differences in TcR-i>, TcR-'Y, and TcR-o 
gene rearrangement patterns were found in 45%, 33%, and 44% of precursor B-ALL (with 
rearrangements or deletions of these genes) respectively (Table 4). 
In 10 precursor B-ALL, no changes in immunogenotype at relapse were found 
(Table 1). The other 20 precursor B-ALL showed major or minor changes at relapse 
(Table 21, Two monoclonal precursor B-ALL (patients 3779 and 37971 had completely diffe-
rent Ig and TcR gene rearrangement patterns at relapse. In patient 3779, each rearranged 
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CDRCDR 
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CDRCDR 
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-
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IGKDE probe CA3 probe 
Figure 1. Southern blot analysis of the 19 genes in saveral precursor 8-ALL patients at diagnosis (0) and relapse (A). Control DNA Ic) and DNA from the 
precursor B·ALL patients were digested with the appropriate restriction enzymes, site-separated, and blotted onto nylon membrane filters, which were 
hybridized with 32P-labeled probes. A. IgH gene analyses using Bg/ll and a combination of BamHI and HliJdlll with the IGHJ6 probe. B, 19K gene analyses 
using Bg/ll with the IGKDE probe. C. IgX gene analyses using a combination of EcoRI and Hindlll with the CX3 probe. The germline bands (G) are indicated 
(A,B). The rearranged IgX gene bands are indicated with arrows ee). Detailed information concerning the configuration of the different Ig genes is given 
in Table 2. 
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TABLE 2. Southern blot analysis of 20 precursor B-ALL patients with differences in immunogenotypO between diagnosis and subsequent 
rolaP'!'e(s). 
OCL.SG 
numbor 
(sex/ago) 
diseaso 
stage 
(time from 
diagnosis)G 
immun<>-
phenotypic 
classification 
IgH monoclonal cases at diagnosis 
2665 
(MIS y) 
2717 
(M/1 y) 
3779 
(F/3 y) 
3797 
(M/2y) 
3869 
(M/9 y) 
3968 
(M/14y) 
4501 
(F/5 y) 
4511 
(M/4y) 
4515 
(F/12 y) 
4616 
(M/1 y) 
4675 
(M/6y) 
4778 
(M/1 y) 
D 
R1 (75) 
R2 (100) 
D 
R{32) 
D 
R(48) 
D 
R (49) 
D 
R (38) 
D 
R (40) 
D 
R (22) 
D 
R (39) 
D 
R(1a) 
D 
R (7) 
D 
R (21) 
D 
R (29) 
common ALL 
common ALL 
common ALL 
common ALL 
null ALL 
common ALL 
common ALL 
common ALL 
AML 
common ALL 
common ALL 
common ALL 
common ALL 
common ALL 
pre·a-ALL 
common ALL 
common ALL 
common ALL 
common ALL 
pre-B-ALL 
pre·B-ALL 
common ALL 
common ALL 
common ALL 
common ALL 
IgH bi-/oligoclonaJ cases at diagnosis 
2308 
(F/S y) 
2678 
(M/1 y) 
3510 
(M/2y) 
3559 
(F/11 mol 
3829 
(M/2 mol 
3963 
(M/9 y) 
3991 
(F/5 y) 
4790 
(F/7 mol 
D 
R (50) 
D 
R1 (3S) 
R2 {66)d 
D 
R (a) 
D 
R (52) 
D 
R (6) 
D 
R (S) 
D 
R (17) 
D 
R (9) 
pre-B-ALL 
pro-B-ALL 
common ALL 
common ALL 
pre-B-ALL 
pre-B-ALL 
pre-B-ALL 
pre-B-All 
pre-B-AlL 
null ALL 
null ALL 
pre-B-ALL 
null ALL 
pre-B-ALL 
AML 
null ALL 
nun ALL 
sample 
8M 
8M 
8M 
8M 
8M 
P8 
8M 
8M 
8M 
8M 
P8 
8M 
8M 
P8 
8M 
8M 
8M 
P8 
8M 
BM 
8M 
BM 
BM 
PB 
PB 
P8 
8M 
BM 
8M 
BM 
8M 
8M 
8M 
8M 
PB 
8M 
BM 
BM 
BM 
8M 
BM 
8M 
94 
85 
89 
90 
97 
58 
92 
9, 
75 
74 
95 
95 
67 
54 
93 
94 
50 
50 
70 
60 
93 
89 
72 
65 
87 
80 
93 
73 
85 
45 
82 
85 
82 
91 
77 
95 
90 
80 
73 
62 
74 
94 
Ig genes/; 
I,H 
R,R,R 
O,R,R 
O,R,R 
R,R 
R,R 
R.R,g 
Rn,Rn 
R,R 
Rn,G 
o,R,g 
D,R 
R,R 
R,R,g 
R,R,g 
R,Rn 
D,D 
O,O,g 
R,R,g 
R,R,g 
R,R,g 
R,R 
R,R 
R,R,g 
R,R,g 
R,R 
R,R,R 
R,R,G 
R,5Rw,G 
An,4Rnw 
I" 
D,G 
D,G 
D,G 
D,D 
D,D 
O,R,g 
O,Rn 
D,G 
G 
O,R,g 
D,R 
G 
G 
D,G 
D,G 
D,D 
O,O,g 
G 
G 
R,A,g 
R,R 
R,R 
R,An,g 
D,G 
D,G 
RW,G 
D,D 
R,R,g 
R,R 
RW,RW,g 
G 
G 
G 
D,G 
R,4RW ,G G 
2Rw,Rnw,G 
2R,4Rw G 
Rn,Rn G 
2R,2RW,g R,G 
2R.g R,G 
2R,7RW,g G 
Rn,Rn G 
I" 
G 
G 
G 
G 
G 
R,R,g 
G 
G 
G 
R,G 
R,G 
G 
G 
G 
G 
G 
R,G 
G 
G 
G 
R,G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
R,G 
R,G 
G 
G 
G 
G 
G 
G 
R,G 
R,G 
G 
G 
TcR genes/; 
TcR·.8 
J.81 J.82 
G 
G 
G 
G 
D,D 
G 
G 
G 
G 
G 
G 
G 
D,G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
D,G 
D,G 
G 
G 
G 
G 
o,o,g 
O,O,g 
G 
G 
G 
G 
G 
R,G 
An,An 
A,R,g 
G 
G 
G 
R,G 
R,G 
G 
R,G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
R,G 
R,Rn 
G 
G 
G 
G 
G 
G 
G 
R,R,G 
R,G 
G 
G 
G 
G 
R,R,g 
R,R,g 
G 
G 
TcR""'Y TcR...5 
G 
R,R 
R,R 
R,R 
R,Rn 
G 
R,R 
R,R 
G 
G 
G 
G 
G 
R,R,g 
R,R 
R,R 
R,R,g 
G 
G 
G 
G 
R,R 
R,R,g 
R,R,g 
R,R 
R,G 
G 
G 
G 
G 
G 
G 
R,R 
An,G 
G 
G 
G 
G 
R,R,G 
0,0,0 
0,0,0 
D,R 
D,D 
G 
D,D 
D,D 
G 
RW,G 
G 
D,D 
o,o,g 
o,O,g 
D,D 
R,R 
O,R,g 
G 
R,G 
o,O,g 
D,D 
R,R 
R,Rn,g 
o,o,g 
D,D 
R,A,g 
R,R 
RW,~,g 
D,R 
D,G 
O,Rw,G 
D,R 
D,R 
Go,R 
RW,G 
G 
R,G O,O,g 
R,G O;O,g 
R,R,g G 
R,R G 
Abbreviations: M, male; F, female: rna, months; y, years; 0, diagnosis; A, relapse; BM, bone marrow; PB, peripheral blood. 
a. Tho time from diagnosis (in months) is time between diagnosis and (first or second) relapse. 
b. The leukomic cell load was determined by the percentages of TdT+, C010+, and/or C019+ cens. In caso of AML the leukemic coli 
load was determinod by tho percentagos of C013+, C033+, COw65 + and/or MPO+ cells. 
c. Configuration of Ig nnd TcR genes: (G) allele in germline configuration; (g) germline band due to the presonce of non-leukemic colis 
(~ 25%); {Rl rearranged band; (Rw) weak rearranged band; (Rn) now rearrangod bnnd, not found at diagnosis; {RnYiJ wonk new 
rearrangod band; (D) dolotion of tho involved gone (sogment). 
d. Second relapso aftor 8M transplantation. 
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Figure 2. Southern blot analysis of TeR genes in several ALL patients at diagnosis (0) and relapse (R). Control 
DNA (el and DNA from ALL patients were digested with the appropriate restriction enzymes, size separated, 
and blotted onto nylon membrane filters, which were hybridized with 32P_labeled probes. A. TcR-.B gene 
analyses using EcoRI with the J.B2 probe. B, TcR-"Y gene analyses using EcoRt with the J')'1.3 probe. C, TcR-li 
gene analyses using 8g111 with the J(;1 probe. The germ line bands (G) are indicated. Detailed information 
concerning the configuration of the different TeR genes is given in Tables 2 and 3. 
19 and TcR gene changed at relapse, while in patient 3797 a completely different IgH gene 
rearrangement pattern was found at relapse with IgL and TcR genes in germ line 
configuration (Table 2). In the other 18 precursor B-ALL with immunogenotypic changes 
at relapse, a clonal relation could be established, based on the presence of at least one 
identically rearranged Ig andlor TcR band (allele) (Table 2). 
In two oligoclonal precursor B-ALL cases (patients 2308 and 3829)' the clonal relation 
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could only be proven by weak rearranged IgH gene bands (one minor subclone) at 
diagnosis, which remained stable at relapse. In patient 2308, this subclone probably also 
had a weak rearranged TcR-o gene band (Vo2-Do3), which remained stable at relapse. This 
could be proven by a mono-allelic 8amHI restriction site polymorphism in the V02 gene 
segment used in this rearrangement (44.45). 
In four precursor 8-ALL (patients 2665, 3510,3869, and 3963) loss of one rearranged 
IgH gene band (patients 2665, 3510, and 3963) andlor one rearranged TcR-o gene band 
(all four cases) was found at relapse, indicating loss of one subclone or loss of one copy 
of chromosome 14. In two monoclonal precursor 8-ALL (patients 4511 and 4616) the Igt-. 
genes changed from germline at diagnosis to one rearranged allele at relapse, with no 
changes in the other Ig genes. In five precursor 8-ALL (patients 2717,3869,3968,4515, 
and 4778), changes in TcR-ii, TcR--y, andlor TcR-o genes were found on one or both alleles, 
while the configuration of the IgH and IgL genes remained stable. Several examples of 
changes in Ig and TcR gene rearrangement patterns in precursor B-ALL at relapse are shown 
in Figures 1 and 2. 
Changes in Ig and TcR gene rearrangement patterns in TMALl at relapse 
Comparative analyses of Ig and TcR gene rearrangement patterns at diagnosis and relapse 
were performed in all 10 T-ALL (Table 3). Differences in IgH gene rearrangement patterns 
between diagnosis and relapse were found in two of the four T-ALL with IgH gene 
rearrangements at diagnosis (Tables 3 and 4). Differences in TcR-ii, TcR--y, and TcR-o gene 
rearrangement patterns were found in 30%, 20% and 10% of T-ALL respectively (Tables 
3 and 4). This concerned five patients, including patient 3288 with subclone formation at 
the TcR-,82 gene level at diagnosis. In all five T -ALL, a clonal relation between diagnosis and 
relapse could be proven based on the presence of at least three identically rearranged [g 
andlor TcR alleles (Table 3). In two CD3+ T-ALL (patients 3288 and 3977), the changes 
inthe TcR-,8 gene configuration did notaffecttheirTcR-a,8+ immunophenotype. Apparently, 
the changes in these patients concerned the non-functionally rearranged TcR-J3 alleles, 
leaving the functionally rearranged alleles unchanged. The change in TcR--y gene 
rearrangement pattern in patient 4564 at relapse is shown in Figure 2. 
Immunophenotypic shifts are related to immunogenotypic shifts at relapse in precursor B~ 
ALL 
In six out of seven precursor B-ALL, the changes in immunophenotypic classification of the 
leukemic cells could be correlated with changes at the Ig and lor TcR gene level (Table 2). 
In four cases, an intra-lineage immunophenotypic shift occurred: in two cases (patients 
2717 and 3963) to an "immature" phenotype and in two cases (patients 2678 and 4501) 
to a more "mature" phenotype. In the two other precursor B-ALL (patients 3797 and 3991), 
an inter-lineage immunophenotypic shift to AML was observed (Table 2). In one patient 
(4714) an immunophenotypic shift from pre-B-ALL to common ALL occurred, while no 
immunogenotypic changes at relapse were found (Table 1). 
In patients 3779 and 3797, no clonal relation in immunogenotype between diagnosis 
and relapse could be established. In patient 3797, this immunogenotypic shift correlated 
with the inter-lineage shift from common ALL at diagnosis to AML at relapse, while patient 
3779 with common ALL also had a common ALL at relapse (Table 2 and Figures 1 and 2). 
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TABLE 3. Southern blot analysis of 10 T-AlL patients m: diagnosis and subsequent relapsels). 
Ig genese TcR genese 
disease 
DCLSG stage immuno- I,H I" I" TcR-,B TcR...,. TcR-o 
number Itime from phonotypic leukemic 
(sex/age) diagnosis18 classification sample cells (%)b J~1 J~2 
Patients without differences between diagnosis and relapse 
3052 0 CD3- T-ALL BM 9B G G G 0.0 R.R R,R R,R 
(FIe yl R (S) CD3- T·ALL BM B2 G G G 0.0 R,R R,R R,R 
3729 0 TcR....,.o+ T-ALL PB 69 G G G R,G G R.R R,R 
(Fill y) R (33) TcR...,.')+ T-ALL PB 75 G G G e.G G R.R R,R 
3987 0 TcR-~.B+ T-ALL PB 95 G G G R,G R,G R,R 0,0 
(Mny) R (31) TcR-a,8+ T-ALL BM 91 G G G R,G R,G R,R 0,0 
4623 0 CD3- T-AlL BM B3 R.R G G D,R R,R R.R D,R 
(M/9y) Rl (12) CD3- T-AlL BM 76 R,R G G D,R R.R R,R D,R 
R2 (21) CD3- T-ALL BM 7B R,R G G D,R R,R R,R D,R 
4727 0 CD3- T-ALL PB 96 G G G R,R G R,R R,R 
(M/7 y) R (12) C03- T-ALL BM 95 G G G R,R G R.R R,R 
R (12) NT tostes NT G G G R,R G R,R R,R 
Patients with differences botween diagnosis and relnpso 
3288 0 TcR-(l/,B+ T-ALL PB BO G G G D,R R,2Rw R.R 0,0 
IF{S yl R (13) TcR-a,B+ T-ALL PB 7B G G G D,R R,Rn R,R 0,0 
3810 0 CD3- T·ALL BM 90 R,R G G D,G R,R R,R R,R 
IM/6y) Rl (17) CD3- T-ALL BM 94 R,G G G D,G Rn,Rn R,R D,R 
R2 (26)0;1 CD3- T-ALL PB 96 R,G G G D.G Rn,Rn R,R D,R 
3977 0 TcR-aP+ T-ALL BM 85 R,G G G D,G R.G R,R D.R 
(M/8V) R (15) TcR-aP+ T-ALL PB 90 R,G G G D,Rn R,Rn R,R D.R 
4564 0 CD3- T-ALL PB B1 G G G R,R R,G R.R 0,0 
(M/3V) R (16) CD3- T-ALL PB 90 G G G R,R R,G Rn,Rn,Rn 0,0 
4643 0 CD3- T-ALL PB 66 R,Rw,G G G D,D,g R,R,g R,R,g R,Rw,G 
(M/10 V) R (14) CD3- T-ALL BM 93 R,G G G 0,0 R,R R,Rn R,R 
Abbreviations: M, male; F, female; V, Vears; 0, diagnosis; R, relapse; 8M, bone marrow; P8, peripl-oera! blood. 
a. The time from diagnosis (montl-os) is time between diagnosis and (first or second) relapse. 
b. The leukemic cell load was determined bv the percentage of TdT+, CvCD3+ or TcR-CD3+ cells. 
c. Configuration of Ig and TcR genos: (G) allole in germline configuration; (g) germlino band duo to the presence of non-Ieukomic cells 
(~ 25%); (R) rearranged band; (R""j weak rearranged band; (Rn) new rearranged band, not found at diagnosis; (D) deletion of the 
involved gene (segment). 
d. Second relapse aftor bone marrow transplantation. 
Although patient 3991 (pre-B-ALLI relapsed with AML with changes on two IgH alieles, the 
clonal relation was based on seven identically rearranged Ig/TcR alleles at diagnosis and 
relapse (Table 2 and Figure 11. 
The changes at the -Ig and TcR gene level in T-ALL were not associated with changes 
in immunophenotypic classification. 
Changes in Ig and TcR gene rearrangement patterns are related to remission duration 
In the 22 monoclonal precursor B-ALL, changes at the IgH and TcR-o gene level were found 
after remission duration of at least 18 months (Tables 1 and 2). The only exception was 
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patient 4616 with an IgA gene rearrangement as single change at relapse (Table 2). 
Changes at the TcR~J3 and TcR--y gene level were found in cases with a remission duration 
of at least 30 months. Changes in rearrangement patterns on at least four Ig or TcR alleles 
were also only found after a remission duration of 30 months. 
In the eight IgH bi-/oligoclonal precursor B-ALL, changes at the Ig and TcR gene level 
were found in cases with a remission duration of at least 6 months. These changes 
occurred only at the IgH and TcR-/) gene level. Changes in IgK, TcR-iS, and TcR,. gene 
rearrangement patterns were found after remission duration of at least 50 months (Table 2). 
In the series of lOT-ALL, changes in IgH and/or TcR gene rearrangement patterns 
occurred in five patients with a remission duration of at least 1 year (Table 3). 
DISCUSSION 
Forty ALL patients were analyzed at diagnosis and relapse for the configuration of their 
Ig and TcR genes by use of Southern blot analysis. Differences in Ig andlor TcR gene 
rearrangement patterns between diagnosis and relapse were detected in 67% (20 cases) 
of precursor B-ALL (including all eight bi-/oligoclonal cases) and 50% (five cases) of T-ALL 
(Table 4). In precursor B-ALL especially, changes in IgH andlor TcR-/) gene rearrangements 
were found (17 casesJ. but also changes in IgK, IgA, TcR-iS, and TcR-y genes (11 cases) 
occurred. The changes in T-ALL concerned the TcR-iS, TcR-y, TcR-/) and lor IgH genes. 
In 15 ALL patients (10 precursor B-ALL and five T-ALL) no differences in Ig and TcR 
gene rearrangement patterns between diagnosis and relapse were found, i.e., the original 
clone caused the relapse (Figure 3). In nine ALL patients with subclone formation at 
diagnosis (eight precursor B-ALL and one T-ALLJ. three different types of immunogenotypic 
changes occurred. First, in four patients, loss of (faint) rearranged Ig and/or TcR gene bands 
at relapse was observed, suggesting selection of a major subclone. Second, in two patients, 
a nearly complete change in immunogenotype at relapse occurred, except for stable 
rearranged IgH and/or TcR-o gene bands, which were faint at diagnosis, suggesting 
selection of a minor subclone (Table 2 and Figure 3). In the remaining three bi-/oligoclonal 
TABLE 4. Changes in Ig and TcR gene rearrangement patterns between diagnosis and relapse in childhood 
ALL. 
Ig genes TcR genes 
19H [9K [9A TcR-~ TcRl' TcR-o TOTAL 
precursor B-ALL 40% 28% 43% 45% 33% 44% 67% 
(n=30) (12/30) (5/18) (317) (5/1 1) (6/18) (12/27) (20/30) 
T-ALL 50% 30% 20% 10% 50% 
(n .. 10) (2/4) (0/0) (0/0) (3/10) (2/10) (1110) (5/10) 
The frequencies only concern ALL with Ig and/or TcR gene rearrangements. If no Ig or TcR gene rearrangement was found at diagnosis 
and/or relapse, the ALL was excluded from the calculations. 
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cases, as well as in 14 of the 16 monoclonal ALL patients, the differences at the Ig and/or 
TcR gene level between diagnosis and relapse were probably due to continuing rearrange-
ment processes in the original clone (Figure 3) (29-36). However, in the latter ALL we 
cannot exclude the expansion of a minor subc[one, which was not detectable at diagnosis 
due to the Southern blot detection limit of approximately 5% (Figure 3). It should be noted 
that especially in ALL with subclone formation at diagnosis, combinations of the mentioned 
processes of clonal evolution might occur. Only two of 25 ALL patients with immunogeno-
typic changes showed completely different 19 and TcR gene rearrangement patterns at 
relapse, suggesting the absence of a clonal relation between the leukemic cell populations 
at diagnosis and at relapse and the development of a secondary leukemia (Figure 3). 
The changes in immunogenotype could be correlated with changes in immunopheno-
typic classification of the leukemic cells in six precursor B-ALL cases. In two precursor B-
ALL (patients 3797 and 3991), an inter-lineage shift to AML occurred, suggesting the 
development of a secondary leukemia. In one of them (patient 3797), indeed a complete 
change in immunogenotype at relapse was found, supporting the diagnosis of secondary 
leukemia. However, in the other case (patient 3991), seven identically rearranged IgH/TcR 
alleles were still present at relapse, indicating that the AML was related to the precursor B-
ALL, and thereby excluding the development of a secondary leukemia. In a third precursor 
8-ALL (patient 3779), the immunophenotype at diagnosis and relapse was identical, but a 
completely different immunogenotype at relapse was found. Based on the long remission 
on~~~;tniC I development of leukemia I diagnosis I remission I relapse 
Clonal relation 
° 
• C::OOOO , C::O~OO 000 no changes 000 
° continuing rearra~ ~o~og , °0°0° selection of major subclone 000 
subclone formation 
o continuing rearra~ ~OeOo • (](](](](] (]i (]i 0 selection of minor subclone (]i (] (]) 
subclone formation 
° 
, °0°0° , @@@@@ (subclono 10rmo.tlon 7) 000 continuing rearrangements @@@ (or $Oloction 01 undetoctable subclono?) 
No clonal relation 
°0°0° ••••• 
° 
, _._-_ .. __ . , 
000 development ••• of secondary leukemia 
Figure 3. Hypothetical diagram of clonal evolution in ALL, based on changes in 19 and TcR gene 
rearrangement patterns. Note that combinations of the mentioned processes of c[onal evolution might occur, 
especially in the leukemias with subc[one formation at diagnosis. [n these cases selection of a minor or major 
subc[one at relapse may be accompanied by further continuing rearrangements, leading to the emergence of 
new subclones. 
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duration (4 years) and the extensive immunogenotypic shifts (on at least 10 alleles), a 
secondary precursor B-ALL was suggested. These three cases emphasize the difficulties in 
defining a secondary leukemia and the importance of cytogenetic analysis of malignant cell 
samples to determine the clonal relation or clonal evolution between diagnosis and relapse. 
Unfortunately, cytogenetic data in ALL patients are not always available, as was the case 
in patients 3779 and 3991. 
Interestingly, the development of changes in Ig and TcR gene rearrangement patterns 
was related to remission duration, suggesting an increasing chance of continuing /g and 
TcR gene rearrangement processes with time. This phenomenon has also been reported by 
Wasserman et aI., who analyzed IgH gene junctional regions in 12 leukemias at diagnosis 
and relapse (34). A second phenomenon was the finding that these changes in Ig and/or 
TcR gene rearrangement patterns occurred in a hierarchical order, i.e. changes in IgH and 
TcR-a genes were already detectable after 6 months of remission duration, whereas 
changes in other Ig and TcR genes were generally found after 1 to 2 years of remission 
duration. This hierarchical order might be related to the hierarchical order in Ig and TcR 
gene rearrangements during B- and T-cell differentiation. 
As indicated earlier, the peR-technique can be used for the amplification of "tumor-
specific" junctional regions of rearranged IgH, TcR-y and/or TcR-a genes to detect MRD in 
ALL (20-27). 
Recently, the significance and prognostic implications of MRD detection by peR in 
childhood ALL at different time points during therapy has been determined (46-48). Rovera 
et al. concluded that PCR detection of high levels of residual disease at the end of induction 
therapy identifies patients at increased risk for relapse during therapy (46,47). Furthermore, 
they concluded that absence of detectable MRD at the end of chemotherapy is not 
sufficient to assure that the patient is cured, indicating that after treatment frequent serial 
monitoring is required for the early prediction of relapse (46,47). Potter et al. subscribe to 
these findings and conclude that detectable MRD at the end of treatment would predict 
future relapse (48). 
It should be noted that the extensive changes reported here in Ig and/or TcR gene 
rearrangement patterns between diagnosis and relapse (clonal evolution) might hamper the 
detection of MRD by PCR-mediated amplification of "leukemia-specific" Ig and/or TcR gene 
junctional regions, especially in case of bi-/oligoclonal precursor 6-ALL (27,49). This might 
lead to false-negative MRD results (27,49). It has been argued that changes in Ig and/or 
TcR gene rearrangement patterns as detected by Southern blotting do not necessarily lead 
to false-negative peR results, because a change in Southern blot band pattern does not 
automatically imply that the complete sequence of the junctional region of a rearranged Ig 
or TcR gene has changed (50). For example, VH replacements in completely rearranged IgH 
genes generally do not affect the original V-O-JH junctional regions, and also the D-JH 
junctional region will generally remain stable in subclones, which rearranged different VH 
gene segments to an identical D-JH precursor. 
Recent studies on IgH junctional regions in 13 bi-/oligoclonal precursor-B-ALL at 
diagnosiS (34-36) showed that, indeed, most multiple IgH gene rearrangements can be 
explained by VH replacements (seven cases), or rearrangement of different VH gene 
segments to a preexisting O-JH rearrangement (four cases). In two cases, unrelated 
junctional regions were found, suggesting de novo IgH gene rearrangements. Also, 
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comparison of junctional regions at diagnosis and subsequent relapse showed that in IgH 
monoclonal precursor B-ALL, the instability of V-O-JH joinings was partly generated via VH 
replacements with a conserved junctional region, partly via rearrangements of different VH 
gene segments to an identical D-JH precursor, and partly due to minor changes in the 
junctional regions (34,51). However, in the two published bi-/oligoclonal precursor B-ALL 
cases, extensive changes in V-O-JH junctional regions were found at relapse, which could 
be explained by outgrowth of a minor subclone, de novo IgH gene rearrangements, and loss 
of a subclone at relapse (35,36). Changes in TcRjunctional regions between diagnosis and 
subsequent relapse were reported in two cases (52,53). One case could be explained by 
the occurrence of continuing rearrangements at the TcR-,,), gene level, and, in the other 
case, the major subclone disappeared as deduced from TcR-a gene analysis (52,53). 
Although in several cases, the V-D-JH or D-JH junctional regions remained unchanged, 
it should be noted that differences in VH gene segments might influence the efficiency of 
the PCR due to changes in VH primer annealing, dependent on the sequence of the newly 
rearranged VH gene segment. This pitfall might partly be overcome by using a panel of 
seven VH FR1 family-specific primers for PCR-mediated MRD detection during follow-up, 
as suggested by Deane et al. (54). 
In Table 5, we have summarized our data concerning the changes and stability of IgH, 
TcR-,)" and TcR-o gene rearrangement patterns at relapse, because the junctional regions 
olthese genes are generally used as peR targets for the detection of MRD. Table 5 shows 
that changes in IgH gene rearrangement patterns at relapse occur at high frequency in 
precursor B-ALL, especially in bi-!oligoclonal cases. Changes in TcR-")' and TcR~o gene rear-
rangements at relapse are found in both precursor 8-ALl and T -ALL, but generally concern 
only one allele. Despite the high frequency of immunogenotypic changes, at least one major 
IgH, TcR--y andlor TcR-a rearranged band (allele) remained stable in 75-90% of precursor 
TABLE 5. Changes in IgH, TeR",,), and TeR";; gene rearrangement patterns in 40 childhood ALL at relapse. 
Changes in rearrangement patterns at relapse Stability of at least one major rearranged band (allele) 
precursor B-ALL 
with monoclonnl 
IgH genes at diag_ 
nosis (n = 22) 
IgH 
1 S% (4/22) 
precursor B-ALL 100% (S/S) 
with biloligoclonal 
IgH genes at diag-
nosis (n .. 8) 
T·ALL 
(n .. 10) 
50% (2/4) 
TeR",,), TeR-o IgH TeR",,), andlor TeR-S 
29% (4/14) 40% (S/20) 90% {19!21)a 72% (13/1S)b 
50% (2/4) 57% (4m 3S% (3/8)C 63% (5/S) 
20% (2/10) 10% (1110) 100% (4/4) 90% (9/10) 
IgH, TeR",), 
andlor TeR·S 
91 % (20/22) 
75% (6/8) 
90% (9/10) 
The frequencies only concern All with IgH, TcR~ and/or TcR-6 geno rearrangements. If no IgH, TcR~ or TcR..'i geno rearrangement was found at 
diagnosis and/or relapse, the ALL was excluded from the calculations. 
a. Patient 451 1 was excluded from the calculations bceause both IgH alleles wore deleted at diagnosis and at relapse. 
b. Patients 3968 and 4616 were excluded from the calculations because of germlina TcR..,.. genes and biallellc TcR~ gene deletions. 
c. In two additional bi-/ollgoclonal casas (patients 2308 and 3829), a rearranged band at relapse was identical to a weak rearranged band at diagnosis, 
suggesting selection of a minor subclone. 
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B-ALL and 90% of T-ALL. The optimal targets for MRD detection in monoclonal precursor 
B-ALL are IgH genes, but it might be valuable to monitor the TcR-')' gene rearrangements 
as well, especially in cases with germline or deleted IgH genes on one or both alleles. In T-
ALL, the TcR-'Y and TcR-a genes represent optimal MRD-PCR targets. However, in 
bi-/oligoclonal precursor B-ALL (30-40% of the total group of precursor B-ALLL it will be 
difficult to estimate which minor or major IgH gene band (allele) will remain stable, 
especially in cases with more than two subclones. This implies that in these leukemias the 
MRD-PCR monitoring should not be restricted to IgH genes, but that TcR-y and TcR-/i gene 
rearrangements should be monitored as well. Therefore, our data indicate that MRD 
detection in ALL patients by peR techniques needs monitoring of two or more junctional 
regions of IgH, TcR-'Y, and/or TcR-o genes in order to prevent false-negative results. 
Our study indicates that changes in Ig and TcR gene rearrangement patterns between 
diagnosis and relapse occur at a high frequency (67% in precursor B-ALL and 50% in T-
ALL) and are caused by different processes of clonal evolution. These changes in 
immunogenotype appear to be related to remission duration and seem to occur in a 
hierarchical order. The heterogeneity reported here in Ig and/or TcR gene rearrangement 
patterns at diagnosis and relapse has implications for the detection of MRD using PCR-
mediated amplification of "tumor-specific" Ig and TcR gene junctional regions, because it 
can be foreseen that subclone formation at diagnosis and clonal evolution at relapse might 
lead to false-negative results. Therefore, it is important to define optimal strategies in 
exploiting IgH, TcR..", and/or TcR-a gene rearrangements for the detection of MRD by use 
of PCR techniques. 
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CHAPTER 5.1 
MOLECULAR BIOLOGY OF ACUTE LYMPHOBLASTIC LEUKEMIA: 
Implications for detection of minimal residual disease' 
A. Beishuizen', E.R. van Wering2, T.M. Breit', K. Hahlen2,3, 
H. Hooijkaas 1, and J.J.M. van Dongen 1 
1. Department of Immunology, University Hospital Dijkzigt/Erasmus University, Rotterdam; 
2. Dutch Childhood Leukemia Study Group, The Hague; 
3. Department of Pediatrics, Subdivision of Hematology-Oncology, Sophia Children's Hospital! 
Erasmus University, Rotterdam, The Netherlands. 
ABSTRACT 
Acute lymphoblastic leukemias (ALL) are characterized by high frequencies of clonal 
chromosome aberrations (ploidy aberrations and translocations) as well as by clonal 
rearrangements of immunoglobulin (lg) and T-cell receptor (TcR) genes. These two types 
of clonal molecular characteristics can be used as patient-specific markers for detection of 
minimal residual disease (MRD) by use of polymerase chain reaction (PCR) technology. 
In case of chromosome aberrations, this concerns translocations which result in fusion 
genes and fusion transcripts, such as in t(9;22), t(1;19), and t(4;11) in precursor B-ALL, 
or aberrations with site-specific breakpoints such as TAL 1 deletions in T-ALL. In fact, any 
precisely identifiable breakpoint fusion region of a chromosome aberration can be used as 
PCR target for MRD detection during follow-up of leukemia patients. So far such breakpoint 
fusion region can be identified in 15-20% of childhood ALL and 25-30% of adult ALL. 
Junctional regions of rearranged Ig and TcR genes represent the second type of MRD-
PCR target, which can be precisely identified in - 80% of precursor 8-ALL and in > 90% 
of T-ALL This especially concerns the junctional regions of rearranged Ig heavy-chain UgH), 
TcR-,)" and TcR-o genes. In contrast to chromosome aberrations, the junctional regions of 
Ig and TcR genes might not remain stable during the disease course, because of continuing 
rearrangement processes and subsequent subclone formation. These continuing 
rearrangements are extensive in IgH genes, resulting in the presence of subclones in 30-
40% of precursor S-ALL at diagnosis and changes in rearrangement patterns at relapse in 
40% of cases. Continuing rearrangement processes also cause changes in TcR-')' and TcR-o 
gene rearrangement patterns at relapse in 10-20% of T-ALL and 35-45% of precursor B-
ALL This heterogeneity in Ig/TcR gene rearrangement patterns at diagnosis and relapse 
might hamper PCR-mediated MRD detection. However in 75-90% of ALL cases, at least 
one IgH, TcR-,)" or TcR-o allele remains stable at relapse. Therefore, two or more junctional 
• Haematol Blood Transfus. in press. 
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regions of different Ig/TcR genes should be monitored for optimal MRD detection during 
follow-up of ALL patients. 
Well-designed prospective studies on large series of ALL patients have to demonstrate 
the clinical impact of MRD detection. 
INTRODUCTION 
Approximately 80-85% of childhood leukemias and approximately 7% of adult 
leukemias represent ALL with an incidence of 3-4 per 100,000 children and 1-2 per 
100,000 adults, respectively. Despite major improvem.ents in ALL treatment during the last 
two decades, 20-30% of children with ALL and 60-75% of adult ALL patients relapse (1-7). 
Apparently, the current treatment protocols are not capable of killing all leukemic cells in 
these patients, although the far majority reach complete remission according to cytomor-
phological criteria. Since the detection limit of cytomorphological techniques is not lower 
than 1-5% leukemic cells, it is obvious that such techniques can only provide superficial 
information about the effectiveness of leukemia treatment. Techniques with a higher 
sensitivity to detect MRD are needed to obtain better insight in the reduction of tumor mass 
during induction treatment and further eradication of the leukemic cells during maintenance 
treatment (Figure 1). 
During the last decade, several methods for detection of MRD have been developed 
and evaluated, such as cytogenetics, cell culture systems, immunological marker analysis, 
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Figure 1. Diagram of putative relative frequencies of ALL cells in peripheral blood and bone marrow during 
treatment and development of relapse. The detection limit of cytomorphological techniques as we[[ as the 
detection limit of immunological marker analysis and peR techniques are indicated. [~Rx == induction 
treatment; M-Rx = maintenance treatment, 
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fluorescence in situ hybridization, and molecular-biological techniques (8~ 18). In most 
studies, the detection limits of these techniques are 1-5% malignant cells. However, 
depending on the immunophenotype and the genotype of the leukemia, immunological 
marker analysis and the peR technique are able to detect lower frequencies of leukemic 
cells, as low as 10-4 to 10-5 (10 to 1 leukemic cells per 100,000 normal cells) (Figure 1) 
(9,10,15,19-21 ). 
In the peR technique, patient-specific nucleotide sequences are used as targets for 
MRD detection, such as junctional regions of rearranged Ig and TcR genes as well as 
breakpoint fusion regions of chromosome aberrations. 
19 and TcR gene rearrangement processes 
Ig and TcR gene complexes consist of multiple variable (V), diversity (0), and joining (J) 
gene segments, combinations which code for the variable protein domains of the antigen-
specific receptors (16). 
The rearrangement processes in Ig and TcR genes during early lymphoid differentiation 
result in specific combinations of V, (D,) and J gene segments, thereby deleting all 
intervening sequences. These gene rearrangements are mediated via recombination signal 
sequences (RSS)' generally heptamer-nonamer sequences, which flank the V, (0,) and J 
gene segments (16,22,23). 
The many possible different combinations of V, (0,) and J gene segments form the so-
called combinatorial diversity. This diversity is drastically increased by random deletion and 
insertion of nucleotides at the junctions of the rearranging gene segments, which together 
form the junctional diversity. The junctional regions are different in each lymphocyte, even 
in unrelated lymphocytes which have rearranged the same V, (D,) and J gene segments 
(16,22,23). Therefore, junctional regions are "fingerprint~like" sequences, which can be 
used for identification of lymphocytes (20). The combined combinatorial and junctional 
diversity not only guarantees the enormous diversity of antigen-specific receptors of normal 
lymphocytes, but also represents an unique diagnostic identification system for "immature" 
and "mature" clonal lymphoproliferative diseases, such as ALL and other lymphoid 
leukemias and lymphomas (24). 
The far majority of both 8-lineage ALL (i.e. precursor 8-ALL) and T-Iineage ALL (T-ALL) 
indeed have rearranged Ig and TcR genes, respectively (24-27). Also crOSS-lineage gene 
rearrangements occur in high frequencies. This especially concerns TcR gene rearrange-
ments in precursor 8-ALL (Table 1) (24,25,27). 
Southern blot and peR analysis of Ig and TcR genes allow the detection of clonal Ig 
and TcR gene rearrangements. Application of the Southern blot technique is based on 
detection of clonal changes in length of restriction fragments due to clonal rearrangements 
of V, (D,) and J gene segments and therefore takes advantage of the combinatorial 
diversity. This technique has a detection limit of -5%, i.e. -5 clonal cells between 100 
normal (polyclonal) cells (16). The peR technique focusses on junctional region of 
rearranged Ig and TcR genes and is more sensitive than the Southern blot technique, 
especially if junctional region-specific probes are used (see below). 
Chromosome aberrations 
Like other malignancies, ALL can be regarded as an acquired genetic disease, which is 
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TABLE 1. Frequencies of Ig and TcR gene rearrangements and deletions in precursor B-ALL and T-ALl. 
IgH Ig' IgA TcR-P TcR"",,/ TcR-o 
R 0 R 0 R R R R 0 
Precursor B-ALL 
In~1081 96% 3% 29% 50% 21% 36% 57% 50% 40% 
T-All 
In~1381 20% 0% 0% 0% 0% 90% 93% 70% 25% 
Total ALL3 81% 2% 23% 40% 17% 47% 64% 54% 37% 
Abbreviations: R, one or both alleles roam.mgod; 0, both allelos deleted or ono allele deleted with the other in germlino configuration. 
a. Estimated frequoncies, based on the fact that in children precursor B-ALL and T-ALL represent 80-85% and 15-20% of ALL. 
respectively and that in adults precursor B·ALL and T-ALl represent 75-80% and 20-25% of ALL. respectively. 
caused by alterations in the structure or expression of critical genes. In particular I 
derangements of genes which normally control growth and differentiation of early lymphoid 
cells are thought to playa role in the development of ALL, such as proto-oncogenes, tumor 
suppressor genes, transcription factors, and especially Ig and TcR genes. The latter is 
illustrated by the fact that chromosome breakpoints in ALL often involve chromosome 
bands, which contain Ig or TcR genes: 14q32 (lgH gene), 2p12 (lgK gene), 22q11 (lgl-
gene), 1 4q11 (TcR-a//) gene complex)' 7q35 (TcR-/3 gene), and 7p15 (TcR-'Y gene). Several 
chromosome aberrations in ALL appear to be associated with particular subtypes (28-30). 
So far, most chromosome aberrations have been detected by routine microscopic 
cytogenetics (G and R band staining patterns). Recently in situ hybridization and flow 
karyotyping have been introduced for detection of chromosome aberrations, but their 
application is dependent on the availability of suitable probes and the resolution of 
scatter/staining patterns of chromosomes, respectively. Futhermore, if the breakpoints of 
a particular chromosome aberration in different patients are well-defined and/or clustered 
in a small area, also Southern blotting and even the peR technique can be used to detect 
these aberrations (see below). 
Several studies indicate that RSS-like sequences probably playa role in aberrant gene 
rearrangements in lymphoid malignancies, especially in chromosome aberrations involving 
Ig and TcR genes. In T-ALL the TcR-all; locus in band 14q11 is frequently involved, such 
as in t(10;14)(q24;q11) and t(1;14)(p34;q11) (31-33). In the latter aberration the TAU 
gene on chromosome 1 is translocated to the TcR-o gene. Studies on this translocation 
have lead to the discovery of site-specific (sub-microscopic) deletions of - 90 kb in the SIL 
gene/TAU gene region on chromosome 1 (31,32). These so-called TAU gene deletions 
are reported to occur in 10-30% of T-ALL (32,34-42). So far five types of TAU deletions 
have been described, all of which represent rearrangements occurring via RSS-like 
sequences (37,39,40). All five types of TAU deletions appear to use the same 5' 
heptamer RSS, located between the first and second S/L exons, but different 3' heptamer-
nonamer RSS, which are located in the 5' part of the TAL 1 locus. This results in the 
deletion of all coding S/L exons and places the coding TAL 1 exons under direct control of 
the SIL gene regulatory elements. The fusion regions of the breakpoints in all five types of 
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TAL 1 deletions show random deletion and insertion of nucleotides. Therefore, these fusion 
regions are different in each patient and resemble junctional regions of rearranged Ig and 
TcR genes (42-44). 
DETECTION OF MRD BY USE OF THE PCR TECHNIQUE 
Basic principles of PCR-mediated MRD detection 
The PCR technique allows selective amplification of a particular DNA segment or messenger 
(m)RNA (after reverse transcription into copy (c)DNA) (45-47). If the target DNA or mRNA 
sequences are tumor-specific, it is possible to detect a few malignant cells in between many 
normal cells. Theoretically the detection limit of the PCR technique is approximately 10-6, 
if a DNA segment is used as PCR target. This is based on the assumption that one cell 
contains -10 pg DNA and that one PCR tube can contain maximally 10 "g DNA. This 
detection limit can indeed be reached, but generally varies between 1 0-4 and 1 0-6, 
dependent on the type of tumor-specific PCR target (15,19,20,48,49). In the initial PCR 
studies on the detection of MRD, well-defined chromosome translocations were used as 
tumor-specific markers (48-51). However, it is also possible to detect MRD by use of PCR-
mediated amplification of junctional regions of rearranged Ig and TcR genes (20,52-59). 
Because the PCR technique is highly sensitive, all possible precautionary measures should 
be taken to prevent cross-contamination of peR products between patient samples in PCR-
mediated MRD studies (47,60). 
Chromosome aberrations as leukemia-specific PCR targets for MRD detection 
In the initial MRD-PCR studies, t(14;18)(q32;q21) and t(9;22)(q34;q11) were used as PCR 
targets (48-51). For this purpose oligonucleotide primers were designed to recognize 
sequences at opposite sides of the breakpoint fusion region, so that the PCR product 
contained the tumor-specific fusion sequences. In routinely performed MRD-PCR analysis, 
the PCR products should not exceed -2 kilobases (kb) (46,47). Therefore, PCR-mediated 
amplification of DNA sequences can only be used for chromosome aberrations in which the 
breakpoints of different patients cluster in a small area (total breakpoint area: < 2 kb), such 
as in t(14; 18) where the BCL2 gene is juxtaposed to one ofthe J gene segments ofthe IgH 
genes (61,62). Other examples are the T-ALL-associated aberrations t(1 ;14)(p34;q11)' 
t(1 0; 14)(q24;q11) and the TAL 1 deletions (31-33). 
In most translocations, the breakpoints are spread over much larger areas than 2 kb. 
This implies that the precise breakpoint recombination area has to be determined for each 
individual patient, which is a laborious and time-consuming effort (63). However, in several 
leukemias it has been found that, as a consequence of the translocation, a new leukemia-
specific fusion gene has been created, which is transcribed into a leukemia-specific fusion 
mRNA. This fusion mRNA can be used as target for the MRD-PCR analysis after reverse 
transcription into eDNA (Table 2). Examples are: bcr-abl mRNA in case of t(9;22) (64-66), 
E2A-PBX1 mRNA in most cases oft(1 ;19) (67-69), and the recently discovered MLL/ALL1-
AF4 mRNA in null ALL with t(4;11 )(q21-q23) (Table 2) (70-78). 
An advantage of using specific chromosome translocations as tumor-specific markers 
is their stability during the disease course. However, only 20-25% of childhood ALL and 
30-35% of adult ALL, have a specific, microscopically detectable chromosome translocation 
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TABLE 2. peR techniques for MRO detection in ALL patients. 
peR analysis of junctional 
regions of 19 or TeR genes(l 
peR analysis of chromosome aberrationsb 
Type of leukemia 
Precursor &-ALL 
T-ALL 
19 or TeR gene 
IgH: V~D~J 
TcR-y: V"f"J'Y 
TcR-& V02-DoS or 
002-063 
IgH: V-O-J 
TcR-y: V,,!-J'Y 
Frequency of 
applicabilityc 
80% 
55% 
40% 
15%? 
90% 
TcR-5: Vo-J5, Do-Jo, 50% 
or V05-D6 
Aberration 
t(9;22)(q34;ql1 ) 
t(l ;19)(q23;p13) 
t(4;11 )(q21 ;q23) 
Freque ncy of 
applicabilityc 
adult: 30-35% 
childhood: 5-8% 
5-8% 
-3% 
deletion in TAL 1 gene 10-30% 
t(l ;14)(p34;ql 1) 1-3% 
t(l O;14)(q24;ql1) 1-3% 
Target 
(mRNA or DNA) 
BCR-ABL (mRNA) 
E2A-PBX1 (mRNA) 
ALL 1-AF4 (mRNA) 
del(TAL 1) (DNA) 
TALt-TcR.o (DNA) 
TCL3-TcR.o (DNA) 
a. The detection limit of peR analysis of junctional regions of rearranged [g and TcR genes varies from 10-3 to 10-6 and 
is dependent on "normal background" and the size of the junctional region. 
b. The detection limit of peR analysis of chromosome aberrations is 10-4 to 10-6• 
c. The indicated percentages represent frequencies within the precursor B--ALL and T-ALL groups. 
and in a part of these aberrations the precise breakpoints are not (yet) known 
(30,36,79,80). 
One should be aware that PCR products obtained via leukemia-specific fusion mRNA 
are not patient-specific. Therefore, false-positive results due to cross-contamination of PCR 
products between samples from different patients are difficult to recognize. This is in 
contrast to the PCR products obtained from breakpoint fusion regions of TAL 1 deletions, 
which can be identified by use of patient-specific oligonucleotide probes (42-44). 
Junctional regions as patient-specific peR targets for MRD detection 
As indicated above, junctional regions of rearranged Ig and TcR genes are "fingerprint-like" 
sequences which are assumed to be different in each lymphocyte and therefore also in each 
ALL. Based on this assumption, it has been suggested that Ig and TcR gene junctional 
regions can be used as targets for MRD-PCR analysis, using V, (D,) and J gene-specific 
oligonucleotides as primers (Table 2) (52-54,56-59). The choice of primers is dependent on 
the type of Ig or TcR gene as well as the rearranged gene segments. It may be possible to 
design general primers, which recognize (virtually) all V or J gene segments of a particular 
Ig or TcR gene complex, or specific primers, which recognize individual V or J gene 
segments or families of V or J gene segments (52-54,81,82). 
An advantage of using IgH, TcR-y, and TcR-o junctional regions as targets for the 
MRO-PCR technique is the fact that the 19H gene complex contains only six VH families and 
six JH gene segments (Figure 2) and the fact that the TcR-y and TcR-o genes contain only 
a few V, (D,) and J gene segments (16,83-89), whereas the junctional regions of most 
complete V-(D-)J rearrangements are large (57,58,82,88-91). This implies that only a 
restricted number of oligonucleotide primers is needed, while the junctional regions will 
differ extensively between the leukemias. In principle, also PCR analysis of junctional 
regions of rearranged Ig light-chain, TcR-a, and TcR-i1 genes may be applicable for detection 
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. I . 3'3,1/ 5 CTGAGGACACGGCCGTGTATIAC CCAGTGGCA7A GAGTCCACTC 3' 5' 1 5' 
VH1 CTCAGTGAAGGTCTCCTGCAAGG CACATGACCCGGTICGTICCCG JH1 
VH2. CCTGCGCTGGTGAAAGCCACAC GACAGGTCGTGGTCGGTCATAG JH2 
VH3 GGTCCCTGAGACTCTCCTGTGC CCGGGTCGCAGGAGACAGGAC JH3 
VH4 GAGACCCTGTCCCTCACCTGC GAGCTCCAAACACTGAAAACCCC JH4 
VH5 CGGGGAGTCTCTGAAGATCTCC CCTCTGAGTCGAACGTCCCAGA JH5 
VH6 TGTGCCATCTCCGGGGACAGTG GACGGACACCCCAAAGGACGC JH6 
Figure 2. Schematic diagram of a VH gene segment joined to a JH gene segment via a fictitious junctional 
region, which consists of DH-derived nucleotides and randomly inserted nucleotides. The approximate position 
of the VH-family-specific primers, VH consensus primer, JH consensus primer, and JH specific primers are 
indicated with arrows. The presented oligonucleotides can be used as primers for the peR-mediated 
amplification of the junctional regions of rearranged IgH genes (52,81,83). 
of MRD, However, especially PCR analysis of TcR-a and TcR-~ genes at the DNA level 
needs many different oligonucleotide primers. 
In -80% of precursor B-ALL, IgH gene rearrangements can be detected by PCR 
analysis with VH and JH primers (92), suggesting that in the remaining cases only 
incompletely rearranged (D-JHI, germline, or deleted IgH genes occur (Table 21, In principle 
V"( and J"( primers detect each TcR..,.. gene rearrangement, whereas -80% of TcR-o gene 
rearrangements in precursor 8-ALL and -70% of TcR-o gene rearrangements in T-ALL can 
be identified by PCR analysis (Table 21 (271, 
The obtained junctional region PCR products can be analysed in a dot blot or Southern 
blot by use of a patient-specific junctional region probe in order to discriminate between the 
leukemia-derived junctional regions and junctional regions from normal cells which have 
rearranged the same (or comparable) V and J gene segments as the leukemic cells. For 
each leukemia one should determine at diagnosis which junctional region(s) can be used as 
targets for the MRO-PCR analysis during follow-up and which primers are optimal for this 
purpose (Table 21, Also the patient-specific junctional region probes have to be designed 
for each individual patient at initial diagnosis (20,21,52-59[' 
PITFALLS OF MRD-PCR ANALYSIS OF JUNCTIONAL REGIONS 
From the above described data, it can be concluded that PCR-mediated amplification 
of junctional regions for detection of MRO is a sensitive technique, which can be applied 
in the majority of ALL. However, one should realize that this technique has several pitfalls 
(Table 31. 
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TABLE 3. Limitations and pitfalls of MRD~PCR analysis of junctional regions. 
1. Occurrence of oligoclonality at 19 or TcR gene level (e.g. IgH gene level in precursor B-ALL). 
Consequence: false-negative results. 
2. Occurrence of clonal evolution at 19 or TeR gene level. 
Consequence: false-negative results. 
3. Background of normal cells with the same rearranged gene segments as the leukemic cells, (e.g. Va1 ~Jo1 
rearrangements and V'YI-J')'2.3 rearrangements occur in 0.1-5% and a large part of normal blood T-
lymphocytes, respectively). 
Consequence: lower sensitivity of the peR technique and high dependence on the specificity of the 
junctional region probe for detection of patient-specific peR products. 
4. Type of rearrangement and size of junctional region (e.g. complete Va~Ja rearrangements have large 
junctional regions, but Da~Da rearrangements have short junctional regions). 
Consequence: size of junctional region influences the sensitivity of the MRD~PCR technique. 
5. Hybridization conditions, washing stringency and exposure time influence the specificity and sensitivity 
of the MRD~PCR technique. 
Consequence: careful evaluation of the conditions for each patient and use of positive and negative 
control samples in various dilutions is necessary. 
Occurrence of oligoclonality 
A necessary condition for the MRD~PCR technique is the stability of the patient-specific 
junctional region during follow-up. However, in 30-40% of precursor B-ALL at diagnosis 
multiple [gH gene rearrangements are found (Figure 3A) (26,93-96). These are probably 
caused by continuing rearrangement processes, which lead to subclone formation 
(bi-/o[igoc[onality) (26,94). Such subc[one formation at diagnosis appeared to be rare atthe 
TcR-'Y and TcR-o gene level in T-ALL and in cross-lineage TcR gene rearrangements in 
precursor B-ALL (24,27,97). 
Occurrence of clonal evolution 
Changes in Ig and TcR gene rearrangement patterns at relapse is also an important pitfall 
in PCR analysis of junctional regions for MRD detection. In 40 children with ALL, we 
compared the 19 and TcR gene rearrangement patterns at diagnosis and relapse. An 
example is shown in Figure 3B. In Table 4, we summarized the data concerning the 
changes and stability of [gH, TcR-'Y' and TcR-1i gene rearrangements at relapse (97). This 
table shows that changes in IgH gene rearrangement patterns at relapse occur at high 
frequency in precursor B-ALL, especially when subclone formation is already present at 
diagnosis (97). Changes in TcR-y and TcR-o gene rearrangements at relapse are found in 
both precursor B-ALL and T-ALL, but generally concern only one alle[e (97). [t should be 
emphasized that Table 4 focusses on changes and stability of gene rearrangements which 
already existed at diagnosis, i.e. "new" rearrangements at relapse in genes which were in 
germline configuration or deleted at diagnosis were not included in the calculations, 
because such rearrangements could not have been used for prospective MRD-PCR studies. 
Figure 4 shows the changes and stability of rearranged [g and TcR gene bands (alle[es) 
and their relation to the remission duration in the 40 childhood ALL cases. Changes in at 
[east one of the three major MRD-PCR targets ([gH, TcR-'Y, and TcR-Ii) were found in 40% 
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Figure 3. Southern blot analysis of IgH genes in several precursor B~ALL patients at diagnosis (A) and one 
precursor B-ALL patient (2308) at diagnosis and subsequent relapse (B). Control DNA and DNA from precursor 
B~ALL patients were digested with 8g/ll and in case of patient 2308 also with BamHIJHlndlll, size~separated, 
and blotted onto nylon membrane filters, which were hybridized with the 32P~labeled IGHJ6 probe. (A) In five 
of the here presented patients, more than two rearranged IgH gene bands were observed. The multiple IgH 
gene bands differed in density in most cases. With cytogenetic analysis we could exclude the presence of 
more than two chromosomes 14. (B) In patient 2308, three distinct and one weak rearranged band, were seen 
at diagnosis in both digests, whereas only one distinct and one weak rearranged band were detected at 
relapse. The weak band at diagnosis was probably identical to the weak band at relapse, but all other bands 
differed in size in both digests, indicating that clonal evolution had occurred in this precursor B~ALL patient 
at relapse. 
(S/22) of the monoclonal precursor B-ALL after remission duration of at least 18 months 
(Figure 4AI. All eight bi-/oligoc[ona[ precursor B-ALL showed changes at relapse in [gH, 
TcR-y, and/or TcR-o genes, which were already found after a short remission duration of 
at [east 6 months (Figure 4BI. In 30% of T-ALL, changes in [gH, TcR-,\" and/or TcR-/) gene 
rearrangement patterns occurred after a remission duration of at least 14 months (Figure 
4C). Despite the high frequency of immunogenotypic changes, at least one major IgH, 
TcR-,\" and/or TcR-/) rearranged band (alle[el remained stable in 75-90% of precursor B-ALL 
and 90% of T-ALL (Figure 4 and Tab[e 41. 
Several reports indicate that changes in IgH gene rearrangements at relapse do not 
necessarily imply that the complete sequence of the junctional regions has changed 
(SS,99). For example, VH replacements in completely rearranged IgH genes generally do not 
affect the original V-O-JH junctional regions, and also the D-JH junctional regions will 
generally remain stable in subclones, which rearranged different VH gene segments to an 
identical D-JH precursor (1001. 
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TABLE 4. Changes in IgH. TcR-,),. and TcR...5 gene rearrangement patterns in 40 childhood ALL at relapse"'. 
Changes in rearrangement patterns at relapse Stability of at least one major rearranged band (allele) 
'9H TcR'"'Y TcR..Q 
precursor a.-ALL , 9% (4f21jb 29% (4/14) 40% (8/20) 
with monoclonal 
19H genes at diag-
nosis (n = 22) 
precuroor B-ALL , 00% (81S) 50% (2{4) 57% (4/7) 
with bl-/ollgoclonal 
IgH genes at diag-
nosis (n=8) 
T-ALL 50% (214) 20% (2/10) 10% (1/10) 
(n=10) 
19H 
90% (19/21)b 
38% (318)d 
100% (4/4) 
TcR......,. and/or TcR-o 
72% (13/18)C 
63% (518) 
90% (9/10) 
IgH, TcR-,)" 
and/or TcR-o 
91% (20(22) 
75% (S/8) 
90% (9/10) 
a. The frequencies only concern ALL with IgH, TcR""')'. and/or TcR..,} gene rearrnngements. If no IgH, TcR...,.. or TcR-<S gene rearrengement W(lS found 
at diagnosis, the ALL wa:; excluded from the calctJlations (all 40 ALL were extensively tested for the occurrence of IgH, TcR-y, and TcR~ gene 
rearrangementsl. "New" rearrangements at relapse in genes which were in germllne configuration or deleted at diagnosIs were also not Included in 
the calculations, because such rearrangements could not have been used for prospective MAO-PeR studies. 
b. One patient was excluded from the calculatlons because both IgH alleles were deleted at diagnosis and at relapse. 
c. Two patients were excluded from the calCUlations because of germllne TcR-y genes and biallelic TcR~ gene deletions at diagnosis. 
d. In two additional bl-/ollgoclonol cases, a rearranged band at relapse was identical to a weak. rearranged band at diagnosis, suggesting selection of 
a minor subclone. 
Our childhood ALL study indicates that IgH genes represent optimal targets for MRD 
detection in monoclonal precursor B~ALL, but it might be valuable to monitor the TcR~'Y 
and/or TcR~o gene rearrangements as well, especially in cases with germline or deleted IgH 
genes on one or both alieles. In T-ALL the TcR-1' and TcR-/i genes represent optimal MRD-
PCR targets (97). However, in bi-/oligoclonal precursor 8-ALL (30-40% of the total group 
of precursor B~ALL), it will be difficult to estimate which minor or major IgH gene band 
(allele) will remain stable, especially in cases with more than two subclones. This implies 
that in these leukemias the MRD-PCR monitoring should not be restricted to IgH genes, but 
that TcR-')' and TcR-o gene rearrangements should be monitored as well. Two recently 
published PCR studies, describing changes and stability of IgH, TcR--y, and TcR-/i gene 
rearrangements at relapse in ALL, subscribed to these findings (101,102). Therefore, we 
conclude that MRD detection in ALL patients by PCR techniques needs monitoring of two 
or more junctional regions of IgH, TcR-,)" and/or TcR-o genes in order to prevent false-
negative results (97). 
The probability of changes in rearrangement patterns appears to increase with time 
(Figure 4). This implies that in case of early relapse generally no changes will be found. This 
might be important for the choice of PCR targets in MRD-PCR studies in adult ALL patients, 
because in adult ALL remission duration is essentially shorter than in childhood ALL. 
Background of normal cells 
The sensitivity of the PCR technique and the specificity of the junctional region probe for 
detection of leukemia-specific peR products is highly dependent on the background of 
normal cells with the same rearranged gene segments as the leukemic cells. This concerns 
for instance Vo1-Jo1 rearrangements and Vyl-Jy2.3 rearrangements which OCCur in 0.1-5% 
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Figure 4. Changes in Ig and TcR gene rearrangement patterns at relapse and their relation with remission 
duration. Each bar summarizes the 19 and TcR gene configuration per patient, who are numbered according 
to the registry of the Dutch Childhood Leukemia Study Group. The letter codes in the boxes of each bar 
indicate the presence (open boxes) or loss (black boxes) of rearranged Ig and TcR gene bands at relapse (H, 
IgH; K, IgK; A, Ig)..; 13, TcR-,6; "(, TcR--y; 0, TcR-li); the numbers indicate the sum of rearranged bands. The 
changes at relapse are shown above the horizontal line (black boxes: loss of rearranged bands; open boxes: 
"new" rearranged bands), whereas the stable rearrangements are shown underneath. A, 22 monoclonal 
precursor 8-ALL (remission duration 6-75 months), B, eight bi-/oligoclonal precursor B-ALL (remission duration 
6-52 months), and C, 10 T-ALL (remission duration 6-53 months). Detailed information concerning the 
changes in Ig and TcR gene configuration at relapse are given in reference 97. 
and in a large part of normal blood T-lymphocytes, respectively (82). This may result in 
lower sensitivity and specificity of the junctional region MRD-PCR technique. 
198 CHAPTERS.1 
Type of rearrangement and size of the junctional region 
It should be emphasized that the detection limit of the MRD-PCR technique is related to the 
size of the junctional region. Junctional regions of complete Vo-Jo rearrangements are three 
to four times larger than V-y-J-y junctional regions (27,57,82), implying that TcR-o junctional 
regions are more suitable targets for MRD-PCR analysis (27,82). However, TcR-o gene 
rearrangements may be incomplete, such as Va-Do and Do-Do rearrangements, which have 
relatively short junctional regions (27,82,103). Incomplete TcR-o gene rearrangements with 
short junctional regions are especially found in precursor 8-ALL, e.g. V02-D03 and 002-053 
(27,90,103-106). This may result in detection limits which are 10-3 to 10-4 . In case of 
short junctional regions, it may theoretically happen that normal cells occur which have 
junctional regions that are identical to those in leukemic cells. 
Technical influences on the MRD~PCR technique 
Finally I it should be emphasized that the specificity and sensitivity of the junctional region 
MRD-PCR technique is influenced by the hybridization conditions, washing stringency and 
film exposure time of the junctional region specific probe. These should be carefully 
determined to obtain reproducible results. 
PCR ANALYSIS FOR MRD DETECTION IN CHILDHOOD ALL 
So far the MRD-PCR studies are restricted to retrospective studies or short-term 
prospective follow-up studies on limited numbers of patients. Most investigators use 
junctional regions of rearranged Ig and TcR genes as PCR targets (55,58,59,92,107-112). 
Analysis of cell samples from ALL patients who developed a relapse, indicate that relapse 
during treatment might be predicted by persisting PCR positivity, often at a high level (e.g. 
10-2 or 10-3), or by an increase of PCR positivity over a period up to 12 months before 
cytomorphological relapse (55,58,59,92, 107,111). Several research groups concluded that 
PCR detection of high levels of residual disease at the end of induction therapy identifies 
patients at increased risk for relapse during therapy (108-111). Furthermore, they 
concluded that absence of detectable MRD at the end of chemotherapy is not sufficient to 
assure that the patient is cured, indicating that after treatment frequent serial monitoring 
is required for the early prediction of relapse (108-111). In a small prospective study of 20 
children followed for 7 to 30 months, Cave et al. found progressive decrease of the tumor 
load and no detectable blasts within 6 months. In three patients who developed BM relapse, 
slower kinetics of decrease were found (112). They concluded that the kinetics of blast-
decrease in the first months of treatment may be of prognostic value (112). 
CONCLUSION 
PCR analysis of chromosomal aberrations and junctional regions of antigen specific 
receptors is valuable for the detection of MRD in ALL. However, one should realize that 
each MRO-PCR target has its own limitations and pitfalls. 
MRD-PCR analysis using chromosome aberrations has the advantage that these 
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aberrations are most probably directly related to the oncogenic event and therefore 
represent stable tumor-specific markers. The first limitation of this technique is the fact that 
in only 1 5-20% of childhood ALL and in 25-30% of adult ALL, chromosome aberrations 
with well-defined breakpoints have been found so far. The second limitation is the fact that 
in many translocations the PCR target is a fusion mRNA, which is not patient-specific and 
therefore might cause false-positive results due to cross-contamination between patient 
samples. 
MRD-PCR analysis using junctional regions of rearranged Ig and TcR genes seems to 
be a promising technique, which can be applied in the majority of ALL. Despite the 
relatively high frequency of changes in Ig and TcR gene rearrangement patterns, which 
might cause false-negative results (due to subclone formation and clonal evolution), at least 
one major IgH, TcR--y, and/orTcR-o rearranged band (allele) remained stable in the majority 
(75-90%) of ALL. Still, the size of the junctional region will influence the detection limit of 
the PCR technique. This especially concerns incomplete TcR-o gene rearrangements, which 
represent the most frequent TcR-o rearrangements in precursor 8-ALL. 
Prospective studies on large groups of ALL patients using several peR targets in 
parallel are needed to evaluate which target is most efficient and reliable for each patient 
group. In the future, the MRD-PCR target of choice will probably depend on the presence 
of a chromosome aberration with well-defined breakpoints and the presence of a rearranged 
Ig and/or TcR gene, as well as on the probability of changes in Ig/TcR gene rearrangement 
patterns. The origin of the cell sample (bone marrow, peripheral blood, or cerebrospinal 
fluid)' its volume, and its cellularity will influence the choice as well. 
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CHAPTER 5.2 
HETEROGENEITY IN JUNCTIONAL REGIONS OF IMMUNOGLOBULIN 
KAPPA DELETING ELEMENT REARRANGEMENTS IN B-CELL LEUKEMIAS: 
A new target for detection of minimal residual disease 
in precursor B-acute lymphoblastic leukemia' 
Auke Beishuizen1, Marie~Anne J. Verhoeven", Timo M. Breit" Elisabeth R. van Wering2, 
Karel Hahlen2•3, Herbert Hooijkaas 1 .. and Jacques J.M. van Dongen 1 
1. Department of Immunology, University Hospital DijkzigtlErasmus University, Rotterdam; 
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ABSTRACT 
Virtually all immunoglobulin {lg)K gene deletions are mediated via rearrangements of 
the so-called kappa deleting element (Kde). Kde rearrangements occur either to V K gene 
segments or to the heptamer recombination signal sequence in the JK-CK intron (intron 
RSS). The junctional regions of Kde rearrangements in 121 B-lineage leukemias {53 
precursor B-acute lymphoblastic leukemia (ALL) and 68 chronic B-cell leukemias} were 
analyzed by the polymerase chain reaction (peR) and subsequent sequencing analysis to 
obtain a more detailed view about Kde rearrangements in B-cell differentiation. 
Variable (V)K gene family usage in VK-Kde rearrangements in B-lineage leukemias was 
comparable to V K gene family usage in functional V K-joining (J)K rearrangements in normal 
and malignant mature B-cells, except for a higher frequency of V KII family usage in 
precursor B-ALL. 
Junctional region sequencing of the Kde rearrangements in precursor B-ALL revealed 
an overall average insertion and deletion of 4.9 and 4.2 nucleotides, respectively, resulting 
in a large junctional diversity, whereas in chronic B-ceII leukemias this N-region insertion 
(-1.6) and deletion (-2.e) was significantly lower. 
These relatively large junctional regions as well as the limited number of primers for 
PCR analysis of Kde rearrangements make the Kde rearrangements a potential peR target 
for minimal residual disease (MRD) detection in precursor B-ALL. The junctional diversity 
of the Kde rearrangements allowed us to design leukemia/patient-specific oligonucleotide 
probes and a detection limit of -1 0~4 was observed in a dilution experiment, proving with 
the MRO-PCR technique. Kde rearrangements occur in - 50% of precursor B-ALL cases and 
remain stable during the disease course as was proven in five studied precursor B-ALL 
• Submitted for publication. 
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patients at relapse. These findings indicate that Kde rearrangements in precursor B-AlL 
represent sensitive and stable patient-specific peR targets for detection of MRD. 
INTRODUCTION 
The various types of 8-lineage leukemias, i.e. precursor B-ALL and B-chronic 
lymphocytic leukemias (ell) are regarded as malignant counterparts of immature and 
mature B-cells, respectively (1-3). Therefore, analysis of these maligancies wilt give more 
insight in 19 gene rearrangement processes during B-cell differentiation (1,4-8). Based on 
leukemia studies, it is found that during B-cell differentiation 19 gene rearrangements occur 
in an ordered manner. First, 19 heavy-chain (lgH) genes rearrange, followed by IgK genes, 
which in turn precede Ig).. gene rearrangements (9-12). In general, 19).. gene rearrangements 
occur after or coincide with IgK gene deletions (11,12). 
The IgK gene locus on chromosome 2p 12 contains approximately 76 V K gene 
segments (13,14), five JK gene segments, one constant (C)K gene segment, and a Kde, 
which is located - 24 kb downstream of the CK gene segment (15-19). The V K gene 
segments are divided in seven families on the basis of sequence homology (13,14,20). 
Forty VK gene segments are clustered and located adjacent to the JK-CK region and are 
indicated as proximal. About 36 VK gene segments are thought to have been duplicated and 
inserted further upstream from the JK-CK region in an inverted orientation and are indicated 
as distal (21,22). 
The far majority (> 98%) of IgK gene deletions are mediated via a site-specific 
rearrangement of the Kde (15-19,23). Kde rearranges via its heptamer-nonamer 
recombination signal sequence (RSS) either to a heptamer RSS located in the intron RSS 
or to heptamer-nonamer RSS at the 3' side of a V K gene segment (Figure 1) (15-18). The 
incidence of Kde-mediated IgK gene deletions (Kde rearrangements) is -- 50% in precursor 
8-All, -32% in Ig"'+ chronic B-cellieukemias, and 100% in Ig).. + chronic 8-cellleukemias 
(23). 
The combinatorial diversity of the Ig molecules of B-Iymphocytes is formed by the 
many possible different combinations of specific V, (D (diversity)), and J gene segments 
of each Ig gene (IgH and Ig light-chain (IgL)) (9,10,24-28). The junctional diversity, 
determined by the junctional region, is made up by D-gene derived nucleotides (in case of 
IgH genes) (10,27), deletion of nucleotides by trimming of the involved gene segments 
J, 
VK VK VK V~.J~ r--1 I~tro~ CK Kdo 
34SRSS 
I11III if-lll---if-lll---i1--®1l I I I' • 1: ___ 
I11III :f-lll---if-lll---i~ 
J, 
v" V>:: v" V~.J",---, Intm~ CK Kde 
34SRSS 
I11III :f-lll---if-lll---i1--®1l I I I' • /~ 
I11III :~:/ 111111!/l!liI!F=·· .......... .. 
Figure 1. Schematic diagrams of IgK 
gene deletions mediated by Kde 
rearrangements. Two types of Kde 
rearrangements can occur: (upper 
diagram) Kde rearrangement to the 
intron RSS; (lower diagram) Kde 
rearrangement to a V K gene seg-
ment. 
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(29), P-region nucleotides (30), and N-region nucleotides (28,29,31). D gene derived 
nucleotides and P-region nucleotides are template dependent, whereas N-nucleotides are 
randomly inserted at the junctions by the enzyme terminal deoxynucleotidyl transferase 
(TdT) (29,31). The combined combinatorial and junctional diversity provides the enormous 
diversity of antigen specific receptors of lymphocytes. 
Junctional regions of Ig and TcR gene rearrangements are regarded as tumor-specific 
markers (32-35), because leukemias and malignant lymphomas represent clonal expansions 
from single transformed cells (5). Currently, it has been proven that IgH gene junctional 
regions as well as junctional regions of T-cell receptor (TcR)-'Y and TcR-o genes can be used 
as targets for MRD detection in ALL by use of the PCR technique (32-39). However, it 
should be noted that the applicability of these patient-specific sequences as targets for the 
MRO-PCR technique is dependent on the occurrence and stability of the involved Ig/TcR 
gene rearrangement (7,35.40.41). In principle, also PCR-mediated MRD detection of 
junctional regions of rearranged IgL or other TcR genes may be used. However, especially 
PCR analysis of TcR-a and TcR-.6 genes needs many different oligonucleotide primers and 
in case of IgL genes the junctional diversity is minimal (35,42). 
The aim of our study was to obtain a more detailed view about Kde rearrangements 
during B-cell differentiation. Therefore, we examined the junctional regions formed by either 
Kde to VI( rearrangements or Kde to the intron RSS rearrangements in a large group of 121 
selected B-lineage leukemias, including 53 precursor B-ALL and 68 chronic B-ceilleukemias. 
Furthermore, we analyzed the applicability of the Kde rearrangements as MRO-PCR target 
by studying the size, the composition, and the stability of the junctional regions in precursor 
B-ALL at diagnosis, and if available, also at relapse. Moreover the leukemia-specificity of 
this MRD-PCR target was evaluated and the detection limit was determined in a dilution 
experiment. 
MATERIALS AND METHODS 
Cell samples 
A large group of 121 B-lineage leukemias at diagnosis and 7 precursor B-ALL also at relapse were selected 
based on the presence of Kde rearrangements as detected by Southern blotting in a previous study and the 
availability of DNA, necessary for the analyses (23,41). This group of leukemias comprised 53 precursor B-
ALL (one null ALL, 38 common ALL, and 14 pre-B-ALL) and 68 chronic B-cell leukemias (60 CLl, four 
prolymphocytic leukemias (PLL), and four hairy cell leukemias (HCL)). Kde rearrangements to VK gene 
segments were found in - 69% of Kde rearrangements in precursor B-ALL, while these were found in 46% . 
of Kde rearrangements in the chronic B-cell leukemia group (23). 
Mononuclear cells (MNC) were obtained from peripheral blood (PB) or bone marrow (BM) samples of 
these 121 B-lineage leukemias or healthy adult volunteers by Ficoll-PaQue centrifugation (density: 1.077 
g/cm3; Pharmacia, Uppsala, Sweden). All MNC samples were frozen and stored in liquid nitrogen. All cell 
samples were obtained with the approval of the Medical Ethics Committee of the University Hospital 
Dijkzigt/Erasmus University, Ronerdam. 
DNA was isolated from MNC samples as described previously {26,43). 
peR and direct sequencing analysis 
peR amplification was performed as described previoUSly (44). An 1.0 p.g sample of DNA, 12.5 pmol of the 
upstream and downstream oligonucleotide primers (Table 1) and one unit of Amp!J7aq DNA polymerase 
(Perkin~Elmer Cetus, Norwalk, CT, USA) were used in each PCR of 100pJ. 
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TABLE 1. Oligonucleotide primers used in peR. hybridi'ZDtion. and sequencing of Kde rearrangements. 
Name Code Size Positionll Sequence Referenceb 
Kde rearrangement peR primers 
5' peR primers 
IGKV[5 
IGKVII5 
IGKVIIIS 
IGKVIV5 
IGKW5 
tGKWts 
tGKVIlS 
lGKID5 
3 • peR primer 
IGKDE3 
VII:I-frl 
VKII·frl 
Vxlll-frl 
VKIV-frl 
V",V-frl 
VKVI-frl 
VJ(VII·frl 
intron-RSS-5 
Kde-3 
-379 bp 
-395 bp 
-383 bp 
-397 bp 
-376 bp 
-388 bp 
-391 bp 
-457 bp 
Kde rearrangement sequence primers 
5 . sequence primers 
tGKVI3 VKI-fr3 -95 bp 
IGKVII3 VK2-fr3 -88 bp 
IGKW3 VK5-fr3 -126 bp 
IGKl3 intron-RSS-3 -104bp 
3 ' sequence primer 
IGKDE3 Kde-5 
Junctional region patient-specific probesc 
patient 2308 (intron) 
patient 3264 (intron) 
patient 3779 (intron) 
patient 3869 (intron) 
patient 4711 (intron) 
patient 5014 (intron) 
patient 3264 (VICII) 
patient 3797 (VIC!) 
patient 4686 (VICI) 
patient 4711 (VICII) 
patient 4865 (VICIII) 
patient 5105 (VICI) 
5' 
·221 bp 
-237 bp 
-225 bp 
-239 bp 
-218bp 
-230 bp 
-233 bp 
-299 bp 
+457 bp 
-41 bp 
-34 bp 
-72 bp 
-50 bp 
+54 bp 
3' 
GTAGGAGACAGAGTCACCATCACT 
GGAGAGCCGGCCTCCATCTCC 
AGGGGAAAGAGCCACTCTCTCC 
GGCGAGAGGGCCACCATCAAc 
CCAGGAGACAAAGTCAACATCTCC 
CTGTGACTCCA(A/G) (A/G1GGAGAAAGTC 
AGGACAGAGGGCCACCATCACC 
GTTATTCCCAAAAGCTTAATCTCAAAG 
TTCATAGACCCTTCAGGCACATGC 
TCAGCAGCCTG (C/Gl AG (C/G) CTGAAGAT 
CAGCAGGGTGGAGGCTGAGGAT 
CAGCGGGTATGGAACAGATTTTAC 
CTATGCCGTGGCCACCCTGTGT 
ATGCAGCTGCAGACTCATGAGG 
CCTGccctcgggGCCCTA 
GCCAGCTTTataccgacccTA 
GATGatggactCCTAGTGGCA 
GCCGTAcccgggaCCAGG 
CTGctggtagcgagGTGGC 
CCTGATGgttgggCCTAGTG 
CTGGCCTCCtcgcaGAGCC 
ATCTCCC!CgggtcgaaGGA 
TACCgtgaacgGCCCAGGG 
ACACTGGCCaccGAGCCCT 
tccggggacggctaaccaG 
CTCCgtcggaCCCTAGTGG 
13 
13 
13 
13 
13 
13 
13 
X67858 
16 
13 
13 
13 
X67858 
16 
a. The position of the 3' end of the oligonucleotide primers is indicated downstream (+) or upstream H of the closest 
joining site (",start of RSS). In case of the IGKDI5 and IGKDI3 primers, it concerns the heptamer RSS in the J/C'"CIC 
intron. 
b. Sequence information used to design the oligonucleotide primers was derived from the indicated literature references 
(13,16,45; Whitehurst et al. EMBL databank accession no. X67858). 
c. Small characters in the sequence represent the nucleotides inserted at the junctional region of the Kde rearrangements 
in the precursor B-ALL patients. 
To evaluate the size differences of short (-250 bpI Kde rearrangement peR products, they were size-
separated by 15% polyacrylamide gel electrophoresis (PAGE) and visualized by ethidium bromide staining. 
To obtain single-stranded peR products for sequencing an asymmetric peR reaction was performed 
followed by a double 50% ethanol extraction (44). 
Fifty pmol sequence primer was used in each reaction (Table 1). The sequence reactions were 
performed with the T7-seQuencing kit (Pharmacia) following manufacturer's instructions using 35S 
radiolabeling, and run in a normal, denaturing 8% polyacrylamide gel. Sequencing was performed in both 
directions. 
Specificity of Kde rearrangement PCR products and determination of the MRo-PCR detection limit 
To determine the specificity of the Kde rearrangement peR products, they were size-separated in 1.0% 
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agarose gels, transferred to Nytran~13N nylon membranes, and UV cross-linked as described (26,45). The 
peR products were analyzed by hybridization using several h-32Pl dATP 5' end-labeled junctional region 
leukemia/patient-specific oligonucleotide probes (Table 1). 
To determine the MRD-PCR detection limit of Kde rearrangements a DNA dilution experiment was 
performed. DNA from a precursor B~ALL patient containing a VKII-Kde rearrangements was diluted in DNA 
from a healthy adult individual. The dilution steps were 1 to 10.8 patient DNA in control PB-MNC DNA. PCR 
reactions with the appropriate oligonucleotide primers were performed subsequently and the PCR products 
were analyzed by hybridization as described above. 
RESULTS 
peR and sequencing analysis of junctional regions of Kde rearrangements 
In all 121 selected B-lineage leukemia cases, the Southern blot data could be confirmed 
with peR analysis of the two types Kde rearrangements with the designed oligonucleotide 
primers (Table 1). Difficulties in obtaining Kde rearrangement peR products could be 
overcome by digestion of DNA with 8g111 in six patients. 
The relative size of the short PCR products was evaluated by 15% PAGE (Figure 2A). 
More variation in size was found in the precursor B-AlL group as compared to the chronic 
B-cellleukemia group. ell patient cL44 represented an exception because of a very short 
PCR product due to extensive trimming of both rearranged segments (see also Figure 2B). 
Direct sequencing of the Kde rearrangement PCR products from 82 B-lineage 
leukemias (34 in precursor 8-AlL and 48 in chronic B-ceilleukemias) revealed the junctional 
region sequences of 86 Kde rearrangements. A representative part of the sequences is 
shown in Figure 28. Similar rearrangements on both alleles of one patient (e.g. two Kde to 
the intron RSS rearrangements or two Kde to V" gene rearrangements) resulted in a mixed 
PCR product as well as mixed sequences. In such cases, we unraveled the mixed 
sequences by matching information about sequences read from both directions. In this way, 
cloning of peR products was unnecessary in all patients. Table 2 summarizes the 
characteristics of the junctional region sequences of Kde rearrangements in B-lineage 
leukemias. The sizes of the junctional regions differed from 0 to maximally 18 nucleotides 
with an average of 4.9 nucleotides in the precursor B-ALl group. The sizes of the junctional 
regions differed from 0 to maximally 8 nucleotides with an average of 1.6 nucleotides in 
the chronic B~ceilleukemia group. In a large part of Kde rearrangements, especially in case 
of V K-Kde rearrangements, no randomly inserted N-region nucleotides were found in chronic 
B-cell leukemias. More N-region nucleotides and trimming of nucleotides was found in the 
junctional regions of Kde rearrangements to the intron RSS, whereas more P-region 
nucleotides were found in the junctional region sequences of Kde rearrangements to V K 
gene segments (Table 2). 
Specificity of patient-specific Oligonucleotide probes and primers 
To determine the specificity of the patient-specific oligonucleotide probes the Kde 
rearrangement peR products of several patient DNA samples were size-separated, blotted 
and successively hybridized with the various patient-specific oligonucleotide probes (Figure 
3). In all cases analyzed, these patient-specific oligonucleotide probes were proven to 
detect exclusively the corresponding Kde rearrangement peR products out of all tested 
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Figure 2. PCR and sequencing analysis of junctional regions of Kde rearrangements. (A) PAGE analysis of Kde 
rearrangement PCR products of several precursor B~ALL and chronic B·cellleukemias. The PCR~mediated amplification 
of the Kde rearrangements was performed using the VI(·family·fr1 and IGKDE3 oligonucleotide primers in case of VI(-Kde 
rearrangements or the IGKl3 and IGKDE3 oligonucleotide primers in case of Kde rearrangements to the intron RSS (Table 
1). (B) Sequences of the junctional regions of Kde rearrangements are aligned with the known VI( germ line sequences, 
with the germline sequences of the JK--CI( intron, and with the Kde germline sequences (double underlined). Lower·case 
characters at the end of a junctional region represent P-region nucleotides (30). All other nucleotides at the junctional 
region represent N-region nuc!eotides. The used patient-specific oligonucleotide probes for hybridization analysis are 
indicated (underlined). 
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TABLE 2. Characteristics of the junctional region sequences of Kde rearrangements in B-lineage leukemiasfl • 
Kde rearrangements to 
VK gene segments the intron RSS 
B-lineage junctional N·rogion P·region doloted junctional N·region P·region deleted 
leukemias nucleotides nucleot'ldes nucleotides nucleotides nucleotides nucleotides nucleotides nucleotides 
precursor B-ALL 4.6 4.5 0.2 3.2 5.3 5.3 0 4.6 
In~341 10-1S1 10-1S1 10-21 10-201 10-11 I 10-11 I 10-171 
chronic B-cell 0.5 0.4 0.2 2.0 2.0 1.9 0.1 3.2 
leukemias 10-31 10-21 10-21 10-91 10-SI 10-SI 10-1 I 10-191 
In~4S1 
a. Average number of nucleotides per rearranged allolo is given. The range is given between brackets. 
patients. In addition, neither in normal BM nor in normal PB positive hybridization signals 
were detected (Figure 3). 
Detection limit of the MRD-PCR technique 
To establish the detection limit of the MRD-PCR technique, DNA of a precursor 8-ALL 
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Figure 3. Diversity of the Kde rearrangement junctional 
region allows patient-specific hybridization. PCR pro-
ducts of the Kde rearrangements from several precursor 
B·ALL patients at diagnosis and/or relapse and normal 
8M and PB were run in an agarose gel and subsequently 
blotted. The filters were successively hybridized with 
four patient-specific oligonucleotide probes which 
exclusively recognized the corresponding PCR product. 
The stability of the MRD-peR target during the disease 
course was proven by positive hybridization signals at 
relapse in two patients (3869 and 4865) after hybridiza-
tion with patient-specific oligonucleotide probes desig-
ned according to sequences at diagnosis. 
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patient with a VKII-Kde rearrangement was diluted in DNA from PB-MNC of a healthy 
individual. peR analysis of the VKlI-Kde rearrangement in each DNA mixture and 
subsequently hybridization of the blotted PCR product with the patient-specific oligonucleo-
tide probe revealed hybridization signals down to the _10-4 dilution mixture (Figure 4). 
Stability of the Kde rearrangement 
The stability of Kde rearrangements at diagnosis and at subsequent relapse can be studied 
in five ways: first, Southern blot analysis reveals identically rearranged 19K gene bands upon 
hybridization with the IGKDE probe in at leasttwo different digests (23,41); second, in case 
of V K-Kde rearrangements, peR analysis shows identical V K family usage; third, after 
blotting of the peR products at relapse positive hybridization signals are detected upon 
hybridization with the patient-specific junctional region oligonucleotide probe, designed 
accordingly to the sequences of the DNA sample at diagnosis; fourth, when using the 
relapse DNA sample as substrate, a PCR product is obtained with a patient-specific 
junctional region primer obtained at diagnosis and the generallGKDE3 primer; and finally, 
sequencing analysis of the junctional region PCR products at diagnosis and relapse results 
in identical sequences. The stability of the Kde rearrangement was proven, when beside the 
first two at least one of the latter three criteria resulted in identical outcome at diagnosis 
and relapse. 
DNA samples of seven precursor 8-ALL patients were analyzed at diagnosis and 
relapse by peR, subsequent hybridization with patient-specific oligonucleotide probes, or 
sequencing analysis. In five precursor 8-ALL patients identical results were obtained proving 
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Figure 4. Dilution experiment in which DNA from a precursor B-ALL patient with a Vldl-Kde rearrangement 
was diluted in PB-MNC from a healthy individual. PCR products obtained after amplification with the IGKVI13 
and IGKDE3 oligonucleotide primers were run in agarose gel (A) and blotted to a nylon membrane, which was 
hybridized with the 32P-1abeled 3264 (V"II) patient-specific junctional region probe (B). Kde rearrangement 
PCR products were detectable down to the _10-4 dilution mixture. The precursor B-ALL patient 3869 was 
used as a positive control. 
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the stability of the Kde rearrangements (Figure 3) and in two patients, the occurrence of 
a secondary leukemia (i.e. acute myeloid leukemia) (patient 3979) and the selection of a 
subclone without Kde rearrangements at relapse (patient 2308) was confirmed (41). 
V" gene segment usage in B-lineage leukemias 
In 69% of Kde rearrangements a V K-Kde rearrangement was found in precursor B-ALL and 
in 46% in chronic B-celileukemias (23). The usage of the different VIC families estimated 
by peR analysis is summarized in Table 3. VKI family members are more frequently used 
in V IC-Kde rearrangements in chronic 8-cell leukemias, whereas in V IC-Kde rearrangements 
in precursor B-ALL more VICII family members were utilized. On the other hand VICIII and 
VICIV family members are equally used by both 8-lineage leukemia groups. Kde rearrange-
ments to the V.V, V.VI, and V.VII families are rare (Table 3). 
All V K gene segment sequences obtained after direct sequencing analysis of V K-Kde 
rearrangements, had significant homology to known germline sequences (13,14). In the 
majority of VK-Kde rearrangements (93%;28/30) in precursor B-ALL and chronic B-cell 
leukemias, proximal VIC gene segments were used. In precursor 8-ALL preferential usage 
of L 1 ,L9, and A30 as V.I family members, A 17 as V.II family member, and A27 as V.III 
family member was found (Figure 28). Only in chronic B-ceilleukemias preferential usage 
of A27 as V.III family member was found (Figure 28). 
TABLE 3. Frequency of VI(. family usage in V,,-Kde rearrangements in B-lineage leukemias. 
V"family Precursor 8-ALL Chronic 8-cell leukemias 
(number of members)a (n=51) (n=47) 
Vxl (23) 39% 47% 
V,dl (14) 27% 17% 
V"III (8) 22% 21% 
V"IV (1) 10% 11% 
V"V (1) 0% 0% 
VxVl (2) 0% 2% 
V"VII (1) 2% 2% 
a. Number of VI( gene segments belonging to a VI( family which are potontially functional or have minor defects but stiU have the 
potention to become function.nl due to mutations (13,14). 
DISCUSSION 
Sequence analysis of the Kde rearrangements either to the intron RSS or to VIC gene 
segments revealed a striking difference in junctional region diversity between precursor B-
ALL and chronic 8-cellleukemias (Figure 2 and Table 2). Three times more insertion of N-
region nuc1eotides and nearly two times more deletion of nucleotides was found in the 
junctional regions of Kde rearrangements in precursor B-ALL as compared to chronic B-cell 
leukemias. Apparently in precursor B-ALL, TdT is still active at the time Kde rearrangements 
take place, whereas in chronic B-cell leukemias, TdT activity was decreased or absent at 
the time Kde rearrangements occurred. Also in normal B-cells junctional regions of VIC-JIC 
gene rearrangements are small due to limited N-region insertion (average 1-2 nucleotides) 
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(46-50). Even in normal precursor B-cells, which rearrange 19K genes at the same time as 
they undergo VH to O-J rearrangements, no much N-region diversity (average < 1 
nucleotides) is found (42). Our findings are in line with the finding that the recombinase 
system as well as TdT are still active in precursor B-ALL (46-48). This is probably related 
to the malignant transformation and maturation arrest in the precursor 8-cell stage. The 
continuous recombinase and TdT activity in precursor 8-ALL cells explains the frequently 
occurring continuous gene rearrangements (7,49,50), including the high frequency of IgK 
gene rearrangements and deletions (23), as well as large N-regions in Kde rearrangements 
(Figure 2B). 
Detection of MRO by use of the peR technique is a powerful tool for monitoring 
leukemic cells during and after treatment, because these techniques are potentially able to 
detect frequencies of 10.5 to 10-6 leukemic cells (35). However, the applicability of the 
MRD-PCR technique is highly dependent on the presence of suitable targets and the 
detection limit of the technique, which is influenced by the occurrence of the involved 
MRD-PCR target in normal cells. Nowadays, chromosome aberrations and IgH, TcR-j', and 
TcR-o gene rearrangements are the most commonly used MRO-PCR targets. In this study, 
we investigated the usage of Kde rearrangements as new MRO-PCR targets. 
We evaluated whether it was possible to use Kde rearrangements in precursor 8-ALL 
as leukemia/patient-specific MRD-PCR target, despite the occurrence of these rearrange-
ments in normal cells. We anticipated that normal cells would not cause a false-positive 
background, because in normal 8-cells the junctional diversity of V K-JK rearrangements and 
probably also the junctional diversity in Kde rearrangements is low (42,51-56). Hybridization 
of patient-specific oligonucleotide probes to Kde rearrangement peR products of various 
sources indeed proved the specificity of the probes, because they were able to detect their 
corresponding PCR products without distinct hybridization to Kde rearrangement PCR 
products from other patients or from normal BM and PB (Figure 3). The sensitivity of this 
new MRO-PCR target was determined by use of a dilution experiment, in which DNA of a 
precursor B--ALL with VKII-Kde rearrangement was diluted in DNA of PB-MNC from a 
healthy individual. This dilution experiment revealed a detection limit of _10-4 (Figure 4). 
IgK gene rearrangements as well as Kde rearrangements are not found in T -ALL and 
are rare in AML (5,57). In contrast, Kde rearrangements occur in -- 50% of precursor B-ALL 
(23), which makes it a potential important MRD-PCR target in these leukemias. 
The stability of the Kde rearrangement can be studied in five ways as mentioned in the 
Result section. The stability of the Kde rearrangement was proven, when beside the first 
two at least one of the latter three criteria mentioned succeeded in identical results at 
diagnosis and relapse. In five of the seven studied precursor a-ALL cases, the stability of 
Kde rearrangements at relapse was proven. In the two other precursor B-ALL cases a 
secondary leukemia to AML and a selection of a sublcone without Kde rearrangements at 
relapse was confirmed (41). The stability of Kde rearrangements seem to be in contrast to 
the continuing rearrangements in precursor B-ALL (7,50). However, it should be noted that 
Kde rearrangements are. 'end-stage' rearrangements, which can not undergo further 
rearrangements. 
Until recently, only a few studies about V K gene usage in IgK gene rearrangements in 
normal and malignant (precursor) B-cells were reported (58-62). But with the discovery of 
the PCR technique (63,64), the analysis of antigen specific receptor gene rearrangements, 
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as well as the analysis of IgK gene rearrangements, is moving rapidly (51-56,65-67). 
However, reports about VK gene usage in Kde rearrangements are still scarce (56). VK 
family usage (V KI~IV) in our Kde rearrangements were compared with V K family usage in 
VK-JK rearrangements as reported in the literature and summarized in Table 4 
(58,61,62,66,67). This comparison revealed that VK family usage in VK-JK gene 
rearrangements and V K-Kde rearrangements is comparable except for a higher tendency of 
VKII family usage in VK-Kde gene rearrangements, especially in precursor B-ALL. The most 
frequently used VK gene segments' of each VK family found in functional VK-JK gene 
rearrangements are also used in VK-Kde gene rearrangements. (52-54,66,67). Distal VK 
gene segments are not frequently used in VK-Kde gene rearrangements. Apparently, the 
usage of V K gene segments is not clearly dependent on the type of rearrangement (V K-JK 
or VK-Kde), but particular VK gene segments (e.g. VKI: L 1 ,L9, and A30, VKII: A 17, and 
VKIII: A27) are probably more prone to rearrange than other VK gene segments. 
In conclusion, sequencing analysis of Kde rearrangements revealed a striking 
difference in size of junctional regions between precursor 8-ALL and chronic 8-cell 
leukemias. This might be related to the ongoing activity of the recombinase system and TdT 
in precursor 8-ALL, due to the malignant transformation and the maturation arrest in the 
precursor 8-cell stage. The relatively large size of the junctional regions of Kde rearrange-
ments and the limited number of primers necessary for optimal PCR analysis of Kde 
rearrangements makes the Kde rearrangement a potential MRD-PCR target in precursor B-
ALL. The suitability of this MRD-PCR target was further established by proving its 
specificity by using leukemia/patient-specific oligonucleotide probes. In addition, the 
sensitivity of this target was analyzed by use of a dilution experiment, which revealed a 
detection limit of _10-4 and the stability was proven by use of patient-specific oligonucleo-
tide probes in precursor B-ALL at diagnosis and at relapse. Therefore, junctional regions of 
Kde rearrangement represent sensitive and stable MRD-PCR targets in precursor B-ALL. 
TABLE 4. V" family usage in V "..,J" rearrangements in normal and malignant lymphoid cells as compared to 
V" family usage in V K-Kde rearrangements in B-lineage leukemias. 
V I(-J" rearrangements V ,,-Kde rearrangements 
Normal Malignant Chronic 8- Precursor 
VI( family 8-cellsa lymphoid cellsb cell leukemias B-ALL 
(n=106) (n=45) (n=50l 
V,I 50% 58% 49% 40% 
V"II 8% 13% 18% 28% 
V"IJI 25% 19% 22% 22% 
V"IV 14% 10% 11 % 10% 
a. Unfortunately, only percentages of VI( family usage in functional VI(-JI( rearrangements were reported in tho literature; data are 
obtained from references (58,61,62). 
b. The malignant lymphoid colis concern precursor a·ALL (n=6), non·Hodgkin lymphoma (n=20), CLL (n= 52), PLL (n =6), HCL (n= 5), 
Waldenstr5m macroglobulinemia (n '" 7), and Multiple myeloma (n = 1 0) and are obtained from references (65·67). 
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CHAPTER 6 
CONCLUDING REMARKS 
6_1 INTRODUCTION 
During the last decades, extensive studies in acute lymphoblastic leukemia (ALL) are 
performed at diagnosis, during follow-up, and at relapse. These studies include analysis at 
the single cell level: analysis of cell morphology, immunophenotype, and karyotype; analysis 
atthe ONA level: immunoglobulin (lg) and T-cell receptor (TcR) gene rearrangement studies; 
and in vitro cell culture analysis. These extensive analyses provided more insight into the 
development of ALL and more knowledge about the characteristics of the leukemic cell as 
well as the occurrence of relapse. Furthermore, leukemias are generally used as a model to 
study normal 8- and T-cell differentiation, since they can be regarded as clonal malignant 
counterparts of normal (immature) 8- or T-cells. 
The main purpose of this study was to get more insight into the factors and 
mechanisms which influence the development of relapse in childhood ALL. In this thesis, 
we have focussed on the analysis of Ig and TcR gene rearrangements at diagnosis and at 
subsequent relapse in ALL, especially in precursor B-ALL. The different findings of the 
immunogenotypic studies have been discussed extensively in the individual chapters of this 
thesis. Therefore, the most significant findings will only be briefly summarized. First, to 
improve the detection of Ig heavy-chain (lgH) and kappa Ig light-chain (lgL) gene 
rearrangements by Southern blot analysis for diagnostic purposes, we carefully determined 
the precise restriction map of the relevant IgH and IgK regions and evaluated the appropriate 
combination of restriction enzymes with newly developed optimal DNA probes (Chapter 2). 
With these optimal Southern blot conditions, Ig and TcR gene rearrangements have been 
analyzed in detail in a large group of precursor S-ALL patients. The results revealed in 30-
40% multiple rearranged IgH gene bands and in 6% multiple rearranged IgK gene bands in 
precursor B-ALL. These multiple rearranged IgH and IgK gene bands are most probably due 
to subclone formation. In the majority of precursor 8-ALL cases, this subclone formation 
(bi-/oligoclonality) is caused by continuing and/or secondary gene rearrangements. In 
addition, cross-lineage TcR gene rearrangements were found in 94% of precursor B-ALL at 
diagnosis (Chapter 3)_ Not only multiple rearranged Ig and crOSS-lineage TcR gene 
rearrangements were observed in precursor B-ALL at diagnosis, but also differences in Ig 
and TcR gene rearrangement patterns between diagnosis and relapse were found. These 
differences (clonal evolution), were detected in -65% of precursor 8-ALL and -50% of 
T-ALL, and could be explained in nearly all cases by continuing and/or secondary gene 
rearrangement processes (Chapter 4)_ The observed heterogeneity in Ig and TcR gene 
rearrangement patterns (subclone formation and clonal evolution) has importantimplications 
forthe detection of minimal residual disease (MRD) by the polymerase chain reaction (PCR)-
mediated amplification of tumor-specific IgH, TcR-,)" and TcR-o gene junctional regions, 
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since subclone formation at diagnosis and clonal evolution at relapse will lead to fa\se-
negative results. It is therefore that a new potentially 'reliable' MRD-PCR target has been 
found and studied in the junctional regions of kappa deleting element (Kde) rearrangements, 
which can be detected in -50% of precursor S-ALL cases (Chapter 5). 
In this Chapter 6, two related questions which can be raised when combining the 
various immunogenetic results described in this thesis, will be discussed. What is the origin 
of the precursor S-ALL cell and can precursor S-ALL serve as a model for normal S-cell 
differentiation? Before discussing these questions, the relevant data from the literature 
concerning normal 8-cell differentiation and our data concerning immunogenetic findings 
in B-lineage leukemias will be summarized. 
6.2 THE ORIGIN OF THE PRECURSOR B-ALL CELL 
The development of the normal B-cell 
The differentiation of B-Iymphocytes from committed precursor cells to antibody-secreting 
plasma cells proceeds through multiple steps that are defined by changes in the expression 
pattern of lineage-specific genes (1-4). The most important process during B-cell 
differentiation in the bone marrow (8M) from immature pro-B-cell to mature 8-lymphocyte 
is the expression of unique Ig molecules on the cell membrane, which are specialized in 
antigen recognition (1,5). Each olthe Ig chains consists of a C (constant) region as well as 
a variable region which is involved in antigen recognition. These variable regions of the Ig 
chain are encoded by combinations of gene segments (V (variable), (D (diversity),) and J 
(joining) gene segments) which are different in each lymphocyte (1,6). The different gene 
segments are joined during rearrangement processes, which occur in a programmed manner 
(first IgH and subsequently IgL gene rearrangements) and are regulated and influenced by 
several proteins, such as products of the recombination activating genes: RAG1 and RAG2 
and terminal deoxynucleotidyl transferase (TdT) (7-10). During B-cell differentiation RAG 
expression is found from pro-B-cell to immature B-cell stage, whereas TdT expression is 
found from the lymphoid stem cell to the pre-S-cell stage (defined by cytoplasmic 191' 
staining) (see also Chapter 2.1) (8,11-15). 
Once the immune system has been built, it contains around 1012 cells of the 8-lineage 
of which 5-10% are precursors that are active in regeneration, whereas 90-95% are 
resting, mature S-Iymphocytes (16). Large numbers of S-Iymphocytes are produced daily 
from lymphoid stem cells within the SM (17-19). During this production of S-Iymphocytes 
a distinct percentage (50-60%) of immature B-cells and self-reactive 8-cells will be aborted, 
in which the latter 8-cells are eliminated through a two-step process of developmental 
arrest and apoptotic cell death (16-21). The reason for the waste of (immature) B-cells is 
unclear. Although the chance of failures during Ig gene rearrangement processes is high, 
each (immature) B-cell has the opportunity to overcome these failures in recombination by 
secondary rearrangements (D-J replacements, V-J replacements, or V replacements), 
besides the presence of two IgH and IgL alleles (6,22-26). A self-reactive B-cell has the 
opportunity to replace its IgK chain by a new IgK chain (via V-J replacement) or by a newly 
assembled IgA chain. These latter processes are a form of receptor editing (27-29). 
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Immunogenotypic findings in precursor B-All cells 
From the literature and our own data we know that TdT and RAG expression is found in all 
precursor B-ALL cells (11-14,30-33). IgH gene rearrangements are found in 96% in 
precursor B-ALL, whereas in 4% of cases the IgH genes are in germline configuration or 
(partly) deleted on both alleles (see Chapter 3.2). Furthermore, biclonality andlor 
oligoclonality at diagnosis has been found in 30-40% of precursor 8-ALL cases at the IgH 
gene level and in -6% at the IgK gene level (see Chapter 3.2 and Table 1). This form of 
subclone formation can be explained by continuing rearrangement processes (see above and 
Chapter 3.2). These continuing rearrangement processes are also (partly) responsible for 
the changes in Ig gene rearrangement patterns (so-called clonal evolution) at relapse in ALL 
(see Chapter 4.3). The development of changes in Ig and TcR gene rearrangement patterns 
was related to remission duration, suggesting an increasing chance of continuing 
rearrangement processes with time. 
IgK gene rearrangements and/or deletions are found in 62% of precursor 8-ALL cases, 
which is a higher percentage than would be expected in normal immature 8-cells because 
TABLE 1. Immunogenetic characteristics of g..lineage leukemias8 • 
IgH genes 
rearrangements (RIG, R/R, D/R) 
biallelic deletions (DID) 
bi~/oligoclonality 
N~region insertiond 
IgK genese 
rearrangements (RIG, R/R, D/R) 
deletions (Kde~mediated) (DIG, DID) 
N~region insertiond (Kde) 
TcR genes 
rearrangements andlor deletions 
N-region insertiond 
Precursor B~ALLb 
96% 
4% 
30~40% 
-10-30 bp 
29% 
50% 
-5 bp 
94% 
Chronic B~cell leukemiasc 
100% 
0% 
<1% 
-10-30 bp 
Ig",+ B~cells: 100% 
Ig>.. + B-cells: 83% 
Ig",+ B~cells: 32% 
Ig>.. + B~cells: 100% 
-1 bp 
? 
a. The immunogenotypic characteristics found in chronic B-cell leukemias are believed to be cemparable with the immunogenotypic 
findings in normal mature B-cells, because these leukemias encompass cells which aro assumed to have gone through the normal 
B-cell differontiation pathway. 
b. The precursor B-ALL include null ALL, common ALL. and pre-B-ALL and their data are obtainad from the various chaptors of this 
thesis. 
c. The chronic Smlg + B-cell leukemias include chronic lymphocytic leukemias, hairy cell leukomias, and pro lymphocytic leukemias and 
their data are obtained from Chapters 2.2, 2.3, and 5.2. 
d. N-rogion insertion is found at tho junctions of V-O and D..J gene rearrangements in case of IgH, TcR-.8, and TcR-.)gonos. The N-region 
insertion is found at the junctions of V..J gene rearrangements in case of TcR--rgenes and at the junctions of V-Kde and intron RSS-
Kde in case of IgK genes. 
0. In 62% of precursor B-ALL cases, 19K gene rearrangements and/or delotions are found. V~JK rearrangoments and Kde-mediatod IgK 
gene deletions (Kde rearrangement to the intron RSS (heptamer)) can be found on one allele simultaneously resulting in a decrease 
of the total number of IgK gene rearrangements and/or delotlons. 
f. Data are obtained from references (43-46). 
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in 10-20% of immature B-cells 19K gene rearrangements are present (Table 1) (see also 
Chapter 2.1 and 2.3) (34-37). Moreover, in normal (immature) B-cellsthejunctional regions 
formed by V" and J" gene rearrangements are small due to limited N-nucleotide insertion 
(N-region) (-1 bp; range: 0-5) (38-41). As soon as IgH gene rearrangements are completed 
during B-cell differentiation, TdT activity starts to decrease, resulting in limited N-regions 
in IgL gene rearrangements. Our data comparing junctional regions formed by Kde 
rearrangements in precursor B-ALL and chronic B-ceilleukemias show that TdT is still active 
in precursor B-ALL as shown by an average N-region of 5 bp (range 0-18 bp), whereas in 
the chronic B-cell leukemias an average N-region of 1 bp (range 0-8 bp) was found, which 
appeared to be comparable with the N-regions found in junctional regions formed by V K-JK 
gene rearrangements in the normal B-cell (Table 1) (see above and Chapter 5.2) (38-41). 
Another striking difference between precursor B-ALL and normal (immature) B-cells is 
the presence of cross-lineage TcR gene rearrangements, occurring in 94% of precursor B-
ALL and in only - 5% in chronic B-cell leukemias and probably not in normal precursor B-
cells (see also Chapter 3.4 and Table 1) (30,42). The various immunogenotypic findings in 
precursor B-ALL and chronic B-cellieukemias are summarized in Table 1. The immunogeno-
typic characteristics found in chronic B-cell leukemias are believed to be comparable with 
the immunogenotypic findings in normal mature B-cells, because these leukemias 
encompass cells which are assumed to have gone through the normal B-cell differentiation 
pathway (47). Although it is not clear where in the B-cell differentiation the malignant 
transformation occurs, apparently the maturation arrest of the 'malignant' B-cell takes place 
in a later stage when the recombinase system is inactive. 
The development of the precursor B-ALL cell 
Although the precursor 8-ALL cell is comparable with its normal counterpart at the 
morphologic and immunophenotypic level, in the majority of cases (> 90%) its immunoge-
notype differs completely from normal (immature) 8-cells. What are the explanations for 
these findings in precursor B-ALL and what can be learned from it, considering the origin 
and the development of precursor 8-ALL? 
A. Are immature B-cells with an aberrant immunogenotype leukemia-target cells? 
B. Are {pre-)abortive B-cells leukemia-target cells? 
C. Represent immunogenotypic abnormalities a genetic deregulation as a result of the 
malignant transformation and maturation arrest of an immature B-cell? 
These three possibilities are visualized in Figure 1. In this hypothetical diagram of the origin 
of the precursor 8-ALL and chronic 8-cellleukemia cells, two compartments are indicated: 
one populated with non-leukemic (precursor) 8-cells, divided in 'normal' (precursor) 8-cells 
and (pre-)abortive B-cells and one populated with leukemic cells (monoclonal or bi-
/oligoclonal cell populations). These two compartments are separated by the malignant 
transformation (oncogenic event). As shown, immunogenotypic aberrations (e.g. early 19K 
gene rearrangements and/or deletions, large N-regions in the junctional regions of Kde 
rearrangements, cross-lineage TcR gene rearrangements, and the increasing chance of 
continuing rearrangement processes with time) occur either before (possibilities A and B) 
or as result of the malignant transformation (possibility C). The fact that these immunoge-
notypic aberrations, untill now, are only found in precursor B-ALL and not in normal 
Normal 
(precursor) 8-ceU 
compartment 
normal B-cells 
(Pre-) abortive B-cells 
Malignant 
transfonnatlon 
Leukemia 
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Figure 1. Hypothetical diagram of the origin of the precursor B-ALL and chronic B-cell leukemia, based on Ig 
and TcR gene rearrangement studies. Indicated are two compartments: one populated with non-leukemic 
(precursor) B-cells, divided in 'normal' (precursor) 8-cells and {pre-)abortive 8-cells and one'populated with 
leukemic cells (monoclonal or bi-/oligoclonal cell populations). These two compartments are separated by the 
malignant transformation. The explanation of the three possibilities in development of (precursor)8-cell 
leukemia are discussed in the text. In case of chronic 8-cell leukemias it is not clear where in the 8-cell 
differentiation the malignant transformation occurs, apparently the maturation arrest of the 'malignant' 8-cell 
takes place in a later stage when the recombinase system is inactive. Abbreviations used: IgH, IgH gene 
rearrangements; Ig,c;, Ig" gene rearrangements with small N-regions; KdeL, Kde rearrangements with large 
N-regions; Kdes, Kde rearrangements with small N-regions; Smlg,,+ ISmlgA + ISmlgL, expression of Ig 
molecules on the cell membrane. 
(immature) B-cells or chronic B-cell leukemias and the fact that RAG and TdT are 
continuously expressed in precursor B-ALL cells, give strong support for possibility C. This 
means that the ongoing activity of the recombinase system as result of the malignant 
transformation and maturation arrest is the cause for these immunogenetic abnormalities. 
Unfortunately, definitive conclusions are difficult to draw. 
The solution to this dilemma may be found in the immunogenotypic characterization 
of normal precursor B-cells. Although currently no indications for the presence of 
immunogenetic abnormalities in normal precursor B-ceUs have been observed, the 
knowledge of immunogenetic characteristics of normal precursor B-cells is limited. 
Precursor B-cells can easily be identified by the presence of TdT expression on the 
nuclear membrane and simultaneously CD1 0 expression on the cell membrane, unfortunate-
ly their number in normal BM is low (children 5-10%; adults 2-5%) and sufficient cells for 
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immunogenotypic analysis are therefore difficult to obtain. This problem may be overcome 
by using regenerating 8M from children treated by chemotherapy for malignancies (e.g. 
solid tumors or brain tumors). Because, in between the therapy protocols, the 8M is often 
loaded with high numbers of CD 1 OrrdT double positive cells (20-50% of mononuclear cells) 
due to regeneration. 
After cell sorting, DNA can be isolated from the precursor B-cells and subsequently 
analyzed. Using the presence of preferential gene rearrangements, which can be easily 
evaluated due to known restriction fragments, can probably answer the raised questions. 
These preferential gene rearrangements are: e.g. Kde rearrangements to the recombination 
signal sequences in the J<-C< intron (intron RSS) and Vo2-Do3 or Do2-Do3 gene 
rearrangements. Within a few years, single precursor 8-cell analysis by use of laser 
microscopy and single cell peR will be possible, providing a new dimension in this field of 
research. 
B-lineage leukemias as a model for normal 8-cell differentiation 
As mentioned above, B-lineage leukemias are generally considered as clonal malignant 
counterparts of normal (immature) B-cells. The clonal cells of these leukemias are thought 
to be frozen in a specific stage of the B-cell differentiation. Precursor B-ALL are assumed 
to originate in the BM from malignantly transformed precursor B-cells. This is confirmed by 
the fact that the precursor B-ALL and its normal counterpart have comparable morphological 
and immunophenotypic characteristics. In addition, although aberrant (e.g. cross-lineage) 
immunological marker expression can be found on precursor B-ALL cells, it cannot be 
excluded that these i aberrant' markers are also found on normal precursor B-cells. 
The immunogenotypic findings in precursor B-ALL described and discussed in this 
thesis are in the far majority not comparable with the immunogenotypic characteristics of 
normal immature B-cells. This raises the question whether it is permitted to use leukemias 
as a model for studying normal lymphoid differentiation, especially in case of Ig and/or TcR 
gene rearrangement studies. We know that leukemias are clonal cell populations, in which 
generally each cell has identical morphological, immunophenotypic, karyotypiC, and 
immunogenotypic features. This phenomenon provides an unique tool for studying the 
'single' cell, which can be easily distinguished from the background of 'normal' cells. This 
is also the case with immortalized ALL cells, the so-called cell lines. Still, the the use of ALL 
or cell lines as a model for normal lymphoid differentiation has its limitations, because it is 
difficult to distinguish between processes occurring as a result of the malignant 
transformation and maturation arrest, and processes due to physiological processes 
occurring in normal (precursor) B-cells. Fortunately, these limitations (especially immunoge-
netic abnormalities) can be recognized and explained easily. 
6.3 PERSPECTIVES 
Although treatment results in childhood ALL have improved considerably during the 
last two decades, still 20·30% of ALL patients develop a relapse. Unfortunately, in adult 
ALL the prognosis is worse, because 60-75% of adult ALL patients will eventually develop 
a relapse. For the most optimal choice of ALL treatment in children and adults, accurate 
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diagnosis and follow-up of ALL and a reliable prognosis of the disease course is important. 
Besides morphological and immunophenotypic analysis at diagnosis, immunogenotypic 
characterization of the malignant cell (population) with the Southern blot technique can 
provide additional information (e.g. subclone formation) I important for prognosis and follow-
up of the patient. Still to prevent unnecessary extensive analyses and needless expense, 
careful evaluation of the various possible analyses in different patients or patient groups 
have to be done. Furthermore, the clinical relevance (lower relapse rates and higher survival 
rates due to adaptation of treatment protocols) of early detection of MRD should be 
investigated in prospective multicenter studies. The costs of these analyses will be high and 
should be considered in the advantages of early detection of MRD. 
Although extensive studies in ALL have given more insight in the origin of ALL, 
explanations for its cause remain ambiguous. Our immunogenotypic studies helped to raise 
a corner of the veil. Future studies especially in normal precursor B-cells will hopefully 
elucidate the relation between the malignant cell and its normal counterpart. 
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SUMMARY 
In children the majority (-85%) of acute leukemias consists of acute lymphoblastic 
leukemia (ALL), while a minority (-15%) consists of acute non-lymphocytic leukemia 
(ANLL). ALL is a disorder characterized by an uncontrolled proliferation of immature 
lymphoid cells originating either in the bone marrow (BM) or in the thymus. In general, each 
ALL cell has identical characteristics, thereby proving that ALL is a clonal disease. Although 
treatment results in childhood ALL have improved considerably during the last two decades, 
still 20-30% of ALL patients develops a relapse. To increase insight into the factors and 
mechanisms which influence the development of a relapse in childhood ALL, extensive 
analyses have been performed on the leukemic cells at diagnosis and subsequent relapse. 
These analyses concerned morphological, immunophenotypic, karyotypic, and 
immunogenotypic analysis. 
Chapter 1 summarizes the present knowledge on epidemiology, etiology, diagnosis, 
treatment, and relapse of childhood ALL. Each year 75-85 children with ALL are diagnosed 
in the Netherlands, with an incidence rate of -3.7 per 100,000 children «16 years). 
Inherited, environmental. and endogenous factors are assumed to be responsible for the 
induction of ALL by various mechanisms and through a multi-step process. Still, in most 
cases the etiology is unknown. Immature B- and T-cells are due to its intrinsic 
developmental program at higher risk of (spontaneous) mutation than other somatic cells, 
particularly at early stages of development. This probably explains the relative high 
frequencies of leukemia in young children. Still, leukemias will only develop through 
mutational events when these mutations effect critical genes, such as proto-oncogenes or 
suppressor genes. The findings of non-random specific chromosomal abnormalities 
associated with ALL supports the important pathogenetic role of genetic alterations. 
The diagnosis of ALL is traditionally based on cytomorphology and cytochemistry of 
BM smears and classified according to the French American British (FAB) classification 
system. With the application of more advanced techniques, such as immunological marker 
analysis, cytogenetic analysis, and molecular analysis, the diagnosis of ALL has become 
more accurate. In addition, these advanced techniques have given the possibility to further 
subcategorize the ALL. The latter appeared to be important for the determination of 
prognostic factors at diagnosis and for stratification in treatment protocols. Chemotherapy 
is the treatment of first choice in childhood ALL. Presently, a complete remission is 
achieved in - 97% of childhood ALL cases with the applied chemotherapy. Bone marrow 
transplantation (BMT) will be done after first relapse during second remission, or in first 
remission in case of the occurrence of special translocations, such as t(9;22) and t(4; 11), 
which are associated with a poor prognosis. Nevertheless, still 20-30% of ALL patients 
relapse. The most common site of ALL relapse is the BM, but extramedullary relapses (e.g. 
in the central nervous system, testis, or other isolated sites) are not unusual. Although 
relatively little is known about the cause of relapse, in the majority of relapse cases a 
relation with the ALL at initial presentation can be proven by identical morphology, 
immunophenotype, karyotype, or immunogenotype. Apparently, despite of the applied 
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cytostatic treatment, residual ALL cells persist. This emphasizes the importance of methods 
to detect residual ALL cells to determine the effectiveness of the applied treatment. 
In general, ALL are regarded as clonal malignant counterparts of normal immature B-
and T-cells. Immunoglobulin (lgi and T-cell receptor (TcRI gene rearrangements, necessary 
for obtaining antigen specific receptor molecules on the cell membrane of mature B- and T~ 
lymphocytes, respectively, occur early during lymphoid differentiation. Therefore, ALL cells 
will have identically rearranged Ig or TcR genes. Chapter 2.1 describes the basic aspects 
of these antigen specific receptor genes and gene rearrangements. Analysis of 19 and TcR 
gene rearrangements by Southern blotting or by the polymerase chain reaction (PCRI 
technique can be used for diagnostic studies. To improve the detection of 19 heavy~chain 
(lgHI and kappa Ig light-chain (IgLI gene rearrangements by Southern blot analysis for 
diagnostic purposes, the precise restriction map of the relevant IgH and 19K regions were 
carefully determined. In addition, the appropriate combinations of restriction enzymes with 
newly developed optimal DNA probes were evaluated (Chapter 2.2 and 2.31. Our extensive 
Southern blot analysis revealed that rearrangements in the JH and JK region are optimally 
detectable by use of J probes, which are complementary to the 3' flanking sequences of 
the J region, such as the IGHJ6 and IGKJ5 probes for detection of IgH and IgK gene 
rearrangements, respectively. Furthermore, at least two different restriction enzyme digests 
which are not affected by polymorph isms, and which produce small restriction fragments 
(generally < 10 kb), are recommended. Small restriction fragments will reduce the chance 
of comigration of germline and/or rearranged bands (Chapter 2.2 and 2.31. 
IgK gene deletions occur in - 50% of precursor B-All and in the far majority (> 98%) 
are mediated via a site-specific rearrangement of a so-called kappa deleting element (Kde). 
Two types of Kde-mediated IgK gene deletions (Kde rearrangements) can occur: i.e. Kde 
rearrangements either to heptamer recombination signal sequences in the JK-CK intron 
(intron RSSI, thereby deleting the CK region, or to a V K gene segment, thereby deleting the 
JK and CK regions. The two types of Kde rearrangements are easily detectable with a newly 
developed Kde probe (IGKDEI. This is in contrast to the inaccurate information obtained 
with the JK and CK probes, because these probes detect deletions only in the form of 
decreased densities of JK and/or CK germline bands in the absence of rearranged bands 
(Chapter 2.31. 
With these optimal Southern blot conditions, Ig gene rearrangements were analyzed 
in a large group of precursor B-All patients at diagnosis (Chapter 3). The results show that 
IgH, IgK, and IgA gene rearrangements and/or deletions occur in 96%, 62%, and 21 % of 
cases, respectively, suggesting a hierarchical order in IgH and Igl gene rearrangements. 
When excluding hyperdiploidy of chromosome 14, multiple IgH and IgK genes were found 
in 30-40% and 6% of cases, respectively. These multiple IgH and IgK gene rearrangements 
are most probably due to subclone formation (bi-/oligoclonality), caused by continuing or 
secondary gene rearrangements in the majority of precursor B-AlL. It has been suggested 
that precursor B-ALL with multiple IgH gene rearrangements have a higher tendency to 
relapse. Although higher relapse rates were found in the oligoclonal group (53%) compared 
with the monoclonal group (20%1, the log rank trend test showed no significance (Chapter 
3.21. 
In five of ten bi-/oligoclonal precursor B-ALl patients differences in IgH gene 
rearrangement patterns between BM and peripheral blood samples at diagnosis were found. 
Summary 231 
These differences could be interpreted as the presence of an extra subclone in two cases 
and differences in size of the subclones in three cases. In all five cases, the extra subclones 
or the relatively larger sized subclones were found in the 8M, suggesting that subclone 
formation in precursor 8-ALL starts in this tissue compartment from which the precursor 
B-ALL cells are thought to originate (Chapter 3.3). 
Chapter 3.4 describes the Southern blot analysis of cross-lineage TcR gene 
rearrangements in precursor B-ALl. In 94% (1011108) of the precursor B-ALL group, at 
least one TcR gene was rearranged. TcR-,8, TcR-'}', and TcR~o gene rearrangements and/or 
deletions were found in 36%, 57%, and 91 % of cases, respectively. TcR~,8 gene 
rearrangements were monoallelic V(D)J,82 rearrangements in 54% and incomplete D,8-Jt32 
rearrangements in 37% of cases. TcR~'Y gene rearrangements most frequently contained 
monoallelic rearrangements to J'Y1 gene segments and -80% of TcR-o gene 
rearrangements represented incomplete Vo2-Do3 or Do2~Do3 gene rearrangements. The 
most likely explanation forthe occurrence of these cross-lineage TcR gene rearrangements 
in precursor B-ALl is that these rearrangements represent a genetic deregulation due to the 
ongoing activity of the recombinase system after malignant transformation and maturation 
arrest. In this way the virtual absence of cross~lineage TcR gene rearrangements in normal 
precursor 8-cells and in mature B-cell malignancies can be explained. Comparison of our 
results with over 400 cases reported in the literature revealed a higher percentage of crossw 
lineage TcR gene rearrangements in our group of precursor B-ALL. This discrepancy is 
probably due to our larger panels of TcR DNA probes (especially for the TcR-i> and TcR-o 
genes). 
One of the important aims of the study was to obtain insight into the mechanisms 
which influence the development of relapse in childhood ALL. For this purpose, several 
comparative analyses at diagnosis and relapse have been performed. Chapter 4.1 
summarizes the relevant comparative cytogenetic data reported in the literature. Karyotypic 
shifts were found in 33% (811246 cases) at relapse. In only a minority of these shifts 
(5%;4181) no clonal relation was found. Our comparative morphological and 
immunophenotypic analyses at diagnosis and relapse in 40 childhood ALL (32 precursor B-
ALL and eight T-ALL) are described in Chapter 4.2. Morphological differences between 
diagnosis and relapse were detected in 34% of precursor 8-ALL and in only one case of T-
ALL. Differences in immunological marker expression were found in 69% of precursor B-
ALL and in 63% of T-ALl. No obvious relation was found between the morphological shifts 
and the marker-shifts. In 10%, the marker-shifts resulted in an intra-lineage shift and in 5% 
in an inter~lineage shift to ANLL in precursor B-ALL.ln T~ALL no intra- or inter-lineage shifts 
were found. Chapter 4.3 summarizes the comparative analYSis of Ig and TcR genes in 40 
childhood ALL (30 precursor B-ALL and 10 T-ALL) at diagnosis and relapse. Differences in 
rearrangement patterns between diagnosis and relapse were found in 67% (20 cases) of 
precursor B-ALL (including all eight analyzed bi-Ioligoclonal cases) and 50% (five cases) of 
T-ALl. In all analyzed Ig (lgH, IgK, and IgA) and TcR (TcR-i>, TcR-,¥, and TcR-o) genes, 
changes were found in precursor B-ALL at relapse. In T-ALl, changes at relapse were 
detected in all Ig and TcR genes except for the IgL genes, which remained in germline 
configuration. Two precursor B-ALL showed completely different Ig and TcR genes 
rearrangement patterns at relapse, suggesting the absence of a clonal relation between the 
leukemic cells at diagnosis and relapse and the development of a secondary leukemia (i.e. 
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ANLL). The clonal evolution in the other 23 ALL patients was based on continuing 
rearrangement processes and selection of subclones. The development of changes in 19 and 
TeR gene rearrangement patterns was related to remission duration, suggesting an 
increasing chance of continuing rearrangement processes with time. 
19 and TeR gene rearrangement patterns in leukemias and malignant lymphomas have 
been used as markers for clonality, which are unique for each malignancy. This especially 
concerns the junctional regions of rearranged 19 and TeR genes, because they are regarded 
as tumor-specific markers. Based on this assumption, the peR technique has been used for 
amplification of the tumor-specific junctional regions of rearranged 19H, TcR-,)" and TcR-o 
genes to detect minimal residual disease (MRD) during follow-up of ALL patients, as 
summarized in Chapter 5.1. The junctional regions of IgH, TcR-y, and TcR-o gene 
rearrangements can be identified in -- 80% of precursor 8-ALL and in > 90% of T -ALL 
(Chapters 3.4 and 5.1). The heterogeneity in Ig and TcR gene rearrangement patterns found 
at diagnosis and relapse might hamper PCR-mediated MRD detection. However in 75-90% 
of ALL cases, at least one IgH, TcR-,)" or TcR-o allele remains stable at relapse. Therefore, 
two or more junctional regions of different IgITcR genes should be monitored for optimal 
MRD detection during follow-up of ALL patients (Chapters 4.3 and 5.1). ALL are also 
characterized by high frequencies of clonal chromosome aberrations (e.g. translocations). 
These translocations result in fusion genes and fusion transcripts, such as t{9;22), t(1 ; 19), 
and t(4;1 1) in precursor 8-ALL or aberrations with site-specific breakpoints such as TAL1 
deletions in T-ALL. So far such breakpoint fusion region can be identified in 15-20% of 
childhood ALL and 25-30% of adult ALL. The main advantage of chromosome aberrations 
as PCR-MRD target is its stability during the disease course (Chapter 5.1). 
Chapter 5.2 describes the analysis of junctional regions formed by Kde rearrangements 
either to the intron RSS or to a Vr. gene segment in B-lineage leukemias (precursor a-ALL 
and chronic B-cell leukemias). Subsequent PCR and sequencing analysis of the junctional 
regions revealed a striking difference between both groups of B-lineage leukemias. An 
average insertion and deletion of 4.9 and 4.2 nucleotides, respectively, resulting in a large 
junctional diversity in precursor B-ALL was found, whereas in chronic 8-cellleukemias this 
junctional diversity was essentially lower (1.0 and 2.5, respectively), especially in the 
junctional regions formed by V r.-Kde rearrangements. This junctional diversity as well as the 
limited number of primers necessary for PCR analysis of Kde rearrangements make Kde 
rearrangements a potential peR target for MRD detection in precursor 8-ALL. Kde 
rearrangements were found in -50% in precursor 8-ALL (Chapter 2.3). A detection limit 
of -- 10-4 was, observed in a dilution experiment and the specificity of the leukemia/patient-
specific olig6nucleotide probes was proven by hybridization analysis. The stability of the 
MRD-PCR target was proven in five precursor B-ALL at relapse. 
Chapter 6 addresses the significance of the various immunogenotypic findings in 
precursor 8-ALL for the development of ALL and the implications for the use of precursor 
8-ALL as a model for normal 8-cell differentiation. The immunogenetic characteristics of the 
precursor 8-ALL (e.g. early IgK gene rearrangements and/or deletions, substantial N-
nucleotide insertion in the junctional regions of Kde rearrangements, and cross-lineage TcR 
gene rearrangements) are generally not found in normal immature B-cells. The most likely 
explanation for these 'aberrant' immunogenetic findings isthatthese 'aberrations' represent 
a genetic deregulation due to ongoing activity of the recombinase system as a result of the 
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malignant transformation and maturation arrest in an immature B~cell stage. The use of 
precursor B~ALL as a model for normal B-cell differentiation has its limitations, because it 
is difficult to distinguish between processes occurring as a result of the malignant 
transformation and maturation arrest, and processes due to physiological mechanisms 
occurring in normal (immature) B-cells. 
We conclude that accurate diagnosis and follow-up of leukemias and lymphomas is 
important for optimal choice of treatment in children and adults. Nowadays, extensive 
analysis (morphological, immunophenotypic, cytogenetic, molecular, and cell culture 
analysis) is possible in almost every leukemia or lymphoma patient at diagnosis to obtain 
all relevant data of the leukemia or lymphoma. In this way a reliable prognosis of the 
disease course can be made and the most optimal treatment can be applied. Still to prevent 
unnecessary extensive analyses and needless expense, careful evaluation of the various 
possible analyses in different patients or patient-groups has to be done. In addition, the 
significance of MRD studies with PCR during follow-up has to be validated in prospective 
multicenter studies. Moreover, the extra costs of these analyses have to be considered 
against the advantages of these MRO-PCR studies for the treatment of ALL and lymphoma 
patients. 

SAMENVATTING 
Acute leukemie op de kinderleeftijd is in ± 85% van de gevallen een acute Iymfatische 
leukemie (ALL) en in ± 15% een acute niet-Iymfatische leukemie (ANLL). ALL is een vorm 
van bloedkanker die wordt gekenmerkt door een ongecontroleerde groei van onrijpe 
Iymfatische cellen in het beenmerg of in de thymus. In het algemeen worden de cellen van 
een ALL beschouwd als kwaadaardige tegenpolen van normale onrijpe 8- en T-ceJ/en. Deze 
ALL cellen blijken vergelijkbare kenmerken te hebben, waarmee het ontstaan uit een eel 
(klonaliteit) van de ALL bevestigd wordt. Ondanks de verbeterde behandelingsresultaten bij 
ALL op de kinderleeftijd gedurende de laatste twintig jaar, ontwikkelt 20 tot 30% van de 
kinderen een recidief. Om het inzicht te vergroten in de factoren en mechanismen welke het 
ontstaan en de verdere ontwikkeling van een recidief van ALL op de kinderleeftijd 
be"invloeden, hebben wij de leukemiecellen uitgebreid geanalyseerd bij zowel diagnose als 
recidief. Dit betreft morfologische, immunofenotypische, cytogenetische en immuno-
genotypische analyses. 
Hoofdstuk 1 beschrijft de huidige kennis van de epidemiologie, etiologie, diagnose, 
behandeling en ontstaan van recidief bij ALL op de kinderleeftijd. Elk jaar worden in 
Nederland 75 tot 85 kinderen met een ALL gediagnostiseerd, met een incidentie van 3,7 
nieuwe patienten per 100.000 kinderen (leeftijd < 16 jaar). Men veronderstelt dat erfelijke, 
omgevings- en endogene factoren verantwoordelijk zijn voor het ontstaan van ALL via een 
meerstaps tumor-inducerend proces. Toch is van de meeste ALL de oorzaak onbekend. 
Vooral in de eerste levensjaren worden B- en T-cellen massaal aangemaakt, omdat 
deze cellen een centrale rol spelen in het afweersysteem, dat zich juist op die leeftijd snel 
ontwikkelt als reactie op de (eerste) contacten met de vele micro-organismen. Onrijpe B-
en T -cell en hebben tijdens hun ontwikkeling een hoger risico op (spontane) mutaties in het 
DNA dan andere lichaamscellen. Dit verklaart waarschijnlijk de relatief hoge frequentie van 
ALL bij jonge kinderen. Een leukemie kan echter aileen ontstaan op basis van mutaties, 
wanneer deze mutaties plaatsvinden in specifieke genen, zoals proto-oncogenen of 
suppressiegenen. De rol van genetische veranderingen bij het ontstaan van leukemie wordt 
benadrukt door de associatie tussen "non-random" chromosoomafwijkingen en 
verschillende typen ALL, zoals voorloper B-ALL en T-ALL. 
Van oudsher wordt ALL gediagnostiseerd en geklassificeerd vol gens het Frans-
Amerikaans-Britse (FAB) klassificatiesysteem, dat gebaseerd is op morfologische en 
cytochemische kenmerken van de leukemiecellen in een beenmerguitstrijkje. Door 
toepassing van meer geavanceerde technieken, zoals immunologische markeranalyse, 
cytogenetische analyse en immunogenetische analyse, is nadere karakterisering van ALL 
mogelijk en kunnen verschillende ALL (sub)typen worden onderscheiden. Oit blijkt belangrijk 
te zijn v~~r de prognose en het vaststellen van het behandelingsprotocol. 
Kinderen met ALL worden in het algemeen behandeld met chemotherapie, waarmee 
bij ongeveer 97% van de kinderen een complete remissie (CR) wordt bereikt; dit betekent 
dat in bloed en beenmerg geen leukemiecellen aantoonbaar zijn met morfologische 
technieken. Een tweede mogelijke therapie, de beenmergtransplantatie (BMT) waarbij 
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beenmerg (BM) van een donor (vaak broer of zus) of "schoon" BM van de patient zelf 
gegeven wordt aan de leukemie patient zal veelal pas worden uitgevoerd na het eerste 
recidief tijdens tweede CR. In bijzondere gevallen, zoals bij specifieke chromosoom 
translocaties met een slechte prognose bijvoorbeeld t(9;22) en t(4;11)) kan BMT worden 
toegepast in eerste CR. Tegenwoordig recidiveert 20 tot 30% van de kinderen met ALL. 
Meestal ontstaat een recidief in het beenmerg, hoewel het niet ongewoon is dat recidieven 
buiten het beenmerg ontstaan, zoals in het centraal zenuwstelsel, in de testis of op andere 
ge'isoleerde locaties. Hoewel nog weinig bekend is over de oorzaak van een ALL recidief, 
wordt in de meerderheid van de recidieven een relatie met de oorspronkelijke leukemiecellen 
bij diagnose gevonden: de morfologische, immunofenotypische, cytogenetische en 
immunogenotypische ken mer ken zijn geheel of gedeeltelijk identiek. Hoewel de patienten 
in CR waren, heeft de chemotherapie blijkbaar niet aile leukemiecellen kunnen doden. Het 
is daarom belangrijk om technieken te ontwikkelen voor het aantonen van kleine aantallen 
resterende leukemiecellen, zodat de effectiviteit van de chemotherapie beter vast gesteld 
kan worden. 
Immunoglobuline (lg) en T-cel-receptor (TcR) genen coderen voor de antigeen-
specifieke receptoren op de celmembraan van respectievelijk rijpe B- en T-cellen. Deze Ig 
en TcR genen zullen vroeg tijdens de Iymfatische differentiatie herschikken met behulp van 
een genherschikkings-enzymsysteem, waarbij V, (D) en J gensegmenten van Ig en TcR 
genen aan elkaar gekoppeld worden. Door de klonaliteit van de ALL zal elke leukemiecel 
identiek herschikte Ig en/of TcR genen hebben. Hoofdstuk 2.1 beschrijft de basale aspecten 
van deze antigeen-specifieke receptorgenen en genherschikkingen. Analyse van de Ig en 
TcR genherschikkingen met behulp van de "Southern blot" techniek en de zogenaamde 
polymerase ketting reactie (peR) techniek kan gebruikt worden voor onderzoek en 
diagnostiek van leukemieen en Iymfomen. Om herkenning van de Ig zware keten (lgH) en 
kappa Ig lichte keten (igL) genherschikkingen met behulp van de "Southern blot" techniek 
te verbeteren, werd een gedetailleerde kaart met knipplaatsen van verschillende relevante 
restrictie-enzymen (restrictie kaart) van de IgH en IgK genen samengesteld. Tevens werden 
optimale combinaties van restrictie-enzymen en nieuw gemaakte DNA probes geselecteerd 
en geevalueerd (Hoofdstuk 2.2 en 2.3). Uitgebreide "Southern blot" analyse maaktduidelijk 
dat herschikkingen in de IgH en IgK genen het best aangetoond kunnen worden met J 
probes die het gebied pal achter de J regio's herkennen zeals onze IGHJ6 en IGKJ5 probes. 
Wij raden hierbij aan om twee verschillende restrictie-enzym digesten te gebruiken, die niet 
beTnvloed worden door polymorfismen en die resulteren in kleine restrictiefragmenten ( < 1 0 
kb). Kleine restrictiefragmenten verkleinen namelijk de kans op co-migratie van kiemlijn 
en/of herschikte banden zodat problemen bij de interpretatie van de analyse veelal 
voorkomen worden (Hoofdstuk 2.2 en 2.3). 
IgK gendeleties komen in ongeveer 50% van de voorloper B-ALL voor. Deze IgK 
gendeleties worden in de meerderheid (> 98%) gereguleerd door een specifieke 
herschikking van het zogenaamde kappa deletie element (Kde). Er zijn twee typen Kde 
herschikkingen bekend: een Kde herschikking naar een heptameer recombinatie signaal 
sequentie in het JK-CK intron (intron RSS), waarbij de CK regio verdwijnt en een Kde 
herschikking naar een V K gensegment, waarbij naast de CK regio ook de JK regio verdwijnt. 
Deze twee typen Kde herschikkingen zijn gemakkelijk te herkennen met een door ons nieuw 
ontwikkelde Kde probe (IGKDE). Het aantonen van deze Kde herschikkingen met de JK en 
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CK probes is veel lastiger of onmogelijk omdat deze probes de Kde herschikkingen aileen 
kunnen herkennen als een zwakker signaal van de JK en/of CK kiemlijn band en zonder dat 
er herschikte banden aanwezig zijn (Hoofdstuk 2.3). 
De optimale "Southern blot" condities werden gebruikt v~~r analyse van Ig 
genherschikkingen bij een grote groep voorloper B-ALL patienten bij diagnose (Hoofdstuk 
3). De resultaten lieten zien dat in de voorloper B-ALL patienten IgH, IgK, en Ig}. 
genherschikkingen en/of deleties voorkomen in respectievelijk 96%, 62% en 21 %. Meer 
dan twee IgH en IgK genherschikkingen werden gevonden bij respectievelijk 30 tot 40% en 
6% van voorloper B-ALL patienten. Deze meerdere IgH en IgK genherschikkingen worden 
veroorzaakt door subkloonvorming (bi-/oligoklonaliteit) binnen de voorloper B-ALL. In de 
meerderheid van de voorloper B-ALL wordt deze subkloonvorming veroorzaakt door 
doorgaande of secundaire genherschikkingen. In de literatuur werd gesuggereerd dat 
voorloper B-ALL patienten met meerdere IgH genherschikkingen een grotere kans hebben 
op een recidief. Hoewel in onze oligoklonale patienten relatief meer recidieven (53%) 
werden gevonden in vergelijking met de monoklonale patienten (20%), was dit verschil toch 
niet significant (Hoofdstuk 3.2). 
In vijf van de tien onderzochte bi-/oligoklonale voorloper B-ALL patienten werden bij 
diagnose verschillen in IgH genherschikkingspatronen gevonden tussen beenmerg en bloed 
celmonsters. Deze verschillen konden bij twee patienten worden geTnterpreteerd als de 
aanwezigheid van een extra subkloon en bij drie patienten als een verschil in omvang van 
de verschillende subklonen. In elke patient werd de extra subkloon of relatief grotere 
subkloon in het beenmerg gevonden. Dit zou kunnen betekenen dat subkloonvorming in 
voorloper B-ALL start in het weefselcompartiment waar normale voorloper B cellen 
ontstaan, nl. het beenmerg. 
Hoofdstuk 3.4 beschrijft de "Southern blot" analyse van "cross-lineage" TcR 
genherschikkingen in voorloper B-ALL. "Cross-lineage" genherschikkingen worden 
gedefinieerd als genherschikkingen die gevonden worden buiten hun eigen normale 
differentiatielijn. In 94% (101/108) van de voorloper B-ALL bleek tenminste een TcR gen 
herschikt te zijn. TcR-.8, TcR-'Y en TcR-o genherschikkingen en/of deleties werden in 
respectievelijk 36%, 57% en 91 % gevonden. TcR-j1 genherschikkingen bestonden 
voornamelijk uit monoallelische V(D)Jj12 herschikkingen (54%) of incomplete Dj1-Jj12 
herschikkingen (37%). De TcR--y genherschikkingen waren voornamelijk J'Y1 herschikkingen, 
terwijl de meeste TcR-o genherschikkingen (±80%) V02-D03 of D02-D03 herschikkingen 
waren. De belangrijkste verklaring voor de aanwezigheid van de ongebruikelijke "cross-
lineage" TcR genherschikkingen in voorloper B-ALL is dat deze genherschikkingen een 
genetische deregulatie vormen, veroorzaakt door een doorgaande aktiviteit van het 
genherschikkings-enzymsysteem ten gevolge van de kwaadaardige transformatie en de 
uitrijpingsblokkade. In normale voorloper B-cellen staat het genherschikkings-enzymsysteem 
tijdelijk aan en is de activiteit van dit enzymsysteem sterk gereguleerd, hetgeen 
waarschijnlijk verklaart dat de ongebruikelijke "cross-lineage" TcR genherschikkingen niet 
of nauwelijks voorkomen in normale onrijpe en rijpe B-cellen en ook niet in rijpe B-
celmaligniteiten, zoals chronische B-celleukemieen. In vergelijking met de "cross-lineage" 
TcR genherschikkingen bij meer dan 400 voorloper S-ALL patienten die in de literatuur 
gepubliceerd zijn, bleek dat in onze voorloper B-ALL groep meer "cross-lineage" TcR 
genherschikkingen werden gevonden. Oit verschil wordt waarschijnlijk veroorzaakt door 
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onze gectetailleerde analyses met een groet aantal DNA probes, vooral voar analyse van de 
TcR-1> en TcR-o genen. 
Een van de belangrijkste doelen van cns onderzoek was om meer inzicht te krijgen in 
de mechanismen die het ontstaan en de verdere ontwikkeling van een recidief bij kinderen 
met ALL be'invloeden. In de literatuur zijn reeds verscheidene vergelijkende analyses bij 
diagnose en recidief gepubliceerd. Hoofdstuk 4.1 vat informatie samen van relevante 
vergelijkende cytogenetische studies. Verancteringen in karyotype bij recidief werden bij 
33% (81/246) van de ALL patienten gevonden. In een minderheid van deze veranderingen 
(5%;4/81) werd geen klonale relatie aangetoond. Onze vergelijkende morfologische en 
immunofenotypische analyses bij diagnose en recidief van 40 kinderen met ALL (32 
voorloper 8-ALL en 8 T-ALL) zijn beschreven in Hoofdstuk 4.2. Veranderingen in de 
morfologie bij recidief werden gevonden bij 34% van de voorloper B-ALL en bij slechts eon 
T-ALL. Verschillen in immunologische marker expressie werden gevonden bij 69% van de 
voorloper B-ALL en 63% van de T-ALL. Er werd geen duidelijke relatie aangetoond tussen 
de morfologische veranderingen en veranderingen in de expressie van immunologische 
markers. Verandering in de expressie van immunologische markers gaat bij 10% van de 
voorloper 8-ALL gepaard met een intra-lineage verandering en bij 5% met een inter-lineage 
verandering naar een ANLL. Hoofdstuk 4.3 vat de informatie samen van de vergelijkende 
analyse van Ig en TcR genen bij diagnose en recidief van 40 kinderen met ALL (30 
voorloper B-ALL en 10 T-ALL). Verschillen in Ig en TcR genherschikkingspatronen tussen 
diagnose en recidief werden gevonden bij 67% (20/30) van de voorloper B-ALL patienten, 
inclusief de acht geanalyseerde bi-Ioligoklonale voorloper B-ALL, en bij 50% (5/10) van de 
T-ALL patienten. Hoewel de veranderingen in herschikkingspatronen ieder gen bleken te 
kunnen treffen, werden bij voorloper 8-ALL vooral veranderingen in IgH en TcR-o genen 
gevonden. Bij T-ALL werden veranderingen gevonden in IgH en de TcR genen, maar de IgL 
genen bleken in kiemlijnconfiguratie te blijven. In twee voorloper 8-ALL patienten werden 
geheel andere Ig en TcR genherschikkingspatronen gevonden bij het recidief vergeleken met 
de diagnose. De afwezigheid van een klonale relatie tussen diagnose en recidief bij deze 
twee patienten kon worden verklaard door de ontwikkeling van een secundaire leukemie 
(ANLL). De klonale evolutie in de overige 23 kinderen met ALL was gebaseerd op 
doorgaande genherschikkingsprocessen en selectie van subklonen. De kans op 
veranderingen in Ig en TcR genherschikkingspatronen bij recidiefbleek deels gerelateerd aan 
de remissieduur. Dit suggereert dat er een grotere kans bestaat op doorgaande 
genherschikkingen naarmate de ALL cellen langer overleven en het genherschikkings-
enzymsysteem langer actief kan zijn. 
De Ig en TcR genherschikkingspatronen worden gebruiktals unieke klonaliteitsmarkers 
in leukemieen en kwaadaardige Iymfomen. Met name de verbindingsplaatsen tussen de 
verschillende, aan elkaar gekoppelde gensegmenten (de zogenaamde "junctional regions") 
van herschikte Ig en TcR genen worden gebruikt. Dit berust op het feit dat de "junctional 
regions" van herschikte Ig en TcR genen sterk kunnen varieren als gevolg van het 
samenkomen van V, (D) en J gensegmenten, het verlies van nucleotiden van deze 
gensegmenten en het toevoegen van extra nucleotiden op de verbindingsplaatsen van de 
gensegmenten. Deze "junctional regions" zijn identiek in elke ALL cel en worden daarom 
als tumor-specifieke markers beschouwd. Op basis van dit gegeven worden met behulp van 
de peR techniek tumor-specifieke "junctional regions" van herschikte IgH, TcR"",), en TcR-o 
Samenvatting 239 
genen vermeerderd om kleine aantallen leukemiecellen tijdens follow-up van ALL patienten 
aan te ton en (Hoofdstuk 5.1). Deze "junctional regions" van IgH, TcR-'Y en TcR-1) 
genherschikkingen kunnen in ongeveer 80% van de voorloper B-ALL en meer dan 90% van 
de T-ALL precies worden ge"identificeerd (Hoofdstukken 4.3 en 5.1). De mogelijke 
verschillen tussen Ig en TcR genherschikkingspatronen bij diagnose en recidief, kan de PCR-
gemedieerde detectie van kleine aantallen leukemiecellen hinderen. Gelukkig blijft in 75 tot 
90% van de ALL patienten tenminste een IgH, TcR--y of TcR-1) gen stabiel bij het recidief. 
Voor optimale detectie van kleine aantallen leukemiecellen is het daarom belangrijk om twee 
of meer "junctional regions" van verschillende Ig en/of TcR genen te gebruiken bij het 
vervolgen van ALL patienten (Hoofdstukken 4.3 en 5.1). 
ALL worden ook gekenmerkt door klonale chromosoomafwijkingen zoals translocaties. 
Fusiegenen en fusie-transcripten zijn het gevolg van deze chromosoomafwijkingen, zoals 
bij t(9;22), t(4;11) en t(1 ;19) in voorloper B-ALL en bij TAL1 deleties in T-ALL. Tot nu toe 
kunnen deze breukpunt-fusie regia's in 15 tot 20% van kinderen met ALL en in 25 tot 30% 
van volwassenen met ALL ge"identificeerd worden. Deze breukpunt-fusie regio's van de 
chromosoomafwijkingen kunnen ook als tumor-specifieke markers gebruikt worden en zijn 
dus geschikt om met behulp van de PCR techniek vermeerderd te worden om kleine 
aantallen leukemiecellen aan te tonen. De stabiliteit van deze chromosoomafwijkingen 
gedurende het ziekteverloop is hierbij het belangrijkste voordeel (Hoofdstuk 5.1). 
Hoofdstuk 5.2 beschrijft de analyse van "junctional regions" gevormd door Kde 
herschikkingen naar de intran RSS en naar V K gensegmenten in voorloper B-ALL en 
chronische B-cel leukemieen. Achtereenvolgende PCR en sequentie analyse van deze 
"junctional regions" bracht een belangrijk verschil aan het licht tussen beide groepen 
leukemieen. Een forse junctionele diversiteit werd gevonden als gevolg van een gemiddelde 
toevoeging en verlies van respectievelijk 4,9 en 4,2 nucleotiden in de "junctional regions" 
van voorloper B-ALL, terwijl bij chronische B-cel leukemieen deze junctionele diversiteit 
aanmerkelijk minder was (respectievelijk 1,0 en 2,5 nucleotiden), vooral in de "junctional 
regions" gevormd door de VK-Kde herschikkingen. De omvangrijke junctionele diversiteit in 
voorloper B-ALL en het beperkte aantal oligonucleotide primers dat nodig is voor de PCR 
analyse van Kde herschikkingen, maken deze Kde herschikkingen een potentieel doelwit 
v~~r de detectie van kleine aantallen leukemiecellen bij patienten met voorloper B-ALl. Deze 
Kde herschikkingen worden in ongeveer 50% van de voorloper B-ALL gevonden (Hoofdstuk 
2.3). Een detectielimiet van ±10-4 (1 leukemiecel tussen 10.000 normale cellen) werd 
gevonden in een verdunningsexperimentwaarbij leukemiecellen werden verdund in normale 
witte bloedcellen. De specificiteitvan de leukemie/patient-specifieke oligonucleotide probes 
werd bewezen door patient-specifieke hybridisatie resultaten. De stabiliteit van dit PCR 
doelwit werd bewezen door identieke PCR, hybridisatie of sequentie-analyse resultaten bij 
diagnose en recidief bij de vijf onderzochte voorloper B-ALl. 
Hoofdstuk 6 bediscussieert de betekenis van de verschillende immunogenetische 
bevindingen in voorloper B-ALL veor het ontstaan en de verdere ontwikkeling van ALL. 
Tevens worden de implicaties v~~r het gebruik van veorloper B-ALL als model voor norma Ie 
B-cel ontwikkeling besproken. De immunogenetische kenmerken van voorloper B-ALL, zoals 
vroege IgK genherschikkingen en/of deleties, verlies en toevoeging van nucleotiden in de 
"junctional regions" van Kde herschikkingen en "cross-lineage" TcR genherschikkingen, 
werden niet of nauwelijks in normale voorloper B-cellen gevonden. De meest waarschijnlijke 
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verklaring voordeze ongebruikelijke immunogenetische bevindingen is datze een genetische 
deregulatie weerspiegelen, veroorzaakt door een doorgaande aktiviteit van het 
genherschikkings-enzymsysteem na kwaadaardige transformatie en de uitrijpingsblokkade 
in een voor!oper 8-cel stadium. Het gebruik van voorloper 8-ALL als model VQar normale B-
eel ontwikkeling blijkt beperkingen te hebben amdat het moeilijk is om onderscheid te 
maken tU$sen processen ten gevolge van de kwaadaardige transformatie en de 
uitrijpingsblokkade en normale fysiologische processen. 
Wij concluderen dat nauwkeurige diagnose en nauwgezette follow-up van leukemieen 
en kwaadaardige Iymfomen belangrijk zijn veor de optimale keuze van behandeling, zowel 
bij kinderen als bij volwassenen. Met de huidige veelheid aan diagnostische technieken 
(morfologie, immunofenotypering, cytogenetica, immunogenetica, cel en weefselkweek, 
etc.) is dit mogelijk bij de meeste patienten met een leukemie of kwaadaardig Iymfoom. 
Hierdoor kan een betrouwbare prognose van het ziekteverloop verkregen worden en de 
meest optimale therapie worden toegepast. Om echter onnodig diagnostisch onderzoek en 
daarmee onnodige uitgaven te voorkomen is een nauwkeurige evaluatie van de diverse 
analyses per patient of patientengroep noodzakelijk. Tevens dient het belang van de peR 
techniek om kleine aantallen leukemiecellen ep te sporen bevestigd te worden in 
prospectieve "multicenter" studies, zodat de extra kosten van deze analyse afgewogen 
kunnen worden tegen de voordelen van deze vorm van diagnostiek voor de behandeling van 
patienten met een leukemie of een maligne Iymfoom. 
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ABBREVIATIONS 
autologous bone marrow transplantation 
acute lymphoblastic leukemia 
acute myeloid leukemia 
acute non-lymphoblastic leukemia 
cytosine arabinoside 
B-cell acute lymphoblastic leukemia 
bone marrow 
bone marrow transplantation 
base pair 
bovine serum albumine 
copy 
constant 
cluster of differentiation/cluster of designation 
chronic lymphocytic leukemia 
central nervous system 
complete remission 
cytoplasmic 
cytoplasmic expression of CD3 antigen 
cytoplasmic immunoglobulin heavy-chain II-
diversity 
dutch childhood leukemia study group 
denaturing gradient-gel e[ectroforese 
deoxyribonucleic acid 
female 
French American British cytomorphological classification of acute leukemias 
flow cytometer 
fluorescence in situ hybridization 
fluorescein isothiocyanate 
GTPase activating protein 
growth factor 
growth factor receptor 
hairy cell leukemia 
high risk group 
hypervariable (or length) polymorphism 
imm unofluorescence 
immunoglobulin 
immunoglobulin heavy-chain 
immunoglobulin light-chain 
immunoglobulin kappa-chain 
immunoglobulin lambda-chain 
heptamer recombination signal sequence located in the JJ(-CK intron 
immunoperoxidase 
joining 
kilobase 
kappa deleting element 
lymph node 
messenger 
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TcR"/, 
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Abbreviations 
male 
monoclonal antibody 
multidrug resistance 
mononuclear cells 
month{s) 
myeloperoxidase 
minimal residual disease 
medium risk group 
nucleotide 
not determined 
non-Hodgkin lymphoma 
not tested 
po]y-acrylamide gel electroforese 
periodic acid-Schiff 
peripheral blood 
phosphate buffered saline 
polymerase chain reaction 
pleura exudate 
pro[ymphocytic leukemia 
acute lymphoblastic leukemia of pre-B cell origin 
recombination activating gene 
restriction fragment lenght polymorphism 
ribonucleic acid 
recombination signal sequence 
room temperature 
surface membrane 
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surface membrane immunoglobuline 
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standard risk groep 
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T~cell receptor 
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tyrosine kinase 
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